---
document_datetime: 2025-05-07 10:52:06
document_pages: 143
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/breyanzi-h-c-004731-ii-0043-g-epar-assessment-report-variation_en.pdf
document_name: breyanzi-h-c-004731-ii-0043-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 244.5832269
conversion_datetime: 2025-12-19 22:49:10.255056
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
30 January 2025 EMA/72407/2025

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Breyanzi

International non-proprietary name: Lisocabtagene maraleucel / Lisocabtagene maraleucel

Procedure No. EMEA/H/C/004731/II/0043/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                            | ..............................................9                                                         |
|-----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ..................................................................................   | 9                                                                                                       |
| 1.2. Steps taken for the assessment of the product                                                                    | ..................................................... 10                                                |
| 2. Scientific discussion                                                                                              | ..............................................................................11                        |
| 2.1. Introduction                                                                                                     | .................................................................................................... 11 |
| 2.1.1. Problem statement                                                                                              | ........................................................................................ 11             |
| 2.1.2. About the product .........................................................................................    | 14                                                                                                      |
| 2.1.3. The development programme/compliance with CAT/CHMP guidance/scientific                                         | advice14                                                                                                |
| 2.1.4. General comments on compliance with GCP                                                                        | ...................................................... 15                                               |
| 2.2. Quality aspects                                                                                                  | ................................................................................................ 15     |
| 2.2.1. Discussion on quality aspects ..........................................................................       | 17                                                                                                      |
| 2.2.2. Conclusion on the quality aspects                                                                              | .................................................................... 17                                 |
| 2.3. Non-clinical aspects..........................................................................................   | 17                                                                                                      |
| 2.3.1. Ecotoxicity/environmental risk assessment........................................................              | 17                                                                                                      |
| 2.4. Clinical aspects                                                                                                 | ................................................................................................ 18     |
| 2.4.1. Introduction                                                                                                   | ................................................................................................. 18    |
| 2.4.2. Pharmacokinetics ..........................................................................................    | 18                                                                                                      |
| 2.4.3. Pharmacodynamics........................................................................................       | 28                                                                                                      |
| 2.4.4. Discussion on clinical pharmacology .................................................................          | 32                                                                                                      |
| 2.4.5. Conclusions on clinical pharmacology ...............................................................           | 34                                                                                                      |
| 2.5. Clinical efficacy                                                                                                | ................................................................................................ 34     |
| 2.5.1. Dose response study(ies) ...............................................................................       | 34                                                                                                      |
| 2.5.2. Main study                                                                                                     | ................................................................................................... 35  |
| 2.5.3. Discussion on clinical efficacy ..........................................................................     | 89                                                                                                      |
| 2.5.4. Conclusions on the clinical efficacy...................................................................        | 95                                                                                                      |
| 2.6. Clinical safety                                                                                                  | .................................................................................................. 95   |
| 2.6.1. Discussion on clinical safety                                                                                  | ...........................................................................121                          |
| 2.6.2. Conclusions on clinical safety                                                                                 | .........................................................................125                            |
| 2.6.3. PSUR cycle                                                                                                     | ..................................................................................................125   |
| 2.7. Risk management plan.....................................................................................125     |                                                                                                         |
| 2.8. Update of the Product information                                                                                | .....................................................................134                                |
| 2.8.1. User consultation..........................................................................................134 |                                                                                                         |
| 3. Benefit-Risk Balance............................................................................134                |                                                                                                         |
| 3.1. Therapeutic Context                                                                                              | ........................................................................................134             |
| 3.1.1. Disease or condition......................................................................................134  |                                                                                                         |
| 3.1.2. Available therapies and unmet medical need                                                                     | ....................................................135                                                 |
| 3.1.3. Main clinical studies                                                                                          | ......................................................................................136               |
| 3.2. Favourable effects...........................................................................................137 |                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects                                                           | ..........................................138                                                           |
| 3.4. Unfavourable effects........................................................................................138  |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                         | .......................................139                                                              |
| 3.6. Effects Table                                                                                                    | ..................................................................................................139   |
| 3.7. Benefit-risk assessment and discussion                                                                           | ..............................................................140                                       |

<div style=\"page-break-after: always\"></div>

3.7.1. Importance of favourable and unfavourable effects ...........................................  140

3.7.2. Balance of benefits and risks  ..........................................................................  141

3.7.3. Additional considerations on the benefit-risk balance .........................................  141

3.8. Conclusions  ....................................................................................................  141

4. Recommendations ...............................................................................  141

5. EPAR changes  ......................................................................................  142

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                                       |
|----------------|------------------------------------------------------------------------------------------------------------------|
| 1L             | First-line treatment                                                                                             |
| 2L             | Having received one line of prior therapy for the disease under study (second- line treatment)                   |
| 2L+            | Having received one or more line of therapy for the disease under study (second-line or later treatment)         |
| 3L             | Having received two lines of prior therapy for the disease under study (third-line treatment)                    |
| 3L+            | Having received two or more lines of prior therapy for the disease under study (third-line or later treatment)   |
| 4L+            | Having received three or more lines of prior therapy for the disease under study(fourth-line or later treatment) |
| ACC            | Analytic Comparator cohort                                                                                       |
| ADR            | Adverse drug reaction                                                                                            |
| AE             | Adverse event                                                                                                    |
| AESI           | Adverse event of special interest                                                                                |
| ASTCT          | American Society for Transplantation and Cellular Therapy                                                        |
| ATA            | Antitherapeutic antibody                                                                                         |
| AUC            | Area under the blood concentration-time curve                                                                    |
| BLA            | Biologics License Application                                                                                    |
| BMB            | Bone marrow biopsy                                                                                               |
| BMS            | BristolMyers Squibb Company                                                                                      |
| B-NHL          | B-cell non-Hodgkin lymphoma                                                                                      |
| BOR            | Best overall response                                                                                            |
| BTKi           | Bruton tyrosine kinase inhibitor                                                                                 |
| CAR            | Chimeric antigen receptor                                                                                        |
| CD             | Cluster of differentiation                                                                                       |
| CFR            | Code of Federal Regulations                                                                                      |
| CHMP           | Committee for Medicinal Products for Human Use                                                                   |
| CHOP           | Cyclophosphamide, doxorubicin, vincristine, and prednisone                                                       |
| CI             | Confidence interval                                                                                              |
| CLL            | Chronic lymphocytic leukemia                                                                                     |
| Cmax           | Maximum observed blood concentration                                                                             |
| CMR            | Complete metabolic response                                                                                      |
| CNS            | Central nervous system                                                                                           |
| COVID-19       | Coronavirus disease 2019                                                                                         |
| CR             | Complete response; Continued remission                                                                           |
| CRF            | Case report form                                                                                                 |
| CRL            | Complete Response Letter                                                                                         |

<div style=\"page-break-after: always\"></div>

| CRMTS         | Center for Biologics Evaluation and Research (CBER) Regulatory Meetings Management Tracking System   |
|---------------|------------------------------------------------------------------------------------------------------|
| CRP           | C-reactive protein                                                                                   |
| CRR           | Complete response rate                                                                               |
| CRS           | Cytokine release syndrome                                                                            |
| CSR           | Clinical study report                                                                                |
| CT            | Computerized tomography                                                                              |
| CV            | Coefficient of variation                                                                             |
| ddPCR         | Digital droplet polymerase chain reaction                                                            |
| DL            | Dose level                                                                                           |
| DLBCL         | Diffuse large B-cell lymphoma                                                                        |
| DNA           | Deoxyribonucleic acid                                                                                |
| DOR           | Duration of response                                                                                 |
| ECA           | External control arm                                                                                 |
| ECG           | Electrocardiogram                                                                                    |
| ECOG          | Eastern Cooperative Oncology Group                                                                   |
| EMA           | European Medicines Agency                                                                            |
| EORTC QLQ-C30 | European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire       |
| EOS           | End of study                                                                                         |
| EQ-5D-5L      | European Quality of Life-5 Dimensions health state classifier to 5 levels                            |
| ESMO          | European Society of Medical Oncology                                                                 |
| FACT-LymS     | Functionality Assessment of Cancer Therapy Lymphoma Subscale                                         |
| FDA           | Food and Drug Administration                                                                         |
| FL            | Follicular lymphoma                                                                                  |
| FL3B          | Follicular lymphoma grade 3B                                                                         |
| FLIPI         | Follicular Lymphoma International Prognostic Index                                                   |
| F/U           | Follow up                                                                                            |
| GELF          | Groupe d'Etude des Lymphomes Folliculaires                                                           |
| GM-CSF        | Granulocyte macrophage colony-stimulating factor                                                     |
| HCP           | Healthcare provider                                                                                  |
| HGBCL         | High grade B cell lymphoma                                                                           |
| HGL           | High grade lymphoma                                                                                  |
| HLH           | Hemophagocytic lymphohistiocytosis                                                                   |
| HR            | Hazard ratio                                                                                         |
| HRQoL         | Health-related quality of life                                                                       |
| HSCT          | Hematopoietic stem cell transplantation                                                              |
| HTA           | Health technology assessment                                                                         |
| ICANS         | Immune effector cell associated neurotoxicity                                                        |

<div style=\"page-break-after: always\"></div>

| ICF       | Informed consent form                                                    |
|-----------|--------------------------------------------------------------------------|
| ICU       | Intensive care unit                                                      |
| IgG       | Immunoglobulin                                                           |
| iiNT      | Investigator-identified neurologic toxicity                              |
| IL        | Interleukin                                                              |
| IND       | Investigational New Drug                                                 |
| iNHL      | Indolent non-Hodgkin lymphoma                                            |
| IPTW      | inverse probability of treatment weighting                               |
| IRB       | Institutional Review Board                                               |
| IRC       | Independent Review Committee                                             |
| IRR       | Infusion-related reaction                                                |
| ISA       | Insertion site analysis                                                  |
| ISS       | Integrated Summary of Safety                                             |
| ITC       | Indirect treatment comparison                                            |
| ITT       | Intention-to-treat                                                       |
| IV        | Intravenous                                                              |
| JTEAC     | JCAR017-treated Efficacy Analysis Cohort                                 |
| KM        | Kaplan-Meier                                                             |
| LBCL      | Large B-cell lymphoma                                                    |
| LDC       | Lymphodepleting chemotherapy                                             |
| LDH       | Lactate dehydrogenase                                                    |
| Liso-cel  | Lisocabtagene maraleucel                                                 |
| LKC       | Leukapheresed cohort                                                     |
| LLOD      | Lower limit of detection                                                 |
| LOD       | Limit of detection                                                       |
| LOT       | Line of therapy                                                          |
| LTFU      | Long term follow-up                                                      |
| LVEF      | Left ventricular ejection fraction                                       |
| MAIC      | Matching-adjusted indirect comparison                                    |
| MAS       | Macrophage activation syndrome                                           |
| Max       | Maximum                                                                  |
| MCL       | Mantle cell lymphoma                                                     |
| Min       | Minimum                                                                  |
| MZL       | Marginal zone lymphoma                                                   |
| N.A.      | Not applicable                                                           |
| NCCN      | National Comprehensive Cancer Network                                    |
| NCI CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NE        | Neurologic event                                                         |

NHL

Non-Hodgkin lymphoma

NOS

Not otherwise specified

NT

Neurotoxicity

N.R.

Not Reached

OR

Odds ratio

ORR

Overall response rate

OS

Overall survival

PCR

Polymerase chain reaction

PD

Progressive disease

PET

Positron emission tomography

PFS

Progressionfree survival

PI3K

Phosphoinositide 3 kinase

PK

Pharmacokinetic(s)

PMBCL

Primary Mediastinal Large B Cell Lymphoma

PML

Progressive multifocal leukoencephalopathy

PMR

Partial metabolic response

POD24

Progression of disease within 24 months of initiation of first-line chemoimmunotherapy with antiCD20 and alkylating agent

POD24-Per protocol   As per protocol definition and case report form: progression of disease within 24 months of diagnosis after initiating treatment with an anti-CD20 and alkylating agent within the first 6 months of initial FL diagnosis

PR

Partial response

PREA

Pediatric Research Equity Act

PRO

Patient reported outcome

PRR

Partial response rate

PS

Propensity score

PT

Preferred term

Q1

First quartile

Q3

Third quartile

QCC

Qualifying Comparator Cohort

QoL

Quality of life

R2

Rituximab and lenalidomide

R-CHOP

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

RCL

Replication-competent lentivirus

R-CVP

Rituximab, cyclophosphamide, vincristine, and prednisone

REMS

Risk evaluation and mitigation strategy

RMP

Risk management plan

R/R

Relapsed or refractory

RR

Response ratio

RW

Real world

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| SAP    | Statistical analysis plan                    |
|--------|----------------------------------------------|
| sBLA   | Supplemental Biologics License Application   |
| SCE    | Summary of Clinical Efficacy                 |
| SCP    | Summary of Clinical Pharmacology             |
| SCS    | Summary of Clinical Safety                   |
| SD     | Stable disease                               |
| SE     | Standard error                               |
| SLL    | Small lymphocytic lymphoma                   |
| SLR    | Systematic literature review                 |
| SOC    | System organ class                           |
| SPD    | Sum of perpendicular diameter                |
| SPM    | Second primary malignancy                    |
| TARC   | Chemokine (C-C motif) ligand 17              |
| T-cell | T-lymphocyte                                 |
| TE     | Transplant eligible                          |
| TEAE   | Treatment-emergent adverse event             |
| THRBCL | Tcell/histiocyte -rich large B-cell lymphoma |
| TLS    | Tumor lysis syndrome                         |
| Tmax   | Time of maximum observed blood concentration |
| TNE    | Transplant non-eligible                      |
| TTNT   | Time to next treatment                       |
| ULN    | Upper limit normal                           |
| US     | United States                                |
| USPI   | United States prescribing information        |
| VAS    | Visual analog scale(s)                       |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 29 July 2024 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                                                | Type    | Annexes affected   |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                      | Type II | I and IIIB         |
| B.II.d.1.a             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                      | Type IB | None               |
| B.II.d.1.a             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                      | Type IB | None               |
| B.II.d.1.e             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range | Type II | None               |

C.I.6 (Type II): Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (R/R) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP has been submitted. Furthermore, as part of the application the MAH is requesting a 1-year extension of the market protection.

The group of variations requested amendments to the Summary of Product Characteristics, Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0448/2023 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. During the procedure, the MAH decided to withdraw the claim.

## Scientific advice

The MAH received Scientific Advice from the CAT/CHMP on 22 July 2021 (EMA/SA/0000062296). The Scientific Advice pertained to clinical aspects of the application.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                         | Concetta Quintarelli                                | N/A             |
|-----------------------------------------------------|-----------------------------------------------------|-----------------|
| Timetable                                           | Timetable                                           | Actual dates    |
| Submission date                                     | Submission date                                     | 29 July 2024    |
| Start of procedure:                                 | Start of procedure:                                 | 17 August 2024  |
| CAT Rapporteur Assessment Report                    | CAT Rapporteur Assessment Report                    | 11 October 2024 |
| PRAC Rapporteur Assessment Report                   | PRAC Rapporteur Assessment Report                   | 14 October 2024 |
| PRAC members comments                               | PRAC members comments                               | N/A             |
| Updated PRAC Rapporteur Assessment Report           | Updated PRAC Rapporteur Assessment Report           | 24 October 2024 |
| CAT and CHMP members comments                       | CAT and CHMP members comments                       | N/A             |
| PRAC Outcome                                        | PRAC Outcome                                        | 31 October 2024 |
| Updated CAT Rapporteur(s) (Joint) Assessment Report | Updated CAT Rapporteur(s) (Joint) Assessment Report | 4 November 2024 |
| CAT Request for Supplementary Information (RSI)     | CAT Request for Supplementary Information (RSI)     | 8 November 2024 |
| CAT Rapporteur Assessment Report                    | CAT Rapporteur Assessment Report                    | 2 January 2025  |
| PRAC Rapporteur Assessment Report                   | PRAC Rapporteur Assessment Report                   | 2 January 2025  |
| PRAC members comments                               | PRAC members comments                               | N/A             |
| Updated PRAC Rapporteur Assessment Report           | Updated PRAC Rapporteur Assessment Report           | 9 January 2025  |
| CAT and CHMP members comments                       | CAT and CHMP members comments                       | N/A             |
| PRAC Outcome                                        | PRAC Outcome                                        | 16 January 2025 |
| Updated CAT Rapporteur Assessment Report            | Updated CAT Rapporteur Assessment Report            | 20 January 2025 |
| CAT Opinion                                         | CAT Opinion                                         | 24 January 2025 |
| CHMP Opinion                                        | CHMP Opinion                                        | 30 January 2025 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Follicular lymphoma (FL) is a heterogeneous condition including B-cell malignancies derived from germinal centre B cells. The histological growth pattern of FL is characterised by a nodular appearance that is always present, although, in more advanced stages, it is no longer predominant. The pseudofollicular structures of FL include both centrocytes (small cleaved follicular centre cells) and c еո tr ο blast ѕ ( large non-cleaved follicular centre cells) and mimics the normal germinal centres of secondary lymphoid follicles. However, unlike reactive follicles, FL neoplastic nodules are usually closely packed and heterogeneous in size and shape.

Сеո tr ο ϲ у te ѕ are typically predominant in classic (Grade 1-3a) FL, while centroblasts might be the main cell component in rare forms with aggressive behaviour (i.e. Grade 3b F Լ , known under the name follicular large B-cell lymphoma in the latest WHO classification of lymphoid neoplasms). Occasional cases of FL may show plasmacytoid differentiation or foci of marginal zone or monocytoid B cells.

The vast majority of FL cases express HLA-DR and are positive for B cell antigens (CD19, CD20, С D79a), С D21, and С D10 (60 percent). CD23 expression is variable.

## Claimed therapeutic indication

Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

## Epidemiology

FL is one of the most common forms of non-Hodgkin lymphoma (NHL), accounting for about 35% of all NHLs. The incidence of FL in the EU is approximately 2.2 cases per 100.000 persons per year, with a higher prevalence in Caucasian populations compared to African and Asians (see e.g. Sant M et al, Blood 2010). FL shows no strong sex predilection, yet its incidence varies with age; with the majority of FL cases arising in middle-aged individuals and older adults (see e.g. Morton LM et al, Blood 2006). The median age at diagnosis is 65 years yet rare cases have been reported also in children and adolescents (see e.g. Lorsbach RB et al, Blood 2002).

## Aetiology and pathogenesis

The aetiology of FL is largely unknown, and its pathogenesis is not fully understood. The majority of FL cases harbour the t(14;18) translocation, which results in the juxtaposition of the B-cell leukemia/lymphoma 2 gene (Bcl2) with the promoter of the immunoglobulin heavy chain gene (IGH). The Bcl2/IGH translocation event is essential in promoting the overexpression of Bcl2, which act as inhibitor of programmed cell death (apoptosis) and results in prolonged cell survival.

<div style=\"page-break-after: always\"></div>

However, since t(14;18) has been detected also in reactive lymphoid tissues and peripheral blood lymphocytes of normal subjects, additional genetic events (e.g. in genes codifying chromatinmodifying enzymes, see Morin RD et al, Nature 2011) are considered to be necessary in order to develop FL. In this regard, approximately 90% of FL demonstrate additional genetic alterations such as loss of 1p, 6q, 10q, and 17p and gains of chromosomes 1, 6p, 7, 8, 12q, X, and 18q/dup. The Igmediated B cell receptor (BCR) pathway, for example, has also been shown to play a role in FL pathogenesis.

## Clinical presentation, diagnosis and stage/prognosis

Most patients with FL present with enlarged and painless superficial lymph nodes. Although large (mostly asymptomatic) abdominal masses are not uncommon, mediastinal masses are rarer. FL is usually widely disseminated at the time of diagnosis and could involve the spleen (40% of all cases), the liver (50% of all cases) or the bone marrow (80% of all cases, see Anderson T et al, Cancer 1982). Involvement of other 'extra-lymphatic' organs is uncommon and invasion of central nervous system is rare compared to other forms of NHL.

Symptoms are uncommon at diagnosis, and only approximately 20% of patients report 'B symptoms' (i.e. fever, night sweats, pruritic and/or unintentional weight loss). Laboratory values are usually noninformative and, despite the large tumour burden, increased serum Լ DH or cytopenias have been reported in less than 25% of patients.

Symptoms in patients with R/R FL are more heterogeneous and might be due to compression/infiltration of visceral organs, peripheral nerves and/or bone tissue.

## Management

FL is characterised by an indolent, relapsing/remitting clinical behaviour and, as a general rule, drug resistance increases, and clinical benefit is reduced, with each subsequent line of therapy.

Current treatment guidelines (see e.g. the 2020 ESMO guidelines for newly diagnosed and relapsed FL, or the NCCN guidelines for classic FL v. 3.2024) recommend that conventional immunochemotherapy should form the backbone of treatment early in the course of the disease (e.g. at frontline or at first relapse). In later settings of relapse/progression, alternative approaches are usually preferred. Therefore, with respect to the claimed indication for Breyanzi, only a selected group of patients can be reasonably expected to benefit from the use of classic immune-chemotherapy regimens such as bendamustine plus rituximab (BR), R-CHOP/R-CVP, or other similar regimens. Rituximab, an anti-CD20 monoclonal antibody, is recommended by current guidelines for the treatment of R/R FL in monotherapy or in combination. Rituximab monotherapy is often preferred in older subjects with indolent disease because of its manageable toxicity profile; in the rituximab arm of the Phase III HOMER study (see e.g. Maloney DG et al, Blood Adv 2020) only subjects with rituximab-sensitive disease could be enrolled, the overall response rate (ORR) was 66%, the complete response rate (CRR) was 20% and the median progression-free survival (PFS) was 19.2 months. The SCHOLAR-5, a large observational study investigating the RW outcomes of subjects with R/R NHLs, showed that the ORR and CRR for subjects with R/R FL receiving various rituximab-based salvage treatments in their 3L+ ranged from 43% to 69% and from 20% to 46%, respectively.

The main clinical need in R/R FL patients is, however, represented by the increasing rate of resistance to rituximab-based regimens in later lines of therapy, together with the reduction in the disease-free time between relapses and the accumulation of treatment-related toxicities.

<div style=\"page-break-after: always\"></div>

The combination of obinutuzumab (a 2 nd  generation anti-CD20 mAb) plus bendamustine (BO), followed by obinutuzumab maintenance, is approved for the treatment of for subjects who did not respond or who progressed during or up to 6 months after treatment with rituximab or rituximab-containing regimens. The results from registrational study GAO4753g/GADOLIN showed that the BOR (CR+PR) in the BO arm was 79.7% and the CRR 15.7%. At the time of approval, the median PFS by IRC in the BO arm was not reached with a median FU of 22 months, nor the median duration of response (DoR) and overall survival (OS). Updated results with a median FU of 57.5 months in the BO arm (see Sehn LH et al, Blood 2019) showed that the median PFS was 24.1 months, and the median OS was still not reached.

The therapy landscape for these patients has observed some changes in recent years, with more chemo-free options becoming available.

Idelalisib and duvelisib are PI3K inhibitors (PI3Kis) approved for the treatment as monotherapy of adult patients with FL that is refractory to two prior therapies. The efficacy outcomes from the registrational studies (single-arm, multicentre study 101-09 and single-arm, multicentre study IPI145-06, respectively) showed ORRs ranging between 40% and 55.6% and CRRs in the range 0% to 16.7%. Long-term outcomes data showed mDoR, mPFS and mOS ranging between 10-12 months, 811 months and 28-61 months, respectively. With respect to safety, long-term treatment with PI3Kis is characterised by significant rates of neutropenia, infection, GI ADRs and rush.

Zanubrutinib (a 2 nd  generation BTK inhibitor) is approved in combination with obinutuzumab (OZ) for the treatment of adult patients with R/R FL who have received at least two prior systemic therapies. Data from Phase 2, randomised, controlled study ROSEWOOD showed in the OZ arm an ORR of 69% (CRR 39.3%), with a 69% DoR rate at 18 months and a median PFS of approximately 28 months.

Lenalidomide is approved in combination with rituximab (RR) for the treatment of adult patients with previously treated FL. The efficacy and safety of the RR regimen was investigated in a phase 3, multicentre, randomised, double- blind controlled study (AUGMENT) which compared RR with rituximab plus placebo in patients with R/R indolent NHLs including FL. With a median follow-up of approximately 28 months, the ORR for FL patients in the RR arm was 80.3%, the CRR 34.7%, the median DoR 36.6 months, the median PFS 39.4 months and the 5-year OS rate was 85.9%.

Mosunetuzumab is an anti-CD20/CD3 T-cell-engaging bispecific mAb approved conditionally for the treatment of adult patients with R/R FL who have received at least two prior systemic therapies. The CMA of Lunsumio was based on the results from a single open-label, multicenter, multi-cohort study (GO29781) in subjects with R/R B-cell NHLs. Efficacy results showed that the ORR was 80%, the CRR 60%, the mDoR 22.8 months, the median PFS 17.9 months and the median OS was not yet reached. Epcoritamab and odronextamab are two additional anti-CD20/CD3 bispecific mABs approved as monotherapy for the treatment of adult patients with R/R FL after two or more lines of systemic therapy that showed similar results to mosunetuzumab.

Tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) are two anti-CD19 CAR T cell (CARTs) advanced medicinal products (ATMPs). Tisa-cel is approved for the treatment of subjects with R/R FL after two or more lines of systemic therapy. Results from the registrational ELARA trial (a Phase 2, open-label, single-arm study) showed that treatment with tisa-cel resulted in high ORR (86%) and CRR (69%), with a median PFS of 18.4 months and median DoR and OS not yet reached after a median follow-up of 20.8 months.

Axi-cel is approved for treatment of patients with R/R FL after three or more lines of systemic therapy. Supporting efficacy data come from study ZUMA-5, a single-arm Phase 2 trial in subjects with R/R indolent NHLs, and sowed that the ORR was 94%, the CRR 78%, the median DoR 38.6 months, the median PFS 39.6 months and the median OS was not yet reached with a median FU of 25.9 months.

<div style=\"page-break-after: always\"></div>

The safety profile of T cell engaging immunotherapies (including bispecific mAbs and CARTs) is characterised by CRS, neurotoxicity including ICANS, infections, persisting hypogammaglobulinemia and cytopenias. Rates and severity of AEs vary across different products.

Overall, despite several products are approved for the treatment of subjects with 3L+ FL, with CAR-T therapies offering the most compelling efficacy, there is a continuous need for efficacious treatments with better safety profiles to further enhance patient outcomes. FL, in fact, remains largely incurable, and death occurs mainly due to histological transformation to aggressive LBCL, infection, or because FL becomes refractory to the available options. Further, a higher medical need can be recognised for POD24 patients (i.e. subjects with early progression), who are at high risk of poor long-term outcomes, with an estimated 5-year OS 50% (vs. 90% in the absence of early progression).

## 2.1.2. About the product

Lisocabtagene maraleucel (Breyanzi; JCAR017; liso-cel) is an advanced therapy medicinal product consisting of autologous CD4+ and CD8+ T cells that have been transduced using a replicationincompetent, self-inactivating lentiviral vector encoding a CD19-specific chimeric antigen receptor (CAR). The CD19-specific CAR contains a murine single chain variable fragment binding domain (FMC63) and the 4-1BB and CD3 ζ chain signalling domains. Breyanzi is administered as separate infusions consisting of a 1:1 ratio of CD4+ and CD8+ cell components.

Breyanzi is already approved in the EU for the treatment of adult patients with:

- Diffuse large B-cell lymphoma  (DLBCL), High grade B cell lymphoma  (HGBCL), Primary Mediastinal Large B Cell Lymphoma  (PMBCL) and Follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy;
- relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.

## 2.1.3. The development programme/compliance with CAT/CHMP guidance/scientific advice

On 22-07-2021, the MAH received scientific advice for liso-cel for treatment of FL and received feedback from the CHMP ( EMA/SA/0000062296). The Scientific Advice covered different points of development of liso-cel in FL; in respect to protocol JCAR017-FOL-001, the advice focused on the proposed development plan for FL to support the benefit/risk assessment of treatment in R/R FL, and about the opportunity of use of the JCAR017-FOL-001 study data, contextualized with a historic control, to support an earlier benefit/risk assessment for heavily treated R/R FL patients. An evaluation about the study endpoints was also provided.

The Applicant was advised to invert the order of the proposed primary endpoint of CRR with one of the first key secondary endpoint of ORR, because it has been outlined that for most registrational CAR T cell single arm studies on which approvals have been granted, the primary endpoint has been ORR rather than CRR. The Applicant was advised that CHMP will consider DOR as determined by an independent review committee (IRC) of importance in performing benefit risk evaluation. Both suggestions have been implemented in the pivotal study protocol.

The CHMP proposed also to conduct the efficacy analysis in an intent-to-treat (ITT) population defined as 'all patients providing informed consent' rather than in the leukapheresed set, because it is considered more in line with the ITT principle. Nevertheless, the use of leukapheresed set is precedented in the setting of CAR-T therapies and the MAH decision to maintain this setting for the

<div style=\"page-break-after: always\"></div>

efficacy analysis is considered acceptable; attention should be posed anyway to patient who underwent leukapheresis without meeting all inclusion/exclusion criteria.

The Applicant was also invited to submit results after at least 12 months of follow-up from the initial response; considering the previous experience in the same setting of Idelalisib trial the MAH accepted this request and provided results at a median follow up of 23.13 months (22.93, 23.26).

Finally, the CHMP discussed the proposal of the MAH to provide the results of supportive studies based on published literature in which subjects treated in the real-world setting or clinical trials were included. The MAH proposed data from real world external control arm study, a systematic literature review and an Indirect Treatment Comparison. The CHMP focused the attention on the missed opportunity of a phase 3 trial, considering the previous experiences in the same setting in which an active comparator was successfully implemented. Although data from supporting studies were adjusted in order to improve the similarity with patients included in the FOL-001, the strength of the evidence provided by this indirect comparison was considered sub-optimal when compared to a randomized clinical trial with an active comparator. The CHMP warned that the absence of an active comparator contemporaneously would need to be justified at the time of a MAA.

## 2.1.4. General comments on compliance with GCP

The MAH stated that the clinical trials included in this submission were performed in accordance with the principles of Good Clinical Practice, as defined by the International Conference on Harmonization (ICH). The clinical trials carried out outside the European Union were confirmed to meet the ethical requirements of Directive 2001/20/EC.

## 2.2. Quality aspects

## Introduction

All  clinical  trial  materials  supporting  the  label  expansion  were  manufactured  per  the  approved manufacturing process (v4) and at commercially approved manufacturing sites. No changes are being proposed to the manufacturing process.

While Study 017001 pertained to patients with relapsed or refractory large B cell lymphoma (LBCL) after two  or  more  lines  of  systemic  therapy  (3L+),  Study  FOL-001  pertains  to  patients  with  relapsed  or refractory Follicular Lymphoma after at least one (2L+) or two (3L+) prior lines of systemic therapy. Therefore, since these patient populations may differ in the characteristics of their starting materials (e.g., memory T cell phenotypes) and their clinical response to the drug product, the following studies are included in this section in support of Study FOL-001:

- Phenotypic and functional characterisation of drug product components manufactured in support of Study FOL-001
- Exploratory correlative analysis of quality attributes associations with clinical efficacy, safety, and pharmacokinetics in Study FOL-001

## Manufacturing Process Development

The  Healthy  Donor  Leukapheresis  Product  was  reassessed  for  3L+  FL  to  confirm  that  process characterisation results are still relevant to 3L+ FL. This assessment was presented.

The drug product v4 manufacturing process produces similar drug product when using leukapheresis from patients or healthy donors as all attributes passed the analyses.

<div style=\"page-break-after: always\"></div>

The methodology described in the original application is unchanged and is applied to Study JCAR017FOL-001 herein.

The residual patient  risk  assessment  based  on  each  unique  product  quality  attribute  considered  the integrated control strategy (ICS). Based on this comprehensive assessment, the overall risk of the drug product to patient safety and product efficacy is considered low.

## Specification

The specification for lisocabtagene maraleucel CD8+ drug product component (liso-cel) covers relevant CQAs.  The quality parameters taken into account for each cell component include appearance, identity, purity, strength, potency and safety.

Information on lots of drug product that were manufactured to support the Study JCAR017-FOL-001 clinical trial was provided.

## Justification of Specifications (CD8+)

The specification of liso-cel (lisocabtagene maraleucel) drug product has been established to confirm its appearance, identity, purity, strength, potency, and safety. The quality attributes of the drug product components  have  been  determined  through  process  and  product  understanding  gained  during development  and  correlative  analyses  with  clinical  outcomes.  The  analytical  procedures  that  were selected  to  ensure  control  of  attributes  in  the  specification  reflect  the  experience  gained  during development  and  manufacture  of  liso-cel,  knowledge  from  other  autologous  gene  and  cellular therapeutics, and their suitability for routine evaluation of attributes that ensure the quality of released drug product component lots. The acceptance criteria in the specification have been established to ensure that the quality of released drug product component lots remain within experience demonstrated to be safe and effective in Study 017001, JCAR017-BCM-001 (BCM-001), JCAR017-BCM-003 (BCM-003) and Relapsed or Refractory Follicular Lymphoma (R/RFL; JCAR017-FOL-001 [FOL-001]).

## Analytical Procedures

The appearance, identity, purity, strength, potency, and safety attributes that are included in the drug product specification were selected based on risk assessments that considered product understanding and process capability. The analytical procedures in the commercial specification were selected based on their performance characteristics and suitability for routine and reliable evaluation of these attributes in a quality control (QC) environment.

## Acceptance Criteria in the Specification for Drug Product

The acceptance criteria in the specification have been established to ensure that the quality of released drug  product  component  lots  remain  within  experience  demonstrated  to  be  safe  and  effective.  In accordance  with  ICH  Q6B,  Q8,  Q9,  and  Q10,  the  following  assessment  of  liso-cel  drug  product  lots acceptance criteria were established based on:

1. Clinical manufacturing batches used for evaluating clinical safety and efficacy
2. T cell biology and the quality attribute-clinical outcome relationship established by correlative analyses
3. Data obtained from manufacturing process development and characterization studies
4. Capabilities of the analytical procedures
5. Pharmacopeia specifications

## Drug Product Component Lots Included in the Specification Assessment

<div style=\"page-break-after: always\"></div>

The  acceptance  criteria  established  in  the  commercial  specification  for  release  and  stability  of  drug product considered data that were acquired from drug product component lots manufactured under GMP conditions in the manufacturing process v4.

To maximize patient access to quality drug product that is within experience demonstrated to be safe and effective, the number of quality attributes and stringency of acceptance criteria in the commercial specification  were  considered.  Therefore,  redundant  controls  were  eliminated  from  the  drug  product specification.  In  addition,  the  cumulative  impact  of  acceptance  criteria  was  considered  to  ensure  an appropriate  balance  between  providing  the  necessary  assurances  of  drug  product  quality,  process control,  and  patient  access  to  drug  product  that  is  within  experience  demonstrated  to  be  safe  and effective in Study 017001, BCM-001, BMC-003 and FOL-001.

## 2.2.1. Discussion on quality aspects

The MAH has performed a limited set of characterisation studies on the CD8+ and CD4+ cell components manufactured for Study FOL-001, pertaining to patients with r/r Follicular Lymphoma (FL) after at least one (2L+) or two (3L+) prior lines of systemic therapy.

The rationale behind this restricted characterisation dataset is that r/r FL patient populations may differ in the characteristics of their starting materials (e.g., memory T cell phenotypes) and their clinical response to the drug product as compared to the clinical setting investigated so far. A relevant number of FOL-001 batches has been considered for each component in the context of this newly generated data, which do not highlight any remarkable differences or give rise to any further considerations as compared to the assessments performed so far for Breyanzi (MA and 2 nd  line EoI). The same consideration applies to the correlative analyses performed between cell components' quality attributes and clinical outcomes (efficacy, safety and PK) and to inform inter-quality attributes correlations.

The batch analysis data for Study FOL-001 has been provided, confirming that the product (and process) is in a state of control.

No new CQAs were identified, nor manufacturing process (v4) or control strategy changes were proposed. The release specification test panel remains unchanged following the inclusion of data from study FOL-001 lots in the dataset to justify the acceptance criteria, with two exceptions that are regarded as acceptable.

## 2.2.2. Conclusion on the quality aspects

In conclusion, the quality aspects linked to the sought EoI are approvable.

## 2.3. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CAT/CHMP.

## 2.3.1. Ecotoxicity/environmental risk assessment

The MAH provided a justification for not submitting a new Environmental Risk Assessment (ERA) in Module 1.6.2 of the present Type II variation, which extends the treatment of liso-cel to include adult patients with relapsed or refractory FL after two or more lines of systemic therapy.

No release of Liso-cel into the environment is foreseen. No relevant changes in the manufacturing

<div style=\"page-break-after: always\"></div>

process of Liso-cel were implemented. Testing for absence of replication-competent lentivirus (RCL) in vector lot is in place. Generation of RCL in patients treated with liso-cel still unlikely.

As the Type II variation does not affect the environmental risk of liso-cel, no monitoring in the environment is considered necessary to protect human health and the environment.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1. Tabular listing of clinical studies included in the application

| Type of Study                                                                                     | Study No.; NCT ID; EudraCT ID; Location of Study Report                                           | Primary Objective(s) of the Study                                                                 | Study Design and Type of Control                                                                  | Test Product(s); Dosage Regimen; Route of Administration                                          | Treatment Duration                                                                                | No. of Subjects Treateda twith Liso-Subject cel                                                   | Population                                                                                        | Study Status; Type of Report                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL) | Efficacy and Safety Studies of Liso-cel Monotherapy: Pertinent to the Claimed Indication (R/R FL)                                                                               |
|                                                                                                   | UncontrolledJCAR017-FOL- 001; NCT04245839; 2019-004081-18; 5.3.5.2                                | Efficacy(ORR)basedon IRCof liso-celinsubjects withR/RFL (Cohorts 1,2, 3)                          | Phase 2 open-label, single-arm, multicohort, multisite trial                                      | Liso-cel; 100×10°CAR+ T cells; intravenous                                                        | Single dose FL                                                                                    | (Cohorts 1,2,3): 130                                                                              | Adult indolent B-NHL (2L+ FL Grade 1, 2, or 3A)                                                   | Ongoing; Interim CSR (27- Jan-2023data cut for FL cohorts) Addendum 01 CSR (10-Jan- 2024 data cut for FL cohorts) Safety data in the SCS (10-Jan- 2024 data cut for FL cohorts) |

## 2.4.2. Pharmacokinetics

The clinical pharmacology profile of Breyanzi in subjects with FL has been characterised based on results from Study FOL-001 Cohorts 1,2 and 3. The secondary objective of this study was to characterize the PK profile of liso-cel; the exploratory objectives were to assess the peripheral biomarkers of liso-cel including soluble factors and changes in immune cell populations and to evaluate the immune responses directed against liso-cel.

Breyanzi dose recommendation of 100 × 10 6  CAR+ viable T cells in Study FOL-001 was selected based on the dosing experience in Study 017001 (Phase 1 study to determine the safety, antitumour activity, and PK of JCAR017 in adult subjects with R/R B-cell NHL, submitted within the initial MA).

<div style=\"page-break-after: always\"></div>

Table 2. Description of Study FOL-001

| Study            | Design                                                                                                                                                           | Study Population                       | Number of FL Subjects (Cohorts 1, 2 and 3) Enrolled   | Dosing                  | PK Sampling Timepoints by PCR                                                                            |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------|
| JCAR017- FOL-001 | A Phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of liso-cel in adult subjects with R/R indolent B-cell NHL | Adult subjects with R/R FL and R/R MZL | Screened Set a : 154 Eligible Set b : 139             | 100 × 10 6 CAR+ T cells | Days 1, 4, 8, 11, 15, 22, 29, 60, 90, 180, 270, 365, 545 and 730 Months 30, 36, 42, 48, 54, and 60 (EOS) |

a Subjects signed informed consent.

b Subjects signed consent who meet all inclusion/exclusion criteria.

## Methods

The following bioanalytical methods were used to assess the PK, PD and immunogenicity of Breyanzi.

Table 3. Bioanalytical methods

| Assessment                                       | Data Cut-off Date   | Laboratory                                      | Status    |
|--------------------------------------------------|---------------------|-------------------------------------------------|-----------|
| Pharmacokinetic Assessments                      |                     |                                                 |           |
| Digital droplet PCR (transgene vector sequences) | 10-Jam-2024         | MolecularMD (Portland, OR)                      | Validated |
| Pharmacodynamie Assessments                      |                     |                                                 |           |
| Flow cytomety (B-cell aplasia)                   | 10-Jam-2024         | Labcorp (Indianapolis, IN)                      | Validated |
| MSD-ECL Immunoassay (Soluble biomarkers)         | 10-Jam-2024         | BioAgilytix, (Boston, MA)                       | Validated |
| Serum Ig. CRP, ferritin                          | 10-Jam-2024         | Measuured by the local labs at individual sites | Validated |
| Immunogenicity Assessments                       |                     |                                                 |           |
| Electochemiluuinescence immumoassay (ATA)        | 10-Jam-2024         | Charles River Laboratories (Reno, NV)           | Validated |

A validated ddPCR assay (CC-MULT-DMPK-3180 validation report and Biomarker report JCAR017-FOL001) was used to quantitate gene expression and a validated ATA assay (JCAR017-DMPK-2774-ADA) was used to evaluate immune responses to the ECD of liso-cel.

In  the  current  application,  the  Applicant  used  a  validated  industry-standard  assay  to  monitor  B-cell aplasia  that  replaced  the  original  method,  a  research-use-only  flow  cytometry  used  in  the  initial Marketing Authorisation.

Soluble biomarkers were analysed using multiplex MSD-ECL immunoassays (validation submitted within the II/05 variation; 00970). Serum Ig, CRP, and ferritin were measured at a local laboratory.

Transgene measurement: pan gag VCN ddPCR Test (CC-MULT-DMPK-3180)

To evaluate the transduction of the target cells (CAR +  cells) with the lentivirus and the persistence of gene transfer the pan gag VCN ddPCR Test was used. The method detects gag DNA sequence of the lentiviral  vector  and  that  of  the  reference  gene  RPPH1  in  nucleic  acids  isolated  from  human  blood. Calculated data are reported as gag copies per μ g (gag copies/ ([genomes x (6.6 pg/genome)] / 106 pg/ μ g)), % gag positive cells (([gag copies/RPPH1 copies] x 2) x 100), and genomes (RPPH1 copies/2).

<div style=\"page-break-after: always\"></div>

Analytical Sensitivity was set as follow: the Limit of Detection of the pan gag VCN ddPCR Test is ≤ 16 copies per 400 ng. The Lower Limit of Quantitation of the Test is 16 copies per 400 ng. The Upper Limit of Quantitation of the Test is 720,000 copies per 400 ng.

## Pharmacokinetics results

The  PK  analyses  were  based  on  PCR.  Noncompartmental  PK  parameters  such  as  Cmax,  Tmax,  and AUC(0-28) were calculated for subjects in the PK Evaluable Analysis Set (subjects who have at least 1 evaluable PK parameter). Persistence of liso-cel transgene in blood was assessed by PCR and defined as a transgene count greater than or equal to the LOD of 16 copies/400 ng reaction which is ~ 40 copies/ μ g. All PK data, including persistence, were summarized descriptively.

The clinical pharmacology of liso-cel has been evaluated in Study FOL-001 in subjects with FL by group and using the analysis datasets described in the tables below.

The MAH submitted an interim clinical pharmacology report (dated September 2023) with data cut-off 27 January 2023 and an Addendum 1 clinical pharmacology report (dated 18 June 2024) with data cutoff 10 January 2024 where the DBL occurred on the same date as for the Study FOL-001 Addendum 01 CSR (06-Mar-2024). As of the latest data cutoff date, the study was still ongoing.

Table 4. Group Information - Study FOL-001

| Group Name in Tables/Figures/Listings and Text   | Study Cohort(s) Included in the Group   |
|--------------------------------------------------|-----------------------------------------|
| 4L+ FL or 4L+                                    | Cohort 1                                |
| 3L FL or 3L                                      | Cohort 2                                |
| 3L+ FL or 3L+                                    | Cohort 1 and Cohort 2                   |
| 2L FL or 2L                                      | Cohort 3                                |
| 2L+ FL or 2L+                                    | All Cohorts (1, 2, and 3)               |

Table 5. Analysis Populations Presented in this SCP - Study FOL-001

| Analysis Population                                                                                                                                                                                                                                                                | 4L+ FL Cohort 1   | 3L FL Cohort 2   | 3L+ FL Cohorts 1 + 2   | 2L FL Cohort 3   | Total 2L+ FL (Cohorts 1, 2, 3)   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------|------------------------|------------------|----------------------------------|
| Leukapheresed Set - Subjects signed consent who undergo leukapheresis and meet all inclusion/exclusion criteria.                                                                                                                                                                   | 65 (100.0)        | 49 (100.0)       | 114 (100.0)            | 25 (100.0)       | 139 (100.0)                      |
| Liso-cel-treated Set - Subjects received a dose of liso-cel                                                                                                                                                                                                                        | 59 (90.8)         | 48 (98.0)        | 107 (93.9)             | 23 (92.0)        | 130 (93.5)                       |
| Liso-cel -treated Efficacy Set - Subjects received a dose of liso-cel with positive disease present before liso-cel administration per IRC. Subjects without baseline assessment repeated after anticancer therapy for disease control and before liso-cel administration excluded | 55 (84.6)         | 48 (98.0)        | 103 (90.4)             | 23 (92.0)        | 126 (90.6)                       |

<div style=\"page-break-after: always\"></div>

Table 5. Analysis Populations Presented in this SCP - Study FOL-001

| Analysis Population                                                                                       | 4L+ FL Cohort 1   | 3L FL Cohort 2   | 3L+ FL Cohorts 1 + 2   | 2L FL Cohort 3   | Total 2L+ FL (Cohorts 1, 2, 3)   |
|-----------------------------------------------------------------------------------------------------------|-------------------|------------------|------------------------|------------------|----------------------------------|
| PK Analysis Set - Subjects with any available PK measurements by PCR in the liso-cel-treated set          | 59 (90.8)         | 48 (98.0)        | 107 (93.9)             | 23 (92.0)        | 130 (93.5)                       |
| PK Evaluable Analysis Set - Subjects with at least one evaluable PK parameter in the liso-cel-treated set | 59 (90.8)         | 47 (95.9)        | 106 (93.0)             | 23 (92.0)        | 129 (92.8)                       |

Percentages are based on Leukapheresed Set.

Peripheral blood samples for PK by ddPCR were collected up to 60 months (pre-treatment, D1, 4, 8, 11, 15, 22, 29, 60, 90, 180, 270, 365, 545, 730 (24 months), 30 months, 36 months, 42 months, 48 months, 54 months, 60 months).

The PK section highlight the results in the 3L+ (cohort 1 and 2) and 2L+ groups (Cohort 1, 2 and 3) that were  evaluated  for  PK-safety  relationship,  while  the  3L+  group  was  evaluated  for  PK-efficacy relationship.

Liso-cel concentration in peripheral blood over time showed a similar pattern in the 4L+, 3L, and 2L groups. In all 3 groups, the liso-cel concentration in the peripheral blood detected by PCR exhibited a rapid expansion followed by a monophasic decline up to 28 days after infusion.

Figure 1. Median PK Concentration Data by Group (Linear and Semi-log Scales) - PK Analysis Set

Limear Seale

<!-- image -->

Upper error bar represeats the third quartile, lower error bar represents the first quartile. Lisocel was given on Study Day 1. Oaly nominal visits up to Day 29 are included in this figure. Values affer the start of subsequent anti-follicular lymphoma therapy are excladed

In the 3L+ group, median Cmax, AUC(0-28), and Tmax were 31336 copies/ μ g, 253400 day*copies/ μ g, and 10.0 days, respectively.

In the 2L+ group, median Cmax, AUC(0-28), and Tmax were 41315 copies/ μ g, 260274 day*copies/ μ g, and 10.0 days, respectively.

<div style=\"page-break-after: always\"></div>

Median Tmax reached 10 days in the 4L+, 3L, and 2L groups. Median Cmax and AUC(0-28) in the 2L group were higher than the 3L group, followed by the 4L+ group. However, inter-subject variability was large for Cmax and AUC(0-28) (geometric CV% &gt; 150%) with exposure ranges overlapping across the groups.

Table 6. Summary of Liso-cel PK parameters in Peripheral Blood by Group - PK Evaluable Analysis Set

|                           | 4L+FL Cohort 1   | 3LFL Cohort 2   | 3L+FL Cohorts 1 + 2   | 2L FL Cohort3   | Total2L+FL Cohorts 1, 2,3   |
|---------------------------|------------------|-----------------|-----------------------|-----------------|-----------------------------|
|                           | N=59             | N=47            | N=106                 | N=23            | N=129                       |
| Cmax (copies/μg)          |                  |                 |                       |                 |                             |
| n                         | 59               | 47              | 106                   | 23              | 129                         |
| Median                    | 29170            | 35815           | 31336                 | 62091           | 41315                       |
| Q1, Q3                    | 10039,82196      | 13804,124019    | 12693,96795           | 45428,176273    | 13717,100239                |
| Min, Max                  | 565,688672       | 238,399591      | 238, 688672           | 1975, 541191    | 238, 688672                 |
| Geometric Mean            | 26247            | 35828           | 30130                 | 67209           | 34763                       |
| Geometric CV%             | 303              | 312             | 307                   | 184             | 295                         |
| Tmax (days)               |                  |                 |                       |                 |                             |
| n                         | 59               | 47              | 106                   | 23              | 129                         |
| Median                    | 10.0             | 10.0            | 10.0                  | 10.0            | 10.0                        |
| Q1, Q3                    | 7.00, 13.0       | 9.00, 10.0      | 8.00, 11.0            | 9.00, 10.0      | 8.00, 11.0                  |
| Min, Max                  | 6.00, 22.0       | 7.00, 21.0      | 6.00, 22.0            | 7.00,11.0       | 6.00, 22.0                  |
| AUC(0-28) (day*copies/ug) |                  |                 |                       |                 |                             |
| 1                         | 57               | 45              | 102                   | 20              | 122                         |
| Median                    | 213741           | 281820          | 253400                | 385668          | 260274                      |
| Q1, Q3                    | 79297,485787     | 112745,905908   | 106099,603488         | 194260,921947   | 107494,645997               |
| Min, Max                  | 7895, 6986370    | 7998,2733453    | 7895, 6986370         | 12599.6849741   | 7895, 6986370               |
| Geometric Mean            | 203158           | 292732          | 238682                | 376523          | 257202                      |
| Geometric CV%             | 256              | 204             | 235                   | 260             | 240                         |

Geometric CV (%) is calculated as follows: CV (%) = 100xsqrt(exp(S^2) - 1), where S^2 denotes the variance of the log-transformedvalues.

Geometric mean is obtained by computing the arithmeticmean of the logarithm-transformed values of PK parameters and then using the exponentiation to return the computation to the original scale.

## Persistence

Persistence of lisocel transgene in the peripheral blood is defined as a transgene count ≥ the LOD. In the 3L+ and 2L+ groups, with longer follow-up based on the 10-Jan-2024 data cut compared to the Interim  Clinical  Pharmacology  report  (cut-off  Jan  2023,  data  up  to  Day  730)  persistence  of  liso-cel transgene was observed up to Month 36 (Day 1095). However, the number of evaluable subjects at Month 36 (Day 1095) was small in the 3L+ and 2L+ groups (N = 2 and N = 3, respectively). At Month 30 (Day 910), persistence of liso-cel transgene was observed in 25.0% (7 of 28 subjects) and 23.5% (8 of 34 subjects) in the 3L+ and 2L+ groups, respectively.

<div style=\"page-break-after: always\"></div>

Table  7.  Summary  of  Persistence  of  Liso-cel  in  Peripheral  Blood  by  PCR  Over  Time  -  PK Analysis Set

| Transgene, n/N (%)   | 4L+FL Cohort 1   | 3L FL Cohort2   | 3L+FL Cohorts1+2   | 2L FL Cohort3   | Total 2L+ FL Cohorts 1, 2, 3   |
|----------------------|------------------|-----------------|--------------------|-----------------|--------------------------------|
| Transgene, n/N (%)   | N=59             | N=48            | N=107              | N=23            | N=130                          |
| Day 29               | 55/57 (96.5)     | 44/46 (95.7)    | 99/103 (96.1)      | 21/22 (95.5)    | 120/125 (96.0)                 |
| Day 60               | 47/53 (88.7)     | 37/44 (84.1)    | 84/97 (86.6)       | 12/17 (70.6)    | 96/114 (84.2)                  |
| Day 90               | 33/56 (58.9)     | 34/46 (73.9)    | 67/102 (65.7)      | 8/21 (38.1)     | 75/123 (61.0)                  |
| Day 180              | 23/49 (46.9)     | 16/39 (41.0)    | 39/88 (44.3)       | 6/20 (30.0)     | 45/108 (41.7)                  |
| Day 270              | 22/48 (45.8)     | 19/41 (46.3)    | 41/89 (46.1)       | 5/20 (25.0)     | 46/109 (42.2)                  |
| Day 365              | 22/46 (47.8)     | 17/38 (44.7)    | 39/84 (46.4)       | 5/19 (26.3)     | 44/103 (42.7)                  |
| Day 545              | 18/40 (45.0)     | 15/36 (41.7)    | 33/76 (43.4)       | 6/20 (30.0)     | 39/96 (40.6)                   |
| Day 730              | 10/26 (38.5)     | 10/31 (32.3)    | 20/57 (35.1)       | 3/11 (27.3)     | 23/68 (33.8)                   |
| Month 30 (Day 910)   | 4/15 (26.7)      | 3/13 (23.1)     | 7/28 (25.0)        | 1/6 (16.7)      | 8/34 (23.5)                    |
| Month 36 (Day 1095)  | 0                | 1/2 (50.0)      | 1/2 (50.0)         | 0/1             | 1/3 (33.3)                     |

Persistence is defined as a transgene count ≥ the LOD.

Concentrationvalues after another anticancer treatment are excludedfrom thesummaries.

n/N = (number of subjects persistent)/(number of subjects for evaluation). For timepoints where there were no evaluable subjects, n/N was reported as 0.

## Subgroup analysis

Subgroup analysis  were  performed  to  assess  the  effect  on  transgene  PK  parameters  (Cmax,  Tmax, AUC[0-28]) by age (&lt; 65, ≥ 65 to &lt; 75, ≥ 75 years old), sex (male, female), region (North America, Europe, Japan), bulky disease (defined as any mass &gt; 7 cm, or 3 or more masses [each &gt; 3 cm] at screening based on investigator assessment, yes/no), pre-LDC SPD status per IRC ( ≥ 50 cm ² , &lt; 50 cm ² ), FLIPI risk category (low/intermediate/high), and modified GELF criteria (yes/no).

In the 3L+ group, no relevant differences were observed.

In the 2L+ group, a potential association was observed between longer Tmax and the presence of bulky disease, however, the median Tmax of subjects with and without bulky disease was the same (10 days). A potential association was also observed between longer Tmax and higher FLIPI risk category, however, the median Tmax was generally comparable between low-, intermediate-, and high-risk groups (9, 10, and 10 days, respectively).

## Non-conforming product

In PK evaluable analysis set, three subjects in 4L+ cohort, one in 3L and one in 2L cohorts received a non-conforming product.

## Comparison with data from BCM-003 (2L LBCL)

The clinical  pharmacology  of  Breyanzi  has  been  characterised  in  LBCL  in  studies  BCM-003,  017006, 017001 and BCM-001, however a comparison with BMC-003 has been reported since the same ddPCR method has been used to analyse the samples.

<div style=\"page-break-after: always\"></div>

Table 8. Summary of Liso-cel Transgene PK Parameters

|                             | Study FOL-001   | Study BCM-003   |
|-----------------------------|-----------------|-----------------|
| Parameter Statistic         | 3L+ FL          | 2L LBCL         |
|                             | N = 106         | N = 84          |
| Cmax (copies/µg)            |                 |                 |
| N                           | 106             | 84              |
| Median                      | 31336           | 33285           |
| Q1, Q3                      | 12693, 96795    | 13848, 94913    |
| Tmax (days)                 |                 |                 |
| N                           | 106             | 84              |
| Median                      | 10.0            | 10.0            |
| Q1, Q3                      | 8.0, 11.0       | 9.0, 11.0       |
| AUC(0-28) (day • copies/µg) |                 |                 |
| N                           | 102             | 84              |
| Median                      | 253400          | 268911          |
| Q1, Q3                      | 106099, 603488  | 114626, 779701  |

Note: n is the number of subjects who had PK parameters.

## PK/efficacy and PK/safety Relationship

The efficacy and safety endpoints are defined as follow:

Table 9. Endpoints

## Efficacy Endpoints

| BOR   | IRC assessment   | BOR is the best disease response recorded from the time of the liso-cel infusion until disease progression, end of study, or the start of another anticancer therapy.?BOR is assigned according to the following order:CR,PR,SD PD,notevaluable,ornotdone Responders are defined assubjects that achieved aBOR of either a CR or a PR up to 60 months after liso-cel infusion. Complete responders are defined as subjects that achieved a BOR of CR up to 60 months after liso-cel infusion.   |
|-------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PFS                                                                               | IRC assessment          | Time from start of liso-cel to disease progression or death from any cause, whichever occurs first.                                                                              |
|-----------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DOR                                                                               | IRCassessment           | Time from first response (CR or PR) to disease progression or deathfrom any cause,whichever occurs first.                                                                        |
| DOR ifBORis CR                                                                    | IRC assessment          | For subjects with a BOR of CR, time from first response (CR or PR) to disease progression or death from any cause,whichever occurs first.                                        |
| Safety Endpoints                                                                  | Safety Endpoints        | Safety Endpoints                                                                                                                                                                 |
| Treatment-emergent adverseeventofCRs categorized as Grade ob versus Grade ≥ 1     | Investigator assessment | A CRS event was captured on the AE CRF using prefeired term of“Cytokine release syndrome”and graded according to the grading scale adapted from Lee.                             |
| Treatment-emergent adverseeventofCRs, categorized as Grade ≤ 2 versus Grade≥3     | Investigator assessment | A CRS event was captured on the AE CRF using prefeired term of“Cytokine release syndrome”and graded according to the grading scale adapted from Lee.                             |
| Treatment-emergent adverseeventofiNT categorized as Grade ob versus Grade ≥ 1     | Investigator assessment | CAR T-cell-related iNT was captured on the AE CRF using the preferred term “neurotoxicity” and graded using NCI CTCAE v5.0 on the basis of the highest individual symptom grade. |
| Treatment-emergent adverseeventofiiNT categorized as Grade ≤ 2 versus Grade ≥ 3   | Investigator assessment | CAR T-cell-related iNT was captured on the AE CRF using the preferred term “neurotoxicity” and graded using NCI CTCAE v5.0 on the basis of the highest individual symptom grade. |
| Treatment-emergent adverse event of hypersensitivity as Grade ob versus Grade ≥ 1 | Investigator assessment | Hypersensitivity events were selected using pre-defined list of preferred terms from MedDRA v26.0.                                                                               |
| Treatment-emergent adverse event of hypersensitivity as Grade ≤2 versus Grade ≥ 3 | Investigator assessment | Hypersensitivity events were selected using pre-defined list of preferred terms from MedDRA v26.0.                                                                               |

New anticancer therapy - anti-lymphoma therapy including both allo- and auto-HSCT is considered as a new antineoplastic therapy

Grade O indicates no CRS, iNT, or hypersensitivity events.

The relationship between PK parameters (Cmax, Tmax, and AUC[0-28]) and dichotomous parameters (BOR, CRS and iiNT) were assessed by Wilcoxon tests. The relationship between PK parameters (Cmax and AUC[0-28]) and time-to-event parameters (PFS, DOR, and DOR if BOR is CR) were assessed by univariable Cox proportional hazards models. The 3L+ group was used for assessment of PK-efficacy relationships. The 3L+ and 2L+ groups were used for assessment of PK-safety relationships.

In the 3L+ group, a potential relationship was observed between higher transgene PK parameters (Cmax and AUC[0-28]) and longer PFS, DOR and DOR if BOR is CR per IRC charter. The relationships between transgene PK parameters and response (BOR of either CR or PR) were not assessed because the number of  evaluable  non-responders was less than 5. A potential relationship was observed between higher Cmax and higher CRR per IRC charter, however the number of evaluable non-CR subjects was small for the assessment (N = 5).

<div style=\"page-break-after: always\"></div>

Table 10. Relationship Between PK Parameters of Liso-cel and Efficacy (3L+ Group) Subjects from Both Liso-cel-treated Efficacy Analysis Set and PK Evaluable Analysis Set

| Variable/ Statistic                                    | Yes                                                   | No                                                | p-value                                           |
|--------------------------------------------------------|-------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Response (BOR of either CR or PR) per IRC charter      | Response (BOR of either CR or PR) per IRC charter     | Response (BOR of either CR or PR) per IRC charter | Response (BOR of either CR or PR) per IRC charter |
| Cmax (copies/µg)                                       |                                                       |                                                   |                                                   |
| n Median Q1, Q3                                        | 100 31336.0 11876.5, 90643.6                          | 2 15567.6 12692.9, 18442.3                        | NA                                                |
| Tmax (days)                                            |                                                       |                                                   |                                                   |
| n Median Q1, Q3                                        | 100 10.0 8.0, 11.0                                    | 2 17.5 14.0, 21.0                                 | NA                                                |
| AUC(0-28) (day•copies/µg)                              |                                                       |                                                   |                                                   |
| n Median Q1, Q3 Complete Response (BOR of CR) n Median | 96 245730.2 96528.0, 622704.0 per IRC charter 35066.0 | 2 161934.9 142725.2, 181144.6 5 12692.9           | NA 0.0300                                         |
| Cmax (copies/µg)                                       | 97                                                    |                                                   |                                                   |
| Tmax (days) n Median Q1, Q3                            | 97 10.0 8.0, 11.0                                     | 5 11.0 9.0, 14.0                                  | 0.2763                                            |
| PFS per IRC charter                                    |                                                       |                                                   |                                                   |
| Cmax Hazard ratio 95% CI                               | 0.37                                                  | 0.59                                              | < 0.0001                                          |
| AUC(0-28)                                              | 0.23,                                                 |                                                   |                                                   |
| Hazard ratio 95% CI                                    | 0.32 0.17,                                            | 0.61                                              | 0.0005                                            |
| AUC(0-28) Hazard ratio 95% CI                          | 0.30                                                  |                                                   |                                                   |
| DOR if BOR is CR per IRC charter                       |                                                       |                                                   | < 0.0001                                          |
| Hazard ratio 95% CI                                    | 0.36 0.22, 0.16,                                      | 0.58 0.59                                         | 0.0005                                            |

<div style=\"page-break-after: always\"></div>

Table 10. Relationship Between PK Parameters of Liso-cel and Efficacy (3L+ Group) Subjects from Both Liso-cel-treated Efficacy Analysis Set and PK Evaluable Analysis Set

| Variable/ Statistic   |            | p-value    |
|-----------------------|------------|------------|
| Hazard ratio          | 0.33       | 0.0026     |
| 95% CI                | 0.16, 0.68 | 0.16, 0.68 |

A response is defined as a complete response or partial response. For response and CR, p-values were based on the Wilcoxon test. The statistical test was only performed if there were at least five subjects in each subgroup.

For PFS, DOR, and DOR if BOR is CR, p-value, hazard ratio for a one-unit increase in log10 transformed Cmax or AUC(0-28), and associated 95% CI were based on a Cox proportional hazards model.

In the 3L+ group, a potential relationship was observed between higher transgene PK parameters (Cmax and AUC[0-28]) and higher incidence of any-grade CRS and any-grade iiNT. A potential relationship was also observed between earlier transgene Tmax and higher incidence of any-grade CRS and any-grade iiNT; however, the difference in median Tmax was small (1 day and 2 days, respectively).

The relationship between PK parameters and Grade ≥ 3 CRS or Grade ≥ 3 iiNT was not assessed because the number of evaluable subjects with Grade ≥ 3 CRS and Grade ≥ 3 iiNT was each less than 5 (N = 1 and N = 3, respectively). Results in the 2L+ group were consistent with those in the 3L+ group.

Table 11. Relationship Between Pharmacokinetic Parameters of Liso-cel and Safety (3L+ and 2L+ Groups) - PK Evaluable Analysis Set

|                             | 3L+ FL (Cohorts 1 + 2)       | 3L+ FL (Cohorts 1 + 2)      | 3L+ FL (Cohorts 1 + 2)     | Total 2L + FL (Cohorts 1, 2, 3)   | Total 2L + FL (Cohorts 1, 2, 3)   | Total 2L + FL (Cohorts 1, 2, 3)   |
|-----------------------------|------------------------------|-----------------------------|----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Variable/ Statistic         | Yes                          | No                          | p-value                    | Yes                               | No                                | p-value                           |
| CRS Status (Any-grade CRS)  | CRS Status (Any-grade CRS)   | CRS Status (Any-grade CRS)  | CRS Status (Any-grade CRS) | CRS Status (Any-grade CRS)        | CRS Status (Any-grade CRS)        | CRS Status (Any-grade CRS)        |
| Cmax (copies/µg)            |                              |                             |                            |                                   |                                   |                                   |
| n Median Q1, Q3             | 63 44539.2 20103.0, 126346.5 | 43 17689.9 6834.8, 59617.0  | 0.0058                     | 75 46862.1 22610.2, 151400.3      | 54 25476.7 9000.6, 62091.3        | 0.0033                            |
| Tmax (days)                 |                              |                             |                            |                                   |                                   |                                   |
| n Median Q1, Q3             | 63 9.0 7.0, 10.0             | 43 10.0 9.0, 12.0           | 0.0272                     | 75 9.0 7.0, 10.0                  | 54 10.0 9.0, 11.0                 | 0.0093                            |
| AUC(0-28) (day • copies/µg) |                              |                             |                            |                                   |                                   |                                   |
| n Median Q1, Q3             | 61 301949.0 149587.8,        | 41 68130.4,                 | 0.0027                     | 72 329731.4 182040.4, 970457.9    | 50 147561.1 68130.4,              | 0.0009                            |
| (Any-grade                  | iiNT)                        |                             |                            |                                   |                                   |                                   |
| Cmax (copies/µg) n          | 17 124019.2                  | 299104.9                    |                            | 21 61771.6,                       | 337709.2                          |                                   |
| iiNT Status                 | 905908.3                     | 142725.2                    |                            | 156159.8                          |                                   |                                   |
| Median Q1, Q3               | 46142.7,                     | 89 28588.6 11582.1, 71373.0 | 0.0008                     | 196958.2                          | 108 33604.2 12304.9, 74763.1      | <0.0001                           |
| Tmax                        | 176559.0                     |                             |                            |                                   | 108                               |                                   |
| (days) n                    |                              | 10.0                        |                            |                                   |                                   | 0.0049                            |
|                             | 17                           | 89                          | 0.0070                     | 21                                |                                   |                                   |
| Median                      | 8.0                          |                             |                            | 8.0                               | 10.0                              |                                   |

<div style=\"page-break-after: always\"></div>

Table 11. Relationship Between Pharmacokinetic Parameters of Liso-cel and Safety (3L+ and 2L+ Groups) - PK Evaluable Analysis Set

|                               | 3L+ FL (Cohorts 1 + 2)   | 3L+ FL (Cohorts 1 + 2)   | 3L+ FL (Cohorts 1 + 2)   | Total 2L + FL (Cohorts 1, 2, 3)   | Total 2L + FL (Cohorts 1, 2, 3)   | Total 2L + FL (Cohorts 1, 2, 3)   |
|-------------------------------|--------------------------|--------------------------|--------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Variable/ Statistic           | Yes                      | No                       | p-value                  | Yes                               | No                                | p-value                           |
| Q1, Q3                        | 7.0, 10.0                | 9.0, 12.0                |                          | 7.0, 10.0                         | 9.0, 11.0                         |                                   |
| AUC(0-28) (day • copies/µg) n | 17                       | 85                       |                          | 20                                | 102                               |                                   |
| Median                        | 912020.3                 | 213457.0                 | 0.0008                   | 970422.8                          | 235723.4                          | 0.0001                            |
| Q1, Q3                        | 377546.3, 1258803.0      | 82990.9, 423360.9        |                          | 431666.4, 1317570.0               | 87330.4, 465744.6                 |                                   |

P-values are based on the Wilcoxon test.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Breyanzi is a CD19-directed genetically modified autologous cellular immunotherapy administered as a defined composition to reduce variability in CD8+ and CD4+ T-cell dose. The CAR is comprised of a murine FMC63 monoclonal antibody-derived single chain variable fragment (scFv), IgG4 hinge region, CD28 transmembrane domain, 4-1BB (CD137) costimulatory domain, and CD3 zeta activation domain. CD3 zeta signalling is critical for initiating T-cell activation and antitumour activity, while 4- 1BB (CD137) signalling enhances the expansion and persistence of Breyanzi.

CAR binding to CD19 expressed on the cell surface of tumour and normal B cells induces activation and proliferation of CAR T cells, release of pro-inflammatory cytokines, and cytotoxic killing of target cells.

## Primary and secondary pharmacology

PD was investigated in A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy  and  Safety  of  JCAR017  in  Adult  Subjects  with  Relapsed  or  Refractory  Indolent  B-cell  NonHodgkin Lymphoma (TRANSCEND FL).

The incidence of B-cell aplasia (defined as &lt; 3% of CD19+ B-cells in peripheral blood lymphocytes) was assessed over time. Peripheral blood samples for flow cytometry (B-cell aplasia) were collected pretreatment, Day 1, 8, 11, 15, 22, 29, 60, 90, 180, 270, 365, 545, 730 and on Months 36, 48 and 60.

Overall, the results and profiles for B-cell aplasia were similar across the groups over time.

Overall,  the  trends  for  serum  immunoglobulins  (IgA,  IgG,  IgM)  were  similar  across  the groups.  The median levels of the 4L+ and 3L were comparable to the 3L+ Group.

The analysis of serum IgG levels did not take into account potential confounding by the administration of IVIG for the treatment of hypogammaglobulinemia.

## Immunogenicity

Samples for immunogenicity assessment were collected pre-treatment, Day 15, 29, 60, 90, 180, 270, 365, 545, 730 (24 months).

<div style=\"page-break-after: always\"></div>

In the 3L+ group, the prevalence of ATA was 1.9% (2 of 103 subjects); the incidence of ATA was 21.6% (22 of 102 subjects) (see Table below). The median time to first positive ATA titer in subjects with treatment-induced  ATA  was  8.77  months  (range:  5.7  -  23.9  months).  One  subject  had  treatmentboosted ATA. Similar results were observed in the 2L+ group (see Table below).

Table 15. Summary of ATA - Liso-cel-treated Analysis Set

|                       | 4L+FL Cohort 1   | 3L FL Cohort 2   | 3L+FL Cohorts 1+2   | 2LFL Cohort 3   | Total 2L+FL Cohorts 1,2,3   |
|-----------------------|------------------|------------------|---------------------|-----------------|-----------------------------|
|                       | N=59             | N=48             | N=107               | N=23            | N=130                       |
| Prevalence of ATA*    |                  |                  |                     |                 |                             |
|                       | 57               | 46               | 103                 | 21              | 124                         |
| Yes, n (%)            | 2 (3.5)          | 0                | 2 (1.9)             | 0               | 2 (1.6)                     |
| No, n (%)             | 55 (96.5)        | 46 (100.0)       | 101 (98.1)          | 21 (100.0)      | 122 (98.4)                  |
| Incidence of ATAb     |                  |                  |                     |                 |                             |
| n                     | 57               | 45               | 102                 | 21              | 123                         |
| Yes, n (%)            | 12 (21.1)        | 10 (22.2)        | 22 (21.6)           | 11 (52.4)       | 33 (26.8)                   |
| No, n (%)             | 45 (78.9)        | 35 (77.8)        | 80 (78.4)           | 10 (47.6)       | 90 (73.2)                   |
| Treatment-induced ATA |                  |                  |                     |                 |                             |
| n                     | 55               | 45               | 100                 | 21              | 121                         |
| Yes, n (%)            | 11 (20.0)        | 10 (22.2)        | 21 (21.0)           | 11 (52.4)       | 32 (26.4)                   |
| No, n (%)             | 44 (80.0)        | 35 (77.8)        | 79 (79.0)           | 10 (47.6)       | 89 (73.6)                   |
| Treatment-boosted ATA |                  |                  |                     |                 |                             |
| n                     | 2                | 0                | 2                   | 0               | 2                           |
| Yes, n (%)            | 1 (50.0)         | 0                | 1 (50.0)            | 0               | 1 (50.0)                    |
| No, n (%)             | 1 (50.0)         | 0                | 1 (50.0)            | 0               | 1 (50.0)                    |

Prevalence of anti-therapeutic antibodies is defined as the percentage of subjects with pre-existing antibodies that bind to liso-cel.

- Incidence of anti-therapeutic antibodies is defined as the percentage of subjects with treatment-induced or antibodies after infusion of liso-cel is considered treatment induced. In a subject with pre-existing antibodies, an increased level of antibodies after infusion of liso-cel is considered treatment boosted.

There was no clear difference in the prevalence of ATA across the groups. The incidence of ATA was generally  comparable  in  the  4L+  and  3L  groups  (21.1%  [12  of  57  subjects]  and  22.2%  [10  of  45 subjects], respectively) whereas higher incidence of ATA was observed in the 2L group (52.4% [11 of 21 subjects]) (Table 4.5.1-1). The median time to first positive ATA titer in subjects with treatment induced  ATA  were  comparable  across  the  groups.  In  addition,  there  was  no  clear  difference  in  the maximum  post-treatment  ATA  titers  observed  in  subjects  with  treatment-induced  ATA  among  the groups.

Clinical parameters (BOR, CRS, iiNT, and hypersensitivity) and transgene PK parameters (Cmax and AUC[0-28]) were summarized by prevalence and incidence of ATA. All endpoints were evaluated in a descriptive  manner and formal statistical comparison were not made. The 3L+ group were used for assessment of ATA with efficacy relationships, while the 3L+ and 2L+ groups were used for assessment of  ATA  with  safety  or  PK  relationships.  Overall,  no  apparent  relationships  of  treatment-induced  or treatment-boosted  ATA  were  observed  with  efficacy,  and  safety.  The  number  of  subjects  with  preexisting ATA was too low to assess any potential relationship with efficacy, safety, or PK.

Effect of ATA on efficacy

<div style=\"page-break-after: always\"></div>

In the 3L+ group, for subjects who had pre-existing ATA, the ORR and CRR per IRC charter were 100% (2 of 2 subjects) (Table below). There were no clear differences in both ORR and CRR per IRC charter between subjects who had treatment-induced or treatment-boosted ATA and subjects who did not have treatment-induced or treatment-boosted ATA.

Table 13. Summary of Response Status vs ATA in Serum - Liso-cel-treated Analysis Set - 3L+ Group

|                                     | ATAPrevalence                       | ATAPrevalence                       | ATAIncidenceb                       | ATAIncidenceb                       |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                     | Yes (N=2)                           | No (N=97)                           | Yes (N=22)                          | No (N=76)                           |
| Efficacy (assessed per IRC charter) | Efficacy (assessed per IRC charter) | Efficacy (assessed per IRC charter) | Efficacy (assessed per IRC charter) | Efficacy (assessed per IRC charter) |
| Response                            |                                     |                                     |                                     |                                     |
| Yes, n (%)                          | 2 (100.0)                           | 94 (96.9)                           | 22 (100.0)                          | 74 (97.4)                           |
| No, n (%)                           | 0                                   | 3 (3.1)                             | 0                                   | 2 (2.6)                             |
| CompleteResponse                    |                                     |                                     |                                     |                                     |
| Yes, n (%)                          | 2 (100.0)                           | 91 (93.8)                           | 21 (95.5)                           | 72 (94.7)                           |
| No, n (%)                           | 0                                   | 6 (6.2)                             | 1 (4.5)                             | 4 (5.3)                             |

Prevalence of anti-therapeutic antibodies is defined as the percentage of subjects with pre-existing antibodies that bind to the ECD of liso-cel (at the pre-liso-cel infusion evaluation).

- Incidence of anti-therapeutic antibodies is defined as the percentage of subjects with treatment-induced or treatment-boosted antibodies that bind to the ECD of liso-cel. In a subject without pre-existing antibodies, development of antibodies after infusion of liso-cel is considered treatment-induced. In a subject with pre-existing antibodies,an increased level of antibodies after infusion of liso-cel is considered treatment-boosted.

## Effect of ATA on safety

In the 3L+ group, of two subjects who had pre-existing ATA, one subject experienced Grade ≥ 3 CRS. There was no incidence of any-grade iiNT or hypersensitivity in subjects who had pre-existing ATA (0 of 2 subjects). There were no clear differences in the incidence of any-grade CRS, Grade ≥ 3 CRS, anygrade iiNT, Grade ≥ 3 iiNT, or Grade ≥ 3 hypersensitivity between subjects who had treatment-induced or treatment-boosted ATA compared with subjects who did not have treatment-induced or treatmentboosted ATA. However, a higher incidence of any-grade hypersensitivity was observed in subjects who had treatment-induced ATA. Similar results were observed in the 2L+ group (see table below).

<div style=\"page-break-after: always\"></div>

Table  14.  Summary  of  CRS,  iiNT  or  Hypersensitivity  vs  ATA  in  Serum  -  Lios-cel-treated Analysis Set - 3L+ and 2L+ Group

|                             | 3L+FL (Colhorts I + 2)      | 3L+FL (Colhorts I + 2)      | 3L+FL (Colhorts I + 2)      | 3L+FL (Colhorts I + 2)      | Total 2L+FL (Cohorts 1, 2, 3)   | Total 2L+FL (Cohorts 1, 2, 3)   | Total 2L+FL (Cohorts 1, 2, 3)   | Total 2L+FL (Cohorts 1, 2, 3)   |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                             | ATA Prevalence              | ATA Prevalence              | ATA Incidence               | ATA Incidence               | ATA Prevalence                  | ATA Prevalence                  | ATA Incideuce                   | ATA Incideuce                   |
|                             | Yes (N=2)                   | No (N=101)                  | Yes (N=22)                  | No (N=80)                   | Yes (N=2)                       | No (N=122)                      | Yes (N=33)                      | No (N=90)                       |
| Any CRS                     |                             |                             |                             |                             |                                 |                                 |                                 |                                 |
| Yes, n (%) No,n (%)         | 1 (50.0) 1 (50.0)           | 61 (60.4) 40 (39.6)         | 14 (63.6) 8 (36.4)          | 48 (60.0) 32 (40.0)         | 1 (50.0) 1 (50.0)               | 71 (58.2) 51 (41.8)             | 20 (60.6) 13 (39.4)             | 52 (57.8) 38 (42.2)             |
| CRS Grade23                 |                             |                             |                             |                             |                                 |                                 |                                 |                                 |
| Yes, n (%) No, n (%)        | 1 (50.0) 1 (50.0)           | 0 101 (100.0)               | 0 22 (100.0)                | 1 (1.3) 79 (98.8)           | 1 (50.0) 1 (50.0)               | 0 122 (100.0)                   | 0 33 (100.0)                    | 1 (1.1) 89 (98.9)               |
| Any iINT                    |                             |                             |                             |                             |                                 |                                 |                                 |                                 |
| Yes,n (%) No, n (%)         | 0 2 (100.0)                 | 16 (15.8) 85 (84.2)         | 3 (13.6) 19 (86.4)          | 13 (16.3) 67 (83.8)         | 0 2 (100.0)                     | 19 (15.6) 103 (84.4)            | 5 (15.2) 28 (84.8)              | 14 (15.6) 76 (84.4)             |
| HNT Grade≥3                 |                             |                             |                             |                             |                                 |                                 |                                 |                                 |
| Yes. n (%) No. n (%)        | 0 2 (100.0)                 | 3 (3.0) 98 (97.0)           | 0 22 (100.0)                | 3(3.8) 77 (96.3)            | 0 2 (100.0)                     | 3(2.5) 119 (97.5)               | 0 33 (100.0)                    | 3(3.3) 87 (96.7)                |
| Any bypersensitivity        | Any bypersensitivity        | Any bypersensitivity        | Any bypersensitivity        | Any bypersensitivity        | Any bypersensitivity            | Any bypersensitivity            | Any bypersensitivity            | Any bypersensitivity            |
| Yes, n (%) No, n (%)        | 0 2 (100.0)                 | 6 (5.9) 95 (94.1)           | 2 (9.1) 20 (90.9)           | 4 (5.0) 76 (95.0)           | 0 2 (100.0)                     | 8 (6.6) 114 (93.4)              | 4 (12.1) 29 (87.9)              | 4(4.4) 86 (95.6)                |
| Hypersensitivity Gradle 2 3 | Hypersensitivity Gradle 2 3 | Hypersensitivity Gradle 2 3 | Hypersensitivity Gradle 2 3 | Hypersensitivity Gradle 2 3 | Hypersensitivity Gradle 2 3     | Hypersensitivity Gradle 2 3     | Hypersensitivity Gradle 2 3     | Hypersensitivity Gradle 2 3     |
| Yes, n (%) No, n (%)        | 0 2 (100.0)                 | 0 101 (100.0)               | 0 22 (100.0)                | 0 80 (100.0)                | 0 2 (100.0)                     | 0 122 (100.0)                   | 0 33 (100.0)                    | 0 90 (100.0)                    |

Prevalence of anti-therapeutie antibodies is defined as the percentage of subjects with pre existing antibodies that bind to the ECD of liso-cel (at the pre-liso-cel infusion evaluation)

Incidence of anti-thernapeutic antibodies is defined as the percentage of subjecis with treatment-induced or treatment-boosted antibodies that bind to the ECD of existing amtibodies, an increased level of antibodies after infusion of liso-cel is considered treatment-boosted.

## Effect of ATA on pharmacokinetics

In the 3L+ group, transgene Cmax and AUC(0-28) of two subjects who had pre-existing ATA were lower than the median values of subjects who did not have pre-existing ATA. There were lower values in transgene AUC(0-28) in subjects who had treatment-induced or treatment-boosted ATA if compared to subjects who did not have treatment-induced or treatment-boosted ATA, however the difference seems small and not clear if related to ATA status. Similar results were observed in the 2L+ group (see table below).

<div style=\"page-break-after: always\"></div>

Table 15. Summary of Lios-cel in Peripheral Blood by PCR vs ATA in Serum - PK Evaluable Analysis Set - 3L+ and 2L+ Groups

|                                  | 3L+FL (Cohorts 1 + 2)              | 3L+FL (Cohorts 1 + 2)            | 3L+FL (Cohorts 1 + 2)             | Total 2L+FL (Cohorts 1, 2, 3)       | Total 2L+FL (Cohorts 1, 2, 3)    | Total 2L+FL (Cohorts 1, 2, 3)      |
|----------------------------------|------------------------------------|----------------------------------|-----------------------------------|-------------------------------------|----------------------------------|------------------------------------|
|                                  | Cmax (copies/μg)                   | (days)                           | AUC(0-28) (day*copies/μg)         | Cmax (copies/μg)                    | (days)                           | AUC(0-28) (day*copies/μg)          |
| Pre-Existing ATA                 | Pre-Existing ATA                   | Pre-Existing ATA                 | Pre-Existing ATA                  | Pre-Existing ATA                    | Pre-Existing ATA                 | Pre-Existing ATA                   |
| 11 Median Q1,Q3                  | 2 4445.050 2580.610, 6309.490      | 2 10.5 8.0, 13.0                 | 2 43877.54 19624.72, 68130.35     | 2 4445.050 2580.610, 6309.490       | 2 10.5 8.0, 13.0                 | 2 43877.54 19624.72, 68130.35      |
| No Pre-Existing ATA              | No Pre-Existing ATA                | No Pre-Existing ATA              | No Pre-Existing ATA               | No Pre-Existing ATA                 | No Pre-Existing ATA              | No Pre-Existing ATA                |
| 1n1 Median Q1,Q3                 | 100 33604.200 13153.260. 96891.610 | 100 10.0 7.5, 11.0               | 97 259171.93 107887.94. 603487.56 | 121 41314.710 14010.300. 100239.030 | 121 10.0 8.0,11.0                | 116 260274.11 109709.64, 673556.12 |
| Treatment-Induced/Boosted ATA    | Treatment-Induced/Boosted ATA      | Treatment-Induced/Boosted ATA    | Treatment-Induced/Boosted ATA     | Treatment-Induced/Boosted ATA       | Treatment-Induced/Boosted ATA    | Treatment-Induced/Boosted ATA      |
| n Median Q1.Q3                   | 22 31051.735 18853.100. 46436.690  | 22 9.0 7.0.10.0                  | 21 220205.52 149587.77. 299104.86 | 33 44655.040 28588.570. 124019.240  | 33 9.0 7.0.10.0                  | 30 245941.29 169034.53. 701115.37  |
| No Treatment-Induced/Boosted ATA | No Treatment-Induced/Boosted ATA   | No Treatment-Induced/Boosted ATA | No Treatment-Induced/Boosted ATA  | No Treatment-Induced/Boosted ATA    | No Treatment-Induced/Boosted ATA | No Treatment-Induced/Boosted ATA   |
| n Median Q1, Q3                  | 80 32797.820 11722.740. 98985.455  | 80 10.0 8.0,11.5                 | 78 260274.11 80717.34. 905908.32  | 90 36822.180 12692.850. 96988.260   | 90 10.0 8.0.11.0                 | 88 265889.27 81854.10. 642291.27   |

Pre-existing antibodies are antibodies that bind to the ECD of liso-cel at the pre-liso-cel infusion evaluation. In a subject without pre-existing antibodies, development of antibodies after infusion of liso-cel is considered treatment-induced.

In a subject with pre-existing antibodies. an increased level of antibodies after infusion of liso-cel is considered treatiment-boosted.

Peripheral blood samples for flow cytometry (T-cell phenotype) were collected pre-treatment, Day 1, 8, 11, 15, 22, 29, 60 and 90. However, results related to this parameter are not available.

## 2.4.4. Discussion on clinical pharmacology

Breyanzi dose recommendation of 100 × 10 6  CAR+ viable T cells in Study FOL-001 was selected based on the dosing experience from Study 017001.

The clinical pharmacology profile of liso-cel in subjects with FL has been characterized based on the results from Cohorts 1, 2 and 3 of clinical study FOL-001 and includes a characterization of the PK profile of liso-cel as described above.

## Methods

Methods for the Pharmacology data collections, as described above, have been considered acceptable and duly validated.

## Pharmacokinetic

<div style=\"page-break-after: always\"></div>

Data from ddPCR of samples collected from Study FOL-001 showed that a higher expansion of cells occurred at Day 10 post-infusion with a decline up to day 29, that is in line with data previously observed in the initial MA and in the clinical study BCM-003 supporting the extension of indication in 2L Large B-Cell Lymphoma (LBCL).

The median Tmax in Cohorts 1 and 2 (4L+ FL and 3L FL) is 10 days with a minimum of 6 days to a maximum of 22; in Cohort 3 (2L FL) the range of Tmax is narrower (9-10 days), but a lower number of patients are included.

In terms of median Cmax, Cohort 3 (2L FL) showed a higher expression (62091 copie/ μ g) compared to Cohort 1 (29170 copie/ μ g) and 2 (35815 copie/ μ g) and lower variability; however, the range of Cmax in Cohort 3 is within that of Cohort 1 and 2.

The median AUC(0-28) in Cohort 3 showed the same trend of the median Cmax, with higher expression and range included in that of Cohort 1 and 2. The variability is high in all cohorts.

The higher expression in Cohort 2 could be due to a higher burden of disease, however no clear conclusions can be drawn due to the high variability and overlapping of expression ranges between cohorts. Some patients showed low level of transgene copies (e.g. CCTH 1081001, CCTH 1101001) and although a relationship has been observed between PK parameters and efficacy endpoints, no conclusion can be drawn on expansion threshold that guarantees efficacy.

Data on persistence are collected until Month 36 (Day 1095), however at this time point very few data are available (3 patients). At Month 30 (day 910) data from 34 patients are available and 23.5% showed persistence. Patients showing a high gag copies/ μ g showed a longer persistence, however there are patients in which the persistence was maintained until day 730 although the gag copies/ μ g were low.

It is of note that persistence in FOL-001 was analysed for a longer period than in Study BCM-003 (i.e. until 17 Months).

Among the subgroup analysis no significant differences were observed on transgene PK parameters (Cmax, Tmax, AUC0-28) by age, sex, region, modified GELF criteria. In Cohort 2L+ (Cohorts 1, 2, 3) a trend of higher median Cmax is observed in preLDC SPD status ≥ 50 cm2 and FLIPI risk category low, however this difference is not statistically significant. Regarding the bulky disease Cohort 3L+ and Cohort 2L+ showed a slightly higher median Cmax, however not statistically significant. In Cohort 2L+ a potential association was observed between longer Tmax and the presence of bulky disease, however, the median Tmax of subjects with and without bulky disease was the same (10 days).

In the PK evaluable analysis set, three subjects in 4L+ cohort, one in 3L and one in 2L cohorts received a non-conforming product, however PK parameters fall within the ranges observed in patients taking the conforming product.

The MAH compared the PK parameters between study FOL-001 and BCM-003 in which the same ddPCR has been used. Cmax, Tmax and AUC0-28 showed similar median values and overlapping of exposure quartiles.

## PK/Efficacy and PK/safety relationship

The 3L+ group (cohort 1 and 2) was used for assessment of PK-efficacy relationships and a potential relationship was observed between higher transgene PK parameters (Cmax and AUC0-28) and efficacy endpoints (longer PFS, DOR and DOR if BOR is CR per IRC charter). A potential relationship was observed between higher Cmax and higher Complete response per IRC charter, however the number of evaluable non-CR subjects was small for the assessment (N = 5).

<div style=\"page-break-after: always\"></div>

The 3L+ and 2L+ groups were used for assessment of PK-safety relationships. As expected, a potential relationship is observed between PK parameters (Cmax, Tmax and AUC0-28) and any-grade CRS and any-grade iiNT.  The difference in median Tmax in patients showing any grade of CRS or iiNT compared to patients free of these events is very small (max 2 hours); considering the setting of use and the monitoring foreseen after the infusion, this does not represent an issue.

## Pharmacodynamics

PD was investigated in A Phase 2, Open-label, Single-arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-cell NonHodgkin Lymphoma (TRANSCEND FL).

The PD parameters assessed were the incidence of B-cell aplasia (defined as &lt; 3% of CD19+ B-cells in peripheral blood lymphocytes), serum immunoglobulins (IgA, IgG, IgM), and a total of 37 soluble biomarkers (analyzed to examine changes in cytokine and chemokine levels following liso-cel infusion).

Overall, the results and profiles for B-cell aplasia over time and the trends for serum immunoglobulins were similar across the groups. B-cell aplasia was maintained through Day 90

## Immunogenicity

Immunogenicity was investigated till 24 months. There was no clear difference in the prevalence of ATA across the groups. The incidence of ATA was generally comparable in the 4L+ and 3L groups (21.1% [12 of 57 subjects] and 22.2% [10 of 45 subjects], respectively) whereas higher incidence of ATA was observed in the 2L group (52.4% [11 of 21 subjects]). The median time to first positive ATA titer in subjects with treatment induced ATA were comparable across the groups. In addition, there was no clear difference in the maximum post-treatment ATA titers observed in subjects with treatment-induced ATA among the groups.

Overall, no apparent relationships of treatment-induced or treatment-boosted ATA were observed with efficacy and safety, with the exception any-grade hypersensitivity, where a higher incidence was observed in subjects who had treatment-induced ATA. The number of subjects with pre-existing ATA was too low to assess any potential relationship with efficacy, safety, or PK. There were lower values in transgene AUC(0-28) in subjects who had treatment-induced or treatment-boosted ATA if compared to subjects who did not have treatment-induced or treatment-boosted ATA, however the difference seems small and not clear if related to ATA status.

## 2.4.5. Conclusions on clinical pharmacology

Overall, the clinical pharmacology profile of liso-cel in subjects with FL has been adequately characterized  and no major differences were noted in the extended FL patient population based on data available.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study(ies)

The Liso-cel dosing recommendation of a target dose of 100 × 10 6  CAR+ viable T cells in Study FOL001 was selected based on the dosing experience in Study 017001, a Phase 1 study in adult subjects with R/R DLBCL NOS (de novo and transformed from indolent lymphoma), HGBCL with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, PMBCL, FL grade 3B, and MCL, object of the initial Marketing authorisation for Breyanzi (Breyanzi EPAR).

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study

## Title of Study

JCAR017-FOL-001 (TRANSCEND FL; Study FOL-001): A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of liso-cel in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)

A specific cohort of patients affected by Marginal Zone Lymphoma was also included in this trial, but it was not considered in the efficacy analysis evaluation. The study contemplates three different phases: Pretreatment, Treatment, and Post-treatment Follow-up. Upon completion or early discontinuation, subjects were asked to participate in a LTFU study (GC-LTFU-001) for up to 15 years after the dose of Liso-cel.

Figure 2. Study Design

<!-- image -->

## Methods

## Study participants

The target study population included adult subjects with R/R FL and R/R MZL.

Depending on cohort assignment, subjects must have received previous treatment as follows:

- -Cohort 1 (4L+ R/R FL): received at least 3 prior lines of systemic therapy. At least 1 of these lines must be a combination which included an anti-CD20 antibody and an alkylating agent. Prior HSCT was permitted as part of a line of prior therapy along with the preceding salvage regimen. A group of 4L+ double-refractory subjects was to be enrolled in this cohort.

<div style=\"page-break-after: always\"></div>

-Cohort 2 (3L R/R FL): received 2 prior lines of systemic therapy. At least 1 of these lines must be a combination which included an anti-CD20 antibody and an alkylating agent. Prior HSCT was permitted as part of a line of prior therapy along with the preceding salvage regimen.

-Cohort 3 (2L R/R FL): received 1 prior line of combination systemic therapy, which included an anti-CD20 antibody and an alkylating agent. A group of POD24-Per Protocol subjects was to be enrolled to this cohort. The 2L subjects that did not meet this definition must instead meet one of the modified GELF criteria.

-Cohort 4 (3L+ R/R MZL): received at least 2 prior systemic therapies, including at least one line of combination systemic therapy, therapy with an anti-CD20 antibody and an alkylating agent, or relapsed after HSCT.

## Main inclusion and exclusion criteria

Eligible subjects must have had:

-  histologically confirmed FL (Grade 1, 2, or 3a) or MZL, as assessed by local pathology, within 6 months of screening

- relapsed or refractory disease as assessed by the Investigator defined as follow:

- a. Relapsed lymphoma is defined as relapse after an initial response of CR or PR to the prior therapy
- b. Refractory lymphoma is defined as a best response of SD or PD after prior therapy

- measurable disease defined as PET-positive disease with at least one PET positive lesion and at least one measurable nodal or extranodal lesion according to the 'Celgene interpretation of the Lugano Classification'.

- ECOG performance status of 0 or 1, and adequate organ functions.

Main exclusion criteria included evidence or history of composite DLBCL and FL, or transformed FL, CNS-only involvement by malignancy (secondary CNS involvement was allowed), or prior CAR T-cell or other genetically-modified cell therapy.

A retrospective central pathology confirmation of the FL diagnosis was required per study protocol.

## Treatments

Protocol-related treatments were relegated to pre-treatment and treatment period as reported below:

## Pretreatment Period

## Leukapheresis

Following screening and enrolment, an unstimulated leukapheresis collection was performed on each subject to obtain a sufficient quantity of PBMCs for the production of the Liso-cel investigational product. Leukapheresis was to occur approximately 5 weeks prior to Liso-cel administration on Day 1. Leukapheresis was required to be scheduled as soon as possible after meeting eligibility requirements, in coordination with the Sponsor. If Liso-cel could not be manufactured, the subject could have had a second leukapheresis procedure performed, as long as they continued to meet eligibility requirements.

Optional Bridging Treatment Between Leukapheresis and LDC

<div style=\"page-break-after: always\"></div>

Anticancer treatment as bridging was allowed for disease control while Liso-cel was manufactured, if deemed necessary by the Investigator (i.e., after leukapheresis and prior to Lymphodepleting Chemotherapy (LDC)).

## Treatment Period

The treatment period was defined as the period of time from the date on which LDC was first administered to Day 29 after Liso-cel infusion. All subjects, including those who prematurely withdrew after the one dose of Liso-cel and those with progressive disease (PD), were asked to complete the post-treatment follow-up visits at the following intervals: Days 60, 90, 180, 270, 365, 545, 730 (Month 24), and Months 30, 36, 42, 48, 54, and 60 (EOS) after Liso-cel administration for disease status and survival, unless otherwise specified.

Subjects were required to be clinically stable, and recovered from any prior toxicities, to receive LDC and proceed with Liso-cel infusion. Neither LDC nor Liso-cel was administered if there was a worsening of performance status (PS) (compared to initial assessment), rapid clinical deterioration, or evidence of rapidly progressive disease. Prior to LDC and Liso-cel administration, subjects were evaluated for evidence of ongoing infection and if an infection was suspected, it was treated, while LDC and Liso-cel treatment were postponed until infection resolution.

## Lymphodepleting Chemotherapy

Upon notification from the Sponsor that Liso-cel was available, LDC was timed so as to be completed 2 to 7 days prior to Liso-cel administration. A low-intensity LDC regimen of fludarabine IV (30 mg/m 2 /day for 3 days) and cyclophosphamide IV (300 mg/m 2 /day for 3 days) was administered prior to Liso-cel administration: LDC administration denoted the start of the Treatment Period.

## Liso-cel Administration

Subjects were premedicated with 500 to 650 mg acetaminophen per os (PO) and 25 to 50 mg diphenhydramine hydrochloride (PO or intravenous (IV)) 30 to 60 minutes prior to Liso-cel administration. These medications were to be repeated every 6 hours as needed based on the Investigator's assessment of symptoms. Premedication with steroids was not allowed. Liso-cel administration was given as a single dose of 100 × 10 6  CAR+ T cells (including CD8+ CAR+ T cells and CD4+ CAR+ T cells) on Study Day 1, 2 to 7 days after completion of LDC. Each Liso-cel dose consisted of CD8+ CAR+ T cells and CD4+ CAR+ T cells. Liso-cel was infused on Day 1 at a single dose of 100 × 10 6  CAR-positive viable T cells (CAR+ T cells), 2 to 7 days after completion of LDC. Subjects were continuously monitored during Liso-cel administration. Vital signs (temperature, respiratory rate, heart rate, blood pressure, and SaO2 by pulse oximetry) were measured approximately every 15 minutes (± 5 minutes), starting from 15 minutes prior to the first IV administration until one hour after the last IV administration, and hourly for the next 2 hours.

## Concomitant medications

Concomitant medications were allowed during the protocol.

Prohibited prior treatments included: alemtuzumab treatment within 6 months of leukapheresis, fludarabine or cladribine treatment within 3 months of leukapheresis, and prior CAR T-cell or other genetically-modified cell therapy.

## Objectives

The primary objective of the study was to determine the antitumoral activity of Liso-cel in patients affected by R/R FL.

<div style=\"page-break-after: always\"></div>

The secondary objectives included to evaluate other measures of efficacy and safety of liso-cel.

## Outcomes/endpoints

## Primary Endpoint

The primary endpoint was the ORR as assessed by PET-CT (for FL) using the 'Lugano Classification', and defined as the percentage of subjects with a best overall response (BOR) of complete response (CR) or partial response (PR) up to 60 months after liso-cel infusion as determined by an IRC (see table below).

Per Study FOL-001 protocol, PET scan was used to evaluate bone marrow lymphoma involvement.

Table 16. Estimands for the primary objective

| Population                                                        | Adult patients with FL who are refractory or relapsed to the prior therapy in Cohort 1 (4L+), Cohort 2 (3L), Cohort 3 (2L) who would encounter the Intercurrent Event of achieving a response (CR or PR) at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification   |
|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                                            | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                                                               |
| Endpoint (variable)                                               | ORR: Achieving a response (CR or PR) at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification                                                                                                                                                                       |
| Population-level summary                                          | Overall response rate is defined as proportion of subjects with an IRC assessed BOR of either CR or PR.                                                                                                                                                                                                                            |
| Intercurrent events and strategy to handle them                   | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                                                    |
| Intercurrent event n 1 Lost to follow-up before achieving a CR/PR | Strategy Composite: subjects are counted as non-responders                                                                                                                                                                                                                                                                         |
| Intercurrent event n 2 Subsequent anti- lymphoma Therapy          | Strategy While-on-treatment: Observations after the intercurrent event are excluded.                                                                                                                                                                                                                                               |
| Intercurrent event n 3                                            | Strategy                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| HSCT as consolidation therapy                                  | Treatment Policy: Disease assessments after the intercurrent event are included regardless of intercurrent event. Subjects who receive HSCT post infusion (but no other anticancer treatment) should continue to undergo scans, unless they have progressive disease   |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intercurrent event n 4 Progression assessed by IRC             | Strategy While-on treatment: Disease assessments after the intercurrent event are excluded.                                                                                                                                                                            |
| Intercurrent event n 5 Death on the same day as CR/PR achieved | Strategy Treatment Policy: Subjects are counted as Responders                                                                                                                                                                                                          |

## Secondary and exploratory objectives/Endpoints

Table 17. Efficacy and PRO Endpoints - Study FOL-001

| Secondary Endpoints                                                                                              | Endpoint description                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Complete response rate (CRR) as assessed by PET-CT (for FL) using the 'Lugano Classification' a                  | Percentage of subjects achieving a CR at any time up to 60 months after liso-cel treatment (EOS)                                                                  |
| Duration of Response (DOR) as assessed by PET-CT and/or CT using the 'Lugano Classification' a                   | Time from first response (CR or PR) to disease progression or death from any cause, whichever occurs first up to 60 months after liso-cel treatment (EOS)         |
| DOR if bets overall responses (BOR) is CR, as assessed by PET-CT and/or CT b using the 'Lugano Classification' a | For subjects with a BOR of CR, time from first response (CR or PR) to disease progression or death from any cause up to 60 months after liso-cel infusion (EOS) c |
| Progression free survival (PFS) as assessed by PET-CT and/or CT using the 'Lugano Classification' a              | Time from start of liso - cel to disease progression or death from any cause, whichever occurs first up to 60 months after liso-cel treatment (EOS)               |
| Overall survival (OS)                                                                                            | Time from start of liso-cel to time of death due to any cause up to 60 months after liso-cel treatment (EOS)                                                      |
| Health related quality of life (HRQoL)                                                                           | HRQoL primary domains of interest assessed by EORTC QLQ - C30 (global health/QoL, physical functioning,                                                           |

<div style=\"page-break-after: always\"></div>

## cognitive functioning, fatigue, pain) and FACT-LymS up to 24 months after liso-cel treatment

| Exploratory                                 |                                                                                                                  |
|---------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| HRQoL                                       | HRQoL parameters assessed by the remaining subscales of: EORTC QLQ-C30, up to 24 months after liso-cel treatment |
| Health Utility and Global Health Assessment | EQ-5D-5L health utility and VAS scores up to 60 months after liso - cel treatment (EOS)                          |
| Hospital Resource Utilization               | Number of inpatient ICU days and outpatient visits up to 60 months after liso-cel treatment (EOS)                |

a Per Study FOL-001 protocol, PET scan was used to evaluate bone marrow lymphoma involvement.

b PET-CT was not required for subjects who reached a PET-CT CR and these subjects could subsequently be monitored by CT only.

c Definition above per protocol. Of note, per SAP version 3.0, DOR if BOR is CR was defined as the time from first complete response to disease progression or death from any cause up to 60 months after liso-cel infusion.

Complete Response Rate (CRR), DOR, PFS and OS were defined as key secondary endpoints and were all assessed by PET-CT scans based on the Lugano Classification.

Regarding the definition of DOR and PFS, the EMA censoring rules were applied, while in the OS analysis all available survival information, including the information from the long-term follow-up study were included.

## Estimands for the key secondary objectives

Table 18. First key secondary endpoint: complete response (CR)

| Population                                      | Adult patients with FL who are refractory or relapsed to the prior therapy in Cohort 1 (4L+), Cohort 2 (3L), Cohort 3 (2L) who would encounter the Intercurrent Event of achieving a CR at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                          | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                                              |
| Endpoint (variable)                             | CR: Achieving a response of CR at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification                                                                                                                                                            |
| Population-level summary                        | Complete response rate is defined as proportion of subjects with an IRC assessed BOR of CR.                                                                                                                                                                                                                       |
| Intercurrent events and strategy to handle them | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                                   |
| Intercurrent event n 1                          | Strategy Composite: subjects are counted as non-responders                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Lost to follow-up before achieving a CR/PR                  |                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intercurrent event n 2 Subsequent anti- lymphoma Therapy    | Strategy While-on-treatment: Observations after the intercurrent event are excluded.                                                                                                                                                                                          |
| Intercurrent event n 3 HSCT as consolidation therapy        | Strategy Treatment Policy: Disease assessments after the intercurrent event are included regardless of intercurrent event. Subjects who receive HSCT post infusion (but no other anticancer treatment) should continue to undergo scans, unless they have progressive disease |
| Intercurrent event n 4 Progression assessed by IRC          | Strategy While-on treatment: Disease assessments after the intercurrent event are excluded.                                                                                                                                                                                   |
| Intercurrent event n 5 Death on the same day as CR achieved | Strategy Treatment Policy: Subjects are counted as Responders                                                                                                                                                                                                                 |

Table 19. Second key secondary endpoint: Duration of response (DOR)

| Population             | Adult patients with FL who are refractory or relapsed to the prior therapy in Cohort 1 (4L+), Cohort 2 (3L), Cohort 3 (2L) who would encounter the Intercurrent Event of achieving a CR at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification   |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s> | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Endpoint (variable)                                                       | DOR: time from first response (CR or PR) to disease progression or death from any cause, whichever occurs first up to 60 months after liso-cel infusion (EOS), which is assessed by IRC using the Lugano Classification   |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population-level summary                                                  | Median DOR with 95% CI                                                                                                                                                                                                    |
| Intercurrent events and strategy to handle them                           | Intercurrent events and strategy to handle them                                                                                                                                                                           |
| Intercurrent event n 1 Lost to follow-up before PD or death               | Strategy Hypothetical: Censored at last adequate response assessment before the intercurrent event                                                                                                                        |
| Intercurrent event n 2 Start a new anti- lymphoma Therapy before PD/death | Strategy Treatment policy: All data are used regardless of this intercurrent event.                                                                                                                                       |

Table 20. Third key secondary endpoint: Progression free survival (PFS)

| Population                                      | Adult patients with FL who are refractory or relapsed to the prior therapy in Cohort 1 (4L+), Cohort 2 (3L), Cohort 3 (2L) who would encounter the Intercurrent Event of achieving a CR at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                          | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                                              |
| Endpoint (variable)                             | PFS is defined as the time from start of liso-cel to disease progression or death from any cause, whichever occurs first up to 60 months after liso-cel infusion (EOS).                                                                                                                                           |
| Population-level summary                        | Median PFS with 95% CI                                                                                                                                                                                                                                                                                            |
| Intercurrent events and strategy to handle them | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                                   |
| Intercurrent event n 1 Lost to follow-up        | Strategy Hypothetical: Censored at last adequate response assessment before the intercurrent event                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Intercurrent event n 2 Start a new anti- lymphoma Therapy before PD/death   | Strategy Treatment policy: All data are used regardless of this intercurrent event.   |
|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|

Table 21. Forth key secondary endpoint: overall survival (OS)

| Population                                                             | Adult patients with FL who are refractory or relapsed to the prior therapy in Cohort 1 (4L+), Cohort 2 (3L), Cohort 3 (2L) who would encounter the Intercurrent Event of achieving a CR at any time up to 60 months after liso-cel infusion, which is assessed by PET-CT by IRC using the Lugano Classification   |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment condition<s>                                                 | Assignment to liso-cel, single administration, in a single arm trial                                                                                                                                                                                                                                              |
| Endpoint (variable)                                                    | OS is defined as the time from start of liso-cel to time of death due to any cause up to 60 months after liso-cel infusion (EOS).                                                                                                                                                                                 |
| Population-level summary                                               | Median OS with 95% CI                                                                                                                                                                                                                                                                                             |
| Intercurrent events and strategy to handle them                        | Intercurrent events and strategy to handle them                                                                                                                                                                                                                                                                   |
| Intercurrent event n 1 Lost to follow-up                               | Strategy Hypothetical: Censored at last adequate response assessment before the intercurrent event                                                                                                                                                                                                                |
| Intercurrent event n 2 Start a new anti- lymphoma Therapy before death | Strategy Treatment policy: All data are used regardless of this intercurrent event.                                                                                                                                                                                                                               |

According to Study FOL-001 protocol subjects were considered enrolled in the trial once they underwent leukapheresis. The Leukapheresed Analysis Set corresponds, therefore, to the ITT Set and includes all subjects who had signed informed consent, met all inclusion/exclusion criteria, and underwent leukapheresis.

## Study assessment

Efficacy has been assessed by radiographic tumour evaluation by diagnostic quality computed tomography (CT)/magnetic resonance imaging (MRI) scans (chest, neck, abdomen and pelvis) and/or positron emission tomography (PET) scans according to the Lugano Classification (Cheson, 2014) and

<div style=\"page-break-after: always\"></div>

has been reviewed by an independent review committee (IRC). For this study, a 'Modified Lugano Classification Criteria' has been used; FL subjects have been primarily be assessed using PET scans.

Notably, PET scans were not required after a subject achieved a complete response (CR) unless progressive disease (PD) was suspected on follow- up CT/MRI scan. Assessment of bone marrow involvement by lymphoma was not routinely used at screening, while a confirmatory bone marrow biopsy (BMB) has been  conducted as soon as logistically feasible after initial PET CR in all FL subjects who did not have a negative BMB between their most recent disease progression prior to screening and initiation of lymphodepleting chemotherapy.

In respect to the risk of Indeterminate Response (IR) due to immunologic-related tumour flare, if a subject demonstrated early tumour progression (defined as occurring prior to 3 months after liso-cel infusion), the investigator was responsible for evaluating whether the subject was experiencing a possible pseudoprogression (i.e., tumour flare, a local inflammatory reaction indicating early tumour response at sites of disease such as lymph nodes). Per protocol, if tumour flare was suspected it was recommended that either a biopsy be performed or the lesion be reassessed in at least 2 weeks, and if there was continued evidence of tumour progression, the date of progressive disease was that of the previous evaluation.

## Sensitivity analyses

Sensitivity analyses of primary and secondary efficacy endpoints, including ORR, CRR, DOR, and PFS, referred as per FDA algorithm, were performed based on the IRC Procedures Document and the use of FDA censoring rules for DOR and PFS, as reported in the table below.

Table 22. Definitions of FDA Algorithm and IRC Charter

| Terminology           | FDA algorithm                                                               | IRC charter                                                                                                                 |
|-----------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Response evaluation   | IRC Procedures Document using the Lugano Classification                     | IRC charter using a modified Lugano Classification (using PET scan instead of BMB for lymphomatous bone marrow involvement) |
| Censoring rules       | FDA censoring rules for DOR and PFS                                         | EMA censoring rules for DOR and PFS                                                                                         |
| Per-protocol analyses | Sensitivity analyses; referred as 'FDA criteria' in the statistical outputs | Primary analyses; referred as 'IRC assessment' in the statistical outputs                                                   |

In particular, attention has been posed on:

- 1) BMB was required to confirm metabolic CR in subjects with a positive, missing, or inconclusive BMB at study entry. Subjects with a negative study entry BMB were exempt from confirmatory biopsies
- 2) The following scenarios were categorized as PD regardless of PET-based metabolic response at that time point:
- a. Complete metabolic response/partial metabolic response on PET and disease progression on CT scan
- b. Stable metabolic disease on PET and disease progression on CT scan

<div style=\"page-break-after: always\"></div>

- c. New lesion on CT scan regardless of whether the new lesion is FDG avid on PET
- d. The application of FDA censoring rules to determine DOR and PFS

## Subgroup analyses

Efficacy subgroup analyses were performed based on demographic variables from subject's baseline status such as:

- -Age
- -Sex
- -Ethnicity
- -Anticancer treatment for disease control (yes vs no)
- -Concomitant G-CSF (yes vs no)

Subgroup analyses and forest plots were performed by cohort for the primary and secondary efficacy endpoints of ORR, CRR, DOR, PFS, and OS.

## Sample size

Assuming a 20% drop out rate, a total of approximately 213 subjects may be enrolled to ensure a total of 170 treatments with Liso-cel divided into 4 cohorts as follows:

- Cohort 1 (4L+ R/R FL): approximately 50 treated subjects
- Cohort 2 (3L R/R FL): approximately 40 treated subjects
- Cohort 3 (2L R/R FL): approximately 20 treated subjects, with a minimum of 10 POD24-Per Protocol subjects
- Cohort 4 (3L+ R/R MZL): approximately 60 treated subjects

The statistical hypothesis for the definition of the ORR threshold was set on literature data about the efficacy of PI3K inhibitors Idelalisib (in 3L+ subjects double refractory, assessed by CT: ORR 54%, CRR 14%,median DOR 11 months and median PFS 11 months; 4 median prior lines of therapy), Copanlisib (3L+ subjects r/r, received rituximab and alkylating agent, assessed by CT: ORR 59%, CRR 14%, median DOR 12 months and median PFS 11 months; 4 median prior lines of therapy) and Duvelisib (3L+ subjects double refractory, assessed by CT: ORR 42%, CRR 1%, median DOR 11 months and median PFS 8 months; 3 median prior lines of therapy).

Based on the literature for 3L+ r/r Marginal Zone Lymphoma (MZL) subjects, the following results have been reported: Ibrutinib data (n=63), 3L+ subjects, assessed by CT: ORR 48%, CRR 3%, median DOR not reached, median PFS 14 months; 2 median prior lines of therapy.

## Randomisation

Not applicable.

## Blinding (masking)

Not applicable.

<div style=\"page-break-after: always\"></div>

## Statistical methods

The hypothesis testing was planned for each of the following analysis group: Analysis Group 1 : 4L+ r/r FL (Cohort 1) Analysis Group 2 : 3L+ r/r FL (Cohort 1 and Cohort 2) Analysis Group 3 : 2L r/r FL (Cohort 3) Analysis Group 4 : 3L+ r/r MZL (Cohort 4) All patients included in the 3L + were eligible regardless of the presence of POD24 status or GELF criteria. Analysis Group 1: 4L+ r/r FL (Cohort 1): The null hypotheses for each endpoint are as follows as assessed by PET-CT: H0: ORR = 50%, CRR = 20%. With a sample size of 50 treated subjects, using 1sided 0.025 level testing, there would be 90% power to detect an ORR of 74% versus 50%, or a CRR of 42% versus 20%, using exact binomial one sample tests unadjusted for the hierarchical testing procedure. Analysis Group 2: 3L+ FL (Cohort 1 and Cohort 2): The analysis of the 3L+ FL population will include approximately 90 treated subjects (approximately 40 3L and 50 4L+). The null hypotheses for each endpoint are as follows as assessed by PET-CT: H0: ORR = 60%, CRR = 30%. With a sample size of 90 subjects, using 1- sided 0.025 level testing there would be 90% power to detect an ORR of 77% versus 60%, or a CRR of 48% versus 30%, using exact binomial one sample tests unadjusted for the hierarchical testing procedure. Analysis Group 3: 2L r/r FL (Cohort 3): The targets for each endpoint are as follows as assessed by PET-CT: Ha: ORR = 80%, CRR = 50%. The analysis of this cohort is for proof of concept. With a sample size of 20 treated subjects, using 1-sided 0.025 level testing, there would be 80% power to detect an ORR of 80% versus 50%, or a CRR of 50% versus 19%, using exact binomial one sample tests unadjusted for the hierarchical testing procedure. Analysis Group 4: 3L+ r/r MZL (Cohort 4): The null hypotheses for each endpoint are as follows as assessed by CT: H0: ORR = 50%, CRR = 5%. With a sample size of 60 treated subjects, using 1-sided 0.025 level testing, there would be 90% power to detect an ORR of 72 % versus 50%, or a CRR of 19 % versus 5%, using exact binomial one sample tests unadjusted for the hierarchical testing procedure. For each of these analysis groups, hierarchical testing was used to control type 1 error with the endpoints being tested in the following order: ORR, CRR. Since Cohort 1 is included in Analysis Groups 1 and 2, a multiplicity adjustment procedure was used between these groups. The following three testing sequences were treated independently: Sequence 1 (Analysis Groups 1 and 2) Sequence 2 (Analysis Group 3) Sequence 3 (Analysis Group 4)

## Figure 3. Testing sequences

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Primary Endpoint

For each analysis group described above, the ORR analysis was a one-sided 0.025 level exact binomial test for whether the ORR was greater than the null hypothesis rate. The primary efficacy analysis tested, for each analysis group, the null hypothesis of O RR ≤ p0, against the alternative hypothesis that ORR &gt; p0 at a 1-sided 0.025 level of significance at the primary analysis, ie,

H0: ORR ≤ p0 vs. H1: ORR &gt; p0.

The primary analysis for Analysis Groups 1 and 2 was planned for when the approximate number of planned treated subjects in both groups was followed for DOR for approximately 12 months after first response of CR or PR per the Investigator's assessment or until death, disease progression, or withdrawal from the study. The approximate number of treated subjects was 50 for Analysis Group 1 (4L+ R/R FL) and 90 for Analysis Group 2 (3L+ R/R FL).

The primary analysis for Analysis Group 3 was planned when the approximate number of planned treated subjects was followed for DOR for approximately 12 months after first response of CR or PR per the Investigator's assessment or until death, disease progression, or withdrawal from the study. The approximate number of treated subjects was 20 for Analysis Group 3 (2L R/R FL).

## Secondary Endpoint of CRR

For each analysis group reported before, the CRR analysis will be a one-sided 0.025 level exact binomial test for whether the CRR is greater than the null hypothesis rate; similar to what reported for the primary endpoint, a multiplicity adjustment procedure was required considering that cohort 1 was included in both analysis group 1 and 2.

The efficacy analysis of CRR will test, for each analysis group, the null hypothesis of CRR ≤ p0 against the alternative hypothesis that CRR &gt; p0 at a 1-sided 0.025 level of significance at the primary analysis, i.e.:

H0: CRR ≤ p0 vs. H1: CRR &gt; p0

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Data cutoff date of 10-Jan-2024.

<!-- image -->

## Recruitment

As of the clinical data cut-off date (10-Jan-2024), all FL subjects (Cohorts 1, 2, and 3) were enrolled (MZL subjects in Cohort 4 were still enrolling), and 115 FL subjects had 12 months of DOR follow up.

## Subject Disposition

As of the data cut-off date (10-Jan-2024), all FL cohorts (Cohorts 1, 2, and 3) had been enrolled. All but one subject in the 3L+ FL group (Cohorts 1 and 2) completed the treatment period (Days 1 to 29). As of the data cut-off date, the median follow-up was 29.96 (24.67, 32.76) months, with the majority (82.2%) of 3L+ FL subjects were ongoing in the post-treatment follow-up period (Day -30 to Month 60).

Table 23. Key Dates and Follow-up - Study FOL-001

| First Subject First Visit                        | 14-Jul-2020               |
|--------------------------------------------------|---------------------------|
| First FL Subject Enrolled (Day of Leukapheresis) | 29-Jul-2020               |
| Last FL Subject Enrolled (and Treated)           | 10-Feb-2022 (04-Apr-2022) |

<div style=\"page-break-after: always\"></div>

| Primary Analysis (hypothesis testing)                          |                      |
|----------------------------------------------------------------|----------------------|
| Clinical Data Cutoff                                           | 27-Jan-2023          |
| Database Lock                                                  | 31-Mar-2023          |
| Median on-study follow-up, months (range: min, max) a          | 18.89 (0.3, 28.2)    |
| Updated Analysis - EU submission (SmPC)                        |                      |
| Clinical Data Cutoff                                           | 10-Jan-2024          |
| Database Lock                                                  | 06-Mar-2024          |
| Median on-study follow-up (3L+ FL), months (range: min, max) a | 29.96 (24.67, 32.76) |

a Study follow-up time in months is defined as: (EOS date - date of liso-cel infusion + 1)/ 30.4375. For subjects continuing on -study follow-up time is defined as: (data cutoff date - date of liso-cel infusion + 1) / 30.4375.

Table 24. Subject Disposition, Pre-liso-cel Treatment - Screened Set

|                                                                        | 4L+ FL Cohort 1 N = 65   | 3L FL Cohort 2 N = 49   | 3L+ FL Cohorts 1 + 2 N = 114   | 2L FL Cohort 3 N = 25   | Total 2L+ FL Cohorts 1, 2, 3 N = 139   | Total N = 154   |
|------------------------------------------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|-----------------|
| Total Number of Subjects Screened                                      |                          |                         |                                |                         |                                        | 154             |
| Number of Subjects Who Discontinued Screening Period a                 |                          |                         |                                |                         |                                        | 15 (9.7)        |
| Primary Reason for Discontinuing Screening Period b                    |                          |                         |                                |                         |                                        |                 |
| Withdrawal by Subject                                                  |                          |                         |                                |                         |                                        | 1 (6.7)         |
| Screen Failure                                                         |                          |                         |                                |                         |                                        | 14 (93.3)       |
| Inclusion/ Exclusion Criteria Failed c                                 |                          |                         |                                |                         |                                        | 14 (93.3)       |
| Subjects Who Met Screening Eligibility                                 |                          |                         |                                |                         |                                        | 139 (90.3)      |
| Leukapheresed                                                          | 65 (100.0)               | 49 (100.0)              | 114 (100.0)                    | 25 (100.0)              | 139 (100.0)                            | 139 (90.3)      |
| Leukapheresed but did not Receive Liso-cel                             | 6 (9.2)                  | 1 (2.0)                 | 7 (6.1)                        | 2 (8.0)                 | 9 (6.5)                                | 9 (5.8)         |
| Reason for Not Receiving Liso-cel                                      |                          |                         |                                |                         |                                        |                 |
| Received Nonconforming Product                                         | 3 (4.6)                  | 1 (2.0)                 | 4 (3.5)                        | 1 (4.0)                 | 5 (3.6)                                | 5 (3.2)         |
| Adverse Event                                                          | 1 (1.5)                  | 0                       | 1 (0.9)                        | 0                       | 1 (0.7)                                | 1 (0.6)         |
| Failure to Meet Inclusion/Exclusion Criteria                           | 1 (1.5)                  | 0                       | 1 (0.9)                        | 1 (4.0)                 | 2 (1.4)                                | 2 (1.3)         |
| Not Reported                                                           | 1 (1.5)                  | 0                       | 1 (0.9)                        | 0                       | 1 (0.7)                                | 1 (0.6)         |
| Completed Pre-Treatment Period                                         | 64 (98.5)                | 49 (100.0)              | 113 (99.1)                     | 24 (96.0)               | 137 (98.6)                             | 137 (89.0)      |
| Discontinued Pre-Treatment Period After Leukapheresis And Prior to LDC | 1 (1.5)                  | 0                       | 1 (0.9)                        | 1 (4.0)                 | 2 (1.4)                                | 2 (1.3)         |
| Reason for Discontinuing Pre- Treatment Period                         |                          |                         |                                |                         |                                        |                 |
| Failure to Meet Treatment Criteria                                     | 1 (1.5)                  | 0                       | 1 (0.9)                        | 1 (4.0)                 | 2 (1.4)                                | 2 (1.3)         |

<div style=\"page-break-after: always\"></div>

| Inclusion/Exclusion Criteria Failed c               | 1 (1.5)   | 0          | 1 (0.9)    | 1 (4.0)   | 2 (1.4)    | 2 (1.3)    |
|-----------------------------------------------------|-----------|------------|------------|-----------|------------|------------|
| Subjects Entered Treatment Period                   | 64 (98.5) | 49 (100.0) | 113 (99.1) | 24 (96.0) | 137 (98.6) | 137 (89.0) |
| Subjects Completed LDC But Did Not Receive Liso-cel | 5 (7.7)   | 1 (2.0)    | 6 (5.3)    | 1 (4.0)   | 7 (5.0)    | 7 (4.5)    |

a Percentages are based on the number of subjects screened b Percentages are based on the number of subjects who discontinued screening period

c Subjects may have more than one inclusion/exclusion criteria failed. inclusion/exclusion criteria were checked again prior to LDC and prior to liso-cel infusion

Table 25. Subject Disposition - Liso-cel-treated Analysis Set

|                                                                      | 4L+ FL Cohort 1 N = 59   | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|----------------------------------------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Subjects Received Liso-cel                                           | 59 (100.0)               | 48 (100.0)              | 107 (100.0)                    | 23 (100.0)              | 130 (100.0)                            |
| Subjects Ongoing on Treatment Period                                 | 0                        | 0                       | 0                              | 0                       | 0                                      |
| Subjects Completed Treatment Period                                  | 59 (100.0)               | 47 (97.9)               | 106 (99.1)                     | 22 (95.7)               | 128 (98.5)                             |
| Subjects Discontinued Treatment Period                               | 0                        | 1 (2.1)                 | 1 (0.9)                        | 1 (4.3)                 | 2 (1.5)                                |
| Primary Reason for Treatment Period Discontinuation                  |                          |                         |                                |                         |                                        |
| Adverse Event                                                        | 0                        | 0                       | 0                              | 1 (4.3)                 | 1 (0.8)                                |
| Withdrawal by Subject                                                | 0                        | 1 (2.1)                 | 1 (0.9)                        | 0                       | 1 (0.8)                                |
| Subjects Continued to Posttreatment Follow-Up Period                 | 59 (100.0)               | 47 (97.9)               | 106 (99.1)                     | 22 (95.7)               | 128 (98.5)                             |
| Subjects Ongoing on Posttreatment Follow-Up Period                   | 51 (86.4)                | 42 (87.5)               | 93 (86.9)                      | 22 (95.7)               | 115 (88.5)                             |
| Subjects Completed Posttreatment Follow-Up Period a                  | 0                        | 0                       | 0                              | 0                       | 0                                      |
| Subjects Discontinued Posttreatment Follow-Up Period                 | 8 (13.6)                 | 5 (10.4)                | 13 (12.1)                      | 0                       | 13 (10.0)                              |
| Primary Reason for Discontinuing Posttreatment Follow-Up Period      |                          |                         |                                |                         |                                        |
| Death                                                                | 5 (8.5)                  | 2 (4.2)                 | 7 (6.5)                        | 0                       | 7 (5.4)                                |
| Withdrawal by Subject                                                | 2 (3.4)                  | 2 (4.2)                 | 4 (3.7)                        | 0                       | 4 (3.1)                                |
| Physician Decision                                                   | 1 (1.7)                  | 0                       | 1 (0.9)                        | 0                       | 1 (0.8)                                |
| Other                                                                | 0                        | 1 (2.1)                 | 1 (0.9)                        | 0                       | 1 (0.8)                                |
| Discontinued Posttreatment Follow-Up Period Due to Covid-19 Pandemic | 0                        | 1 (2.1)                 | 1 (0.9)                        | 0                       | 1 (0.8)                                |
| Subjects Continued to LTFU Protocol b                                |                          |                         |                                |                         |                                        |
| Yes                                                                  | 1 (1.7)                  | 0                       | 1 (0.9)                        | 0                       | 1 (0.8)                                |
| No                                                                   | 7 (11.9)                 | 6 (12.5)                | 13 (12.1)                      | 1 (4.3)                 | 14 (10.8)                              |
| Reason Subject Did Not Continue to LTFU Protocol                     |                          |                         |                                |                         |                                        |
| Death                                                                | 5 (8.5)                  | 3 (6.3)                 | 8 (7.5)                        | 1 (4.3)                 | 9 (6.9)                                |
| Progressive Disease                                                  | 1 (1.7)                  | 0                       | 1 (0.9)                        | 0                       | 1 (0.8)                                |

<div style=\"page-break-after: always\"></div>

| Withdrawal by Subject               | 0       | 1 (2.1)   | 1 (0.9)   | 0   | 1 (0.8)   |
|-------------------------------------|---------|-----------|-----------|-----|-----------|
| Subject Refused                     | 0       | 1 (2.1)   | 1 (0.9)   | 0   | 1 (0.8)   |
| Withdrawal by Subject After Initial | 0       | 1 (2.1)   | 1 (0.9)   | 0   | 1 (0.8)   |
| Consent                             |         |           |           |     |           |
| Other                               | 1 (1.7) | 0         | 1 (0.9)   | 0   | 1 (0.8)   |

Treatment Period is defined as the initiation of lymphodepleting chemotherapy and concludes at Day 29 after liso-cel infusion. Posttreatment Follow-up period is defined as the period starting on day 30 post-liso-cel visit and ending at the 60-month post-liso-cel visit.

a Includes subjects that completed the posttreatment follow-up period based on the prior protocol that only required 2 years.

b  Per protocol, all subjects who either complete the follow-up period specified in the protocol or prematurely withdraw after infusion of liso-cel, would be eligible to enroll in the LTFU study (GC-LTFU-001; to be continued for up to 15 years after liso-cel infusion) at the end of study visit or at the time of withdrawal, respectively; a separate ICF was to be provided for the LTFU study.

## Conduct of the study

## Impact of COVID-19 Pandemic

This study was conducted in 10 countries for FL cohorts including Austria, Canada, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom, and United States. The clinical cutoff date and data base lock  (DBL)  of  the  study  occurred  on  27 -Jan -2023  and  31 -Mar -2023,  respectively,  during  the  global COVID-19 (coronavirus) pandemic. The FDA and EMA both issued guidelines on the management of clinical trials during the COVID-19 pandemic. In response to this public health emergency, the Sponsor developed overarching principles and guidance for the conduct of the Sponsor's clinical research in light of COVID -19.

Impact on data integrity: All CRF data entries were completed, and all critical queries were addressed in all  countries. Throughout the duration of the study, no site has required an increase in Source Data Verification (SDV) due to compliance issues. Mitigation included increased remote data listing review. Therefore, the outstanding SDVs were assessed as not having a significant impact on the integrity of the data.

Protocol deviations: 23 COVID-19 related protocol deviations were captured prior to the clinical cutoff date. None of these protocol deviations had an impact on the quality of the data in this study.

A COVID-19 Safety Surveillance Plan was created by the Sponsor, and newly released MedDRA v23.0 (effective date 04-May-2020) was adopted to retrospectively search for AEs related to COVID-19 in the database.  There  were  2  cases  reporting  the  COVID-19  PTs  (see  below)  for  JCAR017-FOL-001  from 27 -Jan -2023 (LSLV) to 27-Jan-2023 (cutoff date). The COVID-19 PTs include the following:

- COVID-19
- COVID-19 pneumonia
- SARS-CoV-2 test positive

Prior to the DBL, a comprehensive situational analysis was performed by the Sponsor's Data Review Committee to assess the potential impact on the DBL and data quality, and concluded that the DBL should proceed as planned.

## Changes to Planned Analyses

Changes to planned analyses prior to the cutoff date included the following:

SAP Version 2.0 (08-Jul-2021): added the following subgroup analysis: Anticancer treatment for disease control: yes vs. no

<div style=\"page-break-after: always\"></div>

SAP Version 3.0 (05-Oct-2022): added details about the timing of primary analysis; extended the timing for analyses. Clarified that the PRO analyses are based on change from pre-LDC measurement; changed from selected domains of interest to all domains for EORTC QLQ-C30; added analysis for EQ -5D -5L. Added sensitivity analyses of primary and secondary efficacy endpoints, including ORR, CRR, DOR and PFS, based on the description in the IRC Procedures Document and using FDA censoring rules for DOR and  PFS.  To  satisfy  any  EU  and  US  regulatory  requirements,  updated  age  categories  for  subgroup analysis to Age: &lt; 65, ≥ 65 to &lt; 75, ≥ 75 at screening.

## Protocol deviations

## GCP Deviations and Serious Breach

There were no GCP deviations impacting the study, and no sites were closed for GCP issues. No serious breaches were reported.

## Important Protocol Deviations

Table 26. Summary of Protocol Deviations - Leukapheresed Analysis Set

|                                                         | 4L+ FL Cohort 1 N = 65   | 3L FL Cohort 2 N = 49   | 3L+ FL Cohorts 1 + 2 N = 114   | 2L FL Cohort 3 N = 25   | Total 2L+ FL Cohorts 1, 2, 3 N = 139   |
|---------------------------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Subjects With at Least One Protocol Deviation           | 53 (81.5)                | 42 (85.7)               | 95 (83.3)                      | 22 (88.0)               | 117 (84.2)                             |
| Subjects With at Least One Important Protocol Deviation | 2 (3.1)                  | 1 (2.0)                 | 3 (2.6)                        | 0                       | 3 (2.2)                                |
| Protocol Deviations                                     |                          |                         |                                |                         |                                        |
| Procedures/Tests                                        | 32 (49.2)                | 27 (55.1)               | 59 (51.8)                      | 14 (56.0)               | 73 (52.5)                              |
| Laboratory                                              | 14 (21.5)                | 21 (42.9)               | 35 (30.7)                      | 7 (28.0)                | 42 (30.2)                              |
| ICF Issues                                              | 11 (16.9)                | 11 (22.4)               | 22 (19.3)                      | 11 (44.0)               | 33 (23.7)                              |
| Visit Schedule                                          | 47 (72.3)                | 34 (69.4)               | 81 (71.1)                      | 18 (72.0)               | 99 (71.2)                              |
| Study Drug                                              | 1 (1.5)                  | 1 (2.0)                 | 2 (1.8)                        | 1 (4.0)                 | 3 (2.2)                                |
| Inclusion/ Exclusion                                    | 0                        | 1 (2.0)                 | 1 (0.9)                        | 0                       | 1 (0.7)                                |
| Other                                                   | 4 (6.2)                  | 1 (2.0)                 | 5 (4.4)                        | 0                       | 5 (3.6)                                |
| Number of Subjects With                                 |                          |                         |                                |                         |                                        |
| One Deviation                                           | 10 (15.4)                | 5 (10.2)                | 15 (13.2)                      | 4 (16.0)                | 19 (13.7)                              |
| Two Deviations                                          | 6 (9.2)                  | 3 (6.1)                 | 9 (7.9)                        | 2 (8.0)                 | 11 (7.9)                               |
| >2 Deviations                                           | 37 (56.9)                | 34 (69.4)               | 71 (62.3)                      | 16 (64.0)               | 87 (62.6)                              |
| Important Protocol Deviations                           |                          |                         |                                |                         |                                        |
| Procedures/Tests                                        | 2 (3.1)                  | 0                       | 2 (1.8)                        | 0                       | 2 (1.4)                                |
| Inclusion/Exclusion                                     | 0                        | 1 (2.0)                 | 1 (0.9)                        | 0                       | 1 (0.7)                                |
| Number of Subjects With                                 |                          |                         |                                |                         |                                        |
| One Important Deviation                                 | 2 (3.1)                  | 1 (2.0)                 | 3 (2.6)                        | 0                       | 3 (2.2)                                |

## Protocol amendments

<div style=\"page-break-after: always\"></div>

The original protocol for this study was dated 11-Nov-2019. As of the 27-Jan-2023 cutoff date, there were a total of 2 global amendments, 2 country specific amendments (Great Britain and Japan) and 1 country specific addendum (Sweden).

The primary endpoint was changed from CRR to ORR and secondary endpoint from ORR to CRR in Protocol Amendment 1.0 (06-Jul-2021), while the study was ongoing, since ORR has been traditionally used as an endpoint in indolent NHL trial. The interpretation of ORR generally remains consistent across response criteria, while different versions of response criteria are used to define CRR in clinical trials. Importantly, this decision was not influenced by JCAR017-FOL-001 trial data, as no efficacy analyses based on IRC data had been conducted before the protocol amendment.

Table 27. Summary of Key Changes to Protocol JCAR017-FOL-001

| Protocol Amendment/Dat e            | Summary of Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |   Planned Sample Size | Subjects Enrolled at Time of Amendment   |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------|
| Protocol Amendment 2.0/ 10-Jul-2022 | The posttreatment follow-up period was extended from 2 years (24 months) to 5 years (60 months); assessment planning updated accordingly Extended timing for statistical analyses Added new assessment for PD/relapse: local results on target antigen expression if available (ie, CD19 expression in subjects who received prior CD19 - directed therapy) Increased total number of subjects from approximately 188 to approximately 213                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                   213 | 181                                      |
| Protocol Amendment 1.0/ 06-Jul-2021 | Changed primary endpoint from CRR to ORR and secondary endpoint from ORR to CRR Added requirement for BMB to confirm all CMRs in FL subjects as part of a sensitivity analysis Broadened third line population from 'high risk' to 'all comers' given that for FL subjects in the third line of therapy the five-year survival rate is only 20%, highlighting the urgent need for treatment of the 'all comers' population. The hierarchical testing was updated to first test the 3L+ 'all comers' group, followed by the 4L+ group. This was done to acknowledge that the main population of unmet need is the 3L+ population. Increased the number of subjects enrolled in the 4L+ cohort (from 40 to 50) and decreased the number of subjects enrolled in the 3L cohort (from 50 to 40) Added requirement of upper gastrointestinal endoscopy/biopsy for subjects with gastric MALT lymphoma |                   188 | 116                                      |
| Original Protocol/ 11-Nov-2019      | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                   188 | None                                     |

## COVID-19-Related Protocol Deviations

Based on the number and types of protocol deviations, the study primary and secondary endpoints were not impacted by COVID-19, as well as the ability to monitor and manage subjects' safety during the conduct of the study; less than 2% of more than 2 deviations were recorded during the trial.

Table 28. COVID-19 Related Protocol Deviations - Leukapheresed Set

| 4L+ FL Cohort 1 N = 65   | 3L FL Cohort 2 N = 49   | 3L+ FL Cohorts 1 + 2 N = 114   | 2L FL Cohort 3 N = 25   | Total 2L+ FL Cohorts 1, 2, 3 N = 139   |
|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|

<div style=\"page-break-after: always\"></div>

| Subjects With at Least One Covid-19-Related Protocol Deviation   | 10 (15.4)   | 10 (20.4)   | 20 (17.5)   | 3 (12.0)   | 23 (16.5)   |
|------------------------------------------------------------------|-------------|-------------|-------------|------------|-------------|
| Protocol Deviations                                              |             |             |             |            |             |
| Procedures/Tests                                                 | 2 (3.1)     | 1 (2.0)     | 3 (2.6)     | 1 (4.0)    | 4 (2.9)     |
| Visit Schedule                                                   | 8 (12.3)    | 10 (20.4)   | 18 (15.8)   | 2 (8.0)    | 20 (14.4)   |
| Number of Subjects With                                          |             |             |             |            |             |
| One Deviation                                                    | 6 (9.2)     | 9 (18.4)    | 15 (13.2)   | 2 (8.0)    | 17 (12.2)   |
| Two Deviations                                                   | 4 (6.2)     | 0           | 4 (3.5)     | 1 (4.0)    | 5 (3.6)     |
| >2 Deviations                                                    | 0           | 1 (2.0)     | 1 (0.9)     | 0          | 1 (0.7)     |

## Baseline data

Table 29. Key Demographic and Baseline Characteristics - Liso-cel-treated Analysis Set

|                           | 4L+ FL Cohort 1 N = 59    | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|---------------------------|---------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Age (Years)               |                           |                         |                                |                         |                                        |
| N                         | 59                        | 48                      | 107                            | 23                      | 130                                    |
| Median                    | 64                        | 60                      | 62                             | 53                      | 60                                     |
| Q1, Q3                    | 56.0, 70.0                | 53.5, 67.0              | 55.0, 69.0                     | 42.0, 62.0              | 53.0, 68.0                             |
| Min, Max                  | 23, 80                    | 27, 78                  | 23, 80                         | 34, 69                  | 23, 80                                 |
| Age Group (Years) - N (%) | Age Group (Years) - N (%) |                         |                                |                         |                                        |
| < 65                      | 34 (57.6)                 | 31 (64.6)               | 65 (60.7)                      | 18 (78.3)               | 83 (63.8)                              |
| ≥ 65 - < 75               | 18 (30.5)                 | 14 (29.2)               | 32 (29.9)                      | 5 (21.7)                | 37 (28.5)                              |
| ≥ 75                      | 7 (11.9)                  | 3 (6.3)                 | 10 (9.3)                       | 0                       | 10 (7.7)                               |
| Sex - N (%)               |                           |                         |                                |                         |                                        |
| Female                    | 24 (40.7)                 | 17 (35.4)               | 41 (38.3)                      | 6 (26.1)                | 47 (36.2)                              |
| Male                      | 35 (59.3)                 | 31 (64.6)               | 66 (61.7)                      | 17 (73.9)               | 83 (63.8)                              |
| Ethnicity - N (%) a       |                           |                         |                                |                         |                                        |
| Hispanic or Latino        | 4 (6.8)                   | 1 (2.1)                 | 5 (4.7)                        | 1 (4.3)                 | 6 (4.6)                                |
| Not Hispanic or Latino    | 39 (66.1)                 | 35 (72.9)               | 74 (69.2)                      | 15 (65.2)               | 89 (68.5)                              |
| Not Reported              | 16 (27.1)                 | 12 (25.0)               | 28 (26.2)                      | 7 (30.4)                | 35 (26.9)                              |
| Primary Race - N (%) b    |                           |                         |                                |                         |                                        |
| Asian                     | 7 (11.9)                  | 3 (6.3)                 | 10 (9.3)                       | 2 (8.7)                 | 12 (9.2)                               |
| Black or African American | 3 (5.1)                   | 0                       | 3 (2.8)                        | 1 (4.3)                 | 4 (3.1)                                |
| White                     | 31 (52.5)                 | 29 (60.4)               | 60 (56.1)                      | 9 (39.1)                | 69 (53.1)                              |
| Not Collected or Unknown  | 18 (30.5)                 | 16 (33.3)               | 34 (31.8)                      | 11 (47.8)               | 45 (34.6)                              |
| Region - N (%)            |                           |                         |                                |                         |                                        |
| Europe                    | 27 (45.8)                 | 34 (70.8)               | 61 (57.0)                      | 12 (52.2)               | 73 (56.2)                              |
| Japan                     | 6 (10.2)                  | 3 (6.3)                 | 9 (8.4)                        | 1 (4.3)                 | 10 (7.7)                               |

<div style=\"page-break-after: always\"></div>

| North America                                                                                                                | 26 (44.1)                                                                                                                    | 11 (22.9)                                                                                                                    | 37 (34.6)                                                                                                                    | 10 (43.5)                                                                                                                    | 47 (36.2)                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         | Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         | Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         | Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         | Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         | Type of Lymphoma and Histological Subtype/Grade at Screening - N (%)                                                         |
| Grade 1                                                                                                                      | 3 (5.1)                                                                                                                      | 6 (12.5)                                                                                                                     | 9 (8.4)                                                                                                                      | 6 (26.1)                                                                                                                     | 15 (11.5)                                                                                                                    |
| Grade 2                                                                                                                      | 41 (69.5)                                                                                                                    | 31 (64.6)                                                                                                                    | 72 (67.3)                                                                                                                    | 11 (47.8)                                                                                                                    | 83 (63.8)                                                                                                                    |
| Grade 3A                                                                                                                     | 15 (25.4)                                                                                                                    | 10 (20.8)                                                                                                                    | 25 (23.4)                                                                                                                    | 6 (26.1)                                                                                                                     | 31 (23.8)                                                                                                                    |
| Unknown                                                                                                                      | 0                                                                                                                            | 1 (2.1)                                                                                                                      | 1 (0.9)                                                                                                                      | 0                                                                                                                            | 1 (0.8)                                                                                                                      |
| Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               | Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               | Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               | Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               | Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               | Time From Initial B-NHL Diagnosis to Liso-cel Infusion (Years)                                                               |
| N                                                                                                                            | 59                                                                                                                           | 48                                                                                                                           | 107                                                                                                                          | 23                                                                                                                           | 130                                                                                                                          |
| Median                                                                                                                       | 7.288                                                                                                                        | 4.62                                                                                                                         | 5.136                                                                                                                        | 1.993                                                                                                                        | 4.709                                                                                                                        |
| Q1, Q3                                                                                                                       | 4.164, 12.134                                                                                                                | 2.509, 6.341                                                                                                                 | 3.370, 8.794                                                                                                                 | 1.131, 4.394                                                                                                                 | 2.968, 7.860                                                                                                                 |
| Min, Max                                                                                                                     | 1.87, 35.27                                                                                                                  | 0.70, 18.74                                                                                                                  | 0.70, 35.27                                                                                                                  | 0.76, 11.38                                                                                                                  | 0.70, 35.27                                                                                                                  |
| Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 | Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 | Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 | Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 | Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 | Time From Completion of Most Recent Systemic Regimen to Progression (Months)                                                 |
| N                                                                                                                            | 58                                                                                                                           | 46                                                                                                                           | 104                                                                                                                          | 23                                                                                                                           | 127                                                                                                                          |
| Median                                                                                                                       | 1.13                                                                                                                         | 3.55                                                                                                                         | 1.87                                                                                                                         | 3.71                                                                                                                         | 1.91                                                                                                                         |
| Q1, Q3                                                                                                                       | 0.03, 5.62                                                                                                                   | 0.49, 13.04                                                                                                                  | 0.20, 10.20                                                                                                                  | 0.56, 12.91                                                                                                                  | 0.20, 10.81                                                                                                                  |
| Min, Max                                                                                                                     | -4.4, 115.0                                                                                                                  | -2.2, 43.7                                                                                                                   | -4.4, 115.0                                                                                                                  | -4.0, 106.1                                                                                                                  | -4.4, 115.0                                                                                                                  |
| Within ≥ 0 - ≤ 6 Months - N (%)                                                                                              | 31 (52.5)                                                                                                                    | 18 (37.5)                                                                                                                    | 49 (45.8)                                                                                                                    | 11 (47.8)                                                                                                                    | 60 (46.2)                                                                                                                    |
| Within > 6 - ≤ 12 Months - N (%)                                                                                             | 5 ( 8.5)                                                                                                                     | 7 (14.6)                                                                                                                     | 12 (11.2)                                                                                                                    | 2 ( 8.7)                                                                                                                     | 14 (10.8)                                                                                                                    |
| Subjects Progressed Before Regimen Completion - N (%)                                                                        | 13 (22.0)                                                                                                                    | 7 (14.6)                                                                                                                     | 20 (18.7)                                                                                                                    | 4 (17.4)                                                                                                                     | 24 (18.5)                                                                                                                    |
| Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) | Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) | Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) | Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) | Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) | Time From Completion of Most Recent Systemic Regimen to Progression (or Stable Disease if Missing Progression Date) (Months) |
| N                                                                                                                            | 59                                                                                                                           | 48                                                                                                                           | 107                                                                                                                          | 23                                                                                                                           | 130                                                                                                                          |
| Median                                                                                                                       | 1.08                                                                                                                         | 2.61                                                                                                                         | 1.81                                                                                                                         | 3.71                                                                                                                         | 1.82                                                                                                                         |
| Q1, Q3                                                                                                                       | 0.03, 5.62                                                                                                                   | 0.49, 13.04                                                                                                                  | 0.20, 9.59                                                                                                                   | 0.56, 12.91                                                                                                                  | 0.20, 9.59                                                                                                                   |
| Min, Max                                                                                                                     | -4.4, 115.0                                                                                                                  | -2.2, 43.7                                                                                                                   | -4.4, 115.0                                                                                                                  | -4.0, 106.1                                                                                                                  | -4.4, 115.0                                                                                                                  |
| Within ≥ 0 - ≤ 6 Months - N (%)                                                                                              | 31 (52.5)                                                                                                                    | 20 (41.7)                                                                                                                    | 51 (47.7)                                                                                                                    | 11 (47.8)                                                                                                                    | 62 (47.7)                                                                                                                    |
| Within > 6 - ≤ 12 Months - N (%)                                                                                             | 5 (8.5)                                                                                                                      | 7 (14.6)                                                                                                                     | 12 (11.2)                                                                                                                    | 2 (8.7)                                                                                                                      | 14 (10.8)                                                                                                                    |
| Subjects Progressed or With Stable Disease Before Regimen Completion - N (%)                                                 | 14 (23.7)                                                                                                                    | 7 (14.6)                                                                                                                     | 21 (19.6)                                                                                                                    | 4 (17.4)                                                                                                                     | 25 (19.2)                                                                                                                    |
| FLIPI at Screening - N (%)                                                                                                   | FLIPI at Screening - N (%)                                                                                                   | FLIPI at Screening - N (%)                                                                                                   | FLIPI at Screening - N (%)                                                                                                   | FLIPI at Screening - N (%)                                                                                                   | FLIPI at Screening - N (%)                                                                                                   |
| Low Risk (0-1)                                                                                                               | 9 (15.3)                                                                                                                     | 3 (6.3)                                                                                                                      | 12 (11.2)                                                                                                                    | 11 (47.8)                                                                                                                    | 23 (17.7)                                                                                                                    |
| Intermediate Risk (2)                                                                                                        | 14 (23.7)                                                                                                                    | 20 (41.7)                                                                                                                    | 34 (31.8)                                                                                                                    | 4 (17.4)                                                                                                                     | 38 (29.2)                                                                                                                    |
| High Risk (3-5)                                                                                                              | 36 (61.0)                                                                                                                    | 25 (52.1)                                                                                                                    | 61 (57.0)                                                                                                                    | 8 (34.8)                                                                                                                     | 69 (53.1)                                                                                                                    |
| Ann Arbor Stage at Screening - N (%)                                                                                         | Ann Arbor Stage at Screening - N (%)                                                                                         | Ann Arbor Stage at Screening - N (%)                                                                                         | Ann Arbor Stage at Screening - N (%)                                                                                         | Ann Arbor Stage at Screening - N (%)                                                                                         | Ann Arbor Stage at Screening - N (%)                                                                                         |
| Stage I                                                                                                                      | 1 (1.7)                                                                                                                      | 0                                                                                                                            | 1 (0.9)                                                                                                                      | 1 (4.3)                                                                                                                      | 2 (1.5)                                                                                                                      |
| Stage II                                                                                                                     | 4 (6.8)                                                                                                                      | 7 (14.6)                                                                                                                     | 11 (10.3)                                                                                                                    | 5 (21.7)                                                                                                                     | 16 (12.3)                                                                                                                    |
| Stage III                                                                                                                    | 18 (30.5)                                                                                                                    | 21 (43.8)                                                                                                                    | 39 (36.4)                                                                                                                    | 6 (26.1)                                                                                                                     | 45 (34.6)                                                                                                                    |
| Stage IV                                                                                                                     | 36 (61.0)                                                                                                                    | 20 (41.7)                                                                                                                    | 56 (52.3)                                                                                                                    | 11 (47.8)                                                                                                                    | 67 (51.5)                                                                                                                    |

Presence of B-Symptoms at Screening - N (%)

<div style=\"page-break-after: always\"></div>

| Yes                                                                           | 11 (18.6)                                                                 | 7 (14.6)                                                                  | 18 (16.8)                                                                 | 2 (8.7)                                                                   | 20 (15.4)                                                                 |
|-------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| No                                                                            | 46 (78.0)                                                                 | 41 (85.4)                                                                 | 87 (81.3)                                                                 | 19 (82.6)                                                                 | 106 (81.5)                                                                |
| Unknown                                                                       | 2 (3.4)                                                                   | 0                                                                         | 2 (1.9)                                                                   | 2 (8.7)                                                                   | 4 (3.1)                                                                   |
| ECOG Performance Status at Screening - N (%)                                  | ECOG Performance Status at Screening - N (%)                              | ECOG Performance Status at Screening - N (%)                              | ECOG Performance Status at Screening - N (%)                              | ECOG Performance Status at Screening - N (%)                              | ECOG Performance Status at Screening - N (%)                              |
| 0                                                                             | 30 (50.8)                                                                 | 35 (72.9)                                                                 | 65 (60.7)                                                                 | 17 (73.9)                                                                 | 82 (63.1)                                                                 |
| 1                                                                             | 29 (49.2)                                                                 | 13 (27.1)                                                                 | 42 (39.3)                                                                 | 6 (26.1)                                                                  | 48 (36.9)                                                                 |
| ECOG Performance Status Pre-Liso-cel Infusion - N (%)                         | ECOG Performance Status Pre-Liso-cel Infusion - N (%)                     | ECOG Performance Status Pre-Liso-cel Infusion - N (%)                     | ECOG Performance Status Pre-Liso-cel Infusion - N (%)                     | ECOG Performance Status Pre-Liso-cel Infusion - N (%)                     | ECOG Performance Status Pre-Liso-cel Infusion - N (%)                     |
| 0                                                                             | 24 (40.7)                                                                 | 28 (58.3)                                                                 | 52 (48.6)                                                                 | 16 (69.6)                                                                 | 68 (52.3)                                                                 |
| 1                                                                             | 33 (55.9)                                                                 | 17 (35.4)                                                                 | 50 (46.7)                                                                 | 7 (30.4)                                                                  | 57 (43.8)                                                                 |
| 2                                                                             | 1 (1.7)                                                                   | 0                                                                         | 1 (0.9)                                                                   | 0                                                                         | 1 (0.8)                                                                   |
| Not Reported                                                                  | 1 (1.7)                                                                   | 3 (6.3)                                                                   | 4 (3.7)                                                                   | 0                                                                         | 4 (3.1)                                                                   |
| C-Reactive Protein Prior to Liso-cel - N (%)                                  | C-Reactive Protein Prior to Liso-cel - N (%)                              | C-Reactive Protein Prior to Liso-cel - N (%)                              | C-Reactive Protein Prior to Liso-cel - N (%)                              | C-Reactive Protein Prior to Liso-cel - N (%)                              | C-Reactive Protein Prior to Liso-cel - N (%)                              |
| < 20 Mg/L                                                                     | 38 (64.4)                                                                 | 34 (70.8)                                                                 | 72 (67.3)                                                                 | 17 (73.9)                                                                 | 89 (68.5)                                                                 |
| ≥ 20 Mg/L                                                                     | 19 (32.2)                                                                 | 14 (29.2)                                                                 | 33 (30.8)                                                                 | 4 (17.4)                                                                  | 37 (28.5)                                                                 |
| Not Reported                                                                  | 2 (3.4)                                                                   | 0                                                                         | 2 (1.9)                                                                   | 2 (8.7)                                                                   | 4 (3.1)                                                                   |
| Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%)     | Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%) | Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%) | Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%) | Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%) | Lactate Dehydrogenase (LDH) Prior to Lymphodepleting Chemotherapy - N (%) |
| ≤ ULN                                                                         | 32 (54.2)                                                                 | 28 (58.3)                                                                 | 60 (56.1)                                                                 | 17 (73.9)                                                                 | 77 (59.2)                                                                 |
| > ULN                                                                         | 27 (45.8)                                                                 | 20 (41.7)                                                                 | 47 (43.9)                                                                 | 6 (26.1)                                                                  | 53 (40.8)                                                                 |
| ≥ 500 U/L                                                                     | 4 (6.8)                                                                   | 0                                                                         | 4 (3.7)                                                                   | 1 (4.3)                                                                   | 5 (3.8)                                                                   |
| < 500 U/L                                                                     | 55 (93.2)                                                                 | 48 (100.0)                                                                | 103 (96.3)                                                                | 22 (95.7)                                                                 | 125 (96.2)                                                                |
| Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)             | Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)         | Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)         | Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)         | Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)         | Modified GELF Criteria Met at Time of Most Recent Relapse - N (%)         |
| Yes                                                                           | 31 (52.5)                                                                 | 26 (54.2)                                                                 | 57 (53.3)                                                                 | 16 (69.6)                                                                 | 73 (56.2)                                                                 |
| Symptoms Attributable to FL                                                   | 8 (13.6)                                                                  | 5 (10.4)                                                                  | 13 (12.1)                                                                 | 6 (26.1)                                                                  | 19 (14.6)                                                                 |
| Threatened End-Organ Function/ Cytopenia Secondary to Lymphoma/ Bulky Disease | 12 (20.3)                                                                 | 12 (25.0)                                                                 | 24 (22.4)                                                                 | 7 (30.4)                                                                  | 31 (23.8)                                                                 |
| Splenomegaly                                                                  | 1 (1.7)                                                                   | 3 (6.3)                                                                   | 4 (3.7)                                                                   | 0                                                                         | 4 (3.1)                                                                   |
| Steady Progression Over at Least 6 Months                                     | 10 (16.9)                                                                 | 6 (12.5)                                                                  | 16 (15.0)                                                                 | 3 (13.0)                                                                  | 19 (14.6)                                                                 |
| No                                                                            | 28 (47.5)                                                                 | 22 (45.8)                                                                 | 50 (46.7)                                                                 | 7 (30.4)                                                                  | 57 (43.8)                                                                 |
| Double Refractory Status Per CRF - N (%) c                                    | Double Refractory Status Per CRF - N (%) c                                | Double Refractory Status Per CRF - N (%) c                                | Double Refractory Status Per CRF - N (%) c                                | Double Refractory Status Per CRF - N (%) c                                | Double Refractory Status Per CRF - N (%) c                                |
| Yes                                                                           | 36 (61.0)                                                                 | 33 (68.8)                                                                 | 69 (64.5)                                                                 | 11 (47.8)                                                                 | 80 (61.5)                                                                 |
| No                                                                            | 23 (39.0)                                                                 | 15 (31.3)                                                                 | 38 (35.5)                                                                 | 12 (52.2)                                                                 | 50 (38.5)                                                                 |
| POD24 Status Per CRF - N (%) d                                                | POD24 Status Per CRF - N (%) d                                            | POD24 Status Per CRF - N (%) d                                            | POD24 Status Per CRF - N (%) d                                            | POD24 Status Per CRF - N (%) d                                            | POD24 Status Per CRF - N (%) d                                            |
| Yes                                                                           | 21 (35.6)                                                                 | 25 (52.1)                                                                 | 46 (43.0)                                                                 | 12 (52.2)                                                                 | 58 (44.6)                                                                 |
| No                                                                            | 38 (64.4)                                                                 | 23 (47.9)                                                                 | 61 (57.0)                                                                 | 11 (47.8)                                                                 | 72 (55.4)                                                                 |
| POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e            | POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e        | POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e        | POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e        | POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e        | POD24 of First Line Therapy with Anti-CD20 and Alkylator - N (%) e        |
| Yes                                                                           | 27 (45.8)                                                                 | 31 (64.6)                                                                 | 58 (54.2)                                                                 | 15 (65.2)                                                                 | 73 (56.2)                                                                 |
| No                                                                            | 32 (54.2)                                                                 | 16 (33.3)                                                                 | 48 (44.9)                                                                 | 8 (34.8)                                                                  | 54 (43.1)                                                                 |
| Not Estimable                                                                 | 0                                                                         | 1 (2.1)                                                                   | 1 (0.9)                                                                   | 0                                                                         | 1 (0.8)                                                                   |
| Refractory to Last Line of Therapy per CRF - N (%)                            | Refractory to Last Line of Therapy per CRF - N (%)                        | Refractory to Last Line of Therapy per CRF - N (%)                        | Refractory to Last Line of Therapy per CRF - N (%)                        | Refractory to Last Line of Therapy per CRF - N (%)                        | Refractory to Last Line of Therapy per CRF - N (%)                        |
| Yes                                                                           | 24 (40.7)                                                                 | 14 (29.2)                                                                 | 38 (35.5)                                                                 | 3 (13.0)                                                                  | 41 (31.5)                                                                 |

<div style=\"page-break-after: always\"></div>

Baseline characteristic is defined as the latest measurement on or prior to the date of liso-cel infusion.

a Ethnicity \"Not reported\" is auto populated due to local privacy regulations for France, Germany, Sweden, United Kingdom.

b Race \"Not Collected or Unknown\" is auto populated due to local privacy concerns for France, Germany, Sweden, United Kingdom.

- c Double refractory status can be met at any line of therapy that includes an anti-CD20 antibody and alkylating agent. Definition per protocol: double refractory subjects are those who are refractory to both an anti-CD20 antibody and an alkylating agent (defined as subjects who did not respond or progressed during or up to 6 months after completing treatment with an anti-CD20 monoclonal antibody and an alkylating agent) or refractory to antiCD20 maintenance therapy (defined as subjects who did not respond or progressed during or up to 6 months after completing maintenance treatment with an anti-CD20 monoclonal antibody).

d Definition of POD-24 per protocol. As per protocol and CRF, progression of disease within 24 months of diagnosis after initiating treatment with an antiCD20 and alkylating agent within the first 6 months of initial FL diagnosis.

e POD24 definition: progression of disease within 24 months of initiation of first-line chemoimmunotherapy with anti CD20 and alkylating agent.

## Central diagnosis confirmation

Out of the 139 subjects in the second-line therapy or later (2L+) FL Leukapheresed, the diagnosis of FL was  retrospectively  confirmed  by  the  central  pathology  laboratory  for  128 subjects  (92%).  Eleven subjects (third-line therapy or later [3L+] FL, n = 7; second line [2L FL, n = 4) did not have a central pathology confirmation of FL diagnosis due to: For 4 subjects (3L+ FL, n = 3; 2L FL, n = 1) FL diagnosis could not be confirmed by the central pathology laboratory due to insufficient or inadequate sample availability. For these 4 subjects, central pathology analyses could not be performed, and no results are available.

For 4 subjects (3L+ FL, n = 2; 2L FL, n = 2), the central pathology laboratory was able to confirm diagnosis of B-cell lymphoma but was unable to complete testing in order to confirm FL diagnosis in the samples provided. This was due to insufficient or inadequate tissue to complete the immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) testing, hence precluding subclassification of lymphoma.

For  one  3L+  FL  subject,  no  B-cell  lymphoma  was  detected  in  the  sample  analysed  by  the  central pathology laboratory.

For 2 subjects who had central pathology laboratory diagnosis different from FL:

- a) One 2L FL subject had findings not compatible with a B-lymphoid neoplasm according to the central pathology laboratory.
- b) One 3L+ FL subject had findings consistent with large B-cell lymphoma of follicular center origin according  to  the  central  pathology  laboratory.  Per  investigator  and  according  to  local  pathology assessment, the subject had transformed disease to diffuse large B-cell lymphoma, reported after leukapheresis.  The  subject  was  then  discontinued  from  the  study  before  receiving  any  study treatment, because not meeting the required inclusion criterion of FL diagnosis.

## Prior anticancer therapy

Table 30.  Summary of Prior Anticancer Therapies - Liso-cel-treated Analysis Set

|                                    | 4L+ FL Cohort 1 N = 59   | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Number of Lines of Prior Therapies |                          |                         |                                |                         |                                        |
| N                                  | 59                       | 48                      | 107                            | 23                      | 130                                    |
| Median                             | 4                        | 2                       | 3                              | 1                       | 2                                      |
| Q1, Q3                             | 3.0, 5.0                 | 2.0, 2.0                | 2.0, 4.0                       | 1.0, 1.0                | 2.0, 4.0                               |

<div style=\"page-break-after: always\"></div>

| Min, Max                                               | 3, 10     | 2, 3       | 2, 10      | 1, 3       | 1, 10      |
|--------------------------------------------------------|-----------|------------|------------|------------|------------|
| Number of Lines of Prior Therapies - N (%)             |           |            |            |            |            |
| 1                                                      | 0         | 0          | 0          | 22 (95.7)  | 22 (16.9)  |
| 2                                                      | 0         | 47 (97.9)  | 47 (43.9)  | 0          | 47 (36.2)  |
| 3                                                      | 24 (40.7) | 1 (2.1)    | 25 (23.4)  | 1 (4.3)    | 26 (20.0)  |
| 4                                                      | 18 (30.5) | 0          | 18 (16.8)  | 0          | 18 (13.8)  |
| ≥ 5                                                    | 17 (28.8) | 0          | 17 (15.9)  | 0          | 17 (13.1)  |
| Number of Prior Radiation Therapies                    |           |            |            |            |            |
| N                                                      | 59        | 48         | 107        | 23         | 130        |
| Median                                                 | 0         | 0          | 0          | 0          | 0          |
| Q1, Q3                                                 | 0.0, 0.0  | 0.0, 0.0   | 0.0, 0.0   | 0.0, 0.0   | 0.0, 0.0   |
| Min, Max                                               | 0, 5      | 0, 2       | 0, 5       | 0, 2       | 0, 5       |
| Number of Prior Radiation Therapies - N (%)            |           |            |            |            |            |
| 0                                                      | 50 (84.7) | 45 (93.8)  | 95 (88.8)  | 22 (95.7)  | 117 (90.0) |
| 1                                                      | 5 (8.5)   | 2 (4.2)    | 7 (6.5)    | 0          | 7 (5.4)    |
| 2                                                      | 2 (3.4)   | 1 (2.1)    | 3 (2.8)    | 1 (4.3)    | 4 (3.1)    |
| 4                                                      | 1 (1.7)   | 0          | 1 (0.9)    | 0          | 1 (0.8)    |
| ≥ 5                                                    | 1 (1.7)   | 0          | 1 (0.9)    | 0          | 1 (0.8)    |
| Number of Lines of Prior Radiation Therapies a         |           |            |            |            |            |
| N                                                      | 59        | 48         | 107        | 23         | 130        |
| Median                                                 | 0         | 0          | 0          | 0          | 0          |
| Q1, Q3                                                 | 0.0, 0.0  | 0.0, 0.0   | 0.0, 0.0   | 0.0, 0.0   | 0.0, 0.0   |
| Min, Max                                               | 0, 5      | 0, 1       | 0, 5       | 0, 2       | 0, 5       |
| Number of Lines of Prior Radiation Therapies a - N (%) |           |            |            |            |            |
| 0                                                      | 54 (91.5) | 47 (97.9)  | 101 (94.4) | 22 (95.7)  | 123 (94.6) |
| 1                                                      | 2 (3.4)   | 1 (2.1)    | 3 (2.8)    | 0          | 3 (2.3)    |
| 2                                                      | 2 (3.4)   | 0          | 2 (1.9)    | 1 (4.3)    | 3 (2.3)    |
| ≥ 5                                                    | 1 (1.7)   | 0          | 1 (0.9)    | 0          | 1 (0.8)    |
| Number of Lines of Prior Systemic Therapies            |           |            |            |            |            |
| N                                                      | 59        | 48         | 107        | 23         | 130        |
| Median                                                 | 4         | 2          | 3          | 1          | 2          |
| Q1, Q3                                                 | 3.0, 4.0  | 2.0, 2.0   | 2.0, 4.0   | 1.0, 1.0   | 2.0, 4.0   |
| Min, Max                                               | 3, 10     | 2, 2       | 2, 10      | 1, 1       | 1, 10      |
| Number of Lines of Prior Systemic Therapies - N (%)    |           |            |            |            |            |
| 1                                                      | 0         | 0          | 0          | 23 (100.0) | 23 (17.7)  |
| 2                                                      | 0         | 48 (100.0) | 48 (44.9)  | 0          | 48 (36.9)  |
| 3                                                      | 26 (44.1) | 0          | 26 (24.3)  | 0          | 26 (20.0)  |
| 4                                                      | 19 (32.2) | 0          | 19 (17.8)  | 0          | 19 (14.6)  |
| ≥ 5                                                    | 14 (23.7) | 0          | 14 (13.1)  | 0          | 14 (10.8)  |

<div style=\"page-break-after: always\"></div>

| Type of Last Line of Therapy Prior to Liso- cel (Reported in ≥ 10% of subjects)   |                 |            |                     |            |            |
|-----------------------------------------------------------------------------------|-----------------|------------|---------------------|------------|------------|
| Rituximab                                                                         | 19 (32.2)       | 32 (66.7)  | 51 (47.7)           | 20 (87.0)  | 71 (54.6)  |
| Cyclophosphamide                                                                  | 6 (10.2)        | 15 (31.3)  | 21 (19.6)           | 15 (65.2)  | 36 (27.7)  |
| Prednisone                                                                        | 6 (10.2)        | 10 (20.8)  | 16 (15.0)           | 11 (47.8)  | 27 (20.8)  |
| Doxorubicin                                                                       | 4 (6.8)         | 11 (22.9)  | 15 (14.0)           | 11 (47.8)  | 26 (20.0)  |
| Vincristine                                                                       | 4 (6.8)         | 10 (20.8)  | 14 (13.1)           | 10 (43.5)  | 24 (18.5)  |
| Cytarabine                                                                        | 7 (11.9)        | 15 (31.3)  | 22 (20.6)           | 0          | 22 (16.9)  |
| Obinutuzumab                                                                      | 10              | 9 (18.8)   |                     |            | 21 (16.2)  |
| Etoposide                                                                         | (16.9) 6 (10.2) | 11 (22.9)  | 19 (17.8) 17 (15.9) | 2 (8.7) 0  | 17 (13.1)  |
| Lenalidomide                                                                      | 11 (18.6)       | 5 (10.4)   | 16 (15.0)           | 0          | 16 (12.3)  |
| Bendamustine                                                                      | 0               | 10 (20.8)  | 10 (9.3)            | 6 (26.1)   | 16 (12.3)  |
| Radiotherapy Only                                                                 | 0               | 0          | 0                   | 0          | 0          |
| Both Systemic Treatment                                                           |                 |            | 12                  |            | 13         |
| and Radiotherapy                                                                  | 9 (15.3)        | 3 (6.3)    | (11.2)              | 1 (4.3)    | (10.0)     |
| Time From Start of Last Systemic Regimen Prior to Liso-cel (Years)                |                 |            |                     |            |            |
| N                                                                                 | 59              | 48         | 107                 | 23         | 130        |
| Median                                                                            | 0.97            | 1.64       | 1.22                | 1.84       | 1.35       |
| Q1, Q3                                                                            | 0.50, 2.34      | 0.69, 2.21 | 0.64, 2.24          | 1.10, 3.15 | 0.67, 2.59 |
| Min, Max                                                                          | 0.2, 13.1       | 0.2, 5.6   | 0.2, 13.1           | 0.5, 11.3  | 0.2, 13.1  |
| Number of Prior Anticancer Surgeries                                              |                 |            |                     |            |            |
| N                                                                                 | 59              | 48         | 107                 | 23         | 130        |
| Median                                                                            | 0               | 0          | 0                   | 0          | 0          |
| Q1, Q3                                                                            | 0.0, 0.0        | 0.0, 0.0   | 0.0, 0.0            | 0.0, 0.0   | 0.0, 0.0   |
| Min, Max                                                                          | 0, 1            | 0, 1       | 0, 1                | 0, 1       | 0, 1       |
| Number of Prior Anticancer Surgeries - N (%)                                      |                 |            |                     |            |            |
| 0                                                                                 | 56 (94.9)       | 47 (97.9)  | 103 (96.3)          | 22 (95.7)  | 125 (96.2) |
| 1                                                                                 | 3 (5.1)         | 1 (2.1)    | 4 (3.7)             | 1 (4.3)    | 5 (3.8)    |
| Refractory or Relapsed to Last Systemic Therapy - N (%)                           |                 |            |                     |            |            |
| Refractory                                                                        | 24 (40.7)       | 14 (29.2)  | 38 (35.5)           | 3 (13.0)   | 41 (31.5)  |
| Relapsed                                                                          | 35 (59.3)       | 34 (70.8)  | 69 (64.5)           | 20 (87.0)  | 89 (68.5)  |
| Prior Hematopoietic Stem Cell Transplantation - N (%) No                          | 43 (72.9)       | 31 (64.6)  | 74 (69.2)           | 23 (100.0) | 97 (74.6)  |
| Yes                                                                               | 16 (27.1)       | 17 (35.4)  | 33 (30.8)           | 0          | 33 (25.4)  |
| If Yes                                                                            |                 |            |                     |            |            |
| Autologous                                                                        | 16 (27.1)       | 17 (35.4)  | 33 (30.8)           | 0          | 33 (25.4)  |
| Best Response to Last Prior Systemic Regimen N (%)                                |                 |            |                     |            |            |
| Complete Response (CR)                                                            | 19 (32.2)       | 21 (43.8)  | 40 (37.4)           | 13 (56.5)  | 53 (40.8)  |
| Partial Response (PR)                                                             | 17 (28.8)       | 13 (27.1)  | 30 (28.0)           | 9 (39.1)   | 39 (30.0)  |

<div style=\"page-break-after: always\"></div>

| Stable Disease (SD)                                    | 8 (13.6)   | 5 (10.4)   | 13 (12.1)   | 0          | 13 (10.0)   |
|--------------------------------------------------------|------------|------------|-------------|------------|-------------|
| Progressive Disease (PD)                               | 15 (25.4)  | 9 (18.8)   | 24 (22.4)   | 1 (4.3)    | 25 (19.2)   |
| Received Prior PI3K Inhibitors - N (%)                 |            |            |             |            |             |
| Yes                                                    | 26 (44.1)  | 1 (2.1)    | 27 (25.2)   | 0          | 27 (20.8)   |
| No                                                     | 33 (55.9)  | 47 (97.9)  | 80 (74.8)   | 23 (100.0) | 103 (79.2)  |
| Received Prior Rituximab and Lenalidomide (R2) - N (%) |            |            |             |            |             |
| Yes                                                    | 18 (30.5)  | 5 (10.4)   | 23 (21.5)   | 0          | 23 (17.7)   |
| No                                                     | 41 (69.5)  | 43 (89.6)  | 84 (78.5)   | 23 (100.0) | 107 (82.3)  |
| Last Line of Prior Systemic Therapy - N (%)            |            |            |             |            |             |
| PI3K Inhibitors                                        | 15 (25.4)  | 1 (2.1)    | 16 (15.0)   | 0          | 16 (12.3)   |
| Rituximab and Lenalidomide (R2)                        | 11 (18.6)  | 5 (10.4)   | 16 (15.0)   | 0          | 16 (12.3)   |

Prior therapies include any therapies that were stopped before the Leukapheresis.

Systemic therapy includes chemotherapy, immunotherapy and radioimmunotherapy.

Prior systemic anticancer therapies do not include stem cell transplant but do include conditioning regimens for stem cell transplant.

HSCT is considered a line of systemic therapy, but is grouped with preceding chemotherapy regimen and any intervening conditioning regimen including radiation.

a Includes only stand-alone radiotherapies

## Optional Bridging Therapy for Disease Control Prior to LDC

Table 31. Summary of Anticancer Therapies for Disease Control - Liso-cel-treated Analysis Set

|                                                                 | 4L+ FL Cohort 1 N = 59   | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|-----------------------------------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Anticancer Treatment a                                          |                          |                         |                                |                         |                                        |
| Yes                                                             | 29 (49.2)                | 15 (31.3)               | 44 (41.1)                      | 5 (21.7)                | 49 (37.7)                              |
| No                                                              | 30 (50.8)                | 33 (68.8)               | 63 (58.9)                      | 18 (78.3)               | 81 (62.3)                              |
| Type of Treatment                                               |                          |                         |                                |                         |                                        |
| Systemic Treatment Only                                         | 26 (44.1)                | 14 (29.2)               | 40 (37.4)                      | 4 (17.4)                | 44 (33.8)                              |
| Radiotherapy Only                                               | 3 (5.1)                  | 1 (2.1)                 | 4 (3.7)                        | 1 (4.3)                 | 5 (3.8)                                |
| Both Systemic and Radiotherapy                                  | 0                        | 0                       | 0                              | 0                       | 0                                      |
| Systemic Anticancer Medication for Disease Control              |                          |                         |                                |                         |                                        |
| Antineoplastic and Immunomodulating Agents (Reported in ≥ 5% of | 26 (44.1)                | 14 (29.2)               | 40 (37.4)                      | 4 (17.4)                | 44 (33.8)                              |
| Rituximab                                                       | 9 (15.3)                 | 9 (18.8)                | 18 (16.8)                      | 2 (8.7)                 | 20 (15.4)                              |
| Cyclophosphamide                                                | 10 (16.9)                | 6 (12.5)                | 16 (15.0)                      | 1 (4.3)                 | 17 (13.1)                              |
| Gemcitabine                                                     | 7 (11.9)                 | 4 (8.3)                 | 11 (10.3)                      | 1 (4.3)                 | 12 (9.2)                               |
| Vincristine                                                     | 6 (10.2)                 | 5 (10.4)                | 11 (10.3)                      | 0                       | 11 (8.5)                               |
| Oxaliplatin                                                     | 6 (10.2)                 | 3 (6.3)                 | 9 (8.4)                        | 1 (4.3)                 | 10 (7.7)                               |

<div style=\"page-break-after: always\"></div>

| Doxorubicin                                                                                    | 5 (8.5)   | 4 (8.3)   | 9 (8.4)   | 0        | 9 (6.9)   |
|------------------------------------------------------------------------------------------------|-----------|-----------|-----------|----------|-----------|
| Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins (Reported in ≥ 2% of subjects) | 9 (15.3)  | 7 (14.6)  | 16 (15.0) | 3 (13.0) | 19 (14.6) |
| Prednisolone                                                                                   | 3 (5.1)   | 2 (4.2)   | 5 (4.7)   | 0        | 5 (3.8)   |
| Prednisone                                                                                     | 3 (5.1)   | 2 (4.2)   | 5 (4.7)   | 1 (4.3)  | 6 (4.6)   |
| Dexamethasone                                                                                  | 2 (3.4)   | 1 (2.1)   | 3 (2.8)   | 2 (8.7)  | 5 (3.8)   |

a Anticancer treatment for disease control is defined as any systemic therapy or radiation therapy provided to subjects for disease control after leukapheresis and before LDC.

Table 32. Baseline characteristics in all leukapheresed patients

| Characteristic                                                                                                         | All leukapheresed (N=114)   |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Median age, years (range)                                                                                              | 62.0 (23, 80)               |
| ≥ 65 to <75 years, n (%)                                                                                               | 36 (31.6)                   |
| ≥ 75 years, n (%)                                                                                                      | 10 (8.8)                    |
| Male gender, n (%)                                                                                                     | 72 (63.2)                   |
| Prior HSCT, n (%) Autologous HSCT                                                                                      | 34 (29.8)                   |
| High FLIPI score (3-5), n (%)                                                                                          | 66 (57.9)                   |
| Stage III-IV disease at screening, n (%)                                                                               | 102 (89.4)                  |
| ECOG performance status (at screening) ECOG 0, n (%) ECOG 1, n (%)                                                     | 68 (59.6)                   |
| Double refractory, n (%) Progression within 24 months of first line therapy with anti-CD20 and alkylator, n (%) Yes No | 74 (64.9)                   |
| Not estimable                                                                                                          | 63 (55.3) 50 (43.9)         |
| Median number of prior systemic treatments (range)                                                                     | 1 (0.9)                     |
|                                                                                                                        | 3 (2,10)                    |

## Numbers analysed

The Liso-cel-treated Efficacy Analysis Set was the primary population used for the efficacy analyses and the Liso-cel-treated Analysis Set was the primary population used for the safety analyses.

<div style=\"page-break-after: always\"></div>

The difference in numbers between the Liso-cel Treated Analysis Set and the Liso-cel Treated Efficacy Analysis  Set is  due  to  the  exclusion  of  patients  without  an  assessment  prior  to  liso-cel  infusion,  or evidence of Complete Response to the bridging therapy. At last data cutoff, in 3L+ cohort 4 subjects were excluded from the former 107 subjects included in the treated analysis set; therefore, the resulting efficacy analysis set was constituted by 103 patients. The main reason for exclusion of infused patients from the EAS were represented by 'disease evaluation before the end of bridging therapy' (2 cases) and 'abscence of PET-positive disease at baseline per IRC assessment' (2 cases); all 4 subjects excluded from the EAS were in CR at the most recent follow-up.

Table 33. Analysis Populations - Screened Set

| Analysis Population             | 4L+ FL     | 3L FL      | 3L+ FL      | 2L FL      | 2L+ FL      | Total       |
|---------------------------------|------------|------------|-------------|------------|-------------|-------------|
| Screened Set a                  |            |            |             |            |             | 154         |
| Eligible Set b                  |            |            |             |            |             | 139         |
| Leukapheresed (ITT) Set c       | 65 (100.0) | 49 (100.0) | 114 (100.0) | 25 (100.0) | 139 (100.0) | 139 (100.0) |
| Liso - cel - treated Set d      | 59 (90.8)  | 48 (98.0)  | 107 (93.9)  | 23 (92.0)  | 130 (93.5)  | 130 (93.5)  |
| Liso-cel-treated Efficacy Set e | 53 (81.5)  | 48 (98.0)  | 101 (88.6)  | 23 (92.0)  | 124 (89.2)  | 124 (89.2)  |
| Outpatient Analysis Set f       | 12 (18.5)  | 2 (4.1)    | 14 (12.3)   | 1 (4.0)    | 15 (10.8)   | 15 (10.8)   |
| PK Analysis Set g               | 59 (90.8)  | 48 (98.0)  | 107 (93.9)  | 23 (92.0)  | 130 (93.5)  | 130 (93.5)  |
| PK Evaluable Analysis Set h     | 59 (90.8)  | 46 (93.9)  | 105 (92.1)  | 23 (92.0)  | 128 (92.1)  | 128 (92.1)  |
| PRO Analysis Set i              | 56 (86.2)  | 46 (93.9)  | 102 (89.5)  | 20 (80.0)  | 122 (87.8)  | 122 (87.8)  |

Percentages are based on number of Leukapheresed Set.

a Subjects signed informed consent.

b  Subjects signed consent who meet all inclusion/exclusion criteria.

c Subjects signed consent who undergo leukapheresis and meet all inclusion/exclusion criteria.

d  Subjects received a dose of conforming liso cel.

e Subjects received a dose of liso-cel with PET positive disease present before liso-cel administration per IRC. Subjects without baseline assessment repeated after anticancer therapy for disease control and before liso-cel administration were excluded.

f Subjects monitored as an outpatient in liso-cel-treated set.

g  Subjects with any available PK measurements by PCR in the liso-cel-treated set.

h  Subjects with at least one evaluable PK parameter in the liso-cel-treated set.

i Subjects completed pre-LDC PRO questionnaires and with at least one post-baseline measurement in the liso-cel -treated set.

## Extent of exposure

## Lymphodepleting Chemotherapy Exposure

In the Liso-cel-treated Analysis Set, a total 10.0% of subjects received an adjusted dose of fludarabine (11.2% in 3L+ subject and 4.3% in 2L subjects). One (0.9%) subject received an interrupted dose of fludarabine.  One  (0.9%)  3L+  subject  received  an  adjusted  dose  of  cyclophosphamide.  No  subjects received an interrupted dose of cyclophosphamide. The median time from end of LDC to liso-cel infusion (4 days; range, 3 to 12) was consistent with the protocol-specified time (2 to 7 days).

## Manufacturing

Table 34. Manufacturing Summary - Leukapheresed Set

<div style=\"page-break-after: always\"></div>

|                                                                  | 4L+ FL Cohort 1 N = 65                                           | 3L FL Cohort 2 N = 49                                            | 3L+ FL Cohorts 1 + 2 N = 114                                     | 2L FL Cohort 3 N = 25                                            | Total 2L+ FL Cohorts 1, 2, 3 N = 139                             |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Time From Leukapheresis to Liso-cel Product Availability (Day) a | Time From Leukapheresis to Liso-cel Product Availability (Day) a | Time From Leukapheresis to Liso-cel Product Availability (Day) a | Time From Leukapheresis to Liso-cel Product Availability (Day) a | Time From Leukapheresis to Liso-cel Product Availability (Day) a | Time From Leukapheresis to Liso-cel Product Availability (Day) a |
| N                                                                | 60                                                               | 48                                                               | 108                                                              | 24                                                               | 132                                                              |
| Median                                                           | 28.5                                                             | 29                                                               | 29                                                               | 28                                                               | 29                                                               |
| Q1, Q3                                                           | 23.5, 31.5                                                       | 27.5, 31.5                                                       | 26.0, 31.5                                                       | 25.0, 30.0                                                       | 25.5, 31.0                                                       |
| Min, Max                                                         | 20, 55                                                           | 22, 49                                                           | 20, 55                                                           | 19, 38                                                           | 19, 55                                                           |
| Time From Leukapheresis to Liso-cel Infusion (Day) a             | Time From Leukapheresis to Liso-cel Infusion (Day) a             | Time From Leukapheresis to Liso-cel Infusion (Day) a             | Time From Leukapheresis to Liso-cel Infusion (Day) a             | Time From Leukapheresis to Liso-cel Infusion (Day) a             | Time From Leukapheresis to Liso-cel Infusion (Day) a             |
| N                                                                | 59                                                               | 48                                                               | 107                                                              | 23                                                               | 130                                                              |
| Median                                                           | 47                                                               | 51.5                                                             | 50                                                               | 48                                                               | 49                                                               |
| Q1, Q3                                                           | 41.0, 53.0                                                       | 47.0, 64.5                                                       | 42.0, 56.0                                                       | 37.0, 54.0                                                       | 41.0, 55.0                                                       |
| Min, Max                                                         | 31, 313                                                          | 35, 287                                                          | 31, 313                                                          | 33, 72                                                           | 31, 313                                                          |

a Among subjects receiving conforming liso-cel product. Data from nonconforming product is not included in the calculation.

b Manufacturing failure rate is defined as (number of subjects for whom liso-cel product [conforming at time of release] could not be manufactured)/ (number of subjects who had leukapheresis and manufacturing information available) × 100. Rejected lots are excluded from the calculation.

In one case, a delayed infusion was recorded at 313 days after leukapheresis due to persistently positive COVID-19; the subject was infused after the infection resolved. An additional subject also had a delayed infusion 287 days after leukapheresis due to the absence of PET positive disease in non-irradiated lymph nodes after bridging radiation therapy; the subject was infused after disease progression and a PET/CT scan documented PET positive measurable disease.

The reported manufacturing failure in the whole population was similar in the 3L+; the global rate of manufacturing failure was higher in the 4L+ patients, but it is expected considering that this cohort enrolled highly pre-treated patients.

## Liso-cel Exposure

In  the  3L+  Liso-cel-treated  Analysis  Set  the  median  number  of  total  (CD8+  and  CD4+)  liso-cel administered dose cell counts infused was 100.02×10 6  CAR+ T cells (range: 93.4×10 6  to 109.2×10 6 ).

Table 35. Liso-cel Exposure - Liso-cel-treated Analysis Set

|                     | 4L+ FL Cohort 1 N = 59   | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|---------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Liso-cel CD8+ Cells |                          |                         |                                |                         |                                        |
| Planned Volume (mL) |                          |                         |                                |                         |                                        |
| N                   | 59                       | 48                      | 107                            | 23                      | 130                                    |
| Median              | 2                        | 2.15                    | 2                              | 1.8                     | 2                                      |
| Q1, Q3              | 1.70, 3.20               | 1.60, 2.65              | 1.60, 2.90                     | 1.40, 2.40              | 1.60, 2.70                             |
| Min, Max            | 1.3, 8.2                 | 1.1, 12.5               | 1.1, 12.5                      | 1.2, 6.5                | 1.1, 12.5                              |
| Actual Volume (mL)  |                          |                         |                                |                         |                                        |
| N                   | 59                       | 48                      | 107                            | 23                      | 130                                    |
| Median              | 2                        | 2.15                    | 2                              | 1.8                     | 2                                      |
| Q1, Q3              | 1.70, 3.20               | 1.60, 2.65              | 1.60, 2.90                     | 1.40, 2.40              | 1.60, 2.70                             |

<div style=\"page-break-after: always\"></div>

| Min, Max                                                       | 1.3, 8.2                                                       | 1.1, 12.5                                                      | 1.1, 12.5                                                      | 1.2, 6.5                                                       | 1.1, 12.5                                                      |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD8+ Cell Counts Infused (10 6 Cells) |
| N                                                              | 59                                                             | 48                                                             | 107                                                            | 23                                                             | 130                                                            |
| Median                                                         | 49.9                                                           | 49.76                                                          | 49.82                                                          | 50.11                                                          | 49.85                                                          |
| Q1, Q3                                                         | 49.47, 50.53                                                   | 49.37, 50.30                                                   | 49.39, 50.42                                                   | 48.96, 50.30                                                   | 49.36, 50.41                                                   |
| Min, Max                                                       | 42.3, 51.7                                                     | 47.9, 51.6                                                     | 42.3, 51.7                                                     | 48.1, 51.7                                                     | 42.3, 51.7                                                     |
| Was the Infusion Delayed?                                      |                                                                |                                                                |                                                                |                                                                |                                                                |
| Yes                                                            | 2 (3.4)                                                        | 0                                                              | 2 (1.9)                                                        | 0                                                              | 2 (1.5)                                                        |
| No                                                             | 57 (96.6)                                                      | 48 (100.0)                                                     | 105 (98.1)                                                     | 23 (100.0)                                                     | 128 (98.5)                                                     |
| Reason for Delay                                               |                                                                |                                                                |                                                                |                                                                |                                                                |
| Adverse Event                                                  | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Not Reported                                                   | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Was the Infusion Interrupted?                                  |                                                                |                                                                |                                                                |                                                                |                                                                |
| Yes                                                            | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| No                                                             | 58 (98.3)                                                      | 48 (100.0)                                                     | 106 (99.1)                                                     | 23 (100.0)                                                     | 129 (99.2)                                                     |
| Reason for Interruption                                        |                                                                |                                                                |                                                                |                                                                |                                                                |
| Not Reported                                                   | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Liso-cel CD4+ Cells                                            |                                                                |                                                                |                                                                |                                                                |                                                                |
| Planned Volume (mL)                                            |                                                                |                                                                |                                                                |                                                                |                                                                |
| N                                                              | 59                                                             | 48                                                             | 107                                                            | 23                                                             | 130                                                            |
| Median                                                         | 1.7                                                            | 1.75                                                           | 1.7                                                            | 1.5                                                            | 1.7                                                            |
| Q1, Q3                                                         | 1.40, 2.10                                                     | 1.30, 2.15                                                     | 1.40, 2.10                                                     | 1.30, 1.80                                                     | 1.40, 2.10                                                     |
| Min, Max                                                       | 0.9, 7.6                                                       | 0.9, 4.4                                                       | 0.9, 7.6                                                       | 1.1, 4.5                                                       | 0.9, 7.6                                                       |
| Actual Volume (mL)                                             |                                                                |                                                                |                                                                |                                                                |                                                                |
| N                                                              | 59                                                             | 48                                                             | 107                                                            | 23                                                             | 130                                                            |
| Median                                                         | 1.7                                                            | 1.75                                                           | 1.7                                                            | 1.5                                                            | 1.7                                                            |
| Q1, Q3                                                         | 1.40, 2.10                                                     | 1.30, 2.15                                                     | 1.40, 2.10                                                     | 1.30, 1.80                                                     | 1.40, 2.10                                                     |
| Min, Max                                                       | 0.9, 7.6                                                       | 0.9, 4.4                                                       | 0.9, 7.6                                                       | 1.1, 4.5                                                       | 0.9, 7.6                                                       |
| If the Volume Delivered is <90% of                             | If the Volume Delivered is <90% of                             | Assigned                                                       |                                                                |                                                                |                                                                |
| Other                                                          | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Total Number of Liso-cel CD4+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ Cell Counts Infused (10 6 Cells) |                                                                |                                                                |
| N                                                              | 59                                                             | 48                                                             | 107                                                            | 23                                                             | 130                                                            |
| Median                                                         | 50.2                                                           | 49.75                                                          | 49.99                                                          | 50.29                                                          | 50.02                                                          |
| Q1, Q3                                                         | 49.64, 50.74                                                   | 49.21, 50.58                                                   | 49.39, 50.66                                                   | 49.10, 50.74                                                   | 49.28, 50.66                                                   |
| Min, Max                                                       | 43.1, 58.8                                                     | 48.0, 52.0                                                     | 43.1, 58.8                                                     | 47.9, 52.0                                                     | 43.1, 58.8                                                     |
| Was the Infusion Delayed?                                      |                                                                |                                                                |                                                                |                                                                |                                                                |
| Yes                                                            | 2 (3.4)                                                        | 0                                                              | 2 (1.9)                                                        | 0                                                              | 2 (1.5)                                                        |
| No                                                             | 57 (96.6)                                                      | 48 (100.0)                                                     | 105 (98.1)                                                     | 23 (100.0)                                                     | 128 (98.5)                                                     |
| Reason for Delay                                               |                                                                |                                                                |                                                                |                                                                |                                                                |
| Adverse Event                                                  | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Other                                                          | 1 (1.7)                                                        | 0                                                              | 1 (0.9)                                                        | 0                                                              | 1 (0.8)                                                        |
| Was the Infusion                                               | Interrupted?                                                   |                                                                |                                                                |                                                                |                                                                |

<div style=\"page-break-after: always\"></div>

| No                                                                      | 59 (100.0)                                                              | 48 (100.0)                                                              | 107 (100.0)                                                             | 23 (100.0)                                                              | 130 (100.0)                                                             |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Combined Liso-cel Dose                                                  |                                                                         |                                                                         |                                                                         |                                                                         |                                                                         |
| Total Volume of liso-cel CD4+ And CD8+ (mL)                             | Total Volume of liso-cel CD4+ And CD8+ (mL)                             | Total Volume of liso-cel CD4+ And CD8+ (mL)                             | Total Volume of liso-cel CD4+ And CD8+ (mL)                             | Total Volume of liso-cel CD4+ And CD8+ (mL)                             | Total Volume of liso-cel CD4+ And CD8+ (mL)                             |
| N                                                                       | 59                                                                      | 48                                                                      | 107                                                                     | 23                                                                      | 130                                                                     |
| Median                                                                  | 4                                                                       | 3.75                                                                    | 4                                                                       | 3.5                                                                     | 3.8                                                                     |
| Q1, Q3                                                                  | 3.20, 5.00                                                              | 3.15, 5.10                                                              | 3.20, 5.00                                                              | 2.80, 3.90                                                              | 3.10, 4.90                                                              |
| Min, Max                                                                | 2.2, 15.8                                                               | 2.4, 16.7                                                               | 2.2, 16.7                                                               | 2.5, 9.3                                                                | 2.2, 16.7                                                               |
| Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) | Total Number of Liso-cel CD4+ and CD8+ Cell Counts Infused (10 6 Cells) |
| N                                                                       | 59                                                                      | 48                                                                      | 107                                                                     | 23                                                                      | 130                                                                     |
| Median                                                                  | 100.13                                                                  | 99.73                                                                   | 100.02                                                                  | 99.92                                                                   | 100.02                                                                  |
| Q1, Q3                                                                  | 99.26, 100.88                                                           | 98.81, 100.78                                                           | 99.13, 100.87                                                           | 99.09, 100.67                                                           | 99.13, 100.73                                                           |
| Min, Max                                                                | 93.4, 109.2                                                             | 96.6, 101.8                                                             | 93.4, 109.2                                                             | 97.4, 102.9                                                             | 93.4, 109.2                                                             |
| Ratio of CD4+: CD8+ Cell Counts                                         | Ratio of CD4+: CD8+ Cell Counts                                         | Ratio of CD4+: CD8+ Cell Counts                                         | Ratio of CD4+: CD8+ Cell Counts                                         | Ratio of CD4+: CD8+ Cell Counts                                         | Ratio of CD4+: CD8+ Cell Counts                                         |
| N                                                                       | 59                                                                      | 48                                                                      | 107                                                                     | 23                                                                      | 130                                                                     |
| Median                                                                  | 1                                                                       | 1                                                                       | 1                                                                       | 1                                                                       | 1                                                                       |
| Q1, Q3                                                                  | 0.99, 1.02                                                              | 0.99, 1.02                                                              | 0.99, 1.02                                                              | 0.99, 1.02                                                              | 0.99, 1.02                                                              |
| Min, Max                                                                | 0.9, 1.2                                                                | 1.0, 1.1                                                                | 0.9, 1.2                                                                | 0.9, 1.1                                                                | 0.9, 1.2                                                                |

## Subsequent Anticancer Therapy

There were 8 (6.2%) subjects who received subsequent anticancer therapy and the most frequently prescribed  systemic  therapy  regimen  were  antineoplastic  and  immunomodulating  agents  (7  [5.4%] subjects). One (0.8%) subject received radiotherapy. No subjects received surgery or HSCT.

## Outcomes and estimation

## Primary Efficacy Endpoint - Overall Response Rate

Table 36. Overall Response Rate - Per IRC Charter - Sensitivity Analyses -Leukapheresed (ITT) and Per Investigator - Study FOL-001

|                                        | 4L+ FL Cohort 1   | 3L FL Cohort 2   | 3L+ FL Cohorts 1 + 2   |
|----------------------------------------|-------------------|------------------|------------------------|
| ORR per IRC Charter (Liso-cel-treated  |                   |                  |                        |
| Efficacy Analysis                      | N = 55            | N = 48           | N = 103                |
| Set)                                   |                   |                  |                        |
| n (%)                                  | 53 (96.4)         | 47 (97.9)        | 100 (97.1)             |
| 95% CI a                               | (87.5, 99.6)      | (88.9, 99.9)     | (91.7, 99.4)           |
| Sensitivity Analyses                   |                   |                  |                        |
| ORR (Leukapheresed [ITT] Set)          | N = 65            | N = 49           | N = 114                |
| n (%)                                  | 58 (89.2)         | 48 (98.0)        | 106 (93.0)             |
| 95% CI a                               | (79.1, 95.6)      | (89.1, 99.9)     | (86.6, 96.9)           |
| ORR per Investigator (Liso-cel-treated | N = 55            | N = 48           | N = 103                |
| Efficacy Analysis Set)                 |                   |                  |                        |
| n (%)                                  | 54 (98.2)         | 47 (97.9)        | 101 (98.1)             |

<div style=\"page-break-after: always\"></div>

The median time to first response (CR or PR) and median time to first CR was 0.95 months (range: 0.6 to 3.3 months).

## Subgroup analyses

Figure 4. Forest Plot of ORR per IRC Charter - Liso-cel-treated Efficacy Analysis Set, Subjects from 3L+ R/R FL (Cohort 1 and Cohort 2) Analysis Group

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Secondary Efficacy endpoints Complete Response Rate

Table 37. CRR - Per IRC Charter - Sensitivity Analyses -Leukapheresed (ITT) and Per Investigator - Study FOL-001

|                                          | 4L+ FL Cohort 1   | 3L FL Cohort 2   | 3L+ FL Cohorts 1 + 2   |
|------------------------------------------|-------------------|------------------|------------------------|
| CRR per IRC Charter                      |                   |                  |                        |
| (Liso-cel-treated Efficacy Analysis Set) | N = 55            | N = 48           | N = 103                |
| n (%)                                    | 51 (92.7)         | 46 (95.8)        | 97 (94.2)              |
| 95% CI a                                 | (82.4, 98.0)      | (85.7, 99.5)     | (87.8, 97.8)           |
| Sensitivity Analyses                     |                   |                  |                        |
| CRR (Leukapheresed [ITT] Set)            | N = 65            | N = 49           | N = 114                |
| n (%)                                    | 56 (86.2)         | 47 (95.9)        | 103 (90.4)             |
| 95% CI a                                 | (75.3, 93.5)      | (86.0, 99.5)     | (83.4, 95.1)           |
| CRR per Investigator                     |                   |                  |                        |
| (Liso-cel-treated Efficacy Analysis Set) | N = 55            | N = 48           | N = 103                |
| n (%)                                    | 51 (92.7)         | 46 (95.8)        | 97 (94.2)              |
| 95% CI a                                 | (82.4, 98.0)      | (85.7, 99.5)     | (87.8, 97.8)           |

A sensitivity analyses using the 'FDA algorithm' (i.e. requiring a bone marrow biopsy [BMB] to confirm CR) showed a lower CRR compared to the primary analysis per IRC charter. When the FDA algorithm was applied, 22 subjects were downgraded from CR to PR: 19/22 subjects because the BMB results at time  of  CR  were  not  available,  2/22  had  BMB  with  unknown  result,  and  1/22  had  evidence  of lymphomatous BM involvement. Overall, when analyses were performed according to the FDA algorithm, in 3L+ subjects the proportion of reported CRR was consistently lower (72.3%, 95% CI: 62.5, 80.7) and the proportion of PR was higher (25%, 95% CI: 16.4-33.7).

A post-hoc subgroup analysis of time-to-event efficacy outcomes for the 22 subjects with a BOR of CR per IRC charter that was not confirmed using the FDA algorithm showed a trend towards reduced DOR (expected 24-months DOR rate: 58% [34.6-75.5]) and PFS (expected 24-month PFS rate: 58% [34.675.5]) when compared with patients with confirmed CR (expected 24-month DOR rate: 76.9% [67.184.2]) and PFS (expected 24-month PFS rate: 77% [67.2-84.2]).

Figure 5. Forest Plot of CRR per IRC Charter - Liso-cel-treated Efficacy Analysis Set, Subjects from 3L+ R/R FL (Cohort 1 and Cohort 2) Analysis Group

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Duration of Response (DOR)

Table 38. DOR - Analyses per IRC Charter, Leukapheresed (ITT), and Per Investigator - Study FOL-001

|                                                               | 4L+ FL Cohort 1                      | 3L FL Cohort 2         | 3L+ FL Cohorts 1 + 2                  |
|---------------------------------------------------------------|--------------------------------------|------------------------|---------------------------------------|
| DOR per IRC Charter (Liso-cel-treated Efficacy Analysis Set)  | N = 53 responders                    | N = 47 responders      | N = 100 responders                    |
| Median (95% CI) a                                             | 30.85 (30.85, N.A.)                  | N.A.                   | N.A. (30.85, N.A.)                    |
| Min, Max b                                                    | 1.9, 35.0+                           | 1.9, 34.5+             | 1.9, 35.0+                            |
| Median follow-up (from first response), months (95% CI) c     | 23.03 (22.74, 23.23)                 | 23.26 (22.93, 23.39)   | 23.13 (22.93, 23.26)                  |
| Sensitivity Analyses                                          |                                      |                        |                                       |
| DOR (Leukapheresed [ITT] Set) CI) a,                          | N = 58 responders N.A. (30.85, N.A.) | N = 48 responders N.A. | N = 106 responders N.A. (30.85, N.A.) |
| Median (95%                                                   |                                      |                        |                                       |
| Min, Max b                                                    | 1.9, 35.0+                           | 1.9, 34.5+             | 1.9, 35.0+                            |
| Median follow-up (from first response), months (95% CI) c     | 23.10 (22.74, 23.26)                 | 23.26 (22.93, 23.39)   | 23.13 (23.00, 23.26)                  |
| DOR if Best Response is CR (Leukapheresed [ITT] Set)          | N = 56 responders                    | N = 47 responders      | N = 103 responders                    |
| Median (95% CI) a,                                            | N.A. (30.85, N.A.)                   | N.A.                   | N.A. (30.85, N.A.)                    |
| Min, Max b                                                    | 2.1, 35.0+                           | 1.9, 34.5+             | 1.9, 35.0+                            |
| DOR per Investigator (Liso-cel-treated Efficacy Analysis Set) | N = 54 responders                    | N = 47 responders      | N = 101 responders                    |
| Median (95% CI) a                                             | 34.76 (30.85, N.A.)                  | N.A.                   | 34.76 (30.85, N.A.)                   |
| Min, Max b                                                    | 2.1, 35.0+                           | 1.9, 34.5+             | 1.9, 35.0+                            |
| Median follow-up (from first response), months (95% CI) c     | 23.06 (22.74, 23.26)                 | 23.26 (22.97, 23.39)   | 23.13 (23.00, 23.26)                  |

a Median, Q1, Q3 are estimated from KM product-limit estimates b Symbol + indicates a censored value.

c Reverse KM method is used to obtain the median follow-up and its 95% CIs.

Sensitivity analysis per FDA algorithm confirms that DOR in subjects with CR or PR was not reached in 3L+ subjects (95% CI: 18.04, NA) and 2L subjects (95% CI: 19.32, NA).

Figure 6. KM Plot of DOR per IRC Charter - Liso-cel-treated Efficacy Analysis Set, Subjects who Achieved CR or PR 3L+ Subjects

<div style=\"page-break-after: always\"></div>

<!-- image -->

Symbols represent censored observations.

DOR is defined as the interval from the first documentation of response to progressive disease or death from any cause, whichever occurs first.

## DOR if BOR is CR

The median DOR in subjects with a BOR of CR (per protocol and SAP definitions) per IRC charter was not reached in 3L+ subjects (95% CI: 18.04, NA) and 2L subjects (95% CI: 19.32, NA).

Figure 7. KM Plot of DOR if BOR is CR per IRC Charter - Liso-cel-treated Efficacy Analysis Set - 3L+ FL Subjects

## 3L+ Subjects

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Sensitivity analyses supported these data: per FDA algorithm, the median DOR was not reached in 3L+ subjects (95% CI: NA) and 2L subjects (95% CI: NA). Per Investigator assessment, the median DOR was not reached in 3L+ subjects (95% CI: 20.37, NA) and 2L subjects (95% CI: 19.32, NA).

In the 3L+ FL group, DOR was consistent across all subgroups, including age, sex, region, ethnicity, race, anticancer treatment for disease control (yes vs no), received concomitant GCSF (yes vs no).

## Progression Free Survival (PFS)

The median follow-up time for PFS was per IRC charter in the 3L+ FL group was 23.98 months (95% CI: 23.82, 24.15).

Table 39. PFS - Analyses Per IRC Charter, Leukapheresed (ITT), and Per Investigator - Study FOL-001

|                                          | 4L+ FL Cohort 1     | 3L FL Cohort 2     | 3L+ FL Cohorts 1 + 2   |
|------------------------------------------|---------------------|--------------------|------------------------|
| PFS per IRC Charter                      |                     |                    |                        |
| (Liso-cel-treated Efficacy Analysis Set) | N = 55              | N = 48             | N = 103                |
| n (%)                                    | 17 (30.9)           | 12 (25.0)          | 29 (28.2)              |
| Median (95% CI), months a                | 31.77 (31.77, N.A.) | N.A. (16.99, N.A.) | N.A. (31.77, N.A.)     |
| Sensitivity Analyses                     |                     |                    |                        |
| PFS (Leukapheresed [ITT] Set)            | N = 65              | N = 49             | N = 114                |
| n (%)                                    | 20 (30.8)           | 13 (26.5)          | 33 (28.9)              |
| Median (95% CI), months a                | 33.45 (30.55, N.A.) | N.A.               | 33.45 (30.55, N.A.)    |
| PFS per Investigator                     |                     |                    |                        |
| (Liso-cel-treated Efficacy Analysis Set) | N = 55              | N = 48             | N = 103                |
| n (%)                                    | 17 (30.9)           | 12 (25.0)          | 29 (28.2)              |
| Median (95% CI), months a                | 36.14 (31.77, N.A.) | N.A.               | 36.14 (31.77, N.A.)    |

a Median, Q1, Q3 are estimated from KM product-limit estimates.

Figure 8. KM Plot of PFS per IRC Charter - Liso-cel-treated Efficacy Analysis Set 3L+ Subjects

<div style=\"page-break-after: always\"></div>

<!-- image -->

Symbols represent censored observations.

In the 3L+ FL group, PFS was consistent across all subgroups, including age, sex, region, ethnicity, race, anticancer treatment for disease control (yes vs no), received concomitant GCSF (yes vs no).

In female subjects, the estimated PFS at 24 months was slightly higher (77.1%, 95% CI 61.6-85.6) than in males (69.6%, 95% CI 56.6-79.4), but given the large overlap of the Confidence Interval between the  two  groups,  the  difference  was  not  deemed  significant;  the  same  conclusion  can  be  applied  to presence of concomitant therapy with G-CSF (24 month PFS if yes: 76% 95% CI 61.6-85.6%, if no: 68.8%, 06% CI54.1-79.6%).

## Overall Survival (OS)

The median follow-up for OS analysis was 29.47 months (95% CI: 26.51, 29.93).

Table 40. Summary of Efficacy Results - Liso-cel-treated Efficacy Analysis Set - Study FOL-001

|                           | 4L+ FL Cohort 1   | 3L FL Cohort 2    | 3L+ FL Cohorts 1 + 2   |
|---------------------------|-------------------|-------------------|------------------------|
| OS a,b                    | N = 55            | N = 48            | N = 103                |
| Events, n (%)             | 7 (12.7)          | 5 (10.4)          | 12 (11.7)              |
| Median (95% CI), months c | N.A.              | N.A.              | N.A.                   |
| Min, Max, months d        | 3.7, 37.2+        | 5.6, 35.7+        | 3.7, 37.2+             |
| OS rate, %(95% CI) e      |                   |                   |                        |
| 6 months                  | 94.5 (84.0, 98.2) | 97.9 (86.1, 99.7) | 96.1 (90.0, 98.5)      |
| 12 months                 | 90.9 (79.5, 96.1) | 93.7 (81.7, 97.9) | 92.2 (85.0, 96.0)      |
| 18 months                 | 89.1 (77.3, 94.9) | 93.7 (81.7, 97.9) | 91.2 (83.8, 95.3)      |
| 24 months                 | 87.2 (75.1, 93.7) | 89.3 (76.2, 95.4) | 88.2 (80.1, 93.1)      |
| 30 months                 | 87.2 (75.1, 93.7) | 89.3 (76.2, 95.4) | 88.2 (80.1, 93.1)      |
| 36 months                 | 87.2 (75.1, 93.7) | N.A.              | 88.2 (80.1, 93.1)      |
| Follow-up (Months)        |                   |                   |                        |

<div style=\"page-break-after: always\"></div>

- a OS is defined as the interval from the date of liso-cel infusion to the date of death due to any reason.
- b The OS analysis includes all available OS information from both Study FOL-001 as well as GC-LTFU-001 studies.
- c Median, Q1, Q3 are estimated from KM product-limit estimates.
- d Symbol + indicates a censored value.
- e Based on KM estimates.

Sensitivity  analyses  supported  OS  results  in  the  Leukapheresed  (ITT)  Set,  15/114  (13.2%)  3L+  FL subjects had died; most (7 subjects, 6.1%) were due to complications of malignant disease under study.

Figure 9. Kaplan-Meier Plot of Overall Survival - Liso-cel-Treated Efficacy Analysis Set Study FOL-001 - 3L+ FL

<!-- image -->

Symbols represent censored observations.

The OS analysis includes all available OS information from both Study FOL-001 and GC-LTFU-001 (long-term follow-up) studies.

## Ancillary analyses

## Subgroup Analysis

In the 3L+ FL group, OS was consistent across all subgroups, including age, sex, region, ethnicity, race, anticancer treatment for disease control (yes vs no), received concomitant GCSF (yes vs no).

## Post-hoc Analyses

<div style=\"page-break-after: always\"></div>

A sensitivity analysis for patients in 3L+ which comprised all leukapheresed patients excluding subjects who received non-conforming products (N=110 3L+ FL subjects; 107 subjects who received liso-cel within  the  approved  range  of  44  to  120  x  10 6   CAR  positive  viable  T  cells  and  3  subjects  who  were leukapheresed but not infused) showed an ORR of 93.6% (87.3-97.4), a CRR of 90.9% (83.9-95.6).

The median DOR per IRC assessment in subjects with CR or PR was not reached (NA, 95% CI: 30.85, NA).

## Time to Next Treatment

In the liso-cel-treated Efficacy Analysis Set (N = 103, 3L+ FL subjects) and with a median follow up time of 29.31 months (at the time of the data cutoff date of 10-Jan-2024), the median time to next therapy was not reached. Twelve (11.7%) subjects (11 relapsed after achieving response, 1 progressed without achieving response) received subsequent anticancer therapy (SACT) with time to next therapy ranging from 3.7 to 37.2 months.

Five of the 12 3L+ FL subjects who received SACT, had tumour samples collected at time of relapse, which were evaluable for CD19 testing. Per protocol, tumour biopsy had to be performed if clinically feasible as soon as possible after disease progression/relapse or failure to respond. If a tumour biopsy sample  was  available  at  relapse/progression  it  was  tested  for  CD19  expression  using  a  validated research-use-only immunohistochemistry assay. The CD19 H-Score (0-300) was used to report CD19 tumour expression levels.

## Health-related Quality of Life

The  PRO  Analysis  Set  consisted  of  116  (95.1%)  subjects,  122  (100%)  subjects,  and  115  (94.3%) subjects for the EORTC QLQ-C30 questionnaire, FACT-LymS questionnaire, and EQ -5D Utility Index and VAS of the Liso-cel-treated Analysis Set, respectively.

## Completion Rates Across all Questionnaires

Completion rate is defined as the number of subjects submitting a valid PRO assessment at a given timepoint over the number of subjects who are still expected to provide PRO assessment at that time point. Compliance was high at baseline at 95.1% and remained &gt; 70% through Day 545 in 3L+ FL subjects. Available data rate was defined as the number of subjects submitting a valid PRO assessment at a given timepoint over the number of subjects in the PRO Analysis Set.

## -      EORTC QLQ-C30 - Mean Change from Baseline - Secondary Endpoint

Liso-cel demonstrated improvements over time in evaluations of group-level mean change from baseline on EORTC QLQ-C30 for the pre-selected domains of interest, including in the 5 of the 6 pre-selected domains among 3L+ subjects.

In 3L+ FL subjects:

- Fatigue worsened between Day 1 to Day 15, before clinically meaningfully improving between Day 15 and Day 60, and remained consistent thereafter.
- GHS/QoL clinically meaningfully improved between Day 1 to Day 60, and remained consistent thereafter.
- Physical functioning clinically meaningfully improved between Day 29 to Day 60, and remained consistent thereafter.
- Cognitive functioning and pain clinically meaningfully improved between Day 1 to Day 29, and remained consistent thereafter.

<div style=\"page-break-after: always\"></div>

In individual level analyses, from Day 29 onwards, most subjects (~60% to 95%) experienced either meaningful improvement or no meaningful change across visits, and findings were similar across the remaining EORTC domains.

## FACT-LymS - Mean Changes from Baseline - Secondary Endpoint

Across visits  most  subjects  (~60% to 95%) experienced meaningful improvement or no meaningful change on the FACT-LymS. The proportion of subjects with meaningful improvement increased while the proportion of subjects with meaningful worsening decreased from Day 1 to Day 29 and then remained relatively constant.

## EQ-5D-5L

Subjects showed improvement in the EQ-5D-5L summary index between Day 1 to Day 29 and remaining consistent thereafter in 3L+ FL subjects, with a similar trend in 4L+ FL subjects. In 2L FL subjects there was a trend towards improvement at Day 15, 60, and 365, whereas other time points were stable compared to baseline. The improvements did not reach the clinically meaningful improvement threshold.

Subjects showed improvement in the EQ-5D-5L VAS between Day 1 to Day 90 and remaining consistent thereafter  in  3L+  FL  subjects,  with  similar  trends  in  4L+  FL  subjects  and  2L  FL  subjects.  The improvements did not reach the clinically meaningful improvement threshold.

## Hospital Resource Utilization

Hospitalization may have been required after treatment with liso-cel to manage any treatment associated toxicities.  Administration  of  liso-cel  as  inpatient  or  outpatient  setting  was  determined  at  the  PI's discretion.

Table 41. Liso-cel Administration - Liso-cel-treated Analysis Set

|                                                                                                       | 4L+ FL Cohort 1 N = 59   | 3L FL Cohort 2 N = 48   | 3L+ FL Cohorts 1 + 2 N = 107   | 2L FL Cohort 3 N = 23   | Total 2L+ FL Cohorts 1, 2, 3 N = 130   |
|-------------------------------------------------------------------------------------------------------|--------------------------|-------------------------|--------------------------------|-------------------------|----------------------------------------|
| Liso-cel Administration in the Outpatient Setting - N (%)                                             | 6 (10.2)                 | 1 (2.1)                 | 7 (6.5)                        | 1 (4.3)                 | 8 (6.2)                                |
| Liso-cel Administration in the Inpatient Setting - N (%)                                              | 53 (89.8)                | 47 (97.9)               | 100 (93.5)                     | 22 (95.7)               | 122 (93.8)                             |
| Reason for Administration in the Inpatient Setting - N (%)                                            |                          |                         |                                |                         |                                        |
| Lack of Caregiver Support                                                                             | 1 (1.7)                  | 0                       | 1 (0.9)                        | 1 (4.3)                 | 2 (1.5)                                |
| Subject is Staying More Than 60 Minutes From the Clinical Trials Site at the Time of Treatment        | 7 (11.9)                 | 5 (10.4)                | 12 (11.2)                      | 4 (17.4)                | 16 (12.3)                              |
| Subject has Disease Characteristics That, in the Investigator's Clinical Judgment, Put the Subject at | 11 (18.6)                | 2 (4.2)                 | 13 (12.1)                      | 0                       | 13 (10.0)                              |
| Other                                                                                                 | 34 (57.6)                | 40 (83.3)               | 74 (69.2)                      | 17 (73.9)               | 91 (70.0)                              |
| Liso-cel Intended to be Monitored in the Outpatient Setting - N (%)                                   | 12 (20.3)                | 2 (4.2)                 | 14 (13.1)                      | 1 (4.3)                 | 15 (11.5)                              |
| Liso-cel Intended to be Monitored in the Inpatient Setting - N (%)                                    | 47 (79.7)                | 46 (95.8)               | 93 (86.9)                      | 22 (95.7)               | 115 (88.5)                             |
| Liso-cel Actually Monitored in the Outpatient Setting - N (%)                                         | 12 (20.3)                | 2 (4.2)                 | 14 (13.1)                      | 1 (4.3)                 | 15 (11.5)                              |

<div style=\"page-break-after: always\"></div>

| Liso-cel Actually Monitored in the Inpatient Setting - N (%)   | 47 (79.7)   | 46 (95.8)   | 93 (86.9)   | 22 (95.7)   | 115 (88.5)   |
|----------------------------------------------------------------|-------------|-------------|-------------|-------------|--------------|
| Reason for Monitoring in the Inpatient Setting - N (%)         |             |             |             |             |              |
| Lack of Caregiver Support                                      | 1 (1.7)     | 0           | 1 (0.9)     | 1 (4.3)     | 2 (1.5)      |
| PI Decision                                                    | 12 (20.3)   | 10 (20.8)   | 22 (20.6)   | 3 (13.0)    | 25 (19.2)    |
| Disease Characteristics                                        | 10 (16.9)   | 2 (4.2)     | 12 (11.2)   | 0           | 12 (9.2)     |
| Risk of TLS                                                    |             |             |             |             |              |
| Yes                                                            | 10 (16.9)   | 2 (4.2)     | 12 (11.2)   | 0           | 12 (9.2)     |
| Risk Of CRS                                                    |             |             |             |             |              |
| Yes                                                            | 10 (16.9)   | 2 (4.2)     | 12 (11.2)   | 0           | 12 (9.2)     |
| Transportation                                                 | 0           | 1 (2.1)     | 1 (0.9)     | 0           | 1 (0.8)      |
| Other                                                          | 23 (39.0)   | 33 (68.8)   | 56 (52.3)   | 18 (78.3)   | 74 (56.9)    |
| Not Reported                                                   | 1 (1.7)     | 0           | 1 (0.9)     | 0           | 1 (0.8)      |

In the 116 (89.2%) subjects who received liso-cel and who were monitored as inpatients, the most common  reason  for  hospitalization  during  liso-cel  infusion  was  other  (prophylaxis  for  CAR  T  cell administration) (107 [92.2%] subjects). For these 116 subjects, the median duration of hospitalization from liso-cel administration was 15 days (range, 4 to 41). No subjects were admitted to the ICU during liso-cel administration.

Table 42. Summary of Hospitalizations - Liso-cel-Treated Analysis Set, Subjects with Actual Inpatient Monitoring

|                                                                   | 4L+ FL Cohort 1 N = 47 n (%)   | 3L FL Cohort 2 N = 46 n (%)   | 3L+ FL Cohorts 1 + 2 N = 93 n (%)   | 2L FL Cohort 3 N = 22 n (%)   | Total 2L+ FL Cohorts 1, 2, 3 N = 115 n (%)   |
|-------------------------------------------------------------------|--------------------------------|-------------------------------|-------------------------------------|-------------------------------|----------------------------------------------|
| Summary of Hospitalizations During Liso-cel Administration        |                                |                               |                                     |                               |                                              |
| Reason for Hospitalization - N (%)                                |                                |                               |                                     |                               |                                              |
| Adverse Event                                                     | 1 (2.1)                        | 0                             | 1 (1.1)                             | 0                             | 1 (0.9)                                      |
| Per Protocol                                                      | 3 (6.4)                        | 11 (23.9)                     | 14 (15.1)                           | 5 (22.7)                      | 19 (16.5)                                    |
| Other                                                             | 43 (91.5)                      | 35 (76.1)                     | 78 (83.9)                           | 17 (77.3)                     | 95 (82.6)                                    |
| Duration of Hospitalization From Liso-cel Administration (Days) a |                                |                               |                                     |                               |                                              |
| N                                                                 | 47                             | 46                            | 93                                  | 22                            | 115                                          |
| Median                                                            | 15.0                           | 15                            | 15                                  | 12                            | 15                                           |
| Q1, Q3                                                            | 12.0, 16.0                     | 11.0, 15.0                    | 11.0, 15.0                          | 11.0, 15.0                    | 11.0, 15.0                                   |
| Min, Max                                                          | 4, 41                          | 7, 30                         | 4, 41                               | 5, 29                         | 4, 41                                        |
| Duration of ICU Stay From Liso-cel Administration (Days) b        |                                |                               |                                     |                               |                                              |
| N                                                                 | 0                              | 0                             | 0                                   | 0                             | 0                                            |

<div style=\"page-break-after: always\"></div>

| Duration of Non-ICU Stay From Liso-cel Administration (Days) c               |            |            |            |            |            |
|------------------------------------------------------------------------------|------------|------------|------------|------------|------------|
| Median                                                                       | 15.0       | 15         | 15         | 12         | 15         |
| Q1,                                                                          | 12.0,      |            |            |            |            |
| Q3                                                                           | 16.0       | 11.0, 15.0 | 11.0, 15.0 | 11.0, 15.0 | 11.0, 15.0 |
| Min, Max                                                                     | 4, 41      | 7, 30      | 4, 41      | 5, 29      | 4, 41      |
| Summary of Hospitalizations During and Post- Liso-cel Administration         |            |            |            |            |            |
| Total Duration of All Hospitalizations From Liso-cel Administration (Days) d |            |            |            |            |            |
| N                                                                            | 47         | 46         | 93         | 22         | 115        |
| Median                                                                       | 15.0       | 15         | 15         | 14         | 15         |
| Q1, Q3                                                                       | 14.0, 23.0 | 12.0, 17.0 | 14.0, 20.0 | 11.0, 16.0 | 12.0, 18.0 |
| Min, Max                                                                     | 8, 84      | 7, 46      | 7, 84      | 8, 29      | 7, 84      |
| Total Duration of All ICU Stays From Liso-cel Administration (Days) d        |            |            |            |            |            |
| N                                                                            | 2          | 0          | 2          | 1          | 3          |
| Median                                                                       | 5          |            | 5          | 6          | 6          |
| Q1, Q3                                                                       | 3.0, 7.0   |            | 3.0, 7.0   | 6.0, 6.0   | 3.0, 7.0   |
| Min, Max                                                                     | 3, 7       |            | 3, 7       | 6, 6       | 3, 7       |
| Total Duration of All Non-ICU Stays From Liso-cel Administration (Days) d    |            |            |            |            |            |
| N                                                                            | 47         | 46         | 93         | 22         | 115        |
| Median                                                                       | 15.0       | 15         | 15         | 14         | 15         |
| Q1, Q3                                                                       | 14.0, 23.0 | 12.0, 17.0 | 14.0, 18.0 | 11.0, 16.0 | 12.0, 18.0 |
| Min, Max                                                                     | 8, 84      | 7, 46      | 7, 84      | 8, 29      | 7, 84      |

a Duration (days) = date of discharge - liso-cel infusion date + 1

b Duration (days) = date of discharge - date of admission after liso-cel administration + 1. If liso-cel administration took place during ICU stay, then days = date of discharge - liso-cel infusion date + 1.

c Duration (days) = total days in hospital - ICU days.

d Sum of all hospitalization/ICU/non-ICU days on or after liso-cel administration for subjects who had multiple hospitalizations, ICU admissions, or nonICU stays during and post- liso-cel infusion.

Data from subjects who receive subsequent anti-follicular lymphoma therapy are included.

In the 14 (10.7%) subjects who received liso-cel and were monitored as outpatients, 7 (50.0%) subjects were hospitalized after liso-cel administration; 7 (100%) were hospitalized due to an AE.  The median time from liso-cel administration to first hospitalization was 7 days (range, 4 to 16). None of these subjects had ICU stays.

Table 43. Summary of Hospitalizations - Liso-cel-Treated Analysis Set, Subjects with Actual Outpatient Monitoring

| 4L+ FL Cohort N = 12   | 3L FL Cohort   | 3L+ FL Cohorts 1 + 2 N = n (%)   | 2L FL Cohort   | Total 2L+ FL Cohorts 1, 2, 3 N = 15 n (%)   |
|------------------------|----------------|----------------------------------|----------------|---------------------------------------------|
| 1                      | 2              |                                  | 3              |                                             |
|                        | N =            |                                  |                |                                             |
|                        | 2              | 14                               | N = 1          |                                             |
| n (%)                  | n (%)          |                                  | n (%)          |                                             |

Hospitalized After Liso-cel Administration -

N (%)

<div style=\"page-break-after: always\"></div>

| Yes                                                                          | 4 (33.3)   | 2 (100.0)   | 6 (42.9)   | 1 (100.0)   | 7 (46.7)   |
|------------------------------------------------------------------------------|------------|-------------|------------|-------------|------------|
| No                                                                           | 8 (66.7)   | 0           | 8 (57.1)   | 0           | 8 (53.3)   |
| Time From Liso-cel Administration To First Hospitalization (Days) a          |            |             |            |             |            |
| N                                                                            | 4          | 2           | 6          | 1           | 7          |
| Median                                                                       | 6.5        | 8.5         | 7.5        | 7           | 7          |
| Q1, Q3                                                                       | 4.0, 12.5  | 6.0, 11.0   | 4.0, 11.0  | 7.0, 7.0    | 4.0, 11.0  |
| Min, Max                                                                     | 4, 16      | 6, 11       | 4, 16      | 7, 7        | 4, 16      |
| First Hospitalization Within 4 Days After Liso-cel Administration - N (%)    |            |             |            |             |            |
| Yes                                                                          | 2 (50.0)   | 0           | 2 (33.3)   | 0           | 2 (28.6)   |
| No                                                                           | 2 (50.0)   | 2 (100.0)   | 4 (66.7)   | 1 (100.0)   | 5 (71.4)   |
| Summary Of Initial Hospitalizations After Liso-cel Administration            |            |             |            |             |            |
| Reason For Hospitalization - N (%)                                           |            |             |            |             |            |
| Adverse Event                                                                | 4 (100.0)  | 2 (100.0)   | 6 (100.0)  | 1 (100.0)   | 7 (100.0)  |
| Duration Of Initial Hospitalization From Liso-cel Administration (Days) (B)  |            |             |            |             |            |
| N                                                                            | 4          | 2           | 6          | 1           | 7          |
| Median                                                                       | 6          | 5           | 6          | 3           | 5          |
| Q1, Q3                                                                       | 4.0, 7.5   | 3.0, 7.0    | 3.0, 7.0   | 3.0, 3.0    | 3.0, 7.0   |
| Min, Max                                                                     | 3, 8       | 3, 7        | 3, 8       | 3, 3        | 3, 8       |
| Duration Of Initial ICU Stay From Liso-cel Administration (Days) b           |            |             |            |             |            |
| N                                                                            | 0          | 0           | 0          | 0           | 0          |
| Duration Of Initial Non-ICU Stay From Liso- cel Administration (Days) c N    | 4          | 2           | 6          | 1           | 7          |
| Median                                                                       | 6          | 5           | 6          | 3           | 5          |
| Q1, Q3                                                                       | 4.0, 7.5   | 3.0, 7.0    | 3.0, 7.0   | 3.0, 3.0    | 3.0, 7.0   |
| Min, Max                                                                     | 3, 8       | 3, 7        | 3, 8       | 3, 3        | 3, 8       |
| Summary Of Hospitalizations Post- Liso-cel Administration                    |            |             |            |             |            |
| Total Duration Of All Hospitalizations From Liso-cel Administration (Days) d |            |             |            |             |            |
| N                                                                            | 4          | 2           | 6          | 1           | 7          |
| Median                                                                       | 6          | 6.5         | 6.5        | 3           | 6          |
| Q1, Q3                                                                       | 4.0, 7.5   | 6.0, 7.0    | 5.0, 7.0   | 3.0, 3.0    | 3.0, 7.0   |
| Min, Max                                                                     | 3, 8       | 6, 7        | 3, 8       | 3, 3        | 3, 8       |
| Total Duration Of All ICU Stays From Liso- cel Administration (Days) d       |            |             |            |             |            |
| N                                                                            | 0          | 0           | 0          | 0           | 0          |
| Total Duration Of All Non-ICU Stays From Liso-cel Administration (Days) d    |            |             |            |             |            |
| N                                                                            | 4          | 2           | 6          | 1           | 7          |
| Median                                                                       | 6          | 6.5         | 6.5        | 3           | 6          |
| Q1, Q3                                                                       | 4.0, 7.5   | 6.0, 7.0    | 5.0, 7.0   | 3.0, 3.0    | 3.0, 7.0   |

<div style=\"page-break-after: always\"></div>

a Time (days) = date of admission after liso-cel administration - liso-cel infusion date + 1.

b Duration (days) = date of discharge - date of admission after liso-cel administration + 1.

## Supportive studies

The MAH provided three supportive studies to contextualize the effectiveness of Liso-cel in respect to the other existing therapies approved for R/R FL.

## Real-world External Control Arm (ECA) Study (Study CA082013)

Study CA08201342 was a non-interventional, retrospective study of R/R FL subjects who received at least one line of systemic therapy including an CD20 antibody and an alkylating agent in the real-world clinical  oncology  setting  and  historical  clinical  trials,  conducted  to  provide  comparative  effectiveness evidence for Liso-cel versus currently used therapies in the 3L+ R/R FL setting, using propensity score methodologies.

The Liso-cel treated population was comprised of subjects from Study FOL-001. The ECA included:

- observational, real-world, subject-level data from multiple vendors
- clinical  trial  data  from  the  AUGMENT  (CC-5013-NHL-007)  and  MAGNIFY  (CC-5013-NHL-008) studies.

Data from all sources were combined into a single ECA.

## Real-world Study Design

The  retrospective real-world external control arm  did not impose  a  treatment  protocol,  any diagnostic/interventional procedure, or a visit schedule.

Study CA082013 includes 3 cohorts of subjects (from real-world and clinical settings) with FL constructed using external data that are similar to those in Study FOL-001 to form the ECA. All clinical data sources used in this study have treatment options that are in the current scope of standard of care and thus contain subjects suitable for the ECA. A propensity score matched cohort was separately created of subjects from respective analysis groups and corresponding external cohort as an external cohort for direct comparison of effectiveness with liso-cel in Study FOL-001.

## Qualifying Comparator Cohort

The External Control Arm (ECA) subjects in QCC were identified based on the defined inclusion/exclusion criteria, based on those in Study FOL-001. Subjects in the Qualifying Comparator Cohort (QCC) were matched on baseline characteristics with those in the Study FOL-001 population to construct the ACC and  baseline  evaluations  for  Study  FOL-001  Cohort  were  defined  in  the  study  protocol  as  the  last available recorded value on or prior to the date of the first dose of treatment (preferably within 7 days) and not more than 4 weeks (28 days). Baseline was defined for ECA subjects as the closest value to onset of the qualifying LOT collected after completion of previous LOT, but no more than 3 months prior to index date (with the exception of molecular result, which can have been performed more than 3 months prior to index date).

## Cohorts considered for analysis

Two overlapping cohorts were drawn from the ECA cohort: 1) the Qualifying Comparator Cohort (QCC), who met select eligibility criteria similar to those of Study FOL-001; and 2) the Analytic Comparator Cohort (ACC), comprising a subset of patients from the QCC who were matched with the Study FOL-001 population using IPTW and PS matching. The index dates for the QCC and ACC were the start of the first qualifying LOT after satisfying eligibility criteria in the respective analysis groups.

<div style=\"page-break-after: always\"></div>

Two  overlapping  cohorts  were  drawn  from  Study  FOL-001:  the  Liso-cel  (JCAR017)-treated  Efficacy Analysis Cohort (JTEAC) and the Leukapheresed Cohort (LKC). The JTEAC included all subjects in the Liso-cel-treated Analysis Set (all subjects who received a dose of conforming Liso-cel cell product) who had positive disease present before Liso-cel administration based on IRC assessment (PET-CT for FL subjects). The index date for JTEAC was the date of start of infusion of Liso-cel. The LKC included all subjects  who  signed  informed  consent,  who  met  all  inclusion/exclusion  criteria,  and  underwent leukapheresis. The index date for the LKC cohort was the date of start of leukapheresis.

## Study Objective

The primary endpoint for this study was ORR, defined as the percentage of patients achieving a best response of PR or CR as assessed by the investigator. The following key secondary endpoints were assessed: CRR, PFS, OS, TTNT and DOR.

Sensitivity analyses included an analysis in the LKC cohort along with further analyses for the RW cohort and for subjects with and without bridging therapy in the JTEAC cohort.

## Population analyzed

Overall, 103 subjects were included in the JTEAC, 338 were included in the QCC, 114 were included in the LKC, and 107 were included in the RW Cohort. The most common 3L+ treatment regimens in the ECA QCC were lenalidomide + rituximab (N = 195, 57.7%), rituximab (N = 52, 15.4%), bendamustine + rituximab (N = 27, 8.0%), and idelalisib (N = 10, 3.0%) which align with recommended therapies for relapsed or progressed patients in ESMO guidelines. The most common 3L+ treatment regimens in the RW QCC were bendamustine + rituximab (N = 27, 25.2%), lenalidomide + rituximab (N = 14, 13.1%), and idelalisib (N = 10, 9.3%).

## Covariate Balancing using Trimmed Stabilized IPTW

Based on a threshold of 0.2 for the standardized mean difference, there were differences in several covariates before balancing between JTEAC and QCC, including months since last therapy completion, geographic location, prior HSCT, refractory to last LOT, PD within 24 months after the start of the first LOT, bulky disease, International Prognostic Index Group, and disease stage. Similarly, differences were observed between QCC and LKC in terms of months from initial diagnosis, months since last therapy completion, geographic location, prior HSCT, refractory to last LOT, PD within 24 months after the start of the first LOT, bulky disease, and International Prognostic Index Group. None of these differences were present after balancing.

## Demographic and Other Baseline Characteristics

Baseline demographics in the QCC cohort were similar to both the JTEAC and LKC cohorts in terms of mean age, sex, height, double refractory status and number of prior lines of therapies; in the QCC cohort, a  higher  proportion  of  patients  had  bulky  disease  and  more  than  4  extranodal  site  involvement,  as determined by the investigator, compared to the JTEAC and LKC cohorts. The QCC cohort had a lower proportion of patients with prior HSCT, follicular lymphoma grade 2 and 3a, Stage III and Stage IV disease, refractory to the last line of therapy prior to the index line, and POD24 status, compared to the JTEAC and LKC cohorts.

For some characteristics, missing information on baseline disease status was more common in the QCC cohort than in the JTEAC and LKC cohorts. Approximately 17%, 29%, 28% and 3% of patients in the QCC cohort had missing information on bulky disease, Follicular Lymphoma International Prognostic Index, staging information, and double refractory status, respectively, while no subjects in the JTEAC and LKC cohorts had missing information in these categories.

<div style=\"page-break-after: always\"></div>

In general, patients in the QCC cohort had a shorter interval time from the initial diagnosis of B-NHL to the initiation of their first treatment compared to subjects in the JTEAC and LKC cohorts. However, they experienced a longer duration from the initial diagnosis to the index therapy, as well as a longer period from the completion of their last therapy to the start of the index therapy, when compared to subjects in the JTEAC and LKC cohorts.

## Results

Table 44. Comparison of Efficacy Outcomes Adjusted for Trimmed Stabilized IPTW between JTEAC and QCC, LKC, and RW Cohorts (Study CA082013)

| Effect Estimate (95% CI)   | JTEAC (N = 103) vs QCC (N = 338)   | LKC (N = 114) vs QCC (N = 338)   | JTEAC (N = 103) vs RW Cohort (N = 107)   |
|----------------------------|------------------------------------|----------------------------------|------------------------------------------|
| ORR                        | RR:1.3 (1.2, 1.5)                  | RR:1.3 (1.2, 1.5)                | RR: 1.4 (1.1, 1.7)                       |
| CRR                        | RR:2.1 (1.8, 2.5)                  | RR:2.2 (1.9, 2.6)                | RR:2.1 (1.5, 2.8)                        |
| PFS                        | HR: 0.34 (0.20, 0.58)              | HR: 0.32 (0.18, 0.58)            | HR: 0.50 (0.26, 0.94)                    |
| TTNT                       | HR: 0.27 (0.14, 0.51)              | HR: 0.26 (0.13, 0.54)            | HR: 0.27 (0.12, 0.59)                    |
| OS                         | HR: 0.45 (0.19, 1.03)              | HR: 0.47 (0.19, 1.17)            | HR: 0.12 (0.05, 0.29)                    |
| DOR                        | HR: 0.36 (0.20, 0.64)              | -                                | -                                        |

Risk Ratio &gt; 1 and Hazard Ratio &lt; 1 indicates favorable results for liso-cel vs standard of care treatments. Statistically significant results are bolded.

The sensitivity analyses showed consistency with results observed between JTEAC and QCC, supporting the primary analysis. The results remained largely consistent between JTEAC and RW cohort, similar to those observed between JTEAC and QCC. A statistically significant difference in OS was observed in favor of Liso-cel compared to the RW cohort.

## Indirect Treatment Comparison (ITC) for lisocabtagene maraleucel in the treatment of 3L or 4L+ relapsed/refractory follicular lymphoma

## Study Objectives

Study CA08209243 was a non-interventional MAIC study using indirect treatment comparison methods to estimate the comparative efficacy and safety of liso-cel versus mosunetuzumab (a bispecific CD20directed CD3 T-cell engager; GO29781 trial), axi-cel (a CD19 directed autologous CAR T cell therapy; ZUMA-5 trial), and tisa-cel (a CD19 directed autologous CAR T cell therapy; ELARA trial) in patients with 3L+ R/R FL. Outcomes included efficacy  outcomes  (ORR,  CRR,  PFS,  and  DOR)  and  AEs  (CRS,  NEs, infections, prolonged cytopenia, corticosteroid use for CRS management, and tocilizumab use for CRS management).

## Investigational Plan

- -To conduct an ITC, the included studies need to be sufficiently similar to allow for adequate analytic alignment to mitigate sources of bias. A thorough qualitative comparison of the pivotal trials for liso-cel (TRANSCEND FL), mosunetuzumab (GO29781), axi-cel (ZUMA-5), and tisacel (ELARA) was conducted to assess the feasibility of an ITC in terms of the following components: study design characteristics, including phase, visit schedules, and follow-up time
- -Study  eligibility  criteria,  including  clinical  and  diagnostic  definitions,  and  study  treatment protocols (such as use of bridging therapy)
- -Baseline characteristics, including availability, definitions, and assessment of imbalance
- -Outcomes, including availability and definitions

The feasibility assessment was performed using IPD from TRANSCEND FL and published summary level data (SLD) from GO29781, ZUMA-5, and ELARA were used. Analyses of interest included all patients who were enrolled and received treatment (hereafter referred as intention to treat [ITT]) and treated

<div style=\"page-break-after: always\"></div>

efficacy set for the comparison of efficacy outcomes and all patients who were randomized and received study treatment (ie, treated set) for the comparison of safety outcomes.

## Study design

Overall, the trial designs of TRANSCEND FL, GO29781, ZUMA-5, and ELARA were sufficiently similar to allow for MAICs to be performed, as well as for the study eligibility assessments.

Comparisons of baseline characteristics revealed some differences in the definitions or categorizations of patient characteristics such as high tumor bulk, number of prior LOT and R/R status. This required alignment via redefining and recategorizing the variables using IPD from TRANSCEND FL to facilitate a fairer comparison.

## Appropriateness of measurements

By comparing the study design, eligibility criteria, baseline characteristics, and outcomes of TRANSCEND FL, GO29781, ZUMA-5, and ELARA, it was determined that there were significant similarities among these studies to permit indirect comparisons via MAIC. The differences between TRASCEND FL and the other trials are summarized below:

- GO29781: treatment with mosunetuzumab did not involve leukapheresis or lymphodepletion; patients  in  TRANSCEND  FL  also  had  the  option  for  bridging  therapy  during  the  treatment manufacturing process, unlike those in GO29781 who received mosunetuzumab immediately after enrolment, alongside corticosteroid premedication which was prohibited in the TRASCEND FL trial.  Large  differences  in  the  definitions  or  categorizations  of  patient  characteristics  were identified between TRANSCEND FL and GO29781 including high tumor bulk, number of lines of prior  therapy,  and  refractory  or  relapse  status.  To  address  this  variability,  alignments  were performed by redefining the variables using TRANSCEND FL IPD to facilitate a fairer comparison.
- ZUMA-5: a notable difference was observed in the use of bridging therapy during treatment manufacturing, with a higher proportion of patients in TRANSCEND FL receiving bridging therapy (37.4%)  compared  to  ZUMA-5  (3.2%).  Based  on  this  difference,  the  efficacy  and  safety endpoints  excluded patients who received bridging therapy prior to liso-cel infusion (treated efficacy set, N = 61; treated set, N = 63). Three primary differences in definitions between TRANSCEND FL and ZUMA-5 were noted, including high tumor bulk (according to GELF criteria), number of prior LOT, and refractory status to the last previous therapy. Based on this difference, alignments were performed by redefining the variables using TRANSCEND FL IPD.
- ELARA: comparable proportion of patients in TRANSCEND FL receiving bridging therapy (37.4%) relative  to  ELARA  (45.0%).  Consequently,  efficacy  endpoints  were  compared  between  the treated efficacy set (N = 101) from TRANSCEND FL and the efficacy analysis set from ELARA (N = 94). Although definition for bulky disease were the same between trials, there were limited details  on  the  exact  timeframe  measurements  were  taken  in  the  ELARA  trial;  similarly,  a difference in the definition of refractory or relapse status was identified between TRANSCEND FL and ELARA. To make the definitions comparable between trials, alignments were performed by redefining the variables using TRANSCEND FL IPD.

## Overview of statistical analysis

For the MAIC approach, ITCs were formed by 'matching' and 'adjusting' patients from TRANSCEND FL to match the eligible patient population and marginal distribution (eg, mean and variance) of baseline characteristics in patients who received the comparator intervention. Matching consisted of aligning trials on inclusion/exclusion criteria and is required for the positivity assumption of causal inference to be met. Positivity  requires  that  all  patients  have  a  nonzero  probability  of  being  assigned  to  either  trial,  and violations of positivity can bias estimates of treatment effects and their variance. Adjusting consists of weighing patients in TRANSCEND FL so that they represent a population more similar to that of GO29781,

<div style=\"page-break-after: always\"></div>

ZUMA-5, and ELARA. After matching and adjusting patients from TRANSCEND FL, statistical predictions of the outcome of interest are an estimate of the outcome that would have occurred had the comparison population (ie, GO29781, ZUMA-5, ELARA) received liso-cel instead of mosunetuzumab, axi-cel, and tisacel. Point estimates representing an ITC for liso-cel versus comparator treatments were derived as the  difference  between  this  prediction  and  the  estimated  outcome  using  published  SLD  from  the comparator trial. Given that there is no common comparator arm connecting TRANSCEND FL to any of the three comparator trials, unanchored MAICs were conducted for the efficacy and safety analyses. Patients in the TRANSCEND FL IPD were matched and adjusted to comparator trials, GO29781, ZUMA5,  and  ELARA.  Generalized  linear  models  (GLM)  for  binary  outcomes  (ie,  ORR,  CRR)  were  used  to estimate odds ratios (ORs) of liso-cel versus mosunetuzumab and to estimate relative response ratios of liso-cel versus axi-cel and liso-cel versus tisa-cel. For time-to-event outcomes (ie, DoR, PFS), Cox proportional  hazards  (PH)  models  were  used  to  estimate  hazard  ratios  (HRs)  of  liso-cel  vs.  its comparators (ie, mosunetuzumab, axi-cel, and tisa-cel).

For  a  given  set  of  clinical  factors,  separate  MAICs  were  conducted  sequentially,  adjusting  for  one additional  variable  at  a  time  in  an  iterative  process;  after  fitting  each  model,  the  performance  and suitability of each MAIC model was assessed based on the effective sample size, distribution of patients weights and a summary of statistics for each clinical factor before and after matching and adjusting steps. The primary analysis of the MAIC model was chosen based on achieving a balance between these criteria, while also considering the number of clinical factors included.

For all three comparisons, clinical experts separately identified important prognostic factors to adjust for in each MAIC analyses. For each comparison, factors adjusted for in the primary MAIC scenario were selected  based  on  availability  of  data  between  comparator  studies,  similarity  of  variable  definitions, prognostic strength as determined by clinical expert opinion, and impact of adjustment on ESS.

## Results

Table 45. Clinical Summary of MAIC Results for Efficacy Outcomes (Study CA082092)

|                          | Liso-cel vs Mosunetuzumab   | Liso-cel vs Mosunetuzumab   | Liso-cel vs Axi-cel   | Liso-cel vs Axi-cel   | Liso-cel vs Tisa-cel   | Liso-cel vs Tisa-cel   |
|--------------------------|-----------------------------|-----------------------------|-----------------------|-----------------------|------------------------|------------------------|
| Effect Estimate (95% CI) | Naïve a                     | Primary b                   | Naïve a               | Primary b             | Naïve a                | Primary b              |
| ORR                      | OR: 3.31 (1.37, 8.03)       | OR: 3.78 (1.48, 9.67)       | RR: 1.04 (0.98, 1.11) | RR: 1.06 (1.00, 1.12) | RR: 1.14 (1.03, 1.25)  | RR: 1.09 (0.95, 1.25)  |
| CRR                      | OR: 6.24 (2.95, 13.23)      | OR: 6.46 (2.85, 14.65)      | RR: 1.18 (1.02, 1.37) | RR: 1.25 (1.09, 1.45) | RR: 1.37 (1.13, 1.67)  | RR: 1.33 (1.06, 1.68)  |
| PFS                      | HR: 0.35 (0.21, 0.57)       | HR: 0.28 (0.16, 0.49)       | HR: 0.85 (0.45, 1.62) | HR: 1.14 (0.47, 2.74) | HR: 0.43 (0.23, 0.78)  | HR: 0.62 (0.21, 1.87)  |
| DOR                      | HR: 0.41 (0.23, 0.72)       | HR: 0.34 (0.18, 0.63)       | HR: 0.89 (0.45, 1.73) | HR: 1.26 (0.52, 3.05) | HR: 0.54 (0.29, 1.01)  | HR: 0.47 (0.14, 1.65)  |

a Unadjusted b MAIC Scenario

Odd Ratios or Response Ratio &gt; 1 and Hazard Ratio &lt;1 indicates favorable results for liso-cel vs mosunetuzumab / axi-cel / tisa-cel. Statistically significant (nominal p-value) results are bolded .

When the 'FDA algorithm' was applied for the evaluation of response, a different percentage of response can be noted in ZUMA-5 trial, while in ELARA the 'FDA algorithm' was used upfront for the primary analysis. To note, also in ZUMA-5 the evaluation of response was introduced with an amendment during the study.

<div style=\"page-break-after: always\"></div>

Table 46. CRR per IRC Charter and FDA Algorithm in Study FOL-001, ZUMA-5, and ELARA

| Cell Therapy   | Study                                     | CRR per IRC Charter   | CRR per FDA algorithm   |
|----------------|-------------------------------------------|-----------------------|-------------------------|
| Liso-cel       | JCAR017-FOL-001 Data cutoff 27-Jan-2023 a | 95/101 94.1%          | 73/101 72.3%            |
|                | JCAR017-FOL-001 Data cutoff 10-Jan-2024 b | 97/103 94.2%          | 75/103 72.8%            |
| Axi-cel        | ZUMA-5                                    | 68/86 79.1%           | 49/81 60.5%             |
| Tisa-cel       | ELARA                                     | Not reported          | 65/94 69.1%             |

## Systematic literature review of clinical evidence of third line and later (3L+) treatments for follicular lymphoma in adult patients

The objective of this systematic literature review (SLR) was to systematically identify all relevant clinical evidence for therapies used in the treatment of adult patients with R/R FL (grade 1-3A) in the 3L+ and 4L+ setting. Additionally, studies investigating outcomes in 2L+ POD24 patients were included.

The secondary objectives were to assess the feasibility  of  conducting  meta-analyses  of  key  efficacy outcomes reported across studies included in the SLR for each population of interest and to conduct meta-analyses for each of the outcome/population combinations deemed feasible.

## Methodology

Database searches was conducted in Ovid MEDLINE®, Embase, and the Cochrane Central Register of Controlled Trials using the Ovid® search interface; studies investigating R/R FL (grade 1-3A) patients in the 3L+, 4L+, and 2L+ POD24 setting were considered eligible for the research.

Treatments  for  FL  included  systemic  induction  chemotherapies  (ie,  chemotherapy,  immunotherapy, chemoimmunotherapy) recommended by National Comprehensive Cancer Network (NCCN)/European Society for Medical Oncology (ESMO) and/or treatments deemed relevant to current clinical practice for FL.

The report contains reviews conducted from two searches. The first search was run on 17-Sep-2022 and included studies published between January 1998 and September 2022. The second search was run on 26-Jan-2024  and  included  studies  published  between  August  2022  and  January  2024.  The  date restriction of 01-Jan-1998 was chosen to align with the introduction of rituximab use for FL, which was considered  appropriate  for  identifying  studies  of  patients  receiving  relevant  therapies  for  R/R  FL. Bibliographies of identified relevant SLRs and key conference websites were manually searched. Study eligibility was assessed according to pre-specified Population, Intervention, Comparator, Outcome, Study design (PICOS) criteria and was performed in duplicate for database searches and by a single reviewer for manual searches. Studies were eligible if they were in the English language and enrolled R/R FL (grade 1-3A) in the 3L+, 4L+, and 2L+ POD24 setting. Outcomes of interest were OS, progression-free survival (PFS), disease-free survival (DFS), overall response rate (ORR), complete response (CR), partial response (PR), duration of response (DoR), time to next treatment (TTNT), and adverse events (AEs). Data from included records (study design characteristics, patient characteristics, and study findings) were collected using standardized data extraction templates. Data extraction was performed by one reviewer and validated by a second independent reviewer to verify data accuracy and completeness. All conflicts  were  resolved  by  consensus  or  third  independent  reviewer.  Quality  assessment  of  included

<div style=\"page-break-after: always\"></div>

citations was performed using the National Institute for Health and Care Excellence (NICE) checklists by a single reviewer and validated by a second reviewer.

## Statistical considerations

Meta-analysis feasibility assessments were conducted for included studies that reported ORR, CR rate, OS, and/or PFS outcomes for each of 3L+, 4L+, and 2L+ POD24 patient populations. Feasibility was determined based on a qualitative assessment of heterogeneity in study characteristics and clinically significant  patient  baseline  characteristics.  When  deemed  feasible,  meta-analyses  (both  random  and fixed effects)  were  conducted  to  derive  pooled  effect  estimates  for  each  outcome/population combination.

## Results

## Literature Search Results

Two searches have informed the current report: (1) the original 2L+ FL search (17-Sep-2022) and (2) an update to the original search (26-Jan-2024).

Figure 10. PRISMA flow diagram

<!-- image -->

## Study Characteristics

In total, 173 reports covering 71 unique studies were included in this review as reported in the diagram below: four RCTs (one of which only reported induction phase, single-arm data), 27 one non-randomized clinical  trial,  26  single-arm  trials,  two  prospective  observational  studies,  and  38  retrospective observational studies. Most studies reported data on 3L+ populations or subgroups (n = 60 studies, 85%) while data on 4L+ and 2L+ POD24 populations or subgroups were reported in 18 studies (25%) and 20 studies (28%), respectively. The total number of studies reported exceeds 71 as some studies reported outcomes for multiple line of treatment (LOT) groups (ie, 3L+, 4L+,2L+ POD24).

<div style=\"page-break-after: always\"></div>

Three single-arm Phase 2 clinical trials investigated CAR T-cell therapies: TRANSCEND FL, ZUMA-5 and the ELARA trial; in addition to that, one observational study investigated axicabtagene ciloleucel alone and another observational study investigated both axicabtagene ciloleucel and tisagenlecleucel.

Seven clinical trials investigated T-cell engagers: two single arm trials investigated mosunetuzumab (one single-arm phase 2 and one single-arm Phase 1b/2), two single-arm epcoritamab, two trials investigated odronextamab monotherapy while one nonrandomized trial investigated glofitamab.

Fifty-nine (83%) studies investigated other therapies (PI3K therapies, tazemetostat and other chemoimmunotherapy regimens), including 32 studies (54%) that only investigated HSCT (both autologous and allogenic).

## Patient Characteristics

The studies varied in terms of eligible population sample size with four studies ranging from 2 to 9 patients and the remaining 67 studies from 11 to 1,842 patients, median length of follow-up (4.2 months to 13.5 years) and investigated therapies. Additionally, there was significant heterogeneity in terms of patient populations and baseline characteristics across the studies. Most of the studies reported findings for 3L+ FL patients, while there was limited evidence for 4L+ and 2L+ POD24 patients.

Median patient age ranged from 43 to 73 years,36, 40 and the proportion of females ranged from 27% to  88%, although two studies with less than five patients did not include female patients. Nineteen studies (27%) reported median time since diagnosis, which ranged from 19.2 months to 11.4 years. Twenty-seven studies (38%) reported median prior lines of therapy, which ranged from 2 to 4.5 median prior  lines.    Eastern  Cooperative  Oncology  Group  performance  scores,  disease  stage,  and  Follicular Lymphoma International  Prognostic  Index  (FLIPI)  scores  were  reported  in  32%,  39%,  and  31%  of studies, respectively.

## Response Outcomes

Response outcomes (ORR, CR, PR, DoR) were reported in 39 studies (55%), and survival outcomes (OS, PFS, DFS) were reported in 53 studies (75%).  Among conventional therapies in 3L+, ORR ranged from 37% to 84%. Overall survival data was often reported for 3L+ studies, but follow up time for OS varied, making it difficult to compare evidence across studies. In 3L+ patients, the highest ORRs were seen for CAR T-cell therapies (86% to 97%), with lisocabtagene maraleucel having the highest ORR, and among T-cell engagers (78% to 90%), with epcoritamab having the highest ORR. In patients who were treated with lisocabtagene maraleucel, median OS was not reached after a median follow-up of 18.9 months. In the patients who were treated with axicabtagene ciloleucel, median OS was not reached after a median follow-up  of  53.7  months;  in  patients  who  were  treated  with  tisagenlecleucel,  median  OS  was  not reached  at  a  median  follow-up  of  40.6  months.  Among  T-cell  engagers,  median  OS  rates  were  not reached for patients treated with epcoritamab, mosunetuzumab, or odronextamab, after median followup times of 17 months, 37.4 months and 26.6 months, respectively. Although availability of studies in 4L+ was limited, ORR ranged from 33% to 100% in patients who received either conventional therapies, HSCT, or tazemetostat. With respect to novel agents, ORR ranged from 77% to 78% for T-cell engagers and from 88% to 93% for CAR T-cell therapies. Conventional therapies in 2L+ POD24 had ORRs ranging from 47% to 75%, whereas the highest ORRs (80% or 100%) were observed among patients who received  treatment  with  CAR  T-cell  therapies  (82%  to  92%)  or  T-cell  engagers  (68%  to  100%), respectively. Safety outcomes were sparsely reported for the populations of interest, and most safety data pertained to the 3L+ population. Adverse events in patients receiving newer treatment options such as T-cell engagers and CAR T-cell therapies were common, including neutropenia, neurotoxicity, and CRS.

## Meta-analysis outcome

<div style=\"page-break-after: always\"></div>

Various meta-analyses were deemed feasible for 3L+ (ORR, CR rate, 2- and 3-year OS rate, 2- and 3year PFS rate), 4L+ (ORR and CR rate), and 2L+ POD24 (ORR and CR rate).

The results  of  the  meta-analyses  in  the  3L+  setting  provided  pooled  estimates  of  ORR  (74%  [95% confidence interval [CI]: 66%-81%]), CR Rate (55%[95% CI: 45%- 65%]), 2-year OS rate (69% [95% CI: 59%-80%]), 3-year OS rate (78% [95% CI: 74%-82%]), 2-year PFS rate (45% [95% CI: 33%57%]) and 3-year PFS rate (54% [95% CI: 41%-67%]). Sensitivity analyses in 3L+ demonstrated a reduction in ORR, CR rate, and 2-year OS rates when CAR T-cell therapies, T-cell engagers, and HSCT were excluded, with values of 62% (95% CI: 53%-72%), 28% (95% CI: 21%-35%), and 67% (95% CI: 50%-85%), respectively. In the 4L+ setting, the meta-analysis provided a pooled ORR estimate of 68% (95% CI: 56%-80%) and a pooled CR rate estimate of 55% (95% CI: 36%-74%). A sensitivity analysis in 4L+ demonstrated a reduction in ORR when CAR Tcell therapies, T-cell engagers, and HSCT were excluded, with a value of 52% (95% CI: 42%-62%). In the 2L+ POD24 setting, the meta-analyses provided a pooled ORR estimate of 78% (95% CI: 68%-87%) and a pooled CR rate estimateof 56% (95% CI: 44%-68%). A sensitivity analysis in 2L+ POD24 demonstrated a reduction in ORR when CAR Tcell therapies and T-cell engagers were excluded, with a value of 64% (95% CI: 58%-70%).

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 47. Summary of Efficacy Results Per IRC charter (Study FOL-001 - 3L+ FL)

|                                     | Liso-cel-treated Analysis Set   | Liso-cel-treated Analysis Set   | Liso-cel-treated Analysis Set   | Leukapherese d Set      |
|-------------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------|
|                                     | 4L+ FL Cohort 1                 | 3L FL Cohort 2                  | 3L+ FL Cohorts 1 + 2            | 3L+ FL                  |
| Primary Endpoint                    |                                 |                                 |                                 |                         |
| ORR a                               | N = 55                          | N = 48                          | N = 103                         | N = 114                 |
| n (%)                               | 53 (96.4)                       | 47 (97.9)                       | 100 (97.1)                      | 106 (93.0)              |
| 95% CI b                            | (87.5, 99.6)                    | (88.9, 99.9)                    | (91.7, 99.4)                    | (86.6, 96.9)            |
| Secondary Endpoints                 |                                 |                                 |                                 |                         |
| CRR c                               | N = 55                          | N = 48                          | N = 103                         | N = 114                 |
| n (%)                               | 51 (92.7)                       | 46 (95.8)                       | 97 (94.2)                       | 103 (90.4)              |
| 95% CI b                            | (82.4, 98.0)                    | (85.7, 99.5)                    | (87.8, 97.8)                    | (83.4, 95.1)            |
| PRR                                 |                                 |                                 |                                 |                         |
| n (%)                               | 2 (3.6)                         | 1 (2.1)                         | 3 (2.9)                         | 3 (2.6)                 |
| 95% CI b                            | (0.4, 12.5)                     | (0.1, 11.1)                     | (0.6, 8.3)                      | (0.5, 7.5)              |
| DOR d , months                      | N = 53 responders               | N = 47 responders               | N = 100 responders              | N = 106 responders N.A. |
| Median (95% CI) e                   | 30.85 (30.85, N.A.)             | N.A.                            | N.A. (30.85, N.A.)              | (30.85, N.A.)           |
| Min, Max f Probability of Continued | 1.9, 35.0+                      | 1.9, 34.5+                      | 1.9, 35.0+                      | 1.9, 35.0+              |
| 6 months                            | 84.9 (72.1, 92.1)               | 87.2 (73.8, 94.1)               | 86.0 (77.5, 91.5)               | 86.8 (78.7, 92.0)       |
| 12 months                           | 79.1 (65.5, 87.9)               | 82.9 (68.6, 91.0)               | 80.9 (71.7, 87.4)               | 82.0 (73.2, 88.1)       |

<div style=\"page-break-after: always\"></div>

| 18 months                                                              | 75.2 (61.1, 84.8)   | 76.3 (61.3, 86.1)   | 75.7 (66.0, 83.0)   | 76.1 (66.7, 83.2)   |
|------------------------------------------------------------------------|---------------------|---------------------|---------------------|---------------------|
| 24 months                                                              | 73.1 (58.8, 83.1)   | 76.3 (61.3, 86.1)   | 74.6 (64.8, 82.1)   | 75.1 (65.6, 82.3)   |
| 30 months                                                              | 73.1 (58.8, 83.1)   | 76.3 (61.3, 86.1)   | 74.6 (64.8, 82.1)   | 75.1 (65.6, 82.3)   |
| DOR if BOR is CR h , months                                            | N = 53 responders   | N = 47 responders   | N = 100 responders  | N = 103 responders  |
| Median (95% CI) e                                                      | N.A. (30.85, N.A.)  | N.A.                | N.A. (30.85, N.A.)  | N.A. (30.85, N.A.)  |
| Min, Max f                                                             | 2.1, 35.0+          | 1.9, 34.5+          | 1.9, 35.0+          | 1.9, 35.0+          |
| Probability of Continued Response After Initial Response, % (95% CI) g |                     |                     |                     |                     |
| 6 months                                                               | 88.2 (75.7, 94.5)   | 89.1 (75.8, 95.3)   | 88.7 (80.5, 93.6)   | 89.3 (81.5, 93.9)   |
| 12 months                                                              | 82.2 (68.6, 90.3)   | 84.7 (70.5, 92.4)   | 83.4 (74.3, 89.5)   | 84.4 (75.8, 90.1)   |
| 18 months                                                              | 78.1 (63.9, 87.2)   | 78 (62.9, 87.5)     | 78 (68.3, 85.1)     | 78.3 (69.0, 85.2)   |
| 24 months                                                              | 75.9 (61.5, 85.6)   | 78 (62.9, 87.5)     | 76.9 (67.1, 84.2)   | 77.3 (67.8, 84.3)   |
| 30 months                                                              | 75.9 (61.5, 85.6)   | 78 (62.9, 87.5)     | 76.9 (67.1, 84.2)   | 77.3 (67.8, 84.3)   |
| PFS i                                                                  | N = 55              | N = 48              | N = 103             | N = 114             |
| Events, n (%)                                                          | 17 (30.9)           | 12 (25.0)           | 29 (28.2)           | 33 (28.9)           |
| Median (95% CI) e , months                                             | 31.77 (31.77, N.A.) | N.A.                | N.A. (31.77, N.A.)  | 33.45 (30.55, N.A.) |
| Min, Max f , months                                                    | 1.0, 35.9+          | 2.8, 35.5+          | 1.0, 35.9+          | 0.0+, 37.2+         |
| PFS rate (95% CI) g , %                                                |                     |                     |                     |                     |
| 6 months                                                               | 83.6 (70.9, 91.1)   | 93.8 (81.9, 97.9)   | 88.3 (80.4, 93.2)   | 92.9 (86.2, 96.4)   |
| 12 months                                                              | 78.1 (64.7, 86.9)   | 81.1 (66.9, 89.7)   | 79.6 (70.4, 86.2)   | 83.0 (74.7, 88.8)   |
| 18 months                                                              | 74.4 (60.6, 84.0)   | 74.7 (59.8, 84.8)   | 74.5 (64.9, 81.9)   | 77.5 (68.6, 84.2)   |
| 24 months                                                              | 70.5 (56.3, 80.8)   | 74.7 (59.8, 84.8)   | 72.5 (62.7, 80.1)   | 72.9 (63.5, 80.2)   |
| 30 months                                                              | 70.5 (56.3, 80.8)   | 74.7 (59.8, 84.8)   | 72.5 (62.7, 80.1)   | 71.7 (62.2, 79.2)   |
| OS j,k                                                                 | N = 55              | N = 48              | N = 103             | N = 114             |
| Events, n (%)                                                          | 7 (12.7)            | 5 (10.4)            | 12 (11.7)           | 15 (13.2)           |
| Median (95% CI) e , months                                             | N.A.                | N.A.                | N.A.                | N.A.                |
| Min, Max f , months                                                    | 3.7, 37.2+          | 5.6, 35.7+          | 3.7, 37.2+          | 0.0+, 38.5+         |
| OS rate (95% CI) g , %                                                 |                     |                     |                     |                     |
| 6 months                                                               | 94.5 (84.0, 98.2)   | 97.9 (86.1, 99.7)   | 96.1 (90.0, 98.5)   | 98.2 (93.1, 99.6)   |
| 12 months                                                              | 90.9 (79.5, 96.1)   | 93.7 (81.7, 97.9)   | 92.2 (85.0, 96.0)   | 92.9 (86.3, 96.4)   |
| 18 months                                                              | 89.1 (77.3, 94.9)   | 93.7 (81.7, 97.9)   | 91.2 (83.8, 95.3)   | 90.2 (83.1, 94.5)   |
| 24 months                                                              | 87.2 (75.1, 93.7)   | 89.3 (76.2, 95.4)   | 88.2 (80.1, 93.1)   | 87.5 (79.7, 92.4)   |
| 30 months                                                              | 87.2 (75.1, 93.7)   | 89.3 (76.2, 95.4)   | 88.2 (80.1, 93.1)   | 87.5 (79.7, 92.4)   |

a ORR is defined as the proportion of subjects with an objective response of PR or CR according to the Lugano Classification 2014.

b Two-sided 95% CI based on exact Clopper-Pearson method.

c CRR is the proportion of subjects with a BOR of CR.

<div style=\"page-break-after: always\"></div>

- d DOR is defined as the interval from the first documentation of response to progressive disease or death from any cause, whichever occurs first.
- e Median estimated from KM product-limit estimates.
- f Symbol + indicates a censored value.

g Based on KM estimates.

h Per protocol, DOR if BOR is CR is defined as the time from first response (CR or PR) to disease progression or death from any cause up to 60 months after liso-cel infusion (EOS). Per SAP, DOR if BOR is CR is defined as the time from first complete response to disease progression or death from any cause up to 60 months after liso-cel infusion. DOR if BOR is CR results per the SAP definition.

- i PFS is defined as the interval from the date of liso-cel infusion to progressive disease or death due to any cause, whichever occurs first.
- j OS is defined as the interval from the date of liso-cel infusion to the date of death due to any reason.
- k The OS analysis includes all available OS information from both the FOL-001 and GC-LTFU-001 studies.

## 2.5.3. Discussion on clinical efficacy

The  sought  indication  is  for  ' the  treatment  of  adult  patients  with  relapsed  or  refractory  follicular lymphoma (FL) after two or more lines of systemic therapy '; the FOL-001 trial included three cohorts of patients with r/r FL from the second line onwards, although the large majority (107/130 patients) of them were on their 3L+ line of treatment. Data from the remaining 23 second line (2L) patients were only considered as proof of concept of the efficacy of liso-cel in FL.

Based on the study population, the wording of indication is considered appropriate.

## Design and conduct of the clinical study

FOL-001 was a global, Phase 2, open-label, single-arm, multicohort and multicentre study, whose design is in line with other registrational CAR-T trials (i.e. three distinct phases: pretreatment, treatment and post-treatment, follow-up and possibility to participate in a LTFU study). In general, the study schedules and duration of follow-up are deemed appropriate. No specific formal dose response studies in FL were conducted, since the single target dose of 100 × 10 6  CAR+ T cells was ultimately chosen as the dose and regimen across all the liso-cel development program in B-cell malignancies in adults. Overall, based on the available efficacy and safety data with the proposed cell dose in study FOL-001, this is acceptable.

From a regulatory point of view, the single arm nature of FOL-001 has intrinsic limitations, mostly related to the absence of a direct comparison with other approved therapies. Despite the limits, however, the current  base  of  evidence  is  still  in  line  with  what  has  been  previously  considered  adequate  by  the CAT/CHMP to conclude for a positive B/R with other CAR-Ts in similar clinical settings.

To support the data from the pivotal single arm trial, the effects of liso-cel have been contextualised through  indirect  comparisons,  including  a  Real-World  External  Arm  Study,  an  Indirect  Treatment Comparison and a Systematic Literature Review. It should be noted, however, that FL presents with significant biological and clinical heterogeneity (see e.g. Krull JE et al, Cell Rep Med 2024), and a recent evidence based systematic literature and medical review identified more than 20 prognostic factors for R/R FL, including patient demographics and clinical characteristics, disease and treatment characteristics, and laboratory data (see Ubieto Aj et al, Blood 2023 142 (Supplement 1): 7261). Indirect comparison methods require that all factors with a possible prognostic impact on the target outcome are accounted for in the analysis, since all the residual variability is attributed to the intervention. Further uncertainties are introduced by the limited sample size of the studies included in the indirect comparison exercises. Overall, the reliability of the proposed indirect comparisons is considered limited.

In study FOL-001 all patients were required to be either refractory or to have relapsed after their last therapy and no specific time limits after the completion of the previous treatments were requested for the inclusion in the trial. Previous exposure to systemic therapy based on an anti-CD20 antibody and an alkylating agent was considered mandatory for the eligibility: this is supported considering that the use of  the  combination  anti-CD20/alkylating  agent  is  the  standard  of  care  for  the  first-  and  second-line treatment of patients. Patients may have been exposed also to autologous HSCT as a part of the previous treatment regimens.

<div style=\"page-break-after: always\"></div>

Treatment  eligibility  was  defined  according  to  what  is  reported  in  the  principal  guidelines  for  the treatment of FL (NCCN 2019), which require the presence of at least one of the modified GELF criteria or the presence of rapid progression (i.e. POD24). The use of the latest version of the ('modified') GELF criteria is justified, considering that their use was recommended by the NCCN 2019 guidelines, and it is still considered in line with the current management landscape of r/r FL.

Efficacy was assessed by radiographic tumour evaluation by diagnostic quality computed tomography (CT)/magnetic  resonance  imaging  (MRI)  scans  (chest,  neck,  abdomen  and  pelvis)  and/or  positron emission tomography (PET) scans and were reviewed by an independent review committee (IRC). For the assessment of response, a modified version of 'Modified Lugano Classification Criteria' was applied. Overall, the rate of failure in central pathology assessment observed in study FOL-001 (8%) is considered in line with the known risk of failure for this procedure and did not significantly affect the integrity of the trial.

Regarding  the  methodology  applied  to  the  assessment  of  response,  the  evaluation  of  bone  marrow involvement by lymphoma at screening was done by TC/PET and Bone Marrow Biopsy (BMB) was not routinely performed: confirmatory BMBs were conducted as soon as logistically feasible after initial PET CR in all FL subjects who did not have a negative BMB between their most recent disease progression prior to screening and initiation of lymphodepleting chemotherapy. In the current response criteria for lymphoproliferative  diseases  (Cheson  et  al,  JCO  2014)  specific  indications  about  the  possibility  of omission of the BM assessment were reported only for Hodgkin Lymphoma and DLBCL. For other NHL histologies,  the  authors  concluded  that  data  were  insufficient  to  change  the  standard  practice,  and unilateral BMB is still recommended, along with immunohistochemistry and flow cytometry. Therefore, by  applying  the  modified  criteria  of  Lugano  without  BMB  at  baseline,  it  can  be  postulated  that  a percentage of patients with bone marrow involvement at baseline was not diagnosed, but this potential bias was covered by the execution of BMB in all patients who reported a CR at the TC-PET assessment of response.

The introduction of immunologic therapies in the treatment of neoplastic diseases (including lymphomas) created a new category of response defined Indeterminate Response (IR), which is determined by signs suggestive of persistence of disease that are actually determined by a flare reaction. The evaluation protocol for IR reported in FOL-001 was in line with standard guidelines and no cases of IR were reported in the pivotal 3L+ cohort.

Overall, the choice of the endpoint reflects the aim of the study, and ORR has been accepted before as primary evidence of anti-tumoral activity of new drugs in the absence of controls, since spontaneous regression is considered unlikely in such advanced disease settings. Significant and clinically relevant improvements in terms of PFS/OS have been usually accepted as adequate basis to inform B/R decisions in NHLs, however the interpretation of time-to-event endpoints in the absence of controls is complicated, since it is impossible to disentangle the impact of the intervention from the effect of heterogeneity e.g. in  tumour growth rates. In this regard, it is recognised that, in the absence of controlled evidence, measures of anti-tumour activity and depth of response (in terms of ORR/CR rates), along with clinically relevant results in terms of response duration (DOR per IRC) can provide sufficient basis to support the benefit risk evaluations, especially in presence of outstanding efficacy and high unmet medical need.

The  MAH  integrated  the  scientific  advice  provided  by  the  CHMP  in  terms  of  change  of  the  primary endpoint from CRR to ORR (both revised from an Independent Review Committee-IRC). Although the change in the primary endpoint was implemented with Amendment 1 (July 2021) when 116/188 (61.7%) patients were already enrolled in the protocol, the Statistical Analysis Plan was not considered to be severely affected by this decision, especially when the similarly high ORR/CCR observed in study FOL001 are taken into account. Overall, the two amendments applied to the protocol did not affect the integrity of the trial.

<div style=\"page-break-after: always\"></div>

The global incidence of protocol deviations was similar between the overall population of FL (84.2%) and the population of 3L+ patients for which the extension of indication was claimed (83.3%). Although the global rate of deviations was high, the incidence of important protocol deviation was low therefore the effect on the integrity of the trial is not considered relevant.

The study was conducted during the COVID-19 pandemic; overall, based on the number and types of protocol deviations (less than 2% of more than 2 deviations were recorded during the trial), it can be assumed that the conduct of the study was not substantially impacted by COVID-19.

The statistical assumptions are considered in line with the expectation of a single arm trial in the setting of r/r FL.

Notably, the statistical hypothesis for the definition of the primary endpoint was set on literature data about the efficacy of PI3K inhibitors. This assumption can be deemed acceptable considering the time in which  the  protocol  was  drawn,  although  it  is  not  completely  adherent  to  the  current  therapeutic landscape in r/r FL after at least 2 lines of therapy, especially when the recent approval of anti-CD19 CAR T cell and bispecific monoclonal antibody T cell engagers is taken into account. Nevertheless, in the absence of controls, B/R evaluations are based on the totality of evidence and the actual relevance of the selected efficacy threshold beyond futility is limited.

Regarding the efficacy analysis sets, the Applicant proposed a modified version of the ITT population defined as all subjects who have signed informed consent and underwent leukapheresis (Leukapheresed Set). To note, this 'Leukapheresed Set' definition is not perfectly in line with the regulatory definition of ITT, which should include all patients providing informed consent to the trial. Nevertheless, it can be recognised that the production process of a CAR-T can justify a different approach to ITT and, therefore, the proposed modified ITT set can be considered acceptable.

Similarly to other trials in FL involving CAR-Ts, the investigators were allowed to prescribe antineoplastic bridging therapies to stabilize the disease while waiting for liso-cel infusion. The bridging therapy was selected based on the investigators choice and included the current approved therapies for r/r FL; it should be noted that, theoretically, the use of a bridging therapy may induce the CR and, in that case, treatment with liso-cel could be more similar to consolidation rather than salvage therapy. It is noted, however, that the MAH excluded from the Primary Efficacy Set all patients with absence of active disease before  liso-cel  administration  or  without  a  pre-infusion  disease  evaluation  which  could  confirm  the presence of active disease.

## Efficacy data and additional analyses

## Study population

The  primary  efficacy  set  was  defined  by  the  all  leukapheresed  patients  who  received  a  conforming product in presence of active disease before liso-cel infusion. The enrolled population could be considered reflective of R/R FL disease condition; although a limited number of patients in 2L disease were enrolled, a significant amount of POD24 patients were included in that cohort.

As of the data cutoff date (10-Jan-2024), all FL cohorts (Cohorts 1, 2, and 3) had been enrolled. All but one subject in the 3L+ FL group (Cohorts 1 and 2) completed the treatment period (Days 1 to 29). As of  the  data  cutoff  date,  the  median  follow-up  was  29.96  (24.67,  32.76)  months,  with  the  majority (82.2%) of 3L+ FL subjects still ongoing in the post-treatment follow-up period (Day 30 to Month 60). The median duration of follow up is considered acceptable in terms of study design, considering that the statistical hypotheses were set on the efficacy of PI3K, which showed a median duration of response of 12 months. Nevertheless, given the indolent nature of the FL, a longer follow up of the efficacy is being expected in the data collected in the agreed studies mentioned in the RMP (version 5.1).

<div style=\"page-break-after: always\"></div>

Given that the large majority of patients enrolled in the general population was represented by patients in the 3L+ setting, the clinical features at the diagnosis did not substantially differ between the whole population (i.e. including also 2L patients) and the one for which the approval is sought (3L+ group); and only minor differences can be noted.

In particular, in the 3L+ more than half patients presented with double refractory status (64,5%), which resulted slightly higher than what reported in the general FL population (61.5%). The high incidence of double refractory status is expected in later phases of disease, in line with the higher unmet medical need for new therapies in this setting. The median time from initial diagnosis to liso-cel infusion was 4.71 years (range, 0.70 to 35.27 years); the proportion of subjects in the 2L and 3L+ with Ann Arbor Stage IV disease (47.8% and 52.3%) and Grade 3A FL (26.1% and 23.4%) at screening were similar. Subjects in the 2L cohort had a lower median age (53 vs 62 years), a higher proportion of Grade 1 FL (26.1% vs 8.4%), a higher proportion of subjects that had a low-risk FLIPI score at screening (47.8% vs 11.2%), a lower proportion of subjects with CRP ≥ 20 mg/L at baseline (17.4% vs 30.8%), and a lower  proportion  of  subjects  with  LDH  &gt;ULN  at  baseline  (26.1%  vs  43.9%)  compared  to  the  3L+ subjects. However, the 2L cohort had a numerically greater proportion of subjects meeting modified GELF criteria at time of most recent relapse compared to 3L+ subjects (69.6% vs 53.3%), and higher proportion of subjects meeting GELF criteria of symptoms attributable to FL (26.1% vs 12.1%) and threatened end-organ function/cytopenia/bulky disease (30.4% vs 22.4%).

In the 3L+ group (Cohort 1 and Cohort 2), the main reason for treatment eligibility was the fulfilment of at  least  1  of  the  modified  GELF  criteria  (53.3%,  the  majority  of  them  with  'Threatened  End-Organ Function/ Cytopenia Secondary to Lymphoma/ Bulky Disease' [22.4%]); patients with POD 24 status accounted for the 43% of patients. Interestingly, more than half of POD24 patients (54.2%) presented this status after the first line therapy with anti-CD20 and an alkylating agent. The presence of other high-risk factors was well represented in the whole enrolled population, which is expected in later lines of therapy for FL; in 3L+ patients high-risk FLIPI and increased LDH accounted for the 57% and 43.9%, respectively. About 1/3 of patients (32.7%) were highly pre-treated, with a previous exposure to 4 or more different lines.

The median number and characteristic of prior systemic therapies is in line with a R/R population set. Given the large variability in the number of previous therapy lines (2-10), patients were exposed to a variety of treatments: as expected, the most commonly used were chemotherapy agents and anti-CD20 monoclonal antibodies.

The use of bridging therapy in the interval time from Leukapheresis and Liso-cel infusion was permitted in order to ensure a better disease control; the use was not mandatory but based on the investigators' decision. In general, the indolent behaviour of FL can explain the reduced need of bridging therapy for disease control (i.e. 37.7% of patients); similarly, the median time between leukapheresis and infusion was acceptable and similar between the whole enrolled population.

No significant impact from deviations in the lymphodepleting therapy were noted.

The median number of total (CD8+ and CD4+) liso-cel administered dose cell counts infused in the 3L+ Liso-cel-treated Analysis Set was 100.02×10 6  CAR+ T cells (range: 93.4 to 109.2×10 6 ), which is in line with the dose used in the DLBCL.

In respect to the median time from leukapheresis to liso-cel availability, the reported value was similar between  the  whole  population  and  the  3L+  patients  (29  days);  similarly,  the  median  time  from leukapheresis  to  liso-cel  infusion  was  superimposable  between  the  two  settings  (50  and  49  days, respectively).  The peculiarity of few cases requiring longer time as described in the section above does not significantly impact on the integrity of the population enrolled.

<div style=\"page-break-after: always\"></div>

## Primary and Key Secondary Endpoints

The results obtained in terms of ORR (97.1%) can be considered indicative of clinically relevant efficacy in the setting of interest; the percentage of response was homogeneous among the different lines of therapy and substantially consistent also in terms of sensitivity analyses in the Leukapheresed (93%) and Per Investigator set (98.1%). Moreover, the reported ORR was significantly higher compared to the statistical assumption (77%) to refuse the null hypothesis.

The reported CRR rate was also compelling across the different lines of therapy and higher (94.3%) than the statistical assumption threshold for efficacy (48%). Responses were rapidly induced and deep, with a median time to first response (CR or PR) and median time to first CR of 0.95 months (range: 0.6 to 3.3  months).  To  note,  all  sensitivity  analyses  applied  to  this  key  secondary  endpoint  confirmed  the validity of the primary analysis (Leukapheresed set: 90.4%, Per Investigator: 94.2%) except when the FDA algorithm was used. In this regard, despite a similar ORR, in 3L+ subjects the proportion of CRR using the 'FDA algorithm' was lower (72.3%, 95% CI: 62.5, 80.7) and the proportion of PR higher (25%, 95% CI: 16.4-33.7) compared to the primary analysis. The FDA algorithm differed from the 'modified Lugano criteria' used for the primary analysis of study FOL-001 in terms of the mandatory requirement of BMB for the evaluation of response, regardless of the presence of a CR; in general, the FDA approach can be considered more in line with the Lugano recommendations for evaluation of response in PET/TC era (see e.g. Cheson et al, JCO 2014). The FDA algorithm was introduced with Amendment 1, when 84 out of 114 subjects had been already enrolled in the 3L+ FL population. Applying the FDA algorithm, 22 subjects were downgraded from CR to PR: CR could not be confirmed in 19/22 because they did not have  BMB  available,  2  subjects  had  BMB  yet  with  unknown  result,  and  1  subject  had  evidence  of lymphomatous BM involvement. A post-hoc subgroup analysis of time-to-event efficacy outcomes for the 22 subjects with a BOR of CR per IRC charter but with a BOR of PR when the FDA algorithm was used suggested a trend towards reduced DOR (expected 24 months DOR: 58% [34.6-75.5]) and PFS (expected 24 months PFS: 58% [34.6-75.5]) when compared with those reported for patients with a confirmed CR using the FDA algorithm (expected 24 months DOR: 76.9% [67.1-84.2]; expected 24 months PFS: 77% [67.2-84.2]). This finding suggests that some CR in the primary analysis could have been  more  correctly  classified  as  PR  yet  results  from  such  post-hoc  subgroup  analysis  should  be interpreted with caution because of the limited sample size and broad confidence intervals. Therefore, the general considerations about efficacy of liso-cel are not affected by these results.

Results from an additional non-prespecified sensitivity analysis, including all patients who underwent leukaphereses  and  excluding  subjects  who  received  non-conforming  products,  were  also  overall consistent with the primary analysis.

Liso-cel demonstrated a homogeneous effect in respect to the pre-specified subgroups, although in some cases (e.g. patients aged &gt;75: 9 patients, low FLIPI score: 10 patients) the small number of patients increased the uncertainties of effect.

At the DCO of January 2024 and with a median follow-up for the 3L+ patients of 29.96 months (24.67, 32.76), the Time To Event endpoints of DOR, PFS, OS did not reach the median value: although the available follow-up can be considered adequate to weigh the clinical benefit of liso-cel in the context of the current therapeutic landscape of FL, further data with longer follow-up are needed to thoroughly characterise its long-term efficacy. Data are expected to be provided post approval as per the studies included in the RMP version 5.1.

Given the design and the aim of the single arm trial FOL-001, DOR per IRC assumes a value for the isolation of the antitumoral effect of the drug and for its clinical relevance. The median value of DOR was not reached with a median follow-up of 23.13 months (22.93, 23.26) and this result was confirmed also by all sensitivity analyses with the exception of the analysis Per Investigator, which showed a median

<div style=\"page-break-after: always\"></div>

DOR of 34.76 months (30.85, N.A.). Similar results were reported for DOR if BOR is CR, as expected considering that most of the obtained responses were CR.

With a median follow-up of 23.98 months (95% CI: 23.82, 24.15), the median PFS per IRC was not reached, but it can be noted that in the sensitivity analyses (Leukapheresed set, Per Investigator), the median PFS was 33.45 months (30.55, N.A.) and 36.14 months (31.77, N.A.), respectively.

The median OS was not reached at the time of the data DCO (median follow-up of 29.47 months [95% CI: 26.51, 29.93]) as well: 12 deaths had occurred in the study, with an estimated probability of survival of 88.2% (80.1, 93.1) at Month 24. Same value can be noted at the last time point reported at 36 months.

Data about Time to Next Treatment (TTNT) were considered in line with what expected with the setting of  R/R  FL:  12  patients  needed  further  therapy  after  liso-cel  because  of  relapse  (11  subjects)  and progressive disease (1 subject); the median TTNT was not reached at a median follow up of 29.31 months, with a range between 3.7 to 37.2 months. Disease status was not available for 3 patients; in the other cases, 2 deaths were recorded, 1 out of 2 attributable to disease progression. The type of subsequent treatments were in line with the therapeutic landscape of R/R FL. The analysis of CD19 status at  relapse/progression was missing for 7/12 patients; in the remaining cases, the H-score for CD19 expression varied from 1 to 180. Therefore, no conclusions could be drawn regarding CD19 expression and risk of relapse/progression.

Patient Reported Outcomes (PROs) were assessed with three different questionnaires (EORTC QLQ-C30 questionnaire, FACT-LymS questionnaire, and EQ -5D Utility Index VAS) which all showed very similar results. Nevertheless, despite the linear improvement of symptoms and QoL reported in questionnaires, the level of the evidence obtained in absence of a comparison arm is deemed low due to lack of controls and blinding, and its supportive role for the global definition of efficacy of liso-cel is limited.

Overall, the evidence from FOL-001 is considered supportive of the extension of indication for liso-cel for the treatment of 3L+ FL. Although efficacy data came from a limited set of patients and the longterm  benefit  with  liso-cel  is  not  completely  characterised  at  present,  the  available  data  are  still considered adequate to inform Benefit/Risk decisions. Longer-term data from a broader population are still needed, however, to thoroughly characterise the efficacy profile of liso-cel. In this regard, the MAH has committed to provide additional efficacy data in R/R FL from the ongoing long-term follow-up study GM-LTFU-001, from the US-based, non-interventional RW registry study CA082-1175 of patients treated with liso-cel for 3L+ R/R FL in the post-marketing setting, and from the ongoing registry study JCAR017BCM-005 that also includes EU subjects who receive liso-cel post-approval.

## Real World Studies

In  order  to  contextualize  the  results  of  this  single  arm  trial,  the  MAH  reported  the  results  of  three supportive studies (see sections above for details) which indirectly compared the results of Liso-cel to other approved therapies.

- Real World external control arm study

As a general comment, data from this external control arm helped in contextualizing the effect of lisocel compared to common treatments used for the third line therapy. However, considering the large predominance of patients treated with lenalidomide and rituximab, the extrapolation of data is mainly related to this kind of therapy and to other common immune-chemoterapy regimens, while the level of evidence with respect to other therapies like PI3Kis should be considered low.

- Indirect Treatment Comparison (ITC) for lisocabtagene maraleucel in the treatment of 3L or 4L+ relapsed/refractory follicular lymphoma

<div style=\"page-break-after: always\"></div>

In  an  indirect  comparison  (ITC)  with  mosunetuzumab,  axi-cel  and  tisa-cel,  the  effects  of  liso-cel appeared to be superior in respect to mosunetuzumab and similar to other CAR-Ts. Overall, the strength of evidence is necessarily reduced by the intrinsic limitations related to the methodology, the limited sample size of the data sets, the high clinical and biological heterogeneity of FL and uncertainties in CR assessment across studies.

- Systematic  literature  review  of  clinical  evidence  of  third  line  and  later  (3L+)  treatments  for follicular lymphoma in adult patients

The results of the meta-analyses described a homogeneous scenario in which the reported outcomes in terms of ORR, CR rate OS and PFS were significantly reduced when CARTs therapies, T-cell engagers, and  HSCT  are  excluded,  confirming  the  evidence  of  superior  outcomes  with  novel  immunotherapy approaches (both humoral and cell mediated) compared to standard chemo-immunotherapy regimens.

Overall, the results obtained with these indirect comparisons studies were considered informative and supported the contextualisation of efficacy outcomes from study FOL-001. However, in a regulatory perspective,  their role to support  B/R  evaluations  is  limited, mainly  because  of  the  intrinsic methodological limitations and the high clinical and biological heterogeneity of FL which reduces the strength of evidence, even in case of application of standardization techniques like propensity score methodologies and Matched Adjusted Indirect Comparison (MAIC) analyses.

## 2.5.4. Conclusions on the clinical efficacy

Results from the FOL-001 showed that treatment with liso-cel in subjects with 3L+ R/R FL resulted in clinically relevant rates of deep and durable responses.

With all the limits intrinsic in such methodologies, results from the provided indirect comparison exercises also suggested that liso-cel treatment could result in clinically relevant efficacy in the target indication, which is at least in line with what observed with other T cell engaging immunotherapies in the claimed indication.

Longer-term efficacy data from a larger population of patients with R/R FL will be provided post-approval from the ongoing long-term follow-up study GM-LTFU-001, from the US-based, non-interventional RW registry study CA082-1175 of patients treated with liso-cel for 3L+ R/R FL in the post-marketing setting (category 3 studies in the RMP), and from the ongoing registry-based study JCAR017-BCM-005 that also include EU subjects who receive liso-cel in the post-approval setting (Category 1 study in the annex II and the RMP).

## 2.6. Clinical safety

## Introduction

For this proposed indication, the safety evaluation is primarily based on the safety data from Study JCAR017-FOL-001 (TRANSCEND FL).

An overview of safety data from liso-cel treated subjects with R/R FL (n= 130) enrolled in Cohort 1 (4L+ FL), Cohort 2 (3L FL), and Cohort 3 (2L FL) of Study FOL-001 is presented.

A safety analysis of liso-cel in FL by study cohort (i.e., by line of therapy; Cohort 1, Cohort 2, and Cohort 3) and groups (Cohorts 1 + 2 and Cohorts 1 + 2 + 3) is presented.

<div style=\"page-break-after: always\"></div>

Additionally, safety data are included from 3L+ FL subjects (proposed indication, from Cohorts 1 and 2 of Study FOL 001; n= 107) presented side-by-side with the pooled safety data for liso-cel monotherapy treated subjects with 2L and 3L+ LBCL (n= 608) in the existing EU-approved indications.

Finally, a safety summary of 2L+ FL subjects (from Cohorts 1, 2, and 3 of Study FOL-001; n= 130) is presented side-by-side with the pooled safety data for 2L/3L+ LBCL. Together, these analyses allow for comparison of the safety profile of liso-cel in 3L+ FL (proposed indication) and 2L+ FL, respectively, to the known safety profile of liso-cel in the approved SmPC.

## Patient exposure

In Study FOL-001 Cohorts 1, 2, and 3, 154 subjects were screened and 139 subjects underwent leukapheresis as of the cut-off date of 10-Jan-2024. Of these, 130 (93.5%) subjects received LDC and liso-cel infusion and comprised the Liso-cel treated Analysis Set.

In the Liso-cel-treated Analysis Set (n= 130), 128 (98.5%) subjects completed treatment period and continued to post-treatment follow-up period. Two (1.5%) discontinuations during the treatment period were either due to AE (n= 1 subject in Cohort 3) or subject withdrawal (n= 1 subject in Cohort 2).

In the Leukapheresed (ITT) Set (n= 139), 5 (3.6%) subjects were treated with nonconforming product.

As of the cutoff date of 10-Jan-2024, the median study follow-up was 29.72 months (min, max: 0.3, 39.6 months) for all FL subjects.

## Demographic and baseline characteristics

Disease characteristics were reflective of subjects with R/R FL. The key demographic and baseline characteristics were generally similar between the 2L+ FL and 3L+ FL cohorts, with the exception of a higher proportion of 2L+ FL subjects who had a low-risk FLIPI at screening (18.5% vs 11.2%) compared to 3L+ FL subjects.

The median time from start of last systemic regimen prior to liso-cel infusion was 1.35 years (range: 0.2, 13.1); 25.4% (n= 33/130) of subjects received prior autologous HSCT, and the median number of prior systemic therapies was 2 (range: 1, 10). The most commonly used last lines of systemic therapies prior to liso-cel administration were rituximab (54.6% of subjects), cyclophosphamide (27.7% of subjects), and prednisone (20.8% of subjects).

The median time from initial diagnosis to liso-cel infusion was 4.71 years (range, 0.70 to 35.27 years). Anticancer therapy for disease control was permitted between apheresis and lymphodepletion. 37.7% of subjects received bridging therapy for disease control during the liso-cel manufacturing period (33.8% received systemic treatment only and 3.8% received radiotherapy only); the most commonly received bridging therapies were rituximab (15.4% of subjects) and cyclophosphamide (13.1% of subjects).

For additional details on demographic and baseline characteristics of Study FOL-001 Population, please refer to Clinical Efficacy part.

## Liso-cel Product, Dose, and Administration

Administration of liso-cel is preceded by LDC with fludarabine (30 mg/m²/day) plus cyclophosphamide (300 mg/m²/day) (flu/cy) for 3 days to increase the expansion, persistence, and anti-tumor activity of the CAR+ T cells.

<div style=\"page-break-after: always\"></div>

The target dose of liso-cel is single infusion containing 100 × 10 6  CAR+ viable T cells consisting of 1:1 CAR+ CD8+ T cells and CAR+ CD4+ T cells supplied separately in one to four single-dose vials.

In the Liso-cel-treated Analysis Set, the median numbers of total (CD8+ and CD4+) liso-cel administered dose cell counts infused by cohort were as follows:

- Cohort 1: 100.13 × 10 6  CAR+ T cells (range: 93.4 × 10 6  to 109.2 × 10 6 )
- Cohort 2: 99.73 × 10 6  CAR+ T cells (range: 96.6 × 10 6  to 101.8 × 10 6 )
- Cohort 3: 99.92 × 10 6  CAR+ T cells (range: 97.4 × 10 6  to 102.9 × 10 6 )
- Cohorts 1 + 2 (3L+ FL): 100.02 × 10 6  CAR+ T cells (range: 93.4 × 10 6  to 109.2 × 10 6 )
- Cohorts 1 + 2 + 3 (2L+ FL): 100.02 × 10 6  CAR+ T cells (range: 93.4 × 10 6  to 109.2 × 10 6 ).

## Adverse events

## Overall Safety Summary Table 48. Overall Summary of Safety in Study FOL-001

<div style=\"page-break-after: always\"></div>

| Safety Parameter                                               | 4L+FL Cohort 1   | 3L FL Cohort 2   | 3L+ FL Cohorts 1,2   | 2L FL Cohort 3   | 2L+ FL Cohorts 1,2,3   |
|----------------------------------------------------------------|------------------|------------------|----------------------|------------------|------------------------|
| Leukapheresed Set                                              | N=65             | N=49             | N = 114              | N=25             | N= 139                 |
| Deathsa                                                        | 9 (13.8)         | 6 (12.2)         | 15 (13.2)            | 1 (4.0)          | 16 (11.5)              |
| Cause of Death PD                                              | 4 (6.2)          | 3 (6.1)          | 7 (6.1)              | 0                | 7 (5.0)                |
| Death from AE (Not Otherwise Specified)b                       | 3 (4.6)          | 0                | 3 (2.6)              | 1 (4.0)          | 4 (2.9)                |
| Death from Cardiac Event                                       | 1(1.5)           |                  | 1(0.9)               | 0                | 1(0.7)                 |
| Death from Other Cause C                                       | 0                | 3 (6.1)          | 3 (2.6)              | 0                | 3 (2.2)                |
| Death from New Malignancy, or Complication from New Malignancy | 1(1.5)           | 0                | 1(0.9)               | 0                | 1(0.7)                 |
| Liso-cel Analysis Set                                          | N= 59            | N= 48            | N= 107               | N=23             | N= 130                 |
| Subjects with any TEAE                                         | 58 (98.3)        | 48 (100.0)       | 106 (99.1)           | 23 (100.0)       | 129 (99.2)             |
| Grade≥3                                                        | 47 (79.7)        | 39 (81.3)        | 86 (80.4)            | 14 (60.9)        | 100 (76.9)             |
| Grade 5                                                        | 0                | 0                | 0                    | 1(4.3)           | 1 (0.8)                |
| Serious                                                        | 15 (25.4)        | 12 (25.0)        | 27 (25.2)            | 4 (17.4)         | 31 (23.8)              |
| Liso-cel-related                                               | 54 (91.5)        | 42 (87.5)        | 96 (89.7)            | 19 (82.6)        | 115 (88.5)             |
| Liso-cel-related Grade ≥ 3                                     | 34 (57.6)        | 34 (70.8)        | 68 (63.6)            | 13 (56.5)        | 81 (62.3)              |
| Liso-cel-related Grade 5                                       | 0                | 0                | 0                    | 1 (4.3)          | 1(0.8)                 |
| Liso-cel-related serious TEAE                                  | 13 (22.0)        | 8 (16.7)         | 21 (19.6)            | 3 (13.0)         | 24 (18.5)              |
| LDC-related                                                    | 49 (83.1)        | 32 (66.7)        | 81 (75.7)            | 17 (73.9)        | 98 (75.4)              |
| Subjects with any AESI                                         | 40 (67.8)        | 32 (66.7)        | 72 (67.3)            | 15 (65.2)        | 87 (66.9)              |
| CRSe                                                           | 35 (59.3)        | 28 (58.3)        | 63 (58.9)            | 12 (52.2)        | 75 (57.7)              |
| iNTf                                                           | 9 (15.3)         | 8 (16.7)         | 17 (15.9)            | 4 (17.4)         | 21 (16.2)              |
| IRR.                                                           | 0                | 0                | 0                    | 0                | 0                      |
| MASE                                                           | 0                | 0                | 0                    | 1 (4.3)          | 1 (0.8)                |
| TLS                                                            | 0                | 口                | 0                    | 0                | 0                      |
| Hypogammaglobulinemia                                          | 3 (5.1)          | 3 (6.3)          | 6(5.6)               | 1 (4.3)          | 7(5.4)                 |
| Grade > 3 imfections                                           | 3 (5.1)          | 4 (8.3)          | 7 (6.5)              | 0                | 7(5.4)                 |
| SPM                                                            | 4 (6.8)          | 3 (6.3)          | 7 (6.5)              | 2 (8.7)          | 9 (6.9)                |
| Autoimmune disorders                                           | 0                | 0                | 0                    | 0                | 0                      |
| Prolonged cytopenia h                                          | 14 (23.7)        | 12 (25.0)        | 26 (24.3)            | 3 (13.0)         | 29 (22.3)              |

日 Deaths from Study GC-LTFU-00l are included.

b Death fom AE (NOS) included: Cohort l: acute respiratory failure hypoxic (LDC-infusion), acute myeloid leukemia (from Day 9l after infusion), progressive multifocal leukoencephalopathy (from Day 91 after infusion). and Cohort 3: HLH (Day 1-30).

- Death from other cause included: Cohort 2: 2 cases of COVID-19 and erythema multifomme.
- d A TEAE was defined as an AE that started any time from initiation of liso-cel administration through and including 90 days following liso-cel administration.

## Treatment Emergent Adverse Events (TEAEs)

The frequency of TEAEs was consistent across all cohorts (lines of therapy) and groups.

## Table 49. TEAEs by SOC and PT Reported in ≥ 5% by PT in Any Cohort - Liso-cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

| System Organ Class                                 | 4L+EL N =59 n (%)   | 3LFL N = 48 n (%)   | 3L+FL N = 107 n (%)   | 2LFL N=23 n (%)   | 2L+EL N=130 n (%)   |
|----------------------------------------------------|---------------------|---------------------|-----------------------|-------------------|---------------------|
| Preferred Term (A) SUBJECTS WITH AT LEAST ONE TEAE | 58 ( 98.3)          | 48 (100.0)          | 106 ( 99.1)           | 23 (100.0)        | 129 (99.2)          |
| Blood and lymphatic system disorders               | 46 (78.0)           | 38 79.2)            | 84 (78.5)             | 16 69.6)          | 100 (76.9)          |
| Neutropenia                                        | 39 66.1)            | 35 72.9)            | 74 69.2)              | 14 60.9)          | 88 67.7)            |
| Anaemia                                            | 26 44.1)            | 21 43.8)            | 47 43.9)              | 5 21.7)           | 52 40.0)            |
| Thrombocytopenia                                   | 22 37.3)            | 13 27.1)            | 35 32.7)              | 3 13.0)           | 38 29.2)            |
| Leukopenia                                         | 8 (13.6)            | 6 (12.5)            | 14 (13.1)             | 4 17.4)           | 18 (13.8)           |
| Lymphopenia                                        | 8 (13.6)            | 6 (12.5)            | 14 (13.1)             | 5 （ 21.7)         | 19 (14.6)           |
| Febrile neutropenia                                | 2(3.4)              | 4(8.3)              | 6 (5.6)               | (4.3)             | 7(5.4)              |
| Inmne system disordlers                            | 35 (59.3)           | 29 (60.4)           | 64(59.8)              | 13 (56.5)         | 77(59.2)            |
| Cytokine release syndrome                          | 35 5(59.3)          | 28 ( 58.3)          | 63 ( 58.9)            | 12 2(52.2)        | 75 ( 57.7)          |

| System Organ Class                              | 4L+FL N=59 n (号)   | 3LFL N = 48 n (%)   | 3L+FL N = 107      | 2LFL N=23              | 2L+FL N = 130           |
|-------------------------------------------------|--------------------|---------------------|--------------------|------------------------|-------------------------|
| Preferred Term (A)                              |                    |                     | n (%)              | n (号)                  | n (号)                   |
| Gastrointestinaldisorders                       | 28 (47.5)          | 21 (43.8)           | 49 (45.8)          | 12 (52.2)              | 61 (46.9)               |
| Constipation                                    | 14 23.7)           | 6 18.8)             | 23 21.5)           | 4 17.4)                | 27 20.8)                |
| Diarrhoea                                       | 6 15.3)            | 7 14.6)             | 16 15.0)           | 6 26.1)                | 22 16.9)                |
| Nausea                                          | （ 11.9)            | 3 6.3)              | 10 9.3)            | 2 8.7)                 | 12 9.2)                 |
| Abdominal pain                                  | 0                  | 4 8.3)              | 3.7)               | 5(21.7)                | 9 6.9)                  |
| General disorders and acministration site       | 27 ( 45.8)         | 17 ( 35.4)          | 44 ( 41.1)         | 14 ( 60.9)             | 58 ( 44.6)              |
| conditions                                      |                    |                     |                    |                        | 20 (15.4)               |
| Fatigue Asthenia                                | 10 (16.9) 9 15.3)  | 3 6.3) 5 10.4)      | 13 (12.1) 14 13.1) | 7 ( 30.4) 8.7)         | 16 12.3)                |
|                                                 | 9 15.3)            |                     |                    | 8.7)                   | 21 16.2)                |
| Pyrexia                                         | 3 5.1)             | 10 (20.8) 0         | 19 17.8) 3 2.8)    | 2202                   | 3 2.3)                  |
| Non-cardiac chest pain Oedema peripheral        | 2 3.4)             | 2 4.2)              | 4 3.7)             | 8.7)                   | 6 4.6)                  |
| Nervous system disorders                        | 26 44.1)           | 20 41.7)            | 46 43.0)           | 10 43.5)               | 56 43.1)                |
| Headache                                        | 19 32.2)           | 11 22.9)            | 30 28.0)           | 8 34.8)                | 38 29.2)                |
| Tremor                                          | 9 15.3)            | 8 16.7)             | 17 15.9)           | 8.7)                   | 19 14.6)                |
| Aphasia                                         | 6 10.2)            | 1 2.1)              | 7 6.5)             | 22 8.7)                | 6 6.9)                  |
| Dizziness                                       | 3.4)               | 1 2.1)              | 3 2.8)             | 3 (13.0)               | 6 4.6)                  |
| Dysgraphia                                      | 1( 1.7)            | 3 6.3)              | 4 3.7)             | 0                      | 4 3.1)                  |
| Musculoskeletal and connective tissue           | 22 ( 37.3)         |                     |                    |                        | 40 (30.8)               |
|                                                 |                    | 11 ( 22.9)          | 33 ( 30.8)         | 7( 30.4)               |                         |
| disorders Back pain Arthralgia                  | 5 8.5) 4 6.8)      | 0 6 12.5)           | 5 4.7) 10 9.3) 5   | 4 (17.4) 1 4.3) 2 8.7) | 9 6.9) 11 8.5) 7 ( 5.4) |
| Myalgia                                         | 4 6.8)             | 1 ( 2.1)            | 4.7)               |                        |                         |
| Investigations                                  | 13 22.0)           | 13 27.1)            | 26 24.3)           | 26.1)                  | 32 (24.6)               |
| Alanine aminotransferase increased              | 4 6.8)             | 8.3)                | 8 7.5)             | 8.7)                   | 10 7.7)                 |
| Aspartateaminotransferaseincreased              | 4 6.8)             | 4.2)                | 6 5.6)             | 8.7)                   | 8 6.2)                  |
| Neutrophil count decreased                      | 3 5.1)             | 6.3)                | 6 5.6)             |                        | 6 4.6)                  |
| Blood alkaline phosphatase increased            | 1 1.7)             | 42302               | 1 0.9)             | ６２２023 8.7)            | 3 2.3)                  |
| Blood creatinine increased                      | 1 1.7)             | 4.2)                | 3 2.8)             | 13.0)                  | 6 4.6)                  |
|                                                 |                    |                     |                    | 30.4)                  | 32 24.6)                |
| Metabolismandnutritiondisorders Hypokalaemia    | 13 22.0) 7 11.9)   | 12 25.0) 123 2.1)   | 25 23.4) 863 7.5)  | 4.3)                   | 6.9)                    |
| Decreased appetite                              | 6.8)               | 4.2)                | 5.6)               | 7111 4.3)              | 5.4)                    |
| Hyponatraemia                                   | 40                 | 6.3)                | 2.8)               | 4.3)                   | 4 3.1)                  |
| Skin and subcutaneous tissue disorders          | 12 20.3)           | 5 10.4)             | 17 15.9)           | 3 13.0)                | 20 15.4)                |
| Rash                                            | 4 6.8)             | 1 2.1)              | S 4.7) 4 3.7)      | 2 8.71 1 4.3)          | 7 5.4) 5                |
| Pruritus                                        | 1 1.7)             | 3 6.3)              |                    |                        | 3.8)                    |
| System Organ Class Preferred Term (A)           | 4L+ FL N = 59      | 3L FL N = 48        | 3L+FL N = 107      | 2LFL N = 23            | 2L+FL N = 130           |
|                                                 | n (号)              | n (号)               | n (%)              | n (号)                  | n (号)                   |
| Vascular disorders                              | 12 (20.3)          | 6 (12.5) 3 6.3)     | 18 (16.8)          | (17.4)                 | 22 (16.9) 10            |
| Hypotension                                     | 6 (10.2)           |                     | 95 8.4)            | 4.3)                   | 7.7)                    |
| Hypertension                                    | 3(5.1)             | 2 （ 4.2)            | （ 4.7)             | 1(4.3)                 | 6 4.6)                  |
| Respiratory, thoracic and mediastinal disorders | 10 (16.9)          | 7 (14.6)            | 17 ( 15.9)         | 4 ( 17.4)              | 21 (16.2)               |
| Cough                                           | 6 ( 10.2) 0        | （ 2.1) 0            | 7 ( 6.5) 0         | 21 8:3                 | 6 6.9) 2                |
| Pleural effusion                                |                    |                     |                    |                        | 1.5)                    |
| Psychiatric disorders Insormia                  | 6 15.3) 4 6.8)     | 7 14.6) 1 2.1)      | 16 15.0) 4.7)      | 3(13.0) 2 8.7)         | 19 (14.6) 7 5.4)        |
| Confusional state                               | 3 5.1)             | 0                   | 53 2.8)            | 0                      | 3 2.3)                  |
|                                                 | 3 5.1)             | 3 6.3)              | 6 5.6)             |                        | 6 6.9)                  |
|                                                 | 0                  |                     | 1                  | 8.7)                   | 3                       |
| Cardiac disorders Sinus tachycardia             |                    |                     |                    | 3 ( 13.0)              |                         |
|                                                 |                    | 2.1)                | 0.9)               |                        | 2.3)                    |

A TEAE was defined as any AE that occurred from start of liso-cel infusion and up to 90 days after liso-cel infusion. Any AE occurring after the initiation of another anti-FL treatment was not considered a TEAE.

AEs were coded using MedDRA version 26.0.

A subject was counted only once for multiple events within a PT/SOC.

Source: Table 8.2-1 of Study FOL-001 Addendum 01 CSR.1

## Grade 3 and Higher TEAEs

Table 50. Grade 3 or Higher TEAEs by SOC and PT Reported in ≥ 5% by PT in Any Cohort Liso-cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

<!-- image -->

| System Organ Class                                        | 4L+L N=59 n (号)   | 3LFEL N = 48 n (号)   | 3L+FL N = 107 n (号)   | 2LFL N=23 n (号)   | 2L+FL N=130 n (号)   |
|-----------------------------------------------------------|-------------------|----------------------|-----------------------|-------------------|---------------------|
| Preferred Term (A) SUBJECTSWITHATLEASTONEGRADE>=3TEAE (B) | 47 ( 79.7)        | 39 ( 81.3)           | 86 ( 80.4)            | 14 ( 60.9)        | 100 (76.9)          |
| Blood and lymphatic system disorders                      | 42 71.2)          | 35 72.9)             | 77 72.0)              | 14 60.9)          | 91 70.0)            |
| Neutropenia                                               | 36 61.0)          | 31 64.6)             | 67 62.6)              | 12 52.2)          | 79 60.8)            |
| Leukopenia                                                | 7 11.9)           | 8.3)                 | 11 10.3)              | 4 17.4)           | 15 11.5)            |
| Lymphopenia                                               | 7 11.9)           | 45 10.4)             | 12 11.2)              | 17.4)             | 16 12.3)            |
| Anaemia                                                   | 6 10.2)           | 6 12.5)              | 12 11.2)              | 1 4.3)            | 13 10.0)            |
| Thrombocytopenia                                          | 6 10.2)           | 8 16.7)              | 14 13.1)              | 1 4.3)            | 15 11.5)            |
| Febrile neutropenia                                       | 2 3.4)            | 4 8.3)               | 6 5.6)                | 1 4.3)            | 7 5.4)              |
| Investigations                                            | 4 6.8)            | 5 (10.4)             | 6 8.4)                | 1 4.3)            | 10 7.7)             |
| Neutrophilcountdecreased                                  | 3 5.1)            | (6.3)                | 6 5.6)                | 0                 | 6 4.6)              |

A TEAE was defined as any AE that occurred from start of liso-cel infusion and up to 90 days after liso-cel infusion. Any AE occurring after the initiation of anotheranti-FLtreatmentwasnotconsideredaTEAE.

AEs were coded usingMedDRA version 26.0.

A subject was counted only once for multiple events within a PT/SOC.

Source: Table 8.2.1-1 of Study FOL-001 Addendum 01 CSR.

## TEAEs Related to LDC or Liso-cel

LDC-related TEAEs occurred in 75.4% of subjects overall; the frequency of LDC-related TEAEs was similar in 3L+ FL and 2L FL subjects (Table 1).

Liso-cel-related Grade ≥3 TEAEs occurred in 81 (62.3%) subjects and the most frequently reported Grade ≥ 3  TEAEs  ( ≥ 10%  subjects)  were  neutropenia  (47.7%)  and  lymphopenia  (11.5%)  (Table 14.3.1.1.10.1). Of note, most subjects experienced either LDC- or liso-cel-related neutropenia.

## Table 51. Liso-cel-related TEAEs by SOC and PT (≥ 10% Subjects) - Liso cel treated Analysis Set

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | 4L+ FL Cohort l N=59 n (%6)   | 3L FL Cohort 2 N=48 n (%)   | 3L+ FL Cohorts 1 + 2 N=107 n (%)   | 2L FL Cohort 3 N=23 n (%)   | Total 2L+ FL Cohorts 1,2,3 N =130 n (%)   |
|------------------------------------------------------|-------------------------------|-----------------------------|------------------------------------|-----------------------------|-------------------------------------------|
| Subjects IWith at Least One Liso-cel-Related TEAE    | 54 (91.5)                     | 42 (87.5)                   | 96 (89.7)                          | 19 (82.6)                   | 115 (88.5)                                |
| Immune system disorders                              | 35 (59.3)                     | 29 (60.4)                   | 64 (59.8)                          | 13 (56.5)                   | 77 (59.2)                                 |
| Cytokine release syndrome                            | 35 (59.3)                     | 28 (58.3)                   | 63 (58.9)                          | 12 (52.2)                   | 75 (57.7)                                 |
| Blood and lymphatic system disorders                 | 33 (55.9)                     | 34 (70.8)                   | 67 (62.6)                          | 13 (56.5)                   | 80 (61.5)                                 |
| Neutropenia                                          | 27 (45.8)                     | 31 (64.6)                   | 58 (54.2)                          | 12 (52.2)                   | 70 (53.8)                                 |
| Anaemia                                              | 16 (27.1)                     | 17 (35.4)                   | 33 (30.8)                          | 5 (21.7)                    | 38 (29.2)                                 |
| Thrombocytopenia                                     | 15 (25.4)                     | 10 (20.8)                   | 25 (23.4)                          | 2 (8.7)                     | 27 (20.8)                                 |
| Lymphopenia                                          | 8 (13.6)                      | 6 (12.5)                    | 14 (13.1)                          | 3 (13.0)                    | 17 (13.1)                                 |
| General disorders and administration site conditions | 17 (28.8)                     | 14 (29.2)                   | 31 (29.0)                          | 10 (43.5)                   | 41 (31.5)                                 |
| Fatigue                                              | 9 (15.3)                      | 3 (6.3)                     | 12 (11.2)                          | 5 (21.7)                    | 17 (13.1)                                 |
| Pyrexia                                              | 7 (11.9)                      | 8 (16.7)                    | 15 (14.0)                          | 2 (8.7)                     | 17 (13.1)                                 |
| Nervous system disorders                             | 13 (22.0)                     | 12 (25.0)                   | 25 (23.4)                          | 4 (17.4)                    | 29 (22.3)                                 |
|                                                      | 6 (10.2)                      | 6(12.5)                     | 12 (11.2)                          | 2 (8.7)                     | 14 (10.8)                                 |
| Headache                                             | 4 (6.8)                       | 7 (14.6)                    | 11 (10.3)                          | 2(8.7)                      | 13 (10.0)                                 |

Graded using NCI CICAE version 5.0. CRS is graded according to a system based on modified criteria (Lee, 2014)

Frequencies are listed in descending order of the frequency of system organ class and prefered temm within the system organ class based on Analysis Group l (4L+ FL). A Liso-cel TEAE is defined as any AE that occurs from start of Liso-cel imfusion and up to 90 days after Liso-cel infusion. Any AE occuming after the initiation of another antifollicular lymphoma treatment is not considered a TEAE. Related AEs are those for which the Investigator selects Related to Liso-cel on the AE CRF. Missing relationship is considered as Related.

- E Coded using MedDRA version 25.1. A subject is comted only once for multiple events within preferred term'system organ class.

Source: Table 14.3.1.1.9.1

## Adverse Events by Time Period

Most subjects experienced an AE during the Treatment Period. AEs in the post-treatment emergent period (≥ 91 days after liso -cel infusion) were infrequent (data not shown).

## Serious adverse event/deaths/other significant events

## Deaths

Table 52. Summary of Deaths and Causes - Leukapheresed Set

<div style=\"page-break-after: always\"></div>

| Primary Cause                                                                                  | 4L+EL N =65 n (%)   | 3LFL N=49 n (%)   | 3L+FL N =114 n (%)   | 2LEL N=25 n (%)   | 2L+FL N =139 n (%)   |
|------------------------------------------------------------------------------------------------|---------------------|-------------------|----------------------|-------------------|----------------------|
| OVERALLNUMBER OF DEATHS                                                                        | 9 (13.8)            | 6 (12.2)          | 15 ( 13.2)           | 1 (4.0)           | 16 ( 11.5)           |
| CAUSE OF DEATH                                                                                 |                     |                   |                      |                   |                      |
| DEATH FROM MALIGNANT DISEASE UNDER STUDY, OR COMPLICATION DUE TO MALIGNANT DISEASE UNDER STUDY | 4 ( 6.2)            | 3( 6.1)           | 7( 6.1)              | 0                 | 7( 5.0)              |
| DEATH FROM ADVERSE EVENT (NOT OTHERWISE SPECIFIED)                                             | 3( 4.6)             | 0                 | 3( 2.6)              | 1( 4.0)           | 2.9)                 |
| DEATH FROM CARDIAC EVENT                                                                       | 1 （ 1.5)            | 0                 | 1 0.9)               | 0                 | 1 0.7)               |
| DEATH FROM OTHER CAUSE                                                                         | 0                   | 3 6.1)            | 3 2.6)               | 0                 | 3 2.2)               |
| DEATH FROM NEW MALIGNANCY, OR COMPLICATION FROMNEWMALIGNANCY                                   | 1 （ 1.5)            | 0                 | 1 0.9)               | 0                 | 1 0.7)               |
| DEATH                                                                                          |                     |                   |                      |                   | 0                    |
| BETWEEN IEUKAPHERESIS AND LYMPHODEPLETING CHEMOTHERAPY START (A)                               | 0                   | 0                 | 0                    | 0                 |                      |
| BETWEENLYMPHODEPLETING                                                                         | 1( 1.5)             | 0                 | 1( 0.9)              | 0                 | 1( 0.7)              |
| CHEMOTHERAPY AND INFUSION (B) DEATH FROM ADVERSE EVENT (NOT OTHERWISE SPECIFIED)               | 1（ 1.5)             | 0                 | 1（（ 0.9)             | 0                 | 1( 0.7)              |
| INFUSION, DAY 1- 30 (C)                                                                        | 0                   | 0                 | 0                    | 1( 4.0) 4.0)      | 1 （ 0.7)             |
| DEATH FROM ADVERSEEVENT (NOTOTHERWISE SPECIFIED)                                               | 0                   | 0                 | 0                    | 1 (               | 1 0.7)               |
| INFUSION, DAY 31- 90 (D)                                                                       | 0                   | 0                 | 0                    | 0                 | 0                    |
| FROM INFUSION, DAY 91 (E)                                                                      | 8(12.3)             | 6 (12.2)          | 14  ( 12.3)          | 0                 | 14 (10.1)            |
| DEATH FROM MALIGNANT DISEASE UNDER STUDY, OR COMPLICATION DUE TO MALIGNANT DISEASE UNDER STUDY | 4（ 6.2)             | 3(6.1)            | 7( 6.1)              | 0                 | 5.0)                 |
| DEATH FROM ADVERSE EVENT (NOT OTHERWISE SPECIFIED)                                             | 2 (3.1)             | 0                 | 2（ 1.8)              | 0                 | 2 ( 1. 4)            |
| DEATH FROM CARDIAC EVENT                                                                       | 1.5)                | 0                 | 1 0.9)               | 0                 | 1 0.7)               |
| DEATH FROM OTHER CAUSE                                                                         | 0                   | 3 6.1)            | 3 2.6)               | 0                 | 3 2.2)               |
| DEATH FROM NEW MALIGNANCY,OR COMPLICATION FROM NEW MALIGNANCY                                  | 1（ 1.5)             | 0                 | 1 0.9)               | 0                 | 1 0.7)               |

(A) If LDC start date was not available, death is included in this section.

(B) IfLDC start date was available and infusion date was not available, death is included in this section.

(C) This period is defined from the first day of infusion until Day 30 after infusion.

(D) This period is defined from Day 31 until Day 90 after infusion.

(E) This period is defined from Day 91 after infusion.

Deaths from GC-LTFU-001 study are included.

Death from AE (Not Otherwise Specified) included: Cohort 1: acute respiratory failure hypoxic (LDC-infusion),AML (from Day 91 after infusion).

PML (from Day 91 after infusion), and Cohort 3: HLH (Day 1-30).

Death from other cause included: Cohort 2: 2 cases of COVID-19 and erythema multiform.

Source: Table 8.3-1 of Study FOL-001 Addendum 01 CSR.1

## Treatment-emergent Serious Adverse Events

Twenty-four (18.5%) of all FL subjects (n= 130) experienced at least one liso-cel-related serious TEAEs.

## Table 53. Treatment-emergent SAEs by SOC and PT Reported in ≥ 2% by PT in Any Cohort Liso-cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

|                                      | 4L+        | 3LEL       | 3L+EL     | 2LEL     | 2L+EL     |
|--------------------------------------|------------|------------|-----------|----------|-----------|
| System Organ Class                   | N = 59     | N = 48     | N = 107   | N = 23   | N = 130   |
| Preferred Temm (A)                   | n (%)      | n (%)      | n (%)     | n (%)    | n (%)     |
| SUBJECTSWITHATLEASTCNESERIOUSTEAE    | 15 ( 25.4) | 12 ( 25.0) | 27 (25.2) | 4 (17.4) | 31 (23.8) |
| Imune system disorders               | 7 ( 11.9)  | 4 ( 8.3)   | 11 (10.3) | 211 8.7) | 13 (10.0) |
| Cytokine release syndrame            | (11.9)     | 8.3)       | 11 (10.3) | 4.3)     | 12 9.2)   |
| Allergy to inmmnoglobulin therapy.   | 0          | 400        |           | 4.3)     | 1 0.8)    |
| Haemophagocytic lymphohistiocytosis  | 0          |            | 0         | （ 4.3)   | 1 0.8)    |
| Nervous system disorders             | 6.8)       | 2 4.2)     | 6 5.6)    | 1 4.3)   | 7 5.4)    |
| Aphasia                              | 4 6.8)     | 0          | 4 3.7)    | 1 4.3)   | 5 3.8)    |
| Tremor                               | 2 3.4)     | 1 2.1)     | 3 2.8)    | 0        | 3 2.3)    |
| Dyscalculia                          | 1 1.7)     | 1 2.1)     | 2 1.9)    | 0        | 2 1.5)    |
| Dysgraphia                           | 1 1.7)     | 1 2.1)     | 2 1.9)    | 0        | 2 1.5)    |
| Depressed level of consciousness     | 0          | 1 2.1)     | 1 0.9)    | 0        | 1 0.8)    |
| Fine motor skill dysfumction         |            | 1 2.1)     | 1 0.9)    | 0        | 1 0.8)    |
| Speech disorder                      | 0          | 1 2.1)     | 1 0.9)    | 0        | 1 0.8)    |
| Psychiatric disorders                | 6.8)       | 1 2.1)     | 5 4.7)    | 0        | 5 3.8)    |
| Confusional state                    | 2 3.4)     | 0          | 2 1.9)    | 0        | 2 1.5)    |
| Irritability                         | 0          | 1 2.1)     | 1 0.9)    | 0        | 1 ( 0.8)  |
| Blood and lymphatic system disorders | 3 5.1)     | 2 4.2)     | 5 4.7)    | 0        | 5 3.8)    |
| Febrile neutropenia                  | 2 3.4)     | 2 4.2)     | 4 3.7)    | 0        | 4 3.1)    |
| Infections and infestations          | 5.1)       | 8.3)       | 7 6.5)    | 0        | 7 5.4)    |
| COVID-19 pneumonia                   | 00         | 2.1)       | 0.9) 0.9) | 0 0      | 11 0.8)   |
| Cellulitis                           |            |            | 111       |          | 0.8)      |
| Device related bacteraemia           |            | 4111 2. 1) | 0.9)      | 0        | 1 0.8)    |
| Pyelonephritis                       | 0          | 2.1)       | 1 0.9)    | 0        | 1 0.8)    |

|                                                                     | 4L+FL   | 3LFL       | 3L+FL    | 2LL     | 2L+EL    |
|---------------------------------------------------------------------|---------|------------|----------|---------|----------|
| System Organ Class                                                  | N = 59  | N = 48     | N = 107  | N=23    | N = 130  |
| Preferred Tem (A)                                                   | n (%)   | n (%)      | n (%)    | n (%)   | n (%)    |
| Cardiac disorders                                                   | 11:     | 1 ( 2.1)   | 2 （ 1.9) | 0       | 2 1.5)   |
| Atrioventricular block                                              | 1       | 0          | 0.9)     | 0       | 11 0.8)  |
| Bradycardlia                                                        | 0       | i ( 2.1)   | 0.9)     | 0       | 0.8)     |
| General disorders and acministration site conditions                | 1( 1.7) | 2( 4.2)    | 3( 2.8)  | 1( 4.3) | 3.1)     |
| Pyrexia                                                             | 1 1.7)  | 2 ( 4.2) 0 | 3 2.8)   |         | 3 2.3)   |
| Feeling abnomal                                                     | 0       |            | 0        | 1 4.3)  | 1 0.8)   |
| Neoplasms benigm, maligmant and unspecified (incl cysts and polyps) | 1( 1.7) | 0          | 1 0.9)   | 1( 4.3) | 2 1.5)   |
| Adenocarcinoma of colon                                             | 0       | 0          | 0        | 1( 4.3) | 1 0.8)   |
| Gastrointestinal disorders                                          | 0       |            | 0.9)     | 0       | 1 0.8)   |
| Large intestinal obstruction                                        | 0       |            | 0.9)     | 0       | 1 0.8)   |
| Respiratory, thoracic and mediastinal disorders                     | 0       | 1 (2.1)    | 1( 0.9)  | 0       | 1 ( 0.8) |
| Chylothorax                                                         | 0       | 1 (2.1)    | 1( 0.9)  | 0       | 1 (0.8)  |

A TEAE was defined as any AE that occurred from start of liso-cel infusion and up to 90 days after liso-cel infusion. Any AE occurring after the initiation of another anti-FLtreatmentwasnot considered aTEAE.

AEs were coded using MedDRA version 26.0.

A subject was counted only onceformultiple events within a PT/SOC.

Source: Table 14.3.2.2.1.1 of Study FOL-001 Addendum 01 CSR 1

## Other Significant Adverse Events of Special Interest

The frequency of AESIs was consistent across cohorts (lines of therapy) and groups. There were no AESIs in the IRR, TLS, and autoimmune disorder categories.

Table 54. Overall Summary of AESIs - Liso-cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

|                                                     | 4L+EL N = 59 n (%)   | 3LEL N = 48 n (%)   | 3L+FL N = 107 n (%)   | 2LEL N =23 n (%)   | 21+EL N = 130 n (%)   |
|-----------------------------------------------------|----------------------|---------------------|-----------------------|--------------------|-----------------------|
| ANY AESI                                            | 40 ( 67.8)           | 32 ( 66.7)          | 72 ( 67.3)            | 15 ( 65.2)         | 87 ( 66.9)            |
| CYTOKINE RELFASE SYNDROME (CRS)                     | 35 ( 59.3)           | 28 (58.3)           | 63 ( 58.9)            | 12 ( 52.2)         | 75 ( 57.7)            |
| INVESTIGATOR-IDENTIFIEDNEUROLOGICAL TOXICITY (iiNT) | 9 (15.3)             | 8 (16.7)            | 17 ( 15.9)            | 4 (17.4)           | 21 (16.2)             |
| INFUSION RELATED REACTION (IRR)                     | 0                    | 0                   | 0                     | 0                  | 0                     |
| MACROPHAGE ACTIVATION SYNDROME(MAS)                 |                      |                     |                       | 1( 4.3)            | 1 (0.8)               |
| TUMOR LYSIS SYNDROME (TLS)                          | 0                    | 0                   |                       | 0                  |                       |
| HYPOGAMMAGLOBULINAEMIA                              | 3 （ 5.1)             | 3( 6.3)             | 6( 5.6)               | 1 ( 4.3)           | 7（ 5.4)               |
| INFECTIONSGRADE>=3                                  | 3 ( 5.1)             | 4( 8.3)             | 7( 6.5)               | 0                  | 7（ 5.4)               |
| SECONDPRIMARY MALIGNANCY (SEM)                      | 4 6.8)               | 3( 6.3)             | 7( 6.5)               | 2 (8.7)            | 9( 6.9)               |
| AUIOIMMUNEDISORDERS                                 | 0                    | 0                   | 0                     | 0                  | 0                     |
| PROLONGEDCYTOPENIA                                  | 14 ( 23.7)           | 12 ( 25.0)          | 26 ( 24.3)            | 3 (13.0)           | 29 ( 22.3)            |

Related AEs were those for which the Investigator selects 'Related' to liso-cel or LDC on the AE CRF. Missing relationship was considered as Related.

## Cytokine Release Syndrome

The frequency of CRS was consistent across cohorts (lines of therapy) and groups. The most common symptoms of CRS ( ≥ 10%) included pyrexia (56.9%) and hypotension (13.8%). The median time of CRS onset from the time of liso-cel infusion was 6 days (range: 1 to 17 days). CRS resolved in all subjects; the median time to resolution was 3 days (range: 1 to 10 days). Of the subjects treated with concomitant medications for CRS, 18 (13.8%) subjects received tocilizumab only (median 1 dose [range, 1 to 3]), no subjects received corticosteroids only, 15 (11.5%) subjects received both tocilizumab and corticosteroids, and 2 (1.5%) subjects received vasopressors (Table 14.1.5.8 and Table 14.1.5.11 of Study FOL-001 Addendum 01 CSR1).

Table 55. Summary of CRS - Liso-cel treated Analysis Set

|                                 | 4L+FL Cohort 1 N=59   | 3L FL Cohort 2 N=48   | 3L+FL Cohorts 1 + 2 N=107   | 2L FL Cohort 3 N=23   | Total2L+FL Cohorts 1,2,3 N =130   |
|---------------------------------|-----------------------|-----------------------|-----------------------------|-----------------------|-----------------------------------|
| Subjects With at Least One CRS  | 35 (59.3)             | 28 (58.3)             | 63 (58.9)                   | 12 (52.2)             | 75 (57.7)                         |
| Overall Duration Of CRS (Days)a |                       |                       |                             |                       |                                   |
| N                               | 35                    | 28                    | 63                          | 12                    | 75                                |
| Median                          | 3                     | 4                     | 4                           | 3                     | 3                                 |
| Q1, Q3                          | 2.0, 4.0              | 3.0, 5.0              | 2.0, 5.0                    | 2.0, 6.0              | 2.0, 5.0                          |
| Min, Max                        | 1,9                   | 1,10                  | 1,10                        | 2,7                   | 1,10                              |
| Maximum Toxicity Grade          |                       |                       |                             |                       |                                   |
| Grade 1                         | 28 (47.5)             | 20 (41.7)             | 48 (44.9)                   | 7 (30.4)              | 55 (42.3)                         |
| Grade 2                         | 6 (10.2)              | 8 (16.7)              | 14 (13.1)                   | 5 (21.7)              | 19 (14.6)                         |

<div style=\"page-break-after: always\"></div>

| Grade 3   | 1 (1.7)   |           | 1 (0.9)   |           | 1 (0.8)   |
|-----------|-----------|-----------|-----------|-----------|-----------|
| Grade ≤ 2 | 34 (57.6) | 28 (58.3) | 62 (57.9) | 12 (52.2) | 74 (56.9) |
| Grade≥3   | 1 (1.7)   | 0         | 1 (0.9)   | 0         | 1 (0.8)   |

Events that stop/start within 7 days will be considered as a single episode.

a Duration of event is based on event start and stop dates ([stop/cut-off date - start date] + 1).

Source:Table14.3.2.4.21

## Neurological Toxicity

The frequency of iiNT was consistent across cohorts (lines of therapy) and groups. The most common iiNTs by PT ( ≥ 5% of subjects) were tremor (7.7%) and aphasia (6.9%). The median time to iiNT onset from the time of liso-cel infusion was 8 days (range: 4 to 16 days). iiNT resolved in all subjects; the median time to resolution was 4 days (range: 1 to 17 days). Of the subjects treated with concomitant medications for iiNT, no subjects received tocilizumab only, 9 (6.9%) subjects received corticosteroids only, no subjects received both tocilizumab and corticosteroids, no subjects received vasopressors. The selected AE category of iiNT was used to report the CAR T cell-associated signs and symptoms suggestive of neurotoxicity, which include ICANS, as enrolment for Study FOL 001 began prior to 2019 (before ASTCT consensus 2019 for ICANS).

## Table 56. Summary of iiNT - Liso cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

|                                | 4L+ FL Cohort l N= 59   | 3L FL Cohort 2 N=48   | 3L+ FL Cohorts l + 2 N=107   | 2L FL Cohort 3 N=23   | Total 2L+ FL Cohorts 1,2,3 N=130   |
|--------------------------------|-------------------------|-----------------------|------------------------------|-----------------------|------------------------------------|
| Subjects With at Least One iNT | 9 (15.3)                | 8 (16.7)              | 17 (15.9)                    | 4 (17.4)              | 21 (16.2)                          |
| Overall Duration of iNT (Days) |                         |                       |                              |                       |                                    |
| N                              | 9                       | 8                     | 17                           |                       | 21                                 |
| Median                         | 5                       | 3                     | 4                            | 2.5                   | 4                                  |
| Q1, Q3                         | 3.0, 7.0                | 2.0, 5.5              | 2.0, 6.0                     | 1.5, 3.5              | 2.0, 5.0                           |
| Min, Max                       | 1, 17                   | 2.8                   | 1, 17                        | 1.4                   | 1, 17                              |
| Maximum Toxicity Grade         |                         |                       |                              |                       |                                    |
| Grade 1                        | 6 (10.2)                | 6 (12.5)              | 12 (11.2)                    | 3 (13.0)              | 15 (11.5)                          |
| Grade 2                        | 2 (3.4)                 | 0                     | 2 (1.9)                      |                       | 2 (1.5)                            |
| Grade 3                        | 1 (1.7)                 | 2 (4.2)               | 3 (2.8)                      | 1 (4.3)               | 4 (3.1)                            |
| Grade≤2                        | 8 (13.6)                | 6 (12.5)              | 14 (13.1)                    | 3 (13.0)              | 17 (13.1)                          |
| Grade 23                       | 1 (1.7)                 | 2 (4.2)b              | 3 (2.8)                      | 1 (4.3)               | 4 (3.1)                            |

Events that stop/start within 7 days will be considered as a single episode.

iiNT was captured using the preferred term Neurotoxicity and graded using CTCAE v.5.0 on the basis of the highest individual symptom grade.

Duration of event is based on event start and stop dates ([stop/cut-off date - start date] + 1).

After the 10-Jan-2024 data cut-off date, the relation of Grade 3 iilNT (agitation) was re-evaluated by the investigator and updated as not related to liso-cel/LDC/study procedure and not considered as an iiNT event.

Soufce:Table 14.3.2.4.21

## Prolonged cytopenia

In the Liso-cel-treated Analysis Set, prolonged cytopenia, defined as Grade ≥ 3 cytopenia at the Day 29 ( ± 2 days) visit based on local laboratory assessments of neutropenia, thrombocytopenia, or anemia, occurred in 29 (22.3%) subjects (see Table below). Data were consistent across cohorts.

Table 57. Summary of Prolonged Cytopenia - Liso-cel-treated Analysis Set

<div style=\"page-break-after: always\"></div>

|                                                       | 4L+ FL Cohort l N=59 n (%)   | 3L FL Cohort 2 N=48 (%) u   | 3L+FL Cohorts 1 + 2 N =107 (%) u   | 2L FL Cohort 3 N=23 (%) u   | 2L FL Cohort 3 N=23 (%) u                 | Total 2L+ FL Cohorts 1,2,3 N =130 (%) u   |
|-------------------------------------------------------|------------------------------|-----------------------------|------------------------------------|-----------------------------|-------------------------------------------|-------------------------------------------|
| Grade ≥3 Cytopenia                                    | 50 (84.7)                    | 37 (77.1)                   | 87 (81.3)                          | 16 (69.6)                   | 16 (69.6)                                 | 103 (79.2)                                |
| From Day 1 Through Day 29 Visit                       |                              |                             |                                    |                             |                                           |                                           |
| Grade≥3 At Day 29 Visit                               | 14 (23.7)                    | 12 (25.0)                   | 26 (24.3)                          | 3 (13.0)                    | 3 (13.0)                                  | 29 (22.3)                                 |
| Grade≤2 At Day 29 Visit                               | 34 (57.6)                    | 20 (41.7)                   | 54 (50.5)                          | 10 (43.5)                   | 10 (43.5)                                 | 64 (49.2)                                 |
|                                                       | 4L+FL Cohort l N= 59 n (%)   | 3L FL Cohort 2 N=48 n (%)   | 3L+FL Cohorts l + 2 N=107 n (%)    | 2L FL Cohort 3 N=23 n (%)   | Total 2L+ FL Cohorts 1,2, 3 N = 130 n (%) | Total 2L+ FL Cohorts 1,2, 3 N = 130 n (%) |
| Unkmowm At Day 29 Visit                               | 2(3.4)                       | 5 (10.4)                    | 7 (6.5)                            | 3 (13.0)                    | 10 (7.7)                                  | 10 (7.7)                                  |
| Grade ≥ 3 Hemoglobin From Day 1 Through Day 29 Visit  | 12 (20.3)                    | 6 (12.5)                    | 18 (16.8)                          | 4 (17.4)                    | 22 (16.9)                                 | 22 (16.9)                                 |
| Grade≥3 At Day 29 Visit                               | 4 (6.8)                      | 2 (4.2)                     | 6 (5.6)                            | 0                           | 6 (4.6)                                   | 6 (4.6)                                   |
| Grade≤2 At Day 29 Visit                               | 8 (13.6)                     | 3 (6.3)                     | 11 (10.3)                          | 4(17.4)                     | 15 (11.5)                                 | 15 (11.5)                                 |
| Unlmowm At Day 29 Visit                               | 0                            | 1(2.1)                      | 1(0.9)                             | 0                           | 1 (0.8)                                   | 1 (0.8)                                   |
| Grade >3 Platelets From Day l Through Day 29 Visit    | 12 (20.3)                    | 10 (20.8)                   | 22 (20.6)                          | 2 (8.7)                     | 24 (18.5)                                 | 24 (18.5)                                 |
| Grade≥3 At Day 29 Visit                               | 10 (16.9)                    | 8 (16.7)                    | 18 (16.8)                          | 1 (4.3)                     | 19 (14.6)                                 | 19 (14.6)                                 |
| Grade ≤2 At Day 29 Visit                              | 2(3.4)                       | 0                           | 2(1.9)                             | 1 (4.3)                     | 3 (2.3)                                   | 3 (2.3)                                   |
| Unlmowm At Day 29                                     | 0                            | 2 (4.2)                     | 2 (1.9)                            | 0                           | 2 (1.5)                                   | 2 (1.5)                                   |
| Grade ≥ 3 Neutrophils From Day l Through Day 29 Visit | 49 (83.1)                    | 37 (77.1)                   | 86 (80.4)                          | 16 (69.6)                   | 102 (78.5)                                | 102 (78.5)                                |
| Grade≥3 At Day 29 Visit                               | 8 (13.6)                     | 10 (20.8)                   | 18 (16.8)                          | 2 (8.7)                     | 20 (15.4)                                 | 20 (15.4)                                 |
| Grade ≤2 At Day 29 Visit                              | 38 (64.4)                    | 22 (45.8)                   | 60 (56.1)                          | 11 (47.8)                   | 71 (54.6)                                 | 71 (54.6)                                 |
| Unkmowm At Day 29 Visit                               | 3 (5.1)                      | 5 (10.4)                    | 8 (7.5)                            | 3 (13.0)                    | 11 (8.5)                                  | 11 (8.5)                                  |

If multiple test results are available in the window, the maximum grade is selected.

Laboratory results after the initiation of subsequent anti-follieular lymphoma therapy are excluded.

Grade ≥ 3 Cytopenia includes any Grade ≥ 3 decreased hemoglobin, decreased meutrophil count, or decreased platelet count.

Protocol defined window for Day 29 Visit is 29 ± 2 days after liso-cel infusion.

Source: Table 14.3.2.4.10

## Second Primary Malignancy

<div style=\"page-break-after: always\"></div>

In  the  Liso-cel-treated  Analysis  Set,  SPM  was  reported  in  9  (6.9%)  subjects.  12  SPM  events  were reported in 9 subjects: melanoma (Grade 2), colorectal cancer (Grade 3), mucoepidermoid carcinoma (Grade 2), MDS (Grade 4), basal cell carcinoma (Grade 1), SCC/Bowen's disease (Grade 2), AML (2 Grade 4 events and 2 Grade 5 events), rectal cancer (Grade 3), and colon adenocarcinoma (Grade 3). No events of T-cell malignancies were reported.

## Cardiac Events

9 subjects with 2L+ FL experienced TEAEs with SOC of Cardiac disorder, including PT of tachycardia (n=3; Grade 1), sinus tachycardia (n=3; Grade 1/2), palpitations (n=1; Grade 3), bradycardia (n=1; Grade 3), atrioventricular block (n=1; Grade 3). There were no Cardiac disorder AEs reported beyond 90 days after liso-cel infusion. All cardiac TEAEs resolved by Day 33 post liso-cel infusion. No subsequent cardiac events were reported for these patients.

Among the 9 subjects with cardiac TEAEs, 5 subjects developed cardiac TEAE during or approximately 1 to 2 days prior or after the CRS event, and 2 subjects developed cardiac TEAE at least 2 weeks after resolutions  of  CRS;  2  subjects  never  experienced  CRS.  Two  subjects  with  cardiac  TEAE experienced death not related to cardiac events; one died on Day 29 due to Grade 5 HLH and the other died on Day 169 due to COVID-19.

In addition to the above Cardiac disorder TEAEs, one death was reported on Day 171 after liso-cel infusion due to cardiac event of heart failure. The subject was reported to have history of Grade 1 cardiomyopathy. Screening echocardiogram prior to the study treatment showed LVEF of 45%, and screening ECG was interpreted as abnormal but without clinical significance. No acute cardiac events or CRS were reported for this subject during TEAE or post TEAE periods. This death of Cardiac event of heart failure was not reported as AE related to liso-cel.

## Laboratory findings

## Hematology

In the Liso-cel-treated Analysis Set, changes in hematology laboratory results were consistent with the receipt of anticancer therapy for disease control and LDC prior to liso-cel treatment followed by the expected recovery (data not shown).

## Serum Chemistry

In the Liso-cel-treated Analysis Set, most serum chemistry parameters remained stable over time (data not shown).

## Persistence of Viral Vector Sequence Monitoring

Vector ISA was performed if persistence of CAR vector sequence was detected in ≥ 1% of nucleated blood cells at any time point ≥ 12 months after the liso-cel infusion.

In the Liso-cel-treated Analysis Set, 2 subjects met the criteria for ISA: for one subject, the transgene percentage  was  11.4%  at  Month  12,  and  for  the  other  subject  it  was  3.5%  at  Month  24.  ISA  was performed on both samples. Results for the subject with 11.4% transgene at Month 12 showed the sample was polyclonal without evidence of a monoclonal outgrowth. Results for the subject with 3.5% transgene at Month 24 were pending as of the data cutoff date of 10-Jan-2024.

## Replication-competent Lentivirus by Visit

No RCL was detected in the 464 samples tested from the Liso-cel-treated Analysis Set.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Intrinsic Factors

There were no major differences in the frequency of TEAEs and Grade ≥ 3 TEAEs across subgroups (age, sex, ethnicity, race, anticancer treatment of disease control status [yes vs no], and region) in the Lisocel-treated Analysis Set.

## Safety in Outpatient Setting

Administration of liso-cel as inpatient or outpatient was determined at the PI's discretion.

In the Liso-cel-treated Analysis Set, 14 (10.8%) subjects were monitored as outpatients (13 3L+ FL subjects and 1 2L FL subject):

- TEAEs occurred in 14 (100%) subjects overall, 8 (57.1%) experienced Grade ≥ 3 TEAEs, and 7 (50.0%) SAEs.
- AESI occurred in 8 (57.1%) subjects overall, most commonly, CRS (6 [42.9%] subjects) and iiNT (2 [14.3%]) subjects).

50.0% of these subjects were hospitalized after liso-cel administration due to an AE. The median time from liso-cel administration to first hospitalization was 7 days (range, 4 to 16). None of these subjects had ICU stays.

## Pooled Analyses of Safety

Liso-cel pooled safety analyses included side-by-side comparison of each Liso-cel Treated Set in 3L+ FL and 2L+ FL subjects from Study FOL-001 with 2L/3L+ LBCL subjects in EU-approved indications.

## Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

## Subject Disposition

154 subjects were screened in Study FOL-001 and all 139 subjects (including 114 subjects with 3L+ FL) who met the inclusion/exclusion criteria underwent leukapheresis as of the data cut-off date of 10-Jan2024. Of the 114 3L+ FL subjects, 107 (93.9%) received LDC and liso-cel infusion and comprised the 3L+ FL Liso cel Treated Set. 18 out of 107 (16.8%) subjects discontinued the study; the most common reasons for study discontinuation were death and consent withdrawal (see Table below).

Table 58. Subject Disposition - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

|                                          | 3L+FL（FOL-001 Cohorts 1,2) N = 107   | 2L/3L+LBCL Total N= 608   | Overall Total N = 715   |
|------------------------------------------|--------------------------------------|---------------------------|-------------------------|
| STUDY STATUS                             |                                      |                           |                         |
| ONGOING                                  | 88 (82.2)                            | 151 (24.8)                | 239(33.4)               |
| COMPLETED STUDY                          | 1 0.9)                               | 154 (25.3)                | 155 (21.7)              |
| DISCONTINUED FROM STUDY                  | 18 (16.8)                            | 303 (49.8)                | 321 44.9)               |
| ADVERSE EVENT                            | 0                                    | 0                         | 0                       |
| DEATH                                    | 7 6.5)                               | 237 (39.0)                | 244 34.1)               |
| LOST TOFOLLOW-UP                         | 1 0.9)                               | 5 0.8)                    | 6 （ 0.8)                |
| OTHER (A)                                | 3 2.8)                               | 23 3.8)                   | 26 3.6)                 |
| STUDY TERMINATION BY SPONSOR             | 0                                    | 0                         | 0                       |
| SUBJECT WITHDREWCONSENT                  | 7 6.5)                               | 38 6.3)                   | 45 6.3)                 |
| CONSENTED TO THE LONG-TERM FOLLOWUPSTUDY | 1 0.9)                               | 111 18.3）                 | 112 15.7)               |
| SUBJECTS RECEIVED RETREATMENT            | 0                                    | 19 3.1)                   | 19 2.7)                 |

(A) Refer to Listing 2.1.1 of Appendix 2 for details.

## Study Duration

Table 59. Study Duration - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                                    | 3L+FL(FOL-001 Cohorts1,2) N = 107   | 2L/3L+ LBCL Total N= 608   | Overall Total N = 715   |
|------------------------------------|-------------------------------------|----------------------------|-------------------------|
| ON-STUDYFOLLOW-UPTIME (MONTHS) (A) |                                     |                            |                         |
| N                                  | 107 25.38 7.291 27.24               | 608 14.06 9.241 12.39      | 715 15.76 9.839 16.16   |
| MEAN SD                            |                                     |                            |                         |
| MEDIAN                             |                                     |                            |                         |
| Q1，Q3                              | 23.75,30.03                         | 5.54,23.74                 | 6.21,24.15              |
| MIN , MAX                          | 3.7, 37.2                           | 0.2， 45.2                  | 0.2， 45.2               |
| DURATIONOFON-STUDYFOLLOW-UP        |                                     |                            |                         |
| >=1DAY,N(%)                        | 107 (100.0)                         | 608 (100.0)                | 715 (100.0)             |
| >=29DAYS，N（%)                      | 107 (100.0)                         | 595 97.9)                  | 702 98.2)               |
| >=2 MONTHS，N（%）                    | 107 (100.0)                         | 559 91.9)                  | 666 93.1)               |
| （%）NSHINOW=                        | 107 (100.0)                         | 533 87.7)                  | 640 89.5)               |
| >6 MONTHS,N（%)                     | 103 96.3)                           | 442 72.7)                  | 545 76.2)               |
| >=9 MONTHS,N（%)                    | 98 91.6)                            | 372 61.2)                  | 470 65.7)               |
| >12MONTHS，N(%)                     | 98 91.6)                            | 319 52.5)                  | 417 58.3)               |
| >=18MONTHS，N（%)                    | 95 88.8)                            | 231 38.0)                  | 326 45.6)               |
|                                    | 75                                  |                            |                         |
| >=24MONTHS，N（%）                    | 70.1)                               | 128 (21.1)                 | 203 28.4)               |
| TOTALON-STUDYFOLLOW-UPTIME (YEARS) | 226.3                               | 712.6                      | 938.8                   |

(A) The follow-up time was (EOS date - first lisQ-ce1 dose date + 1)/30.4375 for subjects who did not enroll in the LTFU study. If a subject was ongoing in the study, the earliest of the last known alive date or data cut-off date) was used to impute the EOS date for the purpose of the calculation. For subjects who enrolled in the LTFU study, the follow-up time was (min [last known alive date, death date, data cut-off date] - first dose date + 1)/30.4375. Source:Table 2.3.1.1 of Appendix 2.

## Lymphodepleting Chemotherapy and Liso-cel Dose

A low-intensity LDC regimen of fludarabine IV (30 mg/m²/day for 3 days) and cyclophosphamide IV (300 mg/m²/day for 3 days) was administered prior to liso-cel administration. The majority of Liso-cel Treated Set subjects with 3L+ FL (n= 96/107, 89.7%) and 2L/3L+ LBCL (n= 504/608, 82.9%) received the specified dose of fludarabine and cyclophosphamide with no missing doses. The Liso-cel Treated Set subjects with 3L+ FL received a median total liso-cel dose of 100.0 × 10 6  CAR+ T cells (49.8 × 10 6  CD8+ and 50.0 × 10 6  CD4+ CAR+ T cells), which was similar to the dose received by subjects with 2L/3L+ LBCL.

## Demographic and Other Characteristics of 3L+ FL and 2L/3L+ LBCL Populations

The demographics and baseline disease characteristics in the Liso-cel Treated Set subjects with 3L+ FL and 2L/3L+ LBCL were representative of FL and LBCL populations, respectively. In 3L+ FL, 60.7% of subjects had an ECOG PS score of 0 and 43.9% of subjects had LDH ≥ ULN at baseline. The median SPD was 19.89 cm 2  for subjects with 3L+ FL indicating similar burden of disease compared to subjects with 2L/3L+ LBCL (20.91 cm 2 ). Despite similar burden of disease based on SPD, a lower proportion of Lisocel Treated Set subjects with 3L+ FL received anticancer therapy for disease control than subjects with 2L/3L+ LBCL (41.1% vs 60.9%), possibly reflective of a population with less rapidly progressive disease in the 3L+ FL.

## Adverse Events in 3L+ FL and 2L/3L+ LBCL

## Table 60. Overview of TEAEs - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                    | 3L+FL(FOL-001 Cohorts 1, 2) N = 107       | 2L/3L+LBCL Total N = 608                         | Overall Total N = 715                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|-----------------------------------------------------------|
| DURATION OF PERIOD (DAYS)，MEDIAN (RANGE)                                                                                                                                                                                                                                                                                                           | 90.0 (90-90)                              | 90.0 (7-218)                                     | 90.0 (7-218)                                              |
| SUBJECTS WITH ANY TEAE SUBJECIS WITHANY（ GRADE 3-4 TEAE SUBJECIS WITH ANY GRADE 3-5 TEAE SUBJECIS WITHANY GRADE 5 TEAE SUBJECTSWITHANYSERIOUSTEAE                                                                                                                                                                                                  | 106 (99.1) 86 80.4) 86 80.4) .0 27 (25.2) | 602 99.0) 482 79.3) 497 81.7) 15 2.5) 260 42.8)  | 708 (99.0) 568 79.4) 583 81.5) 15 2.1) 287 40.1)          |
| SUBJECISWITHANYLDC-RELATEDTEAE SUBJECTSWITHANYLDC-RELATEDGRADE3-4TEAE SUBJECIS WITHANYLDC-RELATED GRADE 3-5TEAE SUBJECIS WITH ANY LDC-RELATED GRADE 5 TEAE SUBJECTSWITHANYLDC-RELATEDSERIOUSTEAE SUBJECTSWITHANYJCARO17-RELATEDTEAE SUBJECIS WITHANY JCARO17-RELATED SUBJECIS WITHANY JCAR017-RELATED SUBJECIS WITHANYJCARO17-RELATED GRADE 5 TEAE | 81 75.7) 68 63.6) 68 63.6) 8 (7.5)        | 419 68.9) 427 70.2) 8 67 486                     | 579 81.0) 487 68.1) 495 69.2) 8 1.1) 75 (10.5) 582 (81.4) |
| GRADE 3-4TEAE GRADE 3-5TEAE                                                                                                                                                                                                                                                                                                                        | 96 (89.7) 68 63.6) 68 63.6)               | 498 (81.9) 1.3) (11.0) 79.9) 277 45.6) 285 46.9) |                                                           |
|                                                                                                                                                                                                                                                                                                                                                    | 0                                         | 8 1.3) 29.8)                                     | 353 49.4)                                                 |
| SUBJECTSWITHANYJCARO17-RELATED SERIOUSTEAE                                                                                                                                                                                                                                                                                                         |                                           |                                                  |                                                           |
|                                                                                                                                                                                                                                                                                                                                                    |                                           |                                                  | 345 48.3)                                                 |
|                                                                                                                                                                                                                                                                                                                                                    |                                           |                                                  | 8 1.1)                                                    |
|                                                                                                                                                                                                                                                                                                                                                    | 21                                        |                                                  |                                                           |
|                                                                                                                                                                                                                                                                                                                                                    | (19.6)                                    | 181                                              | 202 28.3)                                                 |

CRS was graded based on the Lee criteria.? Other AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies. Themost severegradewas used for AEs that occur more than once in an individual subject during theperiod.

TEAE was defined as an AE that started any time from initiation of liso-cel administration through and including 90 days following the final dose of liso-cel. Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE. Source: Table 3.1.1.1 of Appendix 2.

<div style=\"page-break-after: always\"></div>

## Treatment-emergent Adverse Events

## Table 61. TEAEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class Preferred Temm                    | 3L+FL（FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+IBCL Total N= 608 n (%)   | Overall Total N = 715 n (%)   |
|------------------------------------------------------|---------------------------------------------|---------------------------------|-------------------------------|
| SUBJECTSWITHANYTEAE                                  | 106 ( 99.1)                                 | 602 ( 99.0)                     | 708 (99.0)                    |
| Blood and lymphatic system disorders                 | 84 (78.5)                                   | 494 81.3)                       | 578 (80.8)                    |
| Neutropenia                                          | 74 69.2)                                    | 409 67.3)                       | 483 67.6)                     |
| Anaemia                                              | 47 43.9)                                    | 275 45.2)                       | 322 45.0)                     |
| Thrombocytopenia                                     | 35 32.7)                                    | 228 37.5)                       | 263 36.8)                     |
| Leukopenia                                           | 14 13.1)                                    | 140 23.0)                       | 154 21.5)                     |
| Lyphopenia                                           | 14 13.1)                                    | 69 11.3)                        | 83 11.6)                      |
| General disorders and administration site conditions | 44 ( 41.1)                                  | 386 ( 63.5)                     | 430 ( 60.1)                   |
| Fatigue                                              | 13 (12.1)                                   | 205 (33.7)                      | 218 (30.5)                    |
| Pyrexia                                              | 19 17.8)                                    | 120 19.7)                       | 139 (19.4)                    |
| Oedema peripheral                                    | 4 3.7)                                      | 76 12.5)                        | 80 (11.2)                     |
| Asthenia                                             | 14 13.1)                                    | 49 8.1)                         | 63 8.8)                       |

|                                                 | 3L+FL(FOL-001 Cohorts 1, 2)   | 2L/3L+ LBCL Total N = 608   | Overall Total N = 715 n (%)   |
|-------------------------------------------------|-------------------------------|-----------------------------|-------------------------------|
| System Organ Class Preferred Tem                | N = 107 n (%)                 | n (%)                       |                               |
| Gastrointestinal disorders                      | 49 45.8)                      | 378 (62.2)                  | 427 (59.7)                    |
| Nausea                                          | 10 9.3)                       | 164 27.0)                   | 174 24.3)                     |
| Constipation                                    | 23 21.5)                      | 121 19.9)                   | 144 20.1)                     |
| Diarrhoea                                       | 16 15.0)                      | 127 20.9)                   | 143 (20.0)                    |
| Vomiting                                        | 4 3.7)                        | 88 14.5)                    | 92 12.9)                      |
| Abdominal 1pain                                 | 4 3.7)                        | 70 （ 11.5)                  | 74 (10.3)                     |
| Nervous system disorders                        | 46 43.0)                      | 352 (57.9)                  | 398 55.7)                     |
| Headache                                        | 30 28.0)                      | 154 25.3)                   | 184 25.7)                     |
| Dizziness                                       | 3 2.8)                        | 101 16.6)                   | 104 14.5)                     |
| Tremor                                          | 17 15.9)                      | 82 13.5)                    | 66 (13.8)                     |
| Imune_system disorders                          | 64 59.8)                      | 283 46.5)                   | 347 48.5)                     |
| Cytokine release syndrome                       | 63 58.9)                      | 254 41.8)                   | 317 44.3)                     |
| Hypogammaglobulinaemia                          | 2 1.9)                        | 61 ( 10.0)                  | 63 8.8)                       |
| Metabolism and nutrition disorders              | 25 23.4)                      | 292 (48.0)                  | 317 (44.3)                    |
| Decreased appetite                              | 5.6                           | 124 20.4)                   | 130 18.2)                     |
| Hypokalaemia                                    | 68 7.53                       | 100 16.4)                   | 108 15.1)                     |
| Hypomagmesaemia                                 | 4 3.7)                        | 86 (14.1)                   | 90 (12.6)                     |
| Musculoskeletal and connective tissue disorders | 33 30.8)                      | 244 (40.1)                  | 277 (38.7)                    |
| Arthralgia                                      | 10 9.3)                       | 66 10.9)                    | 76 10.6)                      |
| Back pain                                       | 5 4.7)                        | 65 （ 10.7)                  | 70 9.8)                       |
| Respiratory, thoracic and mediastinal disorders | 17 15.9)                      | 233 (38.3)                  | 250 ( 35.0)                   |
| Cough                                           | 7 6.5)                        | 91 15.0)                    | 98 (13.7)                     |
| Infections and infestations                     | 24 ( 22.4)                    | 208 ( 34.2)                 | 232 （32.4)                    |
| Psychiatric disorders                           | 16 (15.0)                     | 187 ( 30.8)                 | 203 (28.4)                    |
| Insommia                                        | 5 4.7)                        | 67 11.0)                    | 72 10.1)                      |
| Confusional state                               | 3 ( 2.8)                      | 66 (10.9)                   | 69 9.7)                       |
| Vascular disorders                              | 18 (16.8)                     | 184 (30.3)                  | 202 (28.3)                    |
| Hypotension                                     | 9(8.4)                        | 97 (16.0)                   | 106 (14.8)                    |
| Skin and subcutaneous tissue disorders          | 17 ( 15.9)                    | 154 ( 25.3)                 | 171 ( 23.9)                   |
| Investigations                                  | 26 ( 24.3)                    | 134 ( 22.0)                 | 160 ( 22.4)                   |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term             | 3L+FL(FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+IBCL Total N=608 n (%)   | Overall Total N = 715 n (%)   |
|-----------------------------------------------|---------------------------------------------|--------------------------------|-------------------------------|
| Carcliac disorders                            | 6 (5.6)                                     | 129 ( 21.2)                    | 135 ( 18.9)                   |
| Renal andurinary disorders                    | 4(3.7)                                      | 94 ( 15.5)                     | 98 (13.7)                     |
| Injury; poisoning and procecuralconplications | 3 (2.8)                                     | 83 (13.7)                      | 86 ( 12.0)                    |
| Eye disorders                                 | 4 (3.7)                                     | 67 ( 11.0)                     | 71 (9.9)                      |

CRS was graded based on the Lee criteria.? Other AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies. AEswerecodedusingMedDRAversion26.0.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC.

TEAEwas defined as anAE that startedanytimefrom initiation of liso-cel administration throughand including90days following thefinal doseof liso-cel.Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE. Source:Table3.2.1.1ofAppendix 2.

Grade 3 or Higher Treatment-emergent Adverse Events

Table 62. Grade 3 or Higher TEAEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class Preferred Termm   | 3L+FL（FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+IBCL Total N= 608 n (%)           | Overall Total N = 715 n (%)             |
|--------------------------------------|---------------------------------------------|-----------------------------------------|-----------------------------------------|
| SUBJECTSWITHANYGRADE3ORHIGHERTEAE    | 86 (80.4)                                   | 497 ( 81.7)                             | 583 ( 81.5)                             |
| Blood and lymphatic system disorders | 77 72.0) 67 62.6)                           | 460 75.7) 388 63.8) 203 33.4) 177 29.1) | 537 75.1) 455 63.6) 215 30.1) 191 26.7) |
| Neutropenia                          |                                             |                                         |                                         |
| Anaemia                              | 12 11.2)                                    |                                         |                                         |
| Thrambocytopenia                     | 14 13.1)                                    |                                         |                                         |
| Leukopenia                           | 11 10.3)                                    | 127 20.9)                               | 138 19.3)                               |
| Lymphopenia                          | 12 11.2)                                    | 63 (10.4)                               | 75 10.5)                                |
| Metabolism and nutrition disorders   | 2( 1.9)                                     | 80 (13.2)                               | 82 ( 11.5)                              |
| Infections andinfestations           | 7 ( 6.5)                                    | 73 (12.0)                               | 80 (11.2)                               |
| Nervoussystemdisorders               | 3 (2.8)                                     | 62  ( 10.2)                             | 65 (9.1)                                |

AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies. AEs were coded using MedDRA version 26.0. Asubjectwas countedonlyoncefor multipleeventswithin aPT/SOC.

Treatment-emergent Adverse Events Related to Liso-cel

Table 63. Liso-cel-Related TEAEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | 3L+FL(FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+ LBCL Total N = 608 n (%)   | Overall Total N = 715 n (%)   |
|------------------------------------------------------|---------------------------------------------|-----------------------------------|-------------------------------|
| SUBJECISWITHANYLISO-CELRELATEDTEAE                   | 96 ( 89.7)                                  | 486 (79.9)                        | 582 ( 81.4)                   |
| Imne system disorders                                | 64 4( 59.8)                                 | 274 ( 45.1)                       | 338 (47.3)                    |
| Cytokine release syndrcme                            | 63 ( 58.9)                                  | 254 (41.8)                        | 317 (44.3)                    |
| Blood and lymphatic system disorders                 | 67 62.6)                                    | 264 (43.4)                        | 331 46.3)                     |
| Neutropenia                                          | 54.2)                                       | 193 31.7)                         | 251 35.1)                     |
| Anaemia                                              | 30.8)                                       | 124 20.4)                         | 157 22.0)                     |
| Thrambocytopenia                                     | 8325 23.4)                                  | 122 20.1)                         | 147 20.6)                     |
| Leukopenia                                           | 7 .6.5)                                     | 68 11.2)                          | 75 10.5)                      |
| Lynphopenia                                          | 14 (13.1)                                   | 41 6.7)                           | 55 7.7)                       |
| General disorders and acministration site conditions | 31 ( 29.0)                                  | 198 ( 32.6)                       | 229 ( 32.0)                   |
| Fatigue                                              | 12 (11.2)                                   | 96 (15.8)                         | 108 (15.1)                    |
| Pyrexia                                              | 15 (14.0)                                   | 76 (12.5)                         | 91 (12.7)                     |
| Nervous system disorders                             | ( 23.4)                                     | 197 ( 32.4)                       | 222 (31.0)                    |
| Headache                                             | 251 10.3)                                   | 64 10.5)                          | 75 10.5)                      |
| Tremor                                               | 12 (11.2)                                   | 60 (6'6                           | 72 (10.1)                     |
| Gastrointestinal disorders                           | 12 ( 11.2)                                  | 83 (13.7)                         | 95 (13.3)                     |
| Psychiatric disorders                                | 10 (9.3)                                    | 84 (13.8)                         | 94 (13.1)                     |
| Metabolism and nutrition disorders                   | 12 (11.2)                                   | 54 (8.9)                          | 66 (9.2)                      |
| Investigations                                       | 16 ( 15.0)                                  | 45 (7.4)                          | 61 ( 8.5)                     |

CRS was graded based on the Lee criteria. Other AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies. AEswerecodedusingMedDRAversion26.0.

A subject was counted only once for multiple events within a PT/SOC.

TEAE was defined as an AE that started any time from initiation of liso-cel administration through and including 90 days following the final dose of liso-cel. Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE. Source:Tahle310 11ofAnnendix2.

Post Treatment-emergent Period Adverse Events

Table 64. Liso-cel-Related Grade 3 or Higher TEAEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class                                 | 3L+FL（FOL-001 Cohorts 1, 2) N = 107   | 2L/3L+IBCL Total N= 608   | Overall Total N= 715   |
|----------------------------------------------------|---------------------------------------|---------------------------|------------------------|
| Preferred Term                                     | n (%)                                 | n (%)                     | n (%)                  |
| SUBJECTSWITHANYLISO-CELRELATEDGRADE3OR HIGHER TEAE | 68 ( 63.6)                            | 285 ( 46.9)               | 353 (49.4)             |
| Blood and lymphatic system disorders               | 61 57.0)                              | 240 (39.5)                | 301 42.1)              |
| Neutropenia                                        | 52 48.6)                              | 181 (29.8)                | 233 32.6)              |
| Thrambocytopenia                                   | 10 9.3)                               | 96 ( 15.8)                | 106 (14.8)             |
| Anaemia                                            | 9 8.4)                                | 87 (14.3)                 | 96 (13.4)              |
| Lymphopenia                                        | 12 (11.2)                             | 35 5.8)                   | 47 6.6)                |

AEs (except CRS) were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies.

AEswerecodedusingMedDRAversion26.0.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC.

TEAE was defined as an AE that started any time from initiation of liso-cel administration through and including 90 days following the final dose of liso-cel. Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE. Source:Table3.10.1.2ofAppendix2.

Table 65. Overview of AEs - Post-treatment Emergent Period - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                 | 3L+FL(FOL-001 Cohorts 1, 2) N = 107                        | 2L/3L+ LBCL Total N = 559                                                                                           | Overall Total N= 666                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| DURATION OF PERIOD(DAYS)，MEDIAN (RANGE)                                                                                                                         | 740.0 (25-1042)                                            | 359.0 (2-1287)                                                                                                      | 452.0 (2-1287)                                                                                                        |
| SUBJECTSWITHANYAE SUBJECTS WITHANY GRADE3-4AE SUBJECTS WITHANYGRADE3-5AE SUBJECTS WITH ANY GRADE 5 AE SUBJECTSWITHANYSERIOUSAE SUBJECIS WITH ANY LDC-RELATED AE | 37 34.6) 18 16.8) 21 19.6) 3 2.8) 17 15.9) 11 10.3) 4 3.7) | 254 45.4) 124 22.2) 143 25.6) 19 3.4) 85 15.2) 68 15.9) 51 9.1) 56 10.0) 5 0.9) 25 4.5) 111 19.9) 56 10.0) 60 10.7) | 291 43.7) 142 21.3) 164 24.6) 22 3.3) 102 (15.3) 100 15.0) 55 8.3) 61 9.2) 6 0.9) 28 4.2) 137 20.6) 69 10.4) 74 11.1) |
| SUBJECIS XNHLIM LDC-RELATED GRADE 3-4AE                                                                                                                         |                                                            |                                                                                                                     |                                                                                                                       |
| SUBJECISWITHANY1 LDC-RELATED GRADE3-5AE                                                                                                                         | 5 4.7)                                                     |                                                                                                                     |                                                                                                                       |
| SUBJECISWITHANYLDC-RELATED GRADE 5 AE                                                                                                                           | 1 0.9)                                                     |                                                                                                                     |                                                                                                                       |
| SUBJECISWITHANYLDC-RELATEDSERIOUSAE                                                                                                                             | 3 2.8)                                                     |                                                                                                                     |                                                                                                                       |
| SUBJECTSWITHANYJCARO17-RELATEDAE                                                                                                                                | 26 (24.3)                                                  |                                                                                                                     |                                                                                                                       |
| SUBJECIS WITH ANY JCAR017-RELATED GRADE3-4AE                                                                                                                    | 13 12.1)                                                   |                                                                                                                     |                                                                                                                       |
| SUBJECTS WITH ANY JCAR017-RELATED GRADE 3-5AE                                                                                                                   | 14 13.1)                                                   |                                                                                                                     |                                                                                                                       |
| SUBJECIS WITH ANY JCAR017-RELATED GRADE 5 AE                                                                                                                    | 1 0.9)                                                     | 4 0.7)                                                                                                              | 5 0.8)                                                                                                                |
| SUBJECTSWITHANYJCARO17-RELATEDSERIOUSAE                                                                                                                         | 9 8.4)                                                     | 22 3.9)                                                                                                             | 31 4.7)                                                                                                               |

AEs(except CRS) were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies.

The most severe grade was used for AEs that occurred more than once in an individual subject during the period.

Post treatment-emergent period started from 91 days post final liso-cel infusion or initiation of subsequent anticancer therapy/product retreatment if subject initiated subsequent anticancertherapy/productretreatmentpriortoStudyDay91.

Source: Table 3.1.3.1 of Appendix 2.

Table 66. AEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects - Post-treatment Emergent Period - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class Preferred Temm              | 3L+FL(FOL-001 Cohorts 1,2) N = 107 n (%)   | 2L/3L+IBCL Total N=559 n (%)   | Overall Total N= 666 n (%)   |
|------------------------------------------------|--------------------------------------------|--------------------------------|------------------------------|
| SUBJECISWIIHANYAEPOSTTREATMENT-EMERGENT PERIOD | 37 (34.6)                                  | 254 ( 45.4)                    | 291 (43.7)                   |
| Bloodandlymphaticsystemclisorders Neutropenia  | 16 ( 15.0) 12 ( 11.2)                      | 133 (23.8) 66 ( 11.8)          | 149 (22.4) 78 ( 11.7)        |
| Infections and infestations                    | 15 ( 14.0)                                 | 61 ( 10.9)                     | 76 ( 11.4)                   |

AEswerecodedusingMedDRAversion26.0.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC.

Post treatment-emergent period started from 91 days post final liso-cel infusion or initiation of subsequent anticancer therapy/product retreatment if subject initiated subsequent anticancer therapy/product retreatment prior to Study Day 91.

Source: Table 3.7.1.1 of Appendix 2.

Table 67. Grade 3 or Higher AEs by SOC and PT Reported in ≥ 10% of FL or LBCL Subjects Post-treatment Emergent Period - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class PreferredlTermm                           | 3L+FL（FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+IBCL Total N=559 n (%)   | Overall Total N= 666 n (%)   |
|--------------------------------------------------------------|---------------------------------------------|--------------------------------|------------------------------|
| SUBJECTSWITHANYGRADE3ORHIGHERAEPOST TREATMENT-EMERGENTPERIOD | 21 (19.6)                                   | 143 ( 25.6)                    | 164 ( 24.6)                  |
| Blood and lymphatic system disorders                         | 10 (9.3)                                    | 97 ( 17.4)                     | 107 ( 16.1)                  |

AEswere codedusingMedDRAversion26.0.

AsubjectwascountedonlyonceformultipleeventswithinaPT/SoC

Posttreatment-emergentperiodstartedfrom91dayspostfinalliso-celinfusionorinitiationofsubsequent anticancertherapy/productretreatmentifsubjectinitiated subsequent anticancertherapy/productretreatmentpriortoStudyDay91.

Source:Table3.8.1.1 ofAppendix 2.

## Deaths

Table 68. Summary of Deaths - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                                                                                        | 3L+FL（FOL-001 Cohorts1,2) N = 107   | 2L/3L+ LBCL Total N = 608   | Overall Total N = 715   |
|----------------------------------------------------------------------------------------|-------------------------------------|-----------------------------|-------------------------|
| DEATHS OCCURRED AFTER FIRST LISO-CEL INFUSION                                          | 12 ( 11.2)                          | 258 ( 42.4)                 | 270 ( 37.8)             |
| PRIMARY CAUSE OF DEATH                                                                 | 7 （ 6.5)                            | 206 （ 33.9)                 | 213 29.8)               |
| DISEASE PROGRESSION ADVERSE EVENT                                                      | 2 1.9)                              | 23 3.8)                     | 25 3.5)                 |
| COVID-19                                                                               | 2 1.9)                              | 9 1.5)                      | 11 1.5)                 |
| UNKNOWN                                                                                | 0                                   | 6 1.0)                      | 6 0.8)                  |
| OTHER (A)                                                                              | 1 0.9)                              | 14 （ 2.3)                   | 15 2.1)                 |
| DEATHS OCCURRED AFTER FIRST LISOCEL INFUSION AND WITHIN 30 DAYS POST LISO-CEL INFUSION | 0                                   | 12( 2.0)                    | 12 1.7)                 |
| PRIMARY CAUSE OF DEATH                                                                 |                                     |                             |                         |
| DISEASE PROGRESSION                                                                    | 0                                   | 1.2)                        | 7 1.0)                  |
| ADVERSE EVENT                                                                          | 0                                   | 5 0.8)                      | 5 0.7)                  |
| COVID-19                                                                               |                                     |                             |                         |
| UNKNOWN                                                                                |                                     | 0                           | 0                       |
| OTHER (A)                                                                              | 0                                   | 0                           | 0                       |
| DEATHS OCCURRED BETWEEN 31 AND 90 DAYS POST LISO-CEL INFUSION                          | 0                                   | 457.4）                      | 45 ( 6.3)               |
| PRIMARY CAUSE OF DEATH                                                                 |                                     |                             |                         |
| DISEASE PROGRESSION                                                                    | 0                                   | 31 5.1)                     | 31 4.3)                 |
| ADVERSE EVENI                                                                          | 0                                   | 9 1.5)                      | 9 1.3)                  |
| COVID-19                                                                               |                                     | 2 0.3)                      | 2 0.3)                  |
| UNKNOWN                                                                                | 0                                   | 2 0.3)                      | 2 0.3)                  |
| OTHER (A)                                                                              | 0                                   | 1 0.2)                      | 1 0.1)                  |
| DEATHS OCCURRED FROM 91 DAYS POST LISO-CEL INFUSICN UNTIL THE END OF STUDY             | 12 ( 11.2)                          | 201 ( 33.1)                 | 213 ( 29.8)             |
| PRIMARY CAUSE OF DEATH                                                                 |                                     |                             |                         |
| DISEASE PROGRESSION                                                                    | 7 6.5)                              | 168 ( 27.6)                 | 175 (24.5)              |
| ADVERSE EVENT                                                                          | 2 1.9)                              | （ 1.5)                      | 11 1.5)                 |
| COVID-19                                                                               | 2 1.9)                              | 1.2)                        | 9 1.3)                  |
| UNKNOWN                                                                                | 0                                   | 4 0.7)                      | 4 0.6)                  |
| OTHER(A)                                                                               | 1 ( 0.9)                            | 13 （ 2.1)                   | 14 2.0)                 |

## Treatment-emergent Serious Adverse Events

The most commonly reported treatment-emergent SAEs were consistent in Liso-cel Treated Set subjects with 3L+ FL and 2L/3L+ LBCL; the frequency of treatment-emergent SAEs was lower in 3L+ FL than 2L/3L+ LBCL (see Table below).

Table 69. Treatment-emergent SAEs by SOC and PT Reported in ≥ 2% of FL or LBCL Subjects - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

| System Organ Class Preferred Term                                 | 3L+FL(FOL-001 Cohorts 1, 2) N = 107 n (%)   | 2L/3L+IBCL Total N = 608 n (%)   | Overall Total N = 715 n (%)   |
|-------------------------------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------|
| SUBJECTSWITHANYSERIOUSTEAE                                        | 27 ( 25.2)                                  | 260 ( 42.8)                      | 287 (40.1)                    |
| Imune system disorders                                            | 11 10.3)                                    | 101 (16.6)                       | 112 （ 15.7)                   |
| Cytokine release syndrome                                         | 11 i 10.3)                                  | 100 16.4)                        | 111 15.5)                     |
| Nervous system disorders                                          | 5.6)                                        | 12.8)                            | 11.7)                         |
| Aphasia                                                           | ６4０3 3.7)                                   | 2.8)                             | 2.9)                          |
| Encephalopathy                                                    |                                             | 3.3)                             | 2.8)                          |
| Tremor                                                            | 2.8)                                        | 2.3)                             | 忆亿 2.4)                       |
| Infections and infestations                                       | 7 6.5)                                      | 10.0)                            | 9.5)                          |
| Pneumonia                                                         | 0.9)                                        | 6:3 2.1)                         | 矶9 2.0)                       |
| Blood and lymphatic system disorders                              | 54１0                                        | 7.9)                             | 7.4)                          |
| Febrile neutropenia                                               |                                             | 6                                |                               |
| Neutropenia                                                       |                                             | 82:9:17                          |                               |
| Thrombocytopenia                                                  |                                             | 2.8)                             | 2.4)                          |
| Psychiatric disorders                                             | 4.7)                                        | 39 6.4)                          | 44 6.2)                       |
| Confusional state                                                 | ( 1.9)                                      | 19 3.1)                          | 21 2.9)                       |
| General disorders and acministration site conditions              | 3( 2.8)                                     | 29 4.8)                          | 32 （ 4.5)                     |
| Pyrexia                                                           | 3 （ 2.8)                                    | 21 3.5)                          | 24 3.4)                       |
| Gastrointestinal disorders                                        | 1 0.9)                                      | 28 4.6)                          | 220171515 4.1)                |
| Respiratory, thoracic and mediastinal disorders Cardiac disorders | 12 0.9) 1.9)                                | 19151515 3.1) 2.5 5)             | 2.8)                          |
| Musculoskeletal and connective tissue disorders                   |                                             | 2.5 5)                           | 2.4) 2.1)                     |
| Vascular disorders Metabolism and nutrition disorders             | 00                                          | 1512                             | 12                            |
|                                                                   |                                             | 2.5 5) 2.0)                      |                               |

CRS was graded based on the Lee criteria.? Other AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies.

AEs were coded using MedDRA version 26.0.

A subject was counted only once for multiple events within a PT/SOC.

TEAEwasdefinedasanAEthatstartedanytimefrominitiationofliso-celadministrationthroughandincluding90daysfollowingthefinaldoseofliso-cel.Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE. Source: Table 3.6.1.1 of Appendix 2.

## Other Significant Adverse Events of Special Interest

<div style=\"page-break-after: always\"></div>

In Liso-cel Treated Set subjects with 3L+ FL, the most frequently occurring AESIs known to be associated with the therapeutic class of CAR T-cell therapies were CRS (58.9% vs. 41.8% in 2L/3L+ LBCL) and NT (15.9% vs. 24.8% in 2L/3L+ LBCL). Most CRS and NT AESIs were mild to moderate in severity (Grade 1-2); no Grade 5 incidences of either AESI were reported. No subjects had AESIs of IRR, MAS, or TLS. Most AESIs were assessed as liso-cel-related by the investigator.

In Liso-cel Treated Set subjects with 3L+ FL, the incidences of Grade ≥ 3 SPM and hypogammaglobulinemia reported were 0.9% (vs. 0.7% in 2L/3L+ LBCL) and 0% (vs. 0.2% in 2L/3L+ LBCL), respectively, for the treatment-emergent period and 4.7% (vs. 3.4% in 2L/3L+ LBCL) and 0.9% (vs. 0% in 2L/3L+ LBCL), respectively, for the post-treatment-emergent period.

No incidence  of  autoimmune  disorders  was  reported  in  3L+  FL  during  treatment-emergent  or  posttreatment-emergent periods.

The frequency of Grade 3-4 infections and infestations was lower in Liso-cel Treated Set subjects with 3L+ FL compared with 2L/3L+ LBCL (6.5% vs 12%). In 3L+ FL, the most common Grade 3-4 infection and infestation was infections - pathogen unspecified (4.7% subjects); there were no Grade 5 infections and infestations TEAEs.

The  rate  of  prolonged  cytopenia  at  Day  29  was  lower  in  Liso-cel  Treated  Set  subjects  with  3L+  FL compared with 2L/3L+ LBCL (24.3% vs 35.7%, respectively).

## Clinical Laboratory Evaluations in 3L+ FL and 2L/3L+ LBCL

## Hematology

In  Liso-cel  Treated  Set  subjects  with  3L+  FL,  the  changes  in  hematology  laboratory  results  were consistent with the receipt of anticancer therapy for disease control and LDC prior to liso-cel treatment, followed by the expected recovery.

Table  70.  New  or  Worsening  Laboratory  Abnormalities  by  Laboratory  Shift  Treatmentemergent Hematology Laboratory Results - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                            | Subjects with Baseline Result, n   | Subjects with Baseline and at least one Post-baseline   |                            |                                    |                        |                           |
|----------------------------|------------------------------------|---------------------------------------------------------|----------------------------|------------------------------------|------------------------|---------------------------|
|                            |                                    | Result, n                                               | All Grade n (号)            | Grade 3 n (%)                      | Grade 4 n (%)          | Grade 3-4 n (号)           |
| 3L+FLFOL-001Cohorts1，2     |                                    |                                                         |                            |                                    |                        |                           |
| NEUTROPHILCOUNT DECREASED  | 107 107                            | 107 107                                                 | 81 75.7) 64 59.8) 48 44.9) | 17 15.9) 21 19.6) 10 9.3) 440 3.7) | 50 46.7) 27 25.2) 9.3) | 67 62.6) 48 44.9) 10 9.3) |
| WHITE BLOOD CELL DECREASED |                                    |                                                         |                            |                                    |                        |                           |
| ANEMIA                     | 107                                | 107                                                     |                            |                                    |                        |                           |
| PLATELET COUNTDECREASED    | 107                                | 107                                                     | 43 40.2)                   |                                    |                        | 14 13.1)                  |
| LYMPHOCYTE COUNT DECREASED | 107                                | 107                                                     | 8 7.5)                     | 3.7)                               | 1.9)                   | 5.6)                      |
| LYMPHOCYTE COUNT INCREASED | 107                                | 107                                                     | 0                          |                                    |                        | 60                        |
| 2L/3L+LBCLTotal            |                                    |                                                         |                            |                                    |                        |                           |
| NEUTROPHILCOUNTDECREASED   | 608                                | 608                                                     | 483 79.4)                  | 146 24.0)                          | 294 48.4)              | 440 72.4)                 |
| PLATELET COUNT DECREASED   | 608                                | 608                                                     | 401 66.0)                  | 88 14.5)                           | 130 21.4)              | 218 35.9)                 |
| WHITE BLOOD CELL DECREASED | 608                                | 608                                                     | 362 59.5)                  | 132 21.7)                          | 199 32.7)              | 331 54.4)                 |
| ANEMIA                     | 608                                | 608                                                     | 313 51.5)                  | 137 22.5)                          | 0                      | 137 22.5)                 |
| LYMPHOCYTE COUNT DECREASED | 594                                | 592                                                     | 4.4)                       | 6 1.0)                             | 20 3.4)                | 26 4.4)                   |
| LYMPHOCYTE COUNT INCREASED | 594                                | 592                                                     | 26 12 2.0)                 | 0                                  | 0                      | 0                         |
| Overall Total              |                                    |                                                         |                            |                                    |                        |                           |
| NEUTROPHIL COUNTDECREASED  | 715                                | 715                                                     | 564 78.9)                  | 163 22.8)                          | 344 48.1)              | 507 70.9)                 |
| PLATELET COUNT DECREASED   | 715                                | 715                                                     | 444 62.1)                  | 92 12.9)                           | 140 19.6)              | 232 32.4)                 |
| WHITE BLOOD CELLDECREASED  | 715                                | 715                                                     | 426 59.6)                  | 153 21.4)                          | 226 31.6)              | 379 53.0)                 |
| ANEMIA                     | 715                                | 715                                                     | 361 50.5)                  | 147 20.6)                          | 0                      | 147 (20.6)                |
| LYMPHOCYTE COUNT DECREASED | 701                                | 669                                                     | 34 4.9)                    | 10 1.4)                            | 22 3.1)                | 32 4.6)                   |
| LYMPHOCYTE COUNT INCREASED | 701                                | 699                                                     | 12 1.7)                    | 0                                  | 0                      | 0                         |

A treatment-emergent laboratory abnormality was defined as an abnormality that, compared to baseline, worsened by ≥ 1 grade after product infusion and up to 90 days post product infusion. Any laboratory abnormality occurring after the initiation of subsequent anticancer therapy or retreatment were not considered as treatment-emergent.

Baseline was thelast observation collected prior to or on the date of product infusion.

Toxicity grade was determined based on CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies.

Thepercentagewascalculatedbased on thenumber of subjectswithbaseline andatleast onepost-baselineresult.

Source: Table 5.2.1.1 of Appendix 2.

## Clinical Chemistry

In Liso-cel Treated Set subjects with 3L+ FL, most chemistry parameters remained stable over time. Grade 3-4 clinical chemistry laboratory abnormalities were generally lower in the 3L+ FL than 2L/3L+ LBCL. The most frequent Grade 3-4 new or worsening chemistry laboratory abnormality in subjects with FL  was  increased  blood  bilirubin  in  2  (1.9%)  subjects  (see  Table  below).  The  frequency  of  new  or worsening abnormalities in fibrinogen (decreases) was lower in Liso-cel Treated Set subjects with 3L+ FL than in subjects with 2L/3L+ LBCL (all grade 16.3% vs 47%, respectively).

Table  71.  New  or  Worsening  Laboratory  Abnormalities  by  Laboratory  Shift  Treatmentemergent Chemistry Laboratory Results - Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL

<div style=\"page-break-after: always\"></div>

|                                     | Subjects with Baseline   | Subjects with Baseline and at least one Post-baseline   | m               | m             | m    | m             | m               |
|-------------------------------------|--------------------------|---------------------------------------------------------|-----------------|---------------|------|---------------|-----------------|
|                                     | Result, n                | Result, n                                               | All Grade n (%) | Grade 3 n (%) |      | Grade 4 n (%) | Grade 3-4 n (号) |
| 3L+FLFOL-001Cohorts1，2              |                          |                                                         |                 |               |      |               |                 |
| ALANINEAMINOTRANSFERASE INCREASED   | 107                      | 107                                                     | 37 ( 34.6)      | 0             |      | 0             | 0               |
| ASPARTATEAMINOTRANSFERASE INCREASED | 107                      | 107                                                     | 30 (28.0)       | 0             |      | 0             | 0               |
| BLOOD BILIRUBIN INCREASED           | 107                      | 107                                                     | 25 (23.4)       | 2             | 1.9) | 0             | 2 1.9)          |
| HYPONATREMIA                        | 107                      | 107                                                     | 22 20.6)        | 0             |      | 0             | 00              |
| CREATININE INCREASED                | 107                      | 107                                                     | 19 17.8)        | 0             |      | 0             |                 |
| HYPOALBUMINEMIA                     | 107                      | 107                                                     | 17 15.9)        | 0             |      | 0             | 0               |
| HYPOKALEMIA                         | 107                      | 107                                                     | 16 15.0)        | 1             | 0.9) | 0             | 1 0.9)          |
| HYPOMAGNESEMIA                      | 107                      | 105                                                     | 15 14.3)        | 0             |      | 0             |                 |
| HYPERKALFMIA                        | 107                      | 107                                                     | 7 6.5)          | 0             |      | 0             | 0 0 0           |
| HYPERNATREMIA                       | 107                      | 107                                                     | 5 4.7)          | 0             |      | 0             |                 |
| HYPERMAGNESEMIA                     | 107                      | 105                                                     | 3.8)            | 1             | 1.0) | 0             | 1( 1.0)         |
| HYPERURICEMIA                       | 102                      | 100                                                     | N.A.            | N.A.          |      | N.A.          | N.A.            |
| HYPOPHOSPHATEMIA                    | 105                      | 105                                                     | N.A.            | N.A.          |      | N.A.          | N.A.            |
| 2L/3L+ LBCL Total                   |                          |                                                         |                 |               |      |               |                 |
| HYPOPHOSPHATEMIA                    | 608                      | 608                                                     | 189 31.1)       | 63126         | 9.9  | 3 0.5)        | 63 12.4         |
| HYPONATREMIA                        | 608                      | 608                                                     | 174 28.6)       |               | 5.3) | 0             | 32 5.3)         |
| HYPOALBUMINEMIA                     | 608                      | 608                                                     | 171 (28.1)      |               | 2.0) | 0             | 12 2.9          |
| ALANINEAMINOTRANSFERASE INCREASED   | 608                      | 608                                                     | 156 ( 25.7)     |               | 1.0) | 1 0.2)        | 7 ( 1.2)        |
| HYPOKALEMIA                         | 608                      | 608                                                     | 137 (2 22.5)    | 151           | 2.5) | 0             | 15 ! 2.5)       |
| ASPARTATEAMINOTRANSFERASE INCREASED | 608                      | 608                                                     | 135 (22.2)      | 7             | 1.2) | 0             | 77 1.2)         |
| HYPOMAGNESEMIA                      | 608                      | 608                                                     | 116 （ 19.1)     | 0             |      |               | 0               |
| CREATININE INCREASED                | 608                      | 608                                                     | 84 13.8)        |               | 8:33 | 00            | 8:33            |
| HYPERMPGNESEMIA                     | 608                      | 608                                                     | 52 8.6)         |               |      |               |                 |

| Subjects with Baseline Result,n   | Subjects with Baseline and at least   |
|-----------------------------------|---------------------------------------|

Baseline was the last observation collected prior to or on the date of product infusion.

A treatment-emergent laboratory abnormality was defined as an abnormality that, compared to baseline, worsened by ≥1 grade after product infusion and up to 90 days post product infusion. Any laboratory abnormality occurring after the initiation of subsequent anticancer therapy or retreatment were not considered as treatment-emergent.

The percentage was calculated based on the number of subjects with baseline and at least one post-baseline result.

Toxicity grade was determined based on CTCAE version 5.0 for Study FOL-001 and version 4.03 for all other studies.

Source: Table 5.2.2.1 of Appendix 2.

## Liso-cel Treated Set in 2L+ FL and 2L/3L+ LBCL

Safety data from Cohorts 1, 2, and 3 of Study FOL-001 (2L+ FL subjects; n= 130) were analyzed sideby-side with pooled safety data for liso-cel monotherapy treated subjects with 2L/3L+ LBCL (n= 608) (see Table below):

- 1 (0.8%) death was reported as occurring within 30 days after the first liso-cel infusion in 2L+ FL. Deaths of subjects reported at any time after the first liso-cel infusion were 9.2% in liso-cel Treated Set subjects with 2L+ FL and 42.4% in subjects with 2L/3L+ LBCL and most of the deaths reported after the first liso-cel infusion were due to disease progression in both FL and LBCL.

<div style=\"page-break-after: always\"></div>

- The frequency of any grade or Grade 3-4 TEAEs regardless of causality was consistent between subjects with 2L+ FL (99.2% and 76.2%, respectively) and 2L/3L+ LBCL (99.0% and 79.3%, respectively).
- The frequency of all-cause SAEs was lower in subjects with 2L+ FL (23.8%) than 2L/3L+ LBCL (42.8%).
- As for 3L+ FL, the frequency of liso-cel-related any grade and Grade 3-4 TEAEs was higher in subjects with 2L+ FL (88.5% and 61.5%, respectively) than 2L/3L+ LBCL (79.9% and 45.6%, respectively),  but  the  frequency  of  liso-cel  related  SAEs  was  lower  in  subjects  with  2L+  FL (18.5%) than 2L/3L+ LBCL (29.8%).
- As for 3L+ FL, Grade 1-2 CRS was higher in 2L+ FL subjects than 2L/3L+ LBCL (56.9% vs 40.1%, respectively).  However,  the  frequencies  of  Grade  3-4  AESIs  of  CRS  and  iiNT  were  lower  in subjects with 2L+ FL (0.8% and 2.3% subjects, respectively) than 2L/3L+ LBCL (1.6% and 8.4% subjects, respectively).

Table 72. Summary of Safety in Pooled Studies - Liso-cel Treated Set in 2L+ FL (FOL-001) and 2L/3L+ LBCL

| SafetyParameter                             | 2L+FL (FOL-001 Cohorts 1,2,3) N =130   | 2L/3L+LBCL Total N =608   | Overall Total N=738   |
|---------------------------------------------|----------------------------------------|---------------------------|-----------------------|
| Deaths Occurred AfterFirstLiso-cel Infusion | 12 (9.2)                               | 258 (42.4)                | 270 (36.6)            |
| Primary Cause of Death PD                   | 6 (4.6)                                | 206 (33.9)                | 212 (28.7)            |
| AE                                          | 3 (2.3)                                | 23 (3.8)                  | 26 (3.5)              |
| COVID-19                                    | 2 (1.5)                                | 9 (1.5)                   | 11 (1.5)              |
| Unknown                                     | 0                                      | 6 (1.0)                   | 6 (0.8)               |
| Othera                                      | 1 (0.8)                                | 14 (2.3)                  | 15 (2.0)              |
| Subjects with any TEAE                      | 129 (99.2)                             | 602 (99.0)                | 731 (99.1)            |
| Grade 3-4                                   | 99 (76.2)                              | 482 (79.3)                | 581 (78.7)            |
| Grade ≥3                                    | 100 (76.9)                             | 497 (81.7)                | 597 (80.9)            |
| Grade 5                                     | 1 (0.8)                                | 15 (2.5)                  | 16 (2.2)              |
| Serious                                     | 31 (23.8)                              | 260 (42.8)                | 291 (39.4)            |
| SubjectswithanyLDC-related TEAE             | 98 (75.4)                              | 498 (81.9)                | 596 (80.8)            |
| LDC-related Grade3-4                        | 81 (62.3)                              | 419 (68.9)                | 500 (67.8)            |
| LDC-related Grade≥3                         | 81 (62.3)                              | 427 (70.2)                | 508 (68.8)            |
| LDC-related Grade5                          | 0                                      | 8 (1.3)                   | 8 (1.1)               |
| LDC-related Serious                         | 8 (6.2)                                | 67 (11.0)                 | 75 (10.2)             |
| SafetyParameter                             | 2L+FL (FOL-001 Cohorts 1,2,3) N =130   | 2L/3L+LBCL Total N=608    | Overall Total N=738   |
| Subjectswith anyLiso-cel-related TEAE       | 115 (88.5)                             | 486 (79.9)                | 601 (81.4)            |
| Liso-cel-related Grade3-4                   | 80 (61.5)                              | 277 (45.6)                | 357 (48.4)            |
| Liso-cel-related Grade≥3                    | 81 (62.3)                              | 285 (46.9)                | 366 (49.6)            |
| Liso-cel-related Grade 5                    | 1 (0.8)                                | 8 (1.3)                   | 9 (1.2)               |
| Liso-cel-related Serious                    | 24 (18.5)                              | 181 (29.8)                | 205 (27.8)            |
| Subjectswith any treatment-emergentAESI     |                                        |                           |                       |
| CRS                                         | 75 (57.7)                              | 254 (41.8)                | 329 (44.6)            |
| Grade 1-2                                   | 74 (56.9)                              | 244 (40.1)                | 318 (43.1)            |
| Grade 3-4                                   | 1 (0.8)                                | 10 (1.6)                  | 11 (1.5)              |
| iNT                                         | 20 (15.4)                              | 151 (24.8)                | 171 (23.2)            |
| Grade 1-2                                   | 17 (13.1)                              | 100 (16.4)                | 117 (15.9)            |
| Grade 3-4                                   | 3 (2.3)                                | 51 (8.4)                  | 54 (7.3)              |
| IRR                                         | 0                                      | 6 (1.0)                   | 6 (0.8)               |
| MAS                                         | 1 (0.8)                                | 4 (0.7)                   | 5 (0.7)               |
| TLS                                         | 0                                      | 2 (0.3)                   | 2 (0.3)               |
| Grade≥3infections                           | 7 (5.4)                                | 73 (12.0)                 | 80 (10.8)             |

Refer to Listing 2.7.5 in Appendix 2 ofthe Module 2.7.4 SCs29 for details.

Other AEs were graded using CTCAE version 5.0 for Study FOL-001 and version 4.03 for al1 other studies.

The most severe grade was used for AEs that occur more than once in an individual subject during the period.

TEAE was defined as an AE that started any time from initiation of liso-cel administration through and including 90 days following the final dose of liso-cel.Any AE occurring after the initiation of subsequent anticancer therapy or liso-cel retreatment or start of combination therapy (BCM-002) was not considered as a TEAE.

Source: Table 6.2-1 of the Module 2.7.4 SCS, Table 3.9.1.2.1, Table 4.1.1.10.1 from Appendix 3 of the Module 2.7.4 SCS

<div style=\"page-break-after: always\"></div>

## Safety to support the Product Information

The approved dose range of liso-cel in the SmPC is 44 to 120 × 10 6  CAR+ T cells. Thus, pooled safety analyses were performed for 691 subjects receiving liso-cel dose in the range of 44 to 120 × 10 6  CAR+ T cells. These analyses included subjects with 2L+ FL (n= 130; from Study FOL-001), 2L LBCL (n= 177; from studies BCM-003 [Arm B], 017006, and BCM-001 [Cohort 2]), and 3L+ LBCL (n= 384; from studies BCM-001 [Cohorts 1, 3, and 7], 017001, 017007, and BCM-002). ADRs represent all reported TEAEs across LBCL disease histologies and are not restricted to AEs deemed related by the investigator. All grouped terms and PTs are reported with a frequency of 1% or greater in the ADR table (see section 4.8 of the SmPC). Other clinically important ADRs that occurred in less than 1% of subjects treated with liso-cel are included in the ADR table as footnotes.

## Safety related to drug-drug interactions and other interactions

Liso-cel is a cellular product that is generally administered as a one-time infusion. Being a cellular product, liso-cel is not cleared by the usual mechanisms that apply to small molecules or antibodies. No controlled clinical studies have been performed to directly address drug interactions with liso-cel.

## Discontinuation due to adverse events

Given that liso-cel was administered as a single dose for all subjects in Study FOL-001 and follow-up continued for subjects regardless of AEs, this analysis is not applicable.

## Post marketing experience

Liso-cel was approved in the EU for the treatment of adult patients with 3L+ R/R LBCL on 04 Apr-2022 (EMEA/H/C/004731). A Type II variation for extension of indication to include 2L LBCL was approved on 28-Apr-2023. Review of available post-marketing data presented in the most recent Periodic Benefit-Risk Evaluation Report (reporting period 05-Aug-2023 through 04-Feb-2024) did not reveal any significant safety/efficacy concerns that changed the existing benefit-risk profile of liso-cel. The post-marketing data were consistent with the safety profile of liso-cel as previously reported and described in the approved product label.

## 2.6.1. Discussion on clinical safety

For this proposed indication (R/R FL after 2 or more lines of systemic therapy), the safety evaluation was primarily based on the safety data from the Study FOL-001 as of data cutoff of 10-Jan-2024.

All the analysis provided and described in the sections above allow for comparison of the safety profile of liso cel in 3L+ FL (proposed indication) and 2L+ FL (overall FL treated subjects) to the known safety profile of liso-cel in the approved SmPC.

In Study FOL-001, the exposure to liso-cel was adequate and in line with EU SmPC recommendations (i.e., 44 to 120 × 10 6  CAR+ T cells).

As of the data cut-off date of 10-Jan-2024, with a median follow-up of 29.72 (min, max: 0.3, 39.6) months, no new safety concerns with liso-cel were identified in subjects with R/R 2L+ FL.

In the Liso-cel-treated Analysis Set (n= 130), TEAEs occurred in 99.2% of subjects; serious TEAEs occurred in 23.8% of subjects and Grade ≥3 TEAEs occurred in 76.9% of subjects. Most TEAEs were related to liso-cel (115 [88.5%] subjects) or LDC (98 [75.4%] subjects).

<div style=\"page-break-after: always\"></div>

Liso-cel safety profile was consistent across all cohorts (lines of therapy), i.e., Cohort 1 (4L+ FL), Cohort 2 (3L FL), and Cohort 3 (2L FL) (with the exception of lower rate of Grade ≥3 TEAE and any serious TEAE in 2L FL, 60.9% and 17.4%, respectively) and across all groups, i.e., Cohorts 1 and 2 (3L+ FL) and Cohorts 1, 2, and 3 (2L+ FL). TEAEs that led to death occurred in 1 (0.8%) subject (additional details are reported in 'Death' section).

Liso-cel-related TEAEs occurred in 115 (88.5%) subjects overall. In 3L+ FL subjects (n= 107), lisocel TEAEs occurred in 89.7% of subjects and the most common SOCs were blood and lymphatic system disorders (62.6% of subjects), immune system disorders (59.8% of subjects), and general disorders and administration site conditions (29.0% of subjects). These results were consistent with 2L+ FL subjects, and no major differences were observed between 4L+ FL, 3L FL, and 2L subjects.

Liso-cel-related Grade ≥3 TEAEs occurred in 81 (62.3%) subjects overall and the most frequently reported Grade ≥3 TEAEs (≥ 10% subjects) were neutropenia (47.7%) and lymphopenia (11.5%).

Deaths were mainly due to disease progression. In the Leukapheresed (ITT) Set (n= 139), 16 (11.5%) subjects died during study: 1 (0.7%) subject from Cohort 1 died after LDC and before liso-cel infusion (due  to  acute  respiratory  failure,  assessed  by  the  investigator  as  not  related  to  liso-cel/LDC/study procedure); 1 (0.7%) subject from Cohort 3 died after liso-cel infusion, within 30 days after liso-cel infusion (due to occurrence of HLH assessed as related to liso-cel treatment by the investigator); 14 (10.1%) subjects died after the 90-day post-infusion period (from Day 91 after infusion; mainly due to disease  progression).  One  subject  from  Cohort  1  died  due  to  PML  on  Day  190  and  this  event  was considered as related to fludarabine and liso-cel by the investigator. Of note, the subject had undergone four prior lines of systemic therapy, including anti-CD20 antibodies (rituximab and obinatuzamab), which are known to associate with development of PML.

A total of 4 (2.9%) subjects died from AEs, the PTs included: AML, PML, HLH, and acute respiratory failure (hypoxic).

A total of 3 (2.2%) subjects died from other causes, which included: COVID-19, COVID-19 pneumonia, and erythema multiforme.

The COVID-19 rate  and severity were in the expected range for the FL population and overall, the impact of the COVID-19 pandemic on study conduct was limited.

One (0.7%) subject died due to a cardiac event (heart failure, reported as an AE not related to liso-cel). One (0.8%) subject experienced a TEAE that led to death: Hemophagocytic lymphohistiocytosis (HLH) in the 2L FL cohort assessed as related to liso-cel treatment by the investigator. No additional information has  been  provided  on  this  subject.  However,  HLH/MAS  is  adequately  reported  in  the  current  SmPC (section 4.4) and RMP and no updates to the existing SmPC are required based on this fatal case.

AESIs occurred in 87 (66.9%) subjects with 2L+ FL and 72 (67.3%) subjects with 3L+ FL. The frequency of AESIs was consistent across cohorts (lines of therapy) and groups. There were no AESIs in the IRR, TLS, and autoimmune disorder categories. The majority of AESIs were mild to moderate in severity and manageable with protocol-specified guidelines and/or local standard of care.

Cytokine Release Syndrome (CRS). In the Liso-cel-treated Analysis Set (n= 130), CRS occurred in 75 (57.7%) subjects (58.9% in 3L+ FL subjects), including 1 (0.8%) subject with Grade 3 CRS from Cohort 1 (4L+ FL). There were no subjects with Grade 4 CRS and no subjects with fatal CRS. The frequency  of  CRS  was  consistent  across  cohorts  (lines  of  therapy)  and  groups.  The  most  common symptoms of CRS (≥ 10%) included pyrexia (56.9%) and hypotension (13.8%). The median time of CRS onset from the time of liso-cel infusion was 6 days (range: 1 to 17 days). CRS resolved in all subjects; the median time to resolution was 3 days (range: 1 to 10 days). Of the subjects who were treated with concomitant medications for CRS, 18 (13.8%) subjects received tocilizumab only (median

<div style=\"page-break-after: always\"></div>

1 dose [range, 1 to 3]), no subjects received corticosteroids only, 15 (11.5%) subjects received both tocilizumab and corticosteroids, and 2 (1.5%) subjects received vasopressors.

Neurological Toxicity (including ICANS). iiNT occurred in 21 (16.2%) subjects with 2L+ FL (15.9% in 3L+FL subjects), including 4 (3.1%) subjects with Grade 3 iiNT. There were no subjects with Grade 4 iiNT and no subjects with fatal iiNT. The most common iiNTs by PT were tremor (7.7%) and aphasia (6.9%). The median time to iiNT onset from the time of liso-cel infusion was 8 days (range: 4 to 16 days). iiNT resolved in all subjects; the median time to resolution was 4 days (range: 1 to 17 days). Of the subjects who were treated with concomitant medications for iiNT, no subjects received tocilizumab only,  9  (6.9%)  subjects  received  corticosteroids  only,  no  subjects  received  both  tocilizumab  and corticosteroids, no subjects received vasopressors.

Prolonged Cytopenia. In the Liso-cel-treated Analysis Set, prolonged cytopenia, defined as Grade ≥ 3 cytopenia  at  the  Day  29  ( ± 2  days)  visit  based  on  local  laboratory  assessments  of  neutropenia, thrombocytopenia,  or  anemia,  occurred  in  29  (22.3%)  subjects.  Based  on  the  data  presented,  the cytopenias observed after liso-cel infusion seem to be transient.

Second Primary Malignancies (SPMs). In the Liso-cel-treated Analysis Set, a total of 12 SPM events were reported in 9 subjects (6.9%). No events of T-cell malignancies were reported.  When a secondary malignancy occurs, a sample of the neoplastic tissue is requested, and if received, submitted to test for the presence of liso-cel transgene using a validated RNAscope ISH test. Of the 12 SPM events, tumor samples from 7 SPM events were received for testing and no samples were available in the remaining 5 SPM  events.  Of  the  7  tumor  samples  analyzed  by  ISH,  3  were  negative  for  transgene  (AML, mucoepidermoid carcinoma, and adenocarcinoma of colon), 1 failed testing due to insufficient sample quality (MDS), and 3 are pending for ISH results (melanoma, SCC/Bowen's disease, and rectal cancer). In addition to tumor samples, the MAH also requested blood samples at the time of the SPM event for RCL and transgene testing. For the 2 SPM events (AML, and colon adenocarcinoma), where tumor sample tested  negative  for  transgene  as  described  above,  blood  samples  were  negative  for  RCL.  No  blood samples from the remaining 10 SPM events from 8 subjects (mucoepidermoid carcinoma [1], MDS [1], melanoma [1], SCC/Bowen's disease [1], rectal cancer [1], AML [3], BCC [1], and colorectal cancer [1]) were available for testing. The MAH provided additional data for 5 of the 9 subjects previously reported with SPMs. For one subject (105-1002) with SPM of malignant melanoma, the relationship with liso-cel was updated from not suspected to suspected. The event of malignant melanoma was resolved on Day 751 and no recurrence has been reported at the last clinical data available about a year later. The initial results of the ISH testing (inconclusive), has been repeated, confirming negative transgene. The MAH was reminded to put every effort to comply with the PRAC recommendation to have a process in place to adequately handle collection and further testing of tissue samples from patients for whom a secondary T-cell  malignancy  has  been  reported  in  the  post  marketing  setting.  This  process  should  include instructions on prioritization of analyses to be conducted in case of limited availability of tumour tissue sample, bone marrow aspirate, and/or fresh blood from the patient.

Moreover, in the Liso-cel-treated Analysis Set 2 subjects met the criteria for integration site analysis (ISA) : for one subject, the transgene percentage was 11.4% at Month 12, and the other subject (2501006) was 3.5% at Month 24. ISA was performed on both samples. Results for the subject with 11.4% transgene at Month 12 showed the sample was polyclonal without evidence of a monoclonal outgrowth. ISA results for subject 250-1006 were also available, with no evidence of a predominant clone.

Cardiovascular  complications,  likely  associated  with  cytokine  release  syndrome  (CRS)  and  systemic inflammation,  have  been  reported  to  occur  with  CAR-T  ( Camilli  et  al.  Cardio -Oncology 2024; Gill  J. Current Cardiology Reviews, 2023 ).

<div style=\"page-break-after: always\"></div>

Taking into account all data provided, no correlation was identified between baseline cardiac function (ejection fraction and ECG) prior to liso-cel infusion and cardiac events reported post liso-cell infusion. Moreover, in the majority of these subjects, multiple prior lines of chemotherapy (including alkylating agents) were administered and the cardiotoxicity after CAR-T treatment might also be influenced by previous treatments in these patients. The SmPC covers this safety aspect and for the moment, no additional patient monitoring protocols should be advised before or after liso-cel infusion. However, CAR-T therapies (as well as bispecific T-cell engagers), despite their potential life-saving benefits, have been associated with a significant risk of cardiac toxicity. As reported in initial studies from VigiBase ( Karthikeyan et al. Communications Medicine 2024 https://doi.org/10.1038/s43856-024-00540-9), additional analyses are needed to further investigate the cardiovascular profile of CRS occurring in the context of CAR-T therapy. The MAH confirmed that the adverse events of cardiac and vascular disorders are collected through routine pharmacovigilance and data will be presented in upcoming PSURs.

There were no major differences in frequency of TEAEs and Grade ≥ 3 TEAEs across subgroups (age, sex,  ethnicity,  race,  anticancer  treatment  of  disease  control  status  [yes  vs  no],  and  region).  Some variability was observed, potentially due to the small sample size of some subgroups, but no definitive conclusion can be drawn.

In the Pooled Analyses of Safety regarding Liso-cel Treated Set in 3L+ FL and 2L/3L+ LBCL the frequency of any grade or Grade 3-4 TEAEs regardless of causality was consistent between Liso cel Treated Set subjects with 3L+ FL and 2L/3L+ LBCL.

The most commonly reported liso-cel-related all-grade TEAEs were consistent across Liso-cel Treated Set subjects with 3L+ FL and 2L/3L+ LBCL; however, the frequency of all-grade related TEAEs was higher in subjects with FL respect to the subjects with LBCL (89.7% vs. 79.9%). Similarly, the frequency of Grade ≥3 related TEAEs such as neutropenia and lymphopenia were higher in subjects with FL than LBCL (neutropenia 48.6% vs. 29.8%; lymphopenia 11.2% vs. 5.8%, respectively) whereas thrombocytopenia and anemia were lower in subjects with FL than LBCL (thrombocytopenia 9.3% vs. 15.8%; anemia 8.4% vs. 14.3%, respectively).

Regarding AESIs , liso-cel exhibited a manageable safety profile and no new safety concerns emerged. In 3L+ FL subjects compared to 2L/3L+ LBCL, the incidence of CRS, Grade 3-4 CRS, iiNT, and MAS/HLH was 58.9, 0.9%, 15.9%, and 0%, respectively (vs 41.8%, 1.6%, 24.8% and 0.7% in 2L/3L+ LBCL, respectively) and considered manageable using the protocol-specified criteria. The rates of high-grade infections (6.5% vs 12%) and prolonged cytopenia (24.3% vs 35.7%) were considered acceptable, and the reported type an d incidence of Grade ≥ 3 SPMs (4.7% vs 3.4% during post treatment -emergent period) was as expected for a heavily pre-treated population.

Higher rates of CRS and some liso-cel-related hematological AEs (i.e., neutropenia and thrombocytopenia) were observed in 3L+ FL compared to 2L/3L+ LBCL. However, the difference in CRS rates was mainly due to higher rate of Grade 1 CRS and the frequency of hematological AEs, regardless of investigator-assessed relatedness, was similar or lower in 3L+ FL than in 2L/3L+ LBCL.

For Liso-cel Treated Set in 2L+ FL and 2L/3L+ LBCL the safety events reported in 2L+ FL subjects from Study FOL-001 were consistent with those previously reported in 2L/3L+ LBCL subjects. As for 3L+ FL, Grade 1-2 CRS was  higher  in  2L+  FL  subjects  than  2L/3L+  LBCL  (56.9%  vs  40.1%,  respectively). However, the frequencies of Grade 3-4 AESIs of CRS and iiNT were lower in subjects with 2L+ FL (0.8% and 2.3% of subjects, respectively) than 2L/3L+ LBCL (1.6% and 8.4% of subjects, respectively). No new safety signals were identified.

<div style=\"page-break-after: always\"></div>

To  date,  no  clinical  condition  for  EGFRt-mediated  cell  ablation  has  been  identified  in  the  liso-cel development program.

Product Information . Pooled safety analyses were performed for 691 subjects receiving liso-cel dose in the range of 44 to 120 × 10 6  CAR+ T cells. These analyses included subjects with 2L+ FL (n= 130; from Study FOL-001), 2L LBCL (n= 177; from studies BCM-003 [Arm B], 017006, and BCM-001 [Cohort 2]), and 3L+ LBCL (n= 384; from studies BCM-001 [Cohorts 1, 3, and 7], 017001, 017007, and BCM-002). ADRs represent all reported TEAEs across LBCL disease histologies, with frequency of 1% or greater in the ADR table and are not restricted to AEs deemed related by the investigator. Given the consistency between the safety profiles of 2L+ FL and 3L+ FL, the inclusion of the 2L+ FL dataset in the Product Information to provide a more comprehensive dataset is supported.

## 2.6.2. Conclusions on clinical safety

The safety database included 130 FL patients treated with liso-cel in the Study FOL-001. Overall, the safety events reported in this study were consistent with those previously observed in the authorised indication  of  2L/3L+  LBCL  and  were  manageable.  In  general,  similar  rates  of  CAR  T-cell-associated toxicities were observed in this FL population when compared to the 2L/3L+ LBCL population. The data presented in the Summary of Product Characteristics (SmPC) reflect the entire clinical experience at the recommended dose range. With a median follow up of 29.72 (min, max: 0.3, 39.6) months, no new safety concerns with liso-cel were identified in subjects with R/R 2L+ FL. However, while this period would be enough to identify the earlier and immediate AEs, there are certain potential risks for which conclusive  data  could  not  be  obtained  due  to  the  limited  sample  size  and  a  limited  follow-up  time, including the long-term safety. The MAH committed to provide additional safety data post-approval from the ongoing long-term follow-up study GM-LTFU-001, from the US-based, non-interventional RW registry study CA082-1175 including patients treated with liso-cel for 3L+ R/R FL in the post-marketing setting (category 3 studies in the RMP), and from the ongoing registry-based study JCAR017-BCM-005 that also include EU subjects who receive liso-cel in the post-approval setting (Category 1 study in the annex II and RMP).

The safety concerns remain unchanged.

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The MAH submitted an updated RMP version (5.1) with this application.

The (main) RMP changes were the following:

- Expanded indication for the treatment of adult patients with relapsed or refractory follicular lymphoma (R/R FL) after two or more lines of systemic therapy.
- Updated clinical trial exposure and safety data in line with new DLP.
- Updated existing FL and LBCL epidemiology data.
- Update of post-authorisation exposure information in line with new DLP.
- Addition of Study CA082-1175 as a Category 3 APVA in the PV Plan.

<div style=\"page-break-after: always\"></div>

The CAT received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 05.1 is acceptable. In addition, revisions were recommended to be taken into account with the next RMP update, as follows:

Inclusion of FL patients in the category 1 study ongoing registry-based study JCAR017-BCM-005 that also include EU subjects who receive liso-cel in the post-approval setting.

The CAT/CHMP endorsed this advice without changes.

The CAT/CHMP endorsed the Risk Management Plan version 05.1 with the following content:

## Safety concerns

There are no new safety concerns or reclassification of safety concerns in this updated RMP.

Table 73. Summary of Safety Concerns

| Important identified risks   | Cytokine release syndrome Neurologic toxicity including ICANS Infections Hypogammaglobulinaemia Macrophage activation syndrome/haemophagocytic lymphohistiocytosis Tumour lysis syndrome Cytopenia, including bone marrow failure                                                |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Autoimmune disorders Aggravation of graft versus host disease Secondary malignancies/insertional oncogenesis Generation of replication competent lentivirus Immunogenicity Transmission of infectious agents Reduced viability of liso-cel due to inappropriate product handling |
| Missing information          | Impact on pregnancy and lactation Long-term safety Safety in patients < 18 years old Safety in patients ≥ 75 years                                                                                                                                                               |

## Pharmacovigilance plan

No changes were proposed to the pharmacovigilance activities. Current additional pharmacovigilance activities include an imposed category one PASS (JCAR017-BCM-005), a category three LTFU study (GCLTFU-001), and a transgene assay service for testing of patient samples with secondary malignancies.

With the responses to RSI, the MAH submitted an updated RMP Version 5.1 (DLP 04-Feb-2024; sign off 13-Nov-2024). The update included the addition of a category 3 activity: study CA082-1175 collects

<div style=\"page-break-after: always\"></div>

efficacy and safety for patients treated for RR follicular lymphoma in the post-marketing setting in the USA based on CIBMTR registry data.

Table 74. Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                     | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Safety concerns addressed                                                                                                                                                                                                                                                                          | Milestone(s)                                                                                                                                                                                       | Due Date(s)                                                                                                                                                                                                                                                                               |
|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the                                                                                                                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the                                                                                                                                                                                        |
| marketing authorisation PASS (JCAR017- BCM-005) / Ongoing                                          | Primary Objective: To characterise the incidence and severity of selected ADRs, as outlined in the SmPC, in patients treated with liso-cel in the postmarketing setting, and to monitor for potential clinically important AEs that have not yet been identified as part of the liso- cel safety profile. Secondary Objectives: To assess long-term effectiveness in patients treated with liso-cel in the postmarketing setting. To assess the liso-cel safety and effectiveness profile in certain subgroups including but not limited to: • By large B-cell lymphoma subtypes (eg, FL3B, PMBCL, DLBCL not otherwise specified, high grade B-cell lymphoma). • According to geographical regions (eg, Europe). • Subjects aged ≥ 75 years. • Subjects with comorbid conditions (eg, renal impairment, reduced cardiac function). • Subjects with secondary CNS involvement. • Subjects with ECOG performance score ≥ 2. • By possible prognostic factors (eg, high-risk IPI). • Subjects previously exposed to anti-CD19 therapy. | CRS/MAS a /HLH a NT including ICANS b Infections Hypogammaglobulinaemia TLS Cytopenia, including bone marrow failure Secondary malignancies /insertional oncogenesis Impact on pregnancy and lactation (for pregnancy events) Long-term safety Aggravation of GvHD a Safety in patients ≥ 75 years | Protocol Submission to EMA Date of protocol approval by PRAC Start of data collection c Safety reports d Interim reports e Date of Study Completion f Date of Final Study Report Submission to EMA | 14-Apr-2022 01-Dec-2022 Q1 2023 Safety reports every 6 months (eg, aligned with the reporting period of the PSURs); additional reports every 3 months if a new safety concern is identified At Year 5, 10, and 15 or when last patient is out of the registry-based study Q4 2042 Q4 2043 |

<div style=\"page-break-after: always\"></div>

Table 74. Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                                                                                                                                                       | Summary of objectives                                                                                                                                                                                                                                                                                                                                          | Safety concerns addressed                                                                                                                                                                                                            | Milestone(s)                                                                                                                                                                                                                         | Due Date(s)                                                                                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                      | lymphocyte count (< 0.3 × 10 9 /L). Subjects treated with out-                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                      |
| • of-specification product. Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in context of a conditional marketing authorisation or a marketing authorisation under exceptional | • of-specification product. Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in context of a conditional marketing authorisation or a marketing authorisation under exceptional                                                                                                                           | • of-specification product. Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in context of a conditional marketing authorisation or a marketing authorisation under exceptional | • of-specification product. Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in context of a conditional marketing authorisation or a marketing authorisation under exceptional | • of-specification product. Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in context of a conditional marketing authorisation or a marketing authorisation under exceptional |
| the circumstances                                                                                                                                                                                                                    | the circumstances                                                                                                                                                                                                                                                                                                                                              | the circumstances                                                                                                                                                                                                                    | the circumstances                                                                                                                                                                                                                    | the circumstances                                                                                                                                                                                                                    |
| None.                                                                                                                                                                                                                                | None.                                                                                                                                                                                                                                                                                                                                                          | None.                                                                                                                                                                                                                                | None.                                                                                                                                                                                                                                | None.                                                                                                                                                                                                                                |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                        |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. | Infections Cytopenia, including bone marrow failure Autoimmune disorders Secondary malignancies/insertional oncogenesis on pregnancy and Long-term safety                                                                            | Subjects to be followed up for 15 years.                                                                                                                                                                                             |                                                                                                                                                                                                                                      |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. |                                                                                                                                                                                                                                      | Interim reports (5 and 10 years from FSFV [Jul 2018]).                                                                                                                                                                               | Q3 2023 and Q3 2028                                                                                                                                                                                                                  |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. | Impact lactation                                                                                                                                                                                                                     | LSLV                                                                                                                                                                                                                                 | Estimated Q3 2038                                                                                                                                                                                                                    |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. | Safety in patients < 18 years old                                                                                                                                                                                                    | Final database lock                                                                                                                                                                                                                  | Q3 2038                                                                                                                                                                                                                              |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. | Generation of replication competent lentivirus                                                                                                                                                                                       | Final report of GC-LTFU- 001 follow-up of 3L+ large B- cell lymphoma liso-cel treated subjects                                                                                                                                       | Q3 2039                                                                                                                                                                                                                              |
| LTFU study (GC-LTFU-001)/ Ongoing                                                                                                                                                                                                    | Long-term follow-up of safety and efficacy for all paediatric and adult subjects exposed do a GMTcell therapy in Bristol- Myers Squibb sponsored, or Bristol-Myers Squibb alliance partner sponsored, clinical trials in accordance with Health Authorities' guidance for long-term (up to 15 years) follow-up of subjects treated with gene therapy products. |                                                                                                                                                                                                                                      | Safety data will be reported in PSURs.                                                                                                                                                                                               | Submitted in accordance with the EURD list                                                                                                                                                                                           |
| Non- interventional cohort study of patients treated with liso-cel (lisocabtagene maraleucel) for relapsed/refractory follicular lymphoma in the postmarketing                                                                       | To characterize the incidence and severity of selected AEs, including secondary malignancy, and to assess the long-term effectiveness in patients receiving liso-cel to treat R/R FL.                                                                                                                                                                          | CRS/MAS a /HLH a NT including ICANS b Infections Hypogammaglobulinaemia TLS Cytopenia, including bone marrow failure                                                                                                                 | Start of data collection Progress updates                                                                                                                                                                                            | 31-Aug-2024 corresponds to the date from which data extraction starts. Aligned with the reporting period of the PSURs                                                                                                                |

<div style=\"page-break-after: always\"></div>

Table 74. Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                       | Summary of objectives                                                          | Safety concerns addressed                                                                            | Milestone(s)                                                                                      | Due Date(s)                                                                                                                                   |
|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| setting (CA082- 1175) / Ongoing                                                                      |                                                                                | Secondary malignancies /insertional oncogenesis Impact on pregnancy lactation (for pregnancy events) | Interim reports                                                                                   | At Year 5 and 10                                                                                                                              |
|                                                                                                      |                                                                                | and Long-term safety Aggravation of GvHD a Safety in patients ≥ 75 years                             | Date of Study Completion                                                                          | End of Q1 2044 (Study completion 15 years after reaching the defined patient number, no further data will be included in the study analyses.) |
|                                                                                                      |                                                                                |                                                                                                      | Date of Final Study Report Submission to EMA                                                      | Q4 2045                                                                                                                                       |
| Transgene assay service testing of secondary malignancies with insertion site analysis as applicable | Tumour tissue sample testing from patients that develop a secondary malignancy | Secondary malignancies/insertional oncogenesis                                                       | Safety data will be reported in PSURs. European Commission decision + 5 years European Commission | Submitted in accordance with the EURD list. Q2 2026                                                                                           |
|                                                                                                      |                                                                                |                                                                                                      | decision + 10 years                                                                               | Q2 2031                                                                                                                                       |
|                                                                                                      |                                                                                |                                                                                                      | European Commission decision + 15 years                                                           | Q2 2036                                                                                                                                       |

a Included under the category of Other AEs considered related to liso-cel treatment in Study BCM-005.

b NT is a primary endpoint in Study BCM-005, which comprises symptoms of NT, including cerebral oedema.

c Based on the European Commission decision and protocol approval timeline. As the data collection in the EBMT Registry is independent of this study (secondary use of data), the start of data collection corresponds to the date from which data extraction starts. First data extraction for Study BCM-005 will take place 3 months after protocol approved by EMA.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

No changes were proposed to the risk minimisation measures as outlined in the RMP previously. Current additional risk minimisation measures include a Controlled Distribution Programme as well as an educational programme for Healthcare Professionals and Patients.

Table 75. Summary of Risk Minimisation Measures

| Safety Concern                      | Risk Minimisation Measures                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                  |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks          | Important Identified Risks                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                               |
| Cytokine release syndrome           | Routine risk minimisation measures: SmPC Sections 4.2 and 4.4, PL Sections 2 and 3 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: • Educational programme for HCPs and patients • Controlled Distribution Programme      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) |
| Neurologic toxicity including ICANS | Routine risk minimisation measures: SmPC Sections 4.2, 4.4 and 4.7, PL Sections 2 and 3 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: • Educational programme for HCPs and patients • Controlled Distribution Programme | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) |
| Infections                          | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) LTFU study (GC-LTFU-001)   |
| Hypogammaglobu linaemia             | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR                                                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None.                                                                                                                           |

<div style=\"page-break-after: always\"></div>

Table 75. Summary of Risk Minimisation Measures

| Safety Concern                                                       | Risk Minimisation Measures                                                                                                                                                                                      | Pharmacovigilance Activities                                                                                                                                                                       |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                      | Additional risk minimisation measures: None                                                                                                                                                                     | Additional pharmacovigilance activities: PASS (JCAR017-BCM-005)                                                                                                                                    |
| Macrophage activation syndrome/haemop hagocytic lymphohistiocytos is | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management discussed SmPC Section 4.8 - histiocytosis haematophagic listed as an ADR Additional risk minimisation measures:         | US registry study (CA082-1175) Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance                                    |
| Tumour lysis syndrome                                                | Routine risk minimisation measures: SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None                                                                            | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) |
| Cytopenia, including bone marrow failure                             | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management discussed SmPC Section 4.8 and PL Section 4 - listed as an ADR Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) |
| Important Potential Risks                                            | Important Potential Risks                                                                                                                                                                                       |                                                                                                                                                                                                    |
| Autoimmune disorders                                                 | Routine risk minimisation measures: None                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:                                                                                                      |

<div style=\"page-break-after: always\"></div>

Table 75. Summary of Risk Minimisation Measures

| Safety Concern                                  | Risk Minimisation Measures                                                                                                                                                                 | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Additional risk minimisation measures: None                                                                                                                                                | Additional pharmacovigilance activities: LTFU study (GC-LTFU-001)                                                                                                                                                                                                                                                                                           |
| Aggravation of GvHD                             | Routine risk minimisation measures: SmPC Section 4.4, PL Section 2 - warnings, advice and management Additional risk minimisation measures: None                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: Included under the category of Other AEs considered related to liso-cel treatment in PASS                                                                                                                      |
| Secondary malignancies/inse rtional oncogenesis | Routine risk minimisation measures: SmPC Section 4.4 - warnings, advice and management Additional risk minimisation measures: None                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082-1175) LTFU study (GC-LTFU-001) Transgene assay service testing of secondary malignancies with insertion site analysis as applicable |
| Generation of replication competent lentivirus  | Routine risk minimisation measures: None Additional risk minimisation measures: None                                                                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: LTFU study (GC-LTFU-001).                                                                                                                                                                                      |
| Immunogenicity                                  | Routine risk minimisation measures: SmPC Section 4.2 and PL Section 3 - premedication with paracetamol and diphenhydramine or another H1-antihistamine SmPC Section 4.8 - listed as an ADR | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None.                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

Table 75. Summary of Risk Minimisation Measures

| Safety Concern                                                      | Risk Minimisation Measures                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                          |
|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     | Additional risk minimisation measures: None                                                                                                                                                                                                                                                             | Additional pharmacovigilance activities: None.                                                                                                                                                                                                        |
| Transmission of infectious agents                                   | Routine risk minimisation measures: SmPC Sections 4.2, 4.4 (Risk of transmission of infectious agents exists. Guidance on monitoring patients for signs and symptoms of infections), and 6.6, PL Section 2 and Labelling Section 10 - handling instructions Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None                                                                                                     |
| Reduced viability of liso-cel due to inappropriate product handling | Routine risk minimisation measures: SmPC Sections 4.2, 6.3, 6.4, 6.5 and 6.6, PL Section 5 and Labelling Section 9 - handling instructions Additional risk minimisation measures: • Educational programme for HCPs • Controlled Distribution Programme                                                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None.                                                                                                    |
| Missing Information                                                 | Missing Information                                                                                                                                                                                                                                                                                     | Missing Information                                                                                                                                                                                                                                   |
| Impact on pregnancy and lactation                                   | Routine risk minimisation measures: SmPC Section 4.6, PL Section 2- warnings and advice Additional risk minimisation measures: None                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) and US registry study (CA082-1175) for pregnancy events LTFU study (GC-LTFU-001). |
| Long-term safety                                                    | Routine risk minimisation measures: None Additional risk minimisation measures: None                                                                                                                                                                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005)                                                                                   |

<div style=\"page-break-after: always\"></div>

Table 75. Summary of Risk Minimisation Measures

| Safety Concern                    | Risk Minimisation Measures                                                                                                           | Pharmacovigilance Activities                                                                                                                                                                        |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety in patients < 18 years old | Routine risk minimisation measures: SmPC Section 4.2, PL Section 2 - warnings and advice Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: LTFU study (GC-LTFU-001).                              |
| Safety in patients ≥ 75 years     | Routine risk minimisation measures: None Additional risk minimisation measures: None                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: PASS (JCAR017-BCM-005) US registry study (CA082- 1175) |

## 2.8. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC were updated. The Package Leaflet has also been updated accordingly.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet was submitted by the MAH and found acceptable for the following reasons: the readability of the PL of Breyanzi was assessed during the review of the initial MAA, the current new indication in adults has the same route of administration and a similar safety profile as the previously approved indication, Breyanzi is administered by a health care professional and the instructions for preparation, administration, storage and disposal remain unchanged, the general design and layout of the proposed PL have not changed compared to the tested one.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Follicular lymphoma (FL) is the most commonly diagnosed type of indolent non-Hodgkin lymphoma (iNHL), accounting for approximately 35% of all NHLs and 70% of iNHLs in Western Europe and the US; it is a heterogeneous entity that includes tumours derived from germinal centre B cells, both centrocytes and centroblasts. The t(14;18) translocation has been recognized as a genetic hallmark of FL and results in constitutive overexpression of the BCL-2 protein. The disease is characterized by diffuse lymphadenopathy, bone marrow involvement, splenomegaly, and other less common sites of extranodal involvement.

FL is characterised by an indolent, relapsing/remitting clinical behaviour and as a general rule drug resistance increases and clinical benefit is reduced with each subsequent line of therapy.

Current treatment guidelines (2020 ESMO guidelines; NCCN guidelines for classic FL v. 3.2024) recommend that conventional immunochemotherapy is used early in the course of the disease (e.g. at frontline or at first relapse). In later settings of relapse/progression, alternative approaches are usually preferred. Therefore, in the indication claimed for Breyanzi, only a selected group of patients can be reasonably expected to benefit from the use of classic immune-chemotherapy regimens such as bendamustine plus rituximab (BR), R-CHOP/R-CVP, or other similar regimens.

Rituximab, an anti-CD20 monoclonal antibody, is recommended by current guidelines for the treatment of R/R FL in monotherapy or in combination. Rituximab monotherapy is often preferred in older subjects with indolent disease because of its manageable toxicity profile; in the rituximab arm of the Phase III HOMER study (Maloney DG et al, Blood Adv 2020) only subjects with rituximab-sensitive disease could be enrolled, the ORR was 66%, the CRR was 20% and the median PFS was 19.2 months. The SCHOLAR-5, a large observational study investigating the RW outcomes of subjects with R/R NHLs, showed that the ORR and CRR for subjects with R/R FL receiving various rituximab-based salvage treatments in their 3L+ ranged from 43% to 69% and from 20% to 46%, respectively.

The main clinical need in R/R FL patients is represented, however, by the increased rate of resistance to rituximab-based regimens in later lines of therapy, resulting in reduced disease-free intervals between relapses and the accumulation of treatment-related toxicities.

The combination of obinutuzumab (a 2 nd  generation anti-CD20 mAb) plus bendamustine (BO), followed by obinutuzumab maintenance, is approved for the treatment of subjects who did not respond or progressed during or up to 6 months after treatment with rituximab or rituximab-containing regimens. The results from registrational study GAO4753g/GADOLIN showed that the BOR (CR+PR) in the BO arm was 79.7% and the CRR 15.7%. At the time of approval, the median PFS by IRC in the BO arm was not reached nor the median DoR and OS with a median FU of up to 22 months. Updated results with a median FU of 57.5 months in the BO arm (Sehn LH et al, Blood 2019) showed that the median PFS was 24.1 months, while the median OS was still not reached.

The therapy landscape for these patients has also evolved in recent years, with more chemo-free options becoming available.

Idelalisib and duvelisib are PI3K inhibitors (PI3Kis) approved for the treatment as monotherapy of adult patients with FL that are refractory to two prior therapies. The efficacy outcomes from the registrational studies (single-arm, multicentre study 101-09 and single-arm, multicentre study IPI145-06, respectively) showed ORRs ranging between 40% and 55.6% and CRRs in the range 0% to 16.7%. Long-term outcomes data showed mDoR, mPFS and mOS ranging between 10-12 months, 811 months and 28-61 months, respectively. With respect to safety, long-term treatment with PI3Kis is characterised by significant rates of neutropenia, infection, GI ADRs and rush.

<div style=\"page-break-after: always\"></div>

Zanubrutinib (a 2 nd  generation BTK inhibitor) is approved in combination with obinutuzumab (OZ) for the treatment of adult patients with R/R FL who have received at least two prior systemic therapies. Data from Phase 2, randomised, controlled study ROSEWOOD showed in the OZ arm an ORR of 69% (CRR 39.3%), with a 69% DoR rate at 18 months and a median PFS of approximately 28 months.

Lenalidomide is approved in combination with rituximab (RR) for the treatment of adult patients with previously treated FL. The efficacy and safety of the RR regimen was investigated in a phase 3, multicentre, randomised, double-blind, controlled study (AUGMENT) that compared RR with rituximab plus placebo in patients with R/R indolent NHLs, including FL. With a median follow-up of approximately 28 months, the ORR for FL patients in the RR arm was 80.3%, the CRR 34.7%, the median DoR 36.6 months, the median PFS 39.4 months and the 5-year OS rate was 85.9%.

Mosunetuzumab is an anti-CD20/CD3 T-cell-engaging bispecific mAb approved conditionally for the treatment of adult patients with R/R FL who have received at least two prior systemic therapies. The CMA of Lunsumio was based on the results from a single open-label, multicentre, multi-cohort study (GO29781) in subjects with R/R B-cell NHLs. Efficacy results showed that the ORR was 80%, the CRR 60%, the mDoR 22.8 months, the median PFS 17.9 months and the median OS was not yet reached. Epcoritamab and odronextamab are two additional anti-CD20/CD3 bispecific mABs approved as monotherapy for the treatment of adult patients with R/R FL after two or more lines of systemic therapy that showed similar results to mosunetuzumab.

Tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) are two anti-CD19 CAR T cell (CARTs) advanced medicinal products (ATMPs). Tisa-cel is approved for the treatment of subjects with R/R FL after two or more lines of systemic therapy. Results from the registrational ELARA trial (a Phase 2, open-label, single-arm study) showed that treatment with tisa-cel resulted in high ORR (86%) and CRR (69%), with a median PFS of 18.4 months and median DoR and OS not yet reached after a median follow-up of 20.8 months.

Axi-cel is approved for treatment of patients with R/R FL after three or more lines of systemic therapy. Supporting efficacy data come from study ZUMA-5, a single-arm Phase 2 trial in subjects with R/R indolent NHLs, and showed that the ORR was 94%, the CRR 78%, the median DoR 38.6 months, the median PFS 39.6 months and the median OS was not yet reached with a median FU of 25.9 months.

The safety profile of T cell engaging immunotherapies (including bispecific mAbs and CARTs) is characterised by CRS, neurotoxicity including ICANS, infections, persisting hypogammaglobulinemia and cytopenias. Rates and severity of AEs vary across different products.

Overall, despite several products approved for the treatment of subjects with 3L+ FL, with CAR-T therapies offering the most compelling efficacy, there is a continuous need for efficacious treatments with better safety profiles to further enhance patient outcomes. FL, in fact, remains largely incurable, and death occurs mainly due to histological transformation to aggressive LBCL, infection, or because FL becomes refractory to the available options. Further, a higher medical need can be recognised for POD24 patients (i.e. subjects with early progression), who are at high risk of poor long-term outcomes, with an estimated 5-year OS 50% (vs. 90% in the absence of early progression).

## 3.1.3. Main clinical studies

Study FOL-001 was a global Phase 2, open-label, single-arm, multicohort, multicentre study designed to evaluate the efficacy and safety of liso-cel in adult subjects with R/R FL or MZL, with the aim to register an indication for R/R FL subjects after at least 2 previous therapies (3L+). The FOL-001 trial enrolled three distinct patient groups based on the previous number of line therapies (Cohort 1: 4L patients, Cohort 2: 3L patients, Cohort 3: 2L patients); pooled data from Cohort 1 and 2 provided the

<div style=\"page-break-after: always\"></div>

main evidence to support this extension of indication application; data from Cohort 3 were only supportive.

No specific dose-response study was conducted for FL, and the single target dose of 100 × 10 6  CAR+ T cells already approved for LBCLs was eventually selected as recommended dose across the whole lisocel development program in B-cell malignancies in adults, including FL.

The MAH provided further contextualisation of the results from study FOL-001 through indirect comparisons, including a Real-World External Arm Study (RWEAS), an unanchored MAIC and a Systematic Literature Review (SLR).

Treatment eligibility was defined in accordance with the main clinical guidelines for the treatment of FL (NCCN 2019), which requires the presence of at least one of the modified GELF criteria or the presence of the POD24; efficacy was assessed by radiographic tumour evaluation by diagnostic quality computed tomography (CT)/magnetic resonance imaging (MRI) scans (chest, neck, abdomen and pelvis) and/or positron emission tomography (PET) scans and were reviewed by an independent review committee (IRC), according to a modified version of the 'Lugano Response Criteria'.

The primary endpoint of study FOL-001 was ORR, while CRR and time to event endpoints like DOR, PFS and OS were analysed as secondary ones.

The number of patients included in the 3L+ liso-cel treated efficacy set was n=107 out of 114 subjects who was leukapheresed in study FOL-001. Four subjects received non-conforming products, 3 were not infused because of AE, failure to meet inclusion/exclusion criteria and 'other'. Subjects with no PET positive disease before liso-cel infusion or with no pre-infusion PET scan (n=4) were excluded from the liso-cel treated efficacy set. Similarly to other trial in FL involving CAR-T, the investigators were allowed to prescribe antineoplastic bridging therapies to stabilize the disease while waiting for liso-cel infusion. Bridging therapy was selected based on the Investigators choice and included the current approved therapies for r/r FL.

## 3.2. Favourable effects

Efficacy data from study FOL-001 in a heavily pre-treated population (the median number of prior lines of therapy was n=3 and 64.5% of patients were double-refractory to rituximab and alkylating agents) showed that treatment with liso-cel resulted in high rates of deep and rapidly induced responses: the ORR by IRC was 97.1% (95%CI 91.7, 99.4) and the CRR by IRC 94.3% (95%CI 87.8, 97.8), with a median time to first response/first CR of 0.95 months (range: 0.6 to 3.3 months).

Response rates were consistent in most pre-specified sensitivity analyses (ORR in the Leukapheresed set: 93%, ORR Per Investigator assessment: 98.1%) and subgroup analyses, including patients with high risk factors at baseline like POD24 status, refractoriness to the last line of therapy and high LDH value at baseline.

Responses with liso-cel were generally durable: with a median follow up of 29.96 months (95%CI 24.67, 32.76), median DOR by IRC was not reached (95%CI 30.85 months, NA; range 1.9, 35.0+). Consistent results were observed in the Leukapheresed set (mDoR not reached) and in the analysis by Investigator assessment (median DoR 34.76 months).

With the limits intrinsic in indirect comparisons (ICs) in heterogeneous conditions such as FL, the results from the three IC exercises provided by the MAH are suggestive of an efficacy with liso-cel that is at least similar to that of other T cell engaging immunotherapies, including CARTs.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

- The  evidence  supporting  the  efficacy  of  liso-cel  in  the  target  population  comes  from  one  single uncontrolled, open-label study.
- At the DCO of January 2024 and with a median follow-up for the 3L+ patients of 29.96 months the DOR, PFS and OS analyses were not sufficiently mature.
- Significant and clinically relevant improvements in terms of PFS/OS have been historically accepted as adequate basis to inform B/R decisions in NHLs; the interpretation of time-to-event endpoints in the absence of controls is complicated, since disentangling e.g. the impact of the intervention from the effect of heterogeneity in tumour growth rate is not possible.
- The sample size and follow-up of study FOL-001 is limited to thoroughly characterise the clinical benefit with liso-cel, especially in terms of long-term efficacy and activity in subgroups of clinical relevance. Additional efficacy data will be provided post-approval from the long-term follow-up study GC-LTFU-00, from the US-based non-interventional, RW study CA082-1175 in 3L+ R/R FL patients treated with liso-cel, and from the registry-based study JCAR017-BCM-005, which also includes EU subjects who receive liso-cel in the post-approval setting.
- The relevance of the efficacy threshold selected to claim efficacy is limited in the current treatment paradigm  and  contextualisation  of  the  efficacy  results  for  3L+  subjects  with  R/R  FL  relies  on unanchored indirect comparisons. FL presents with significant biological and clinical heterogeneity and the reliability of indirect comparison methods is based in the assumption that all factors with prognostic value are accounted for in the analysis. Such assumption is hardly acceptable in FL.
- When the 'FDA algorithm' (which requires CR confirmation by bone marrow biopsy) was applied, the proportion of 3L+ subjects who achieved CR was consistently lower compared to the 'primary' analysis (72.3% vs. 94.1%, respectively). Subjects with 'unconfirmed CR' as per the FDA algorithm showed a trend towards shorter DoR and PFS compared to subjects with 'confirmed CR'. Some degree of overestimation in the CR rate observed in the primary analysis of study FOL-001 cannot be excluded.
- Due to lack of blinding and controls, the reliability of the linear improvement in symptoms and QoL reported in study FOL-001 is uncertain.

## 3.4. Unfavourable effects

- Unfavourable effects of liso-cel in FL are consistent with the generally known identified risks, i.e., CRS, neurotoxicity and prolonged cytopenias.
- The most common adverse reactions of any grade were neutropenia (68%), CRS (58%), anaemia (40%), headache (29%), thrombocytopenia (29%) and constipation (21%).
- The most common serious adverse reactions were CRS (9%), aphasia (4%), febrile neutropenia (3%), pyrexia (2%) and tremor (2%).
- The most common Grade 3 or higher adverse reactions included neutropenia (61%), leukopenia (12%), lymphopenia (12%), thrombocytopenia (12%) and anaemia (10%).
- CRS occurred in 57.7% of patients, 0.8% of whom experienced Grade 3 CRS (no fatal events). The median time to onset was 6 days (range: 1 to 17 days) and the median duration of CRS was 3 days (range: 1 to 10 days).  The  most  common  manifestations  of  CRS  included  pyrexia (56.8%)  and hypotension (13.8%). 33 of 130 (25%) patients received tocilizumab and/or a corticosteroid for CRS

<div style=\"page-break-after: always\"></div>

after infusion of Breyanzi. Eighteen (13.8%) patients received tocilizumab only, 15 (11.5%) received tocilizumab and a corticosteroid and no patients received corticosteroids only.

- iiNT including ICANS occurred in 16.2% of patients receiving Breyanzi, including Grade 3 in 3.1% of patients (no fatal events). The  median  time  to  onset  of the first  event  was  8 days (range: 4 to 16 days); 100% of all neurologic toxicities occurred within the first 8 weeks following Breyanzi infusion. The median duration of neurologic toxicities was 3 days (range: 1 to 17 days). The most common neurologic toxicities included tremor (7.7%) and aphasia (6.9%).
- Grade 3 or higher cytopenias present at Day 29 following Breyanzi administration, occurred in 22.3% of patients, and included thrombocytopenia (14.6%), neutropenia (15.4%) and anaemia (4.6%).
- Grade 3 infections occurred in 5.4% of patients.

## 3.5. Uncertainties and limitations about unfavourable effects

The safety database included 130 FL patients treated with liso-cel in the Study FOL-001. Generally, the spectrum of the unfavourable effects of liso-cel as a CAR-T cell product is known, and currently no major additional issues seem to arise. With a median follow up of 29.72 (min, max: 0.3, 39.6) months, no new safety concerns with liso-cel were identified in subjects with R/R 2L+ FL. However, while this period would be enough to identify the earlier and immediate AEs, there are certain potential risks for which conclusive data could not be obtained due to the limited sample size and a limited follow-up time, including the long-term safety. Additional safety data will be provided post-approval from the long-term follow-up study GC-LTFU-00, from the US-based non-interventional, RW study CA082-1175 in 3L+ R/R FL patients treated with liso-cel in the post-marketing setting, and from the registry-based study JCAR017-BCM-005, which also includes EU subjects who receive liso-cel in the post-approval setting.

## 3.6. Effects Table

Table 76.  Effects Table for liso-cel in treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (Data cutoff: 10-Jan-2024)

| Effect                      | Short description                                                     | Unit   | Treatment                                            | Control (none)   | Uncertainties / Strength of evidence                                               | Reference s   |
|-----------------------------|-----------------------------------------------------------------------|--------|------------------------------------------------------|------------------|------------------------------------------------------------------------------------|---------------|
| Favourable Effects          | Favourable Effects                                                    |        |                                                      |                  |                                                                                    |               |
| Overall Response Rate       | Best OR (CR or PR) per IRC charter based on the Lugano classification | %      | Efficacy Set: 97.1% ITT Set: 93.0%                   | N/A              | Single arm trial with limited sample size High rates of deep and durable responses | Study         |
| Complete response rate      | Best OR of CR per IRC charter based on the Lugano classification      | %      | Efficacy Set: 94.2% ITT Set: 90.4%                   | N/A              | Consistent results across most                                                     | FOL-001       |
| Median Duration of response | Time from first response (Complete response, CR or partial            | Months | Efficacy Set: N.R. ITT Set: N.R. Efficacy Set: 75.7% | N/A              | sensitivity analysis and pre-specified subgroups                                   |               |

<div style=\"page-break-after: always\"></div>

Notes: * The safety database included 130 FL patients treated with liso-cel in the Study FOL-001.

| Effect                                      | Short description                                                                                     | Unit   | Treatment      | Control (none)   | Uncertainties / Strength of evidence             | Reference s     |
|---------------------------------------------|-------------------------------------------------------------------------------------------------------|--------|----------------|------------------|--------------------------------------------------|-----------------|
| %of Response at 18 months                   | response, PR) to progressive disease or death from any cause (whichever occurs first) per IRC charter |        | ITT Set: 76.1% |                  |                                                  |                 |
| Unfavourable Effects                        | Unfavourable Effects                                                                                  |        |                |                  |                                                  |                 |
| Cytokine release syndrome                   |                                                                                                       | N (%)  | 75/130 (57.7%) | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
| Investigator identified neurologic toxicity |                                                                                                       | N (%)  | 21/130 (16.2%) | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
| Prolonged cytopenia                         | ≥ Grade 3                                                                                             | N (%)  | 29/130 (22.3%) | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
| Infections                                  | ≥ Grade 3                                                                                             | N (%)  | 7/130 (5.4%)   | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
| Second Primary Malignancy                   | ≥ Grade 3                                                                                             | N (%)  | 9/130 (6.9%)   | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
| Hypogammaglo bulinaemia                     |                                                                                                       | N (%)  | 7/130 (5.4%)   |                  | Safety profile consistent across treatment lines | Study FOL-001 * |
|                                             | Overall deaths                                                                                        | N (%)  | 16/139 (11.5%) |                  | Safety profile consistent across treatment lines | Study FOL-001 * |
| Deaths                                      | Due to PD                                                                                             | N (%)  | 7/139 (5%)     | N/A              | Safety profile consistent across treatment lines | Study FOL-001 * |
|                                             | Due to TEAES                                                                                          | N (%)  | 4/139 (2.9%)   |                  | Safety profile consistent across treatment lines | Study FOL-001 * |

Abbreviation: N/A= not applicable

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

FL is an indolent malignancy characterised by a relapsing/remitting clinical behaviour. Despite several agents/combinations being approved for the treatment of R/R FL, drug resistance increases with each subsequent line of therapy and clinical benefit, especially in terms of long-term disease control, is reduced. Due to progressing disease in the context of widespread refractoriness or to histological transformation to aggressive LBCL, most patients with R/R FL have a reduced life expectancy compared to the general population.

Results from pivotal study FOL-001 showed that treatment with liso-cel provides a consistent and clinically relevant antitumoral effect in a setting of patients in advanced stages of relapse and with high rates of refractoriness. In particular, high rates of rapid, deep and durable responses could be observed (i.e. ORR by IRC 97.1%, CRR by IRC: 94.2%, median DOR by IRC not reached with a median follow-up of 29.96 months). Although CR rate is not a validated surrogate endpoint for long-term clinical benefit in R/R FL, depth of response has been associated with prolonged disease-free intervals in FL (see e.g. Sargent et al, JCO 2015), which are considered of relevance for patients.

<div style=\"page-break-after: always\"></div>

The toxicity profile of liso-cel in FL is generally consistent with the known identified risks of CAR T cell therapy,  i.e.,  CRS,  neurotoxicity  and  prolonged  cytopenias.  The  most  common  adverse  reactions reported in study FOL-001 were, in fact, neutropenia (68%), CRS (58%), anaemia (40%), headache (29%),  thrombocytopenia  (29%)  and  constipation  (21%).  CRS  and  iiNT  were  not  uncommon  but occurred  early  after  treatment  (100%  of  all  neurologic  toxicities  occurred  within  the  first  8 weeks following  liso-cel  infusion)  and  usually  resolved  within  a  week.  Severe  CRS  and  iiNT  events  were uncommon and no fatal events were reported.

The main clinical uncertainties relate to the lack of control, the limited sample size (which did not allow to characterise rare adverse drug reactions nor the efficacy of liso-cel in clinically relevant subgroups) and the current follow-up that is not sufficient to fully capture the long-term benefit and risks of lisocel, yet relevant in a chronic condition such as FL; further long-term data are expected in the post approval setting as committed by the MAH in specific safety and efficacy long term follow up studies. Although only subjects with Grade 1-3a FL (i.e. indolent or 'classical' FL) could be enrolled in study FOL-001, it is noted that Breyanzi is already approved for the treatment of the more aggressive Grade 3b FL after at least 2 prior lines of therapy.

## 3.7.2. Balance of benefits and risks

Based on the current evidence, the overall B/R of liso-cel in the claimed indication is considered favourable, since the high rates of deep and durable responses balance the known risks associated with anti-CD19 CAR T cell therapy.

Uncertainties remain, however, due to the limited sample size, short follow-up and the uncontrolled nature of the available evidence.

## 3.7.3. Additional considerations on the benefit-risk balance

To better characterize the long-term clinical benefit with liso-cel in the claimed indication, and its efficacy and safety in clinically relevant subgroups, additional clinical data will be provided post-approval from the long-term follow-up study GC-LTFU-00, from a US-based non-interventional, RW study CA082-1175 in 3L+ R/R FL patients treated with liso-cel in the post-marketing setting (category 3 study in the RMP), and from the registry-based study JCAR017-BCM-005, which also includes EU subjects who receive lisocel in the post-approval setting (category 1 study in the RMP and annex II condition).

## 3.8. Conclusions

The B/R of Breyanzi in the claimed indication is considered positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CAT/CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

<div style=\"page-break-after: always\"></div>

| Variations accepted   | Variations accepted                                                                                                                                 | Type    | Annexes affected   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| B.II.d.1.e            | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range | Type II | None               |
| B.II.d.1.a            | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                      | Type IB | None               |
| B.II.d.1.a            | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                      | Type IB | None               |
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                      | Type II | I and IIIB         |

A grouped application consisting of:

C.I.6 (Type II): Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (r/r) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is also updated in accordance. Version 5.1 of the RMP was also submitted.

The group of variations led to amendments of the Summary of Product Characteristics, Package Leaflet and the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CAT/CHMP by consensus is of the opinion that Breyanzi is not similar to Gazyvaro, Kymriah, Lunsumio and Yescarta within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## Additional market protection

During the assessment for the submitted request for additional market protection, the MAH decided to withdraw the claim and this has been acknowledged.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this group of variations. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

<div style=\"page-break-after: always\"></div>

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Breyanzi -H-C-004731-II-0043G